---
document_datetime: 2023-09-21 20:24:09
document_pages: 230
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/gamifant-epar-refusal-public-assessment-report_en.pdf
document_name: gamifant-epar-refusal-public-assessment-report_en.pdf
version: success
processing_time: 159.4615635
conversion_datetime: 2025-12-18 09:26:50.725738
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

12 November 2020 EMA/656530/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Gamifant

International non-proprietary name: emapalumab

Procedure No. EMEA/H/C/004386/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................7                                |                                                                                                          |
|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................7     |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.......................................................10               |                                                                                                          |
| 1.3. Steps taken for the re-examination procedure                                                                         | .......................................................11                                                |
| 2. Scientific discussion                                                                                                  | ..............................................................................13                         |
| 2.1. Problem statement .............................................................................................13    |                                                                                                          |
| 2.1.1. Disease or condition.........................................................................................13    |                                                                                                          |
| 2.1.2. Epidemiology and risk factors............................................................................13        |                                                                                                          |
| 2.1.3. Biologic features..............................................................................................13  |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis..........................................................................14       |                                                                                                          |
| 2.1.5. Management...................................................................................................14    |                                                                                                          |
| 2.2. Quality aspects                                                                                                      | ..................................................................................................18     |
| 2.2.1. Introduction....................................................................................................18 |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................19    |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                         | ................................................................................21                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................24                      |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ......................24                                                                                 |
| 2.2.6. Recommendations for future quality development................................................24                   |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                 | ............................................................................................25           |
| 2.3.1. Introduction....................................................................................................25 |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                       | .................................................................................................25      |
| 2.3.3. Pharmacokinetics.............................................................................................26    |                                                                                                          |
| 2.3.4. Toxicology                                                                                                         | ......................................................................................................28 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                          | .........................................................30                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................30         |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................30           |                                                                                                          |
| 3. Clinical aspects......................................................................................31               |                                                                                                          |
| 3.1.1. Introduction....................................................................................................31 |                                                                                                          |
| 3.1.2. Pharmacokinetics.............................................................................................34    |                                                                                                          |
| 3.1.3. Pharmacodynamics..........................................................................................37       |                                                                                                          |
| 3.1.4. Discussion on clinical pharmacology...................................................................39           |                                                                                                          |
| 3.1.5. Conclusion clinical pharmacology.......................................................................42          |                                                                                                          |
| 3.2. Clinical efficacy                                                                                                    | ..................................................................................................43     |
| 3.2.1. Dose response study........................................................................................43      |                                                                                                          |
| 3.2.1. Main studies                                                                                                       | ...................................................................................................43    |
| 3.2.2. Discussion on clinical efficacy............................................................................90      |                                                                                                          |
| 3.2.3. Conclusions on the clinical efficacy.....................................................................96        |                                                                                                          |
| 3.3. Clinical safety                                                                                                      | ....................................................................................................97   |
| 3.3.1. Discussion on clinical safety ............................................................................         | 117                                                                                                      |
| 3.3.2. Conclusions on the clinical safety.....................................................................            | 123                                                                                                      |
| 3.4. Risk Management Plan                                                                                                 | ...................................................................................... 124               |
| 3.5. Pharmacovigilance............................................................................................        | 124                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 3.6. New Active Substance.......................................................................................                              | 125                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 3.7. Product information ..........................................................................................                           | 125                                                                                                       |
| 3.7.1. User consultation...........................................................................................                           | 125                                                                                                       |
| 4. Benefit-Risk Balance............................................................................125                                        |                                                                                                           |
| 4.1. Therapeutic Context .........................................................................................                            | 125                                                                                                       |
| 4.1.1. Disease or condition.......................................................................................                            | 125                                                                                                       |
| 4.1.2. Available therapies and unmet medical need.....................................................                                        | 126                                                                                                       |
| 4.1.3. Main clinical studies                                                                                                                  | ....................................................................................... 126               |
| 4.2. Favourable effects                                                                                                                       | ............................................................................................ 127          |
| 4.3. Uncertainties and limitations about favourable effects...........................................                                        | 127                                                                                                       |
| 4.4. Unfavourable effects.........................................................................................                            | 129                                                                                                       |
| 4.5. Uncertainties and limitations about unfavourable effects                                                                                 | ....................................... 129                                                               |
| 4.6. Benefit-risk assessment and discussion...............................................................                                    | 133                                                                                                       |
| 4.6.1. Importance of favourable and unfavourable effects............................................                                          | 133                                                                                                       |
| 4.6.2. Balance of benefits and risks...........................................................................                               | 133                                                                                                       |
| 4.6.3. Additional considerations on the benefit-risk balance                                                                                  | ......................................... 134                                                             |
| 4.7. - Conclusions...................................................................................................                         | 136                                                                                                       |
| 5. Recommendations...............................................................................136                                          |                                                                                                           |
| 6. Re-examination of the CHMP opinion dated 23 July 2020....................137                                                               |                                                                                                           |
| 6.1. Detailed grounds for re-examination submitted by the applicant ............................                                              | 137                                                                                                       |
| 6.1.1. Ground #1....................................................................................................                          | 137                                                                                                       |
| 6.1.2. Ground #2 - Efficacy and study design.............................................................                                     | 153                                                                                                       |
| 6.1.3. Ground #3 - Pharmacokinetics/Pharmacodynamics                                                                                          | ........................................... 179                                                           |
| 6.1.4. Ground #4 - Safety.......................................................................................                              | 181 195                                                                                                   |
| 6.1.5. Ground #5 - GCP inspection ...........................................................................                                 |                                                                                                           |
| 6.1.6. Ad-hoc Expert Group meeting on Explanation............................................................................................ | emapalumab.................................................. 208                                          |
| 6.1.7. Oral                                                                                                                                   | 213                                                                                                       |
| 6.1.8. Overall conclusion on grounds for re-examination..............................................                                         | 213                                                                                                       |
| 7. Benefit-risk balance following re-examination                                                                                              | ....................................215                                                                   |
| 7.1. Therapeutic Context .........................................................................................                            | 215                                                                                                       |
| 7.1.1. Disease or condition.......................................................................................                            | 215                                                                                                       |
| 7.1.2. Available therapies and unmet medical                                                                                                  | need..................................................... 215                                             |
| 7.1.3. Main clinical studies                                                                                                                  | ....................................................................................... 216               |
| 7.2. Favourable effects                                                                                                                       | ............................................................................................ 216          |
| 7.3. Uncertainties and limitations about favourable effects...........................................                                        | 217                                                                                                       |
| 7.4. Unfavourable effects.........................................................................................                            | 219                                                                                                       |
| 7.5. Uncertainties and limitations about unfavourable effects                                                                                 | ....................................... 220                                                               |
| 7.6. Effects Table....................................................................................................                        | 220                                                                                                       |
| 7.7. Benefit-risk assessment and discussion...............................................................                                    | 223                                                                                                       |
| 7.7.1. Importance of favourable and unfavourable effects............................................                                          | 223                                                                                                       |
| 7.7.2. Balance of benefits and risks...........................................................................                               | 224                                                                                                       |
| 7.8. Conclusions                                                                                                                              |                                                                                                           |
|                                                                                                                                               | ..................................................................................................... 225 |

<div style=\"page-break-after: always\"></div>

## 8. Recommendations following re-examination  ....................................... 225

Gamifant

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Adverse event

ALT

Alanine aminotransferase

ANC

Absolute neutrophil count

AST

Aspartate aminotransferase

ATA

Anti-therapeutic antibodies

ADA

Anti-drug antibodies

ATG

Anti-thymocyte globulin

CI

Confidence interval

CMV

Cytomegalovirus

CNS

Central nervous system

CpG-ODN

CpG oligodeoxynucleotides

CSA

Cyclosporine-A

CSF

Cerebrospinal fluid

CSR

Clinical Study Report

CU

Compassionate use

CXCL9

Chemokine (C-X-C motif) ligand 9

CXCL10

Chemokine (C-X-C motif) ligand 10

DIC

Disseminated intravascular coagulation

EBV

Epstein-Barr virus

EOT 04

End of treatment in the NI-0501-04 study

G-CSF

Granulocyte colony stimulating factor

GI

Gastrointestinal

GVHD

Graft versus host disease

HIT

Hybrid Immunotherapy

HLH

Haemophagocytic lymphohistiocytosis

HSCT

Hematopoietic stem cell transplant

ICU

Intensive care unit

IFNγ

Interferon gamma

IT

Intrathecal

ITT

Intention to treat

IV

Intravenous

LCMV

Lymphocytic choriomeningitis virus

LDH

Lactate dehydrogenase

LPS

lipopolysaccharide

MAC

Myeloablative conditioning

mAb

Monoclonal antibody

MAS

Macrophage activation syndrome

max

Maximum

min

Minimum

MoA

Mechanism of action

MOF

Multiple organ failure

MPN

Methylprednisolone

NA

Not applicable or not available

NE

Not estimable

NC

Non-clinical

NK

Natural killer

ORR

Overall response rate

<div style=\"page-break-after: always\"></div>

| OS     | Overall survival                                                 |
|--------|------------------------------------------------------------------|
| PD     | Pharmacodynamic                                                  |
| pHLH   | Primary Haemophagocytic lymphohistiocytosis                      |
| PK     | Pharmacokinetics                                                 |
| PPND   | Pre- and postnatal development study                             |
| Q1     | First quartile                                                   |
| Q3     | Third quartile                                                   |
| RIC    | Reduced intensity conditioning                                   |
| ROC    | Receiver Operating Characteristic                                |
| sCD25  | Soluble CD25 (also referred to as soluble interleukin-2receptor) |
| sHLH   | Secondary haemophagocytic lymphohistiocytosis                    |
| sIL-2R | Soluble IL-2 receptor                                            |
| sJIA   | Systemic juvenile idiopathic arthritis                           |
| TE-AE  | Treatment emerging adverse event                                 |
| TE-SAE | Treatment emerging serious adverse event                         |
| TMDD   | Target-mediated drug disposition                                 |
| ULN    | Upper limit of normal                                            |
| US     | United States                                                    |
| VP-16  | Etoposide                                                        |
| yrs    | Years                                                            |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Novimmune BV submitted on 30 July 2018 an application for marketing authorisation to the European Medicines Agency (EMA) for Gamifant, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 28 January 2016. On 10 June 2020, the applicant changed to Swedish Orphan Biovitrum AB (publ).

Emapalumab (also known as NI-0501) was designated as an orphan medicinal product EU/3/10/749 on 9 th  of June 2010 in the following condition: treatment of HLH.

Gamifant was granted eligibility to PRIME on 26 May 2016 in the following indication: treatment of primary haemophagocytic lymphohistiocytosis.

Eligibility to PRIME was granted at the time in view of the following:

HLH is a very rare and life-threatening condition. The median survival has been reported to be less than 2 months after diagnosis when left untreated. Another more recent study reported the estimated 5-year probability of survival in patients with suspected or diagnosed primary HLH to be approximately 54% at a median follow-up of 6.2 years. There are no authorised treatments and although HSCT is potentially curative in primary HLH, a reduced disease activity is a prerequisite for performing the procedure. The unmet medical need is justified based on the poor prognosis and lack of available treatments.

-NI-0501 is a potential new and targeted drug for the treatment of HLH. Data obtained in several nonclinical models of HLH support the role of IFNγ in the pathobiology of the disease and suggest that neutralisation of this cytokine is associated with disease amelioration.

-Preliminary results show a favourable response in 13 of the 18 evaluable patients: 7 patients with a complete response, 5 partial responses, and 1 HLH improvement. Four patients had an insufficient response and two patients died due to disease progression. 10 patients proceeded to transplant with low/no signs of disease activity. Results on glucocorticoid tapering and improvement in a few patients with CNS symptoms are also supportive. No major risk of infusion-related reactions has been noted; infections remain a potential risk.

In conclusion, the eligibility for PRIME is supported by nonclinical data and by a clinical proof of concept that has been established. The magnitude of effect recorded so far in terms of response rate is deemed clinically relevant; not least as disease control is a prerequisite for HSCT. The achievement of also complete responses is noted.

The applicant applied for the following indication: Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or studies.

<div style=\"page-break-after: always\"></div>

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0358/2017 and P/0152/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0358/2017 and P/0152/2018 had not yet been completed as some measures had been deferred.

The PDCO issued an opinion on compliance for the PIP P/0358/2017 and P/0152/2018.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Conditional marketing authorisation

The applicant requested consideration of its application for a Conditional Marketing Authorisation in accordance with Article 14-a of Regulation (EC) No 726/2004.

## Accelerated assessment

The applicant requested accelerated assessment in accordance to Article 14 (9) of Regulation (EC) No 726/2004.

## New active Substance status

The applicant requested the active substance emapalumab contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## PRIME support

Upon granting of eligibility to PRIME, Robert Hemmings was appointed by the CHMP as rapporteur.

A kick-off meeting was held on 18 July 2016. The objective of the meeting was to discuss the development programme and regulatory strategy for the product. The applicant was recommended to address the following key issues through relevant regulatory procedures:

## Quality aspects :

Need for a mature application and recommendation to ask for SA in relation to comparability testing between GLP toxicology batches and clinical batches.

## Non-clinical aspects:

Consider need of a chronic toxicology study to support development and seek SA on this subject.

Regulatory aspects:

<div style=\"page-break-after: always\"></div>

PIP strategy, regulatory options for filing such as conditional approval and approval under exceptional circumstances. Seek SA in relation to post approval activities

Discuss any potential inspections at a next pre-submission meeting.

## Protocol assistance

The applicant received the following Protocol assistance on the development relevant for the indication subject to the present application:

| Date             | Reference                                 | SAWP co-ordinators                         |
|------------------|-------------------------------------------|--------------------------------------------|
| 15 March 2012    | EMA/H/SA/2248/1/2012/PA/PED/SME/III       | Dr David Brown, Prof. Brigitte Blöchl-Daum |
| 23 February 2017 | EMA/H/SA/2248/3/2016/PA/PED/SME/PR/II     | Dr Jan Mueller-Berghaus, Dr Jan Sjöberg    |
| 22 June 2017     | EMA/H/SA/2248/2/FU/1/2017/PA/PED/PR/SME/I | Dr Mair Powell, Dr Carin Bergquist         |
| 10 November 2017 | EMA/H/SA/2248/2/2016/PA/PED/SME/PR/I      | Dr David Brown, Dr Hans Ovelgönne          |

The Protocol assistance pertained to the following quality, non-clinical, and clinical aspects:

## Quality:

- Agreement on the proposal to demonstrate comparability between the batches used in the toxicity studies, clinical study and PPQ batches in support of licensure.
- Overall approach for the drug substance manufacturing process, the approach for the validation of the process, drug substance specifications and monitoring of the reference preparations.
- Agreement with the stability study protocols and the proposed strategy to validate the shipment of the drug substance.
- Suitability of the PPQ batches for commercial supply regarding the endotoxin acceptance criterion.
- Comparability of batches and the stability data to support a shelf-life for the commercial batch.
- Acceptance criteria for the in-process control and the proposed control strategies.
- Acceptability of the stability data from the clinical batches to support a specific shelf life for the commercial drug product.
- Proposal to conduct a drug product shipping validation study.

## Non-clinical:

- Adequacy of the non-clinical toxicology package to support administration of NI-0501 to paediatric patients with HLH including infants and toddlers and to support a MAA.

## Clinical:

- Adequacy of the open label single arm study design for the treatment of active HLH to support a MAA, including the acceptability of the published historical summaries as comparator for this indication.
- Acceptability of the proposed patient populations, in particular regarding the age as well as the form and stage of the disease.

<div style=\"page-break-after: always\"></div>

- Acceptability of the primary efficacy endpoints for the pilot phase and the proposed transition rules to proceed from the pilot to the pivotal phase of the study.
- Acceptability of the primary and secondary efficacy endpoints of the pivotal phase to support a MAA.
- Acceptability of the proposed dose and schedule of administration in the planned clinical programme as well as the proposed safety database.
- Acceptability of an extension protocol.
- Acceptability of the dosing strategy and in particular of the proposed individualised dosing concept and agreement that the dose can be adjusted based on the PK/PD characteristics of the product.
- Acceptability on the proposed analyses of the SAP, in particular regarding the primary endpoint, the underlying assumptions to declare the study successful and additional analyses to support the efficacy of the product.
- Acceptability on the proposed analyses of the SAP regarding the safety analyses.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Paula Boudewina van Hennik Co-Rapporteur:  Ingrid Wang

The appointed co-rapporteur had no such prominent role in Protocol assistance relevant for the indication subject to the present application.

| The application was received by the EMA on                                                                                                                              | 30 July 2018     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                                | 16 August 2018   |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                          | 6 November 2018  |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                       | 5 November 2018  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                     | 19 November 2018 |
| The PRAC Rapporteur's updated Assessment Report was circulated to all PRAC members on                                                                                   | 26 November 2018 |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                 | 13 December 2018 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                     | 26 April 2019    |
| The following GCP inspection(s) were requested by the CHMP and their outcome taken into consideration as part of the Quality/Safety/Efficacy assessment of the product: |                  |
| A triggered GCP inspection of trial NI-0501-04, took place at the sponsor (in Switzerland), two investigator sites (one in the USA and one in Italy)                    | 12 Feb 2020      |

<div style=\"page-break-after: always\"></div>

| and the bioanalytical laboratory (in Switzerland) between 19 August 2019 and 6 December 2019. The outcome of the inspection carried out was issued on:                                   |              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                  | 04 June 2019 |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 14 June 2019 |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                  | 27 June 2019 |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                          | 26 May 2020  |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                         | 11 June 2020 |
| The CHMP agreed on a 2nd list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                              | 25 June 2020 |
| The applicant submitted the responses to the 2 nd CHMP List of Outstanding Issues on                                                                                                     | 30 June 2020 |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the 2 nd List of Outstanding Issues to all CHMP members on                                                    | 10 July 2020 |
| The Rapporteurs circulated the updated Joint Assessment Report on the responses to the 2 nd List of Outstanding Issues to all CHMP members on                                            | 16 July 2020 |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                  | 21 July 2020 |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a negative opinion for granting a marketing authorisation to Gamifant on | 23 July 2020 |

## 1.3. Steps taken for the re-examination procedure

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Andrea Laslop

Co-Rapporteur:  Sinan Bardakci Sarac

| The applicant submitted written notice to the EMA, to request a re- examination of Gamifant CHMP opinion of 23 July 2020., on   | 05 August 2020                       |
|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| The CHMP appointed Andrea Laslop as Rapporteur and Sinan Bardakci Sarac as Co-Rapporteur on                                     | 17 September 2020 and 27 August 2020 |
| The applicant submitted the detailed grounds for the re-examination (Appendix 2 of Final Opinion) on                            | 14 September 2020                    |
| The re-examination procedure started on                                                                                         | 15 September 2020                    |

<div style=\"page-break-after: always\"></div>

| The Rapporteur's re-examination assessment report was circulated to all CHMP members on                                                                                                                                                                                                                                             | 09 October 2020   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The Co-Rapporteur's assessment report was circulated to all CHMP members on                                                                                                                                                                                                                                                         | 09 October 2020   |
| The Rapporteurs circulated the Joint Assessment Report on the detailed grounds for re-examination to all CHMP members on                                                                                                                                                                                                            | 23 October 2020   |
| Ad hoc Expert group experts were convened to address questions raised by the CHMP on The CHMP considered the views of the experts as presented in the minutes of this meeting                                                                                                                                                       | 30 October 2020   |
| The detailed grounds for re-examination were addressed by the applicant during an oral explanation before the CHMP on                                                                                                                                                                                                               | 10 November 2020  |
| The CHMP, in the light of the scientific data available and the scientific discussion within the Committee, re-examined its initial opinion and in its final opinion concluded that the application did not satisfy the criteria for conditional authorisation and did not recommend the granting of the marketing authorisation on | 12 November 2020  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Haemophagocytic lymphohistiocytosis (HLH) is a rare group of disorders of uncontrolled immune activation associated with severe hypercytokinaemia due to a highly stimulated but ineffective immune response. HLH can be categorised as primary (prior to availability of genetic testing known as familial) or secondary (acquired). Primary HLH corresponds to genetically inherited forms including both inherited autosomal recessive familial disorder and immune deficiency-driven haemophagocytosis syndromes. Secondary (acquired) HLH occurs in the setting of infectious, malignant, rheumatologic, or metabolic conditions.

## 2.1.2. Epidemiology and risk factors

The incidence of HLH in paediatrics is estimated as 1 to 225 per 300,000 live births and varies by geographic region. The incidence ranges from 1.2/1,000,000 children/year in Sweden to 7.5/10,000 children in Turkey. Primary HLH usually manifests at a young age, often between 1- 6 months of age. The incidence in the adult population is unknown, but cases are reported in adults, usually associated with heterozygous mutations.

## 2.1.3. Biologic features

Primary HLH is caused by a variety of genetic mutations, most affecting the cytotoxic function of T lymphocytes and natural killer (NK) cells. Most often mutations are seen in genes coding for perforin, which is a pore forming cytolytic protein found in the granules of cytotoxic T cell and NK cells. Also, mutations in genes coding for proteins involved in cytotoxic granule activation, intracellular granule trafficking, priming or release of cytotoxic granules (e.g. Munc13-4/18-2, Syntaxin 11, RAB27A in Griscelli syndrome type II, LYST in Chediak-Higashi syndrome and AP3B1 in Hermansky-Pudlak syndrome type II) have been identified. Mutations in genes that result in immune defects related to the regulation of EBV reactivation are also associated with HLH, including SH2D1A and BIRC4/XIAP in X-linked lymphoproliferative disease. More recently, mutations involved in T-cell function including IL2-inducible T-cell kinase (ITK), CD27, and a magnesium transporter gene have also been reported in association with HLH linked to EBV infection (Allen 2015, Brisse 2016, Morimoto 2016).

Due to these genetic mutations, NK cells and/or cytotoxic T cells fail to eliminate infected cells, including activated macrophages, from th e body and instead continuously secrete inflammatory cytokines. Macrophages are activated by these cytokines and also produce cytokines themselves. This results in a vicious cycle that amplifies the cytokine secretion of CTL, NK cells, and macrophages, thus generating a cytokine storm (hypersecretion of proinflammatory cytokines, a.o. IFNγ, TNFα, IL -6, and M-CSF). Sometimes an infectious trigger can be identified (usually EBV) preceding the HLH.

Several underlying mechanisms for HLH have been proposed. One of them suggests a central role for IFNγ as the cause of disease. This is based on the observations in perforin knock -out mice, supported by the observation of high IFNγ levels in pHLH patients. Once infected with lymphocytic choriomeningitis virus (mice need a viral trigger to develop HLH), the mice develop an HLH-like disease dependent on CD8+ T cells and IFNγ production. When the high levels of IFNγ are neutrali sed by an

<div style=\"page-break-after: always\"></div>

antiIFNγ antibody, the clinical and laboratory abnormalities are reverted, and surviv al rate improves. On the contrary, the ablation of other cytokines had no impact on survival in mice [Jordan et al, 2004]. Based on the data from animal model neutralisation of IFNγ is proposed as a novel targeted treatment strategy for pHLH by the applicant.

Note that although IFNγ -mediated inflammation is a significant feature of HLH, the spectrum of mechanisms that potentially lead to pathologic inflammation are more likely complex and beyond a single pathway (Allen 2015, Brisse 2016).

## 2.1.4. Clinical presentation, diagnosis

A variety of clinical symptoms can be associated with HLH, such as prolonged fever, hepatosplenomegaly and pancytopenia. Patients may have already experienced a prolonged hospitalisation or clinical deterioration without a clear diagnosis before the possibility of HLH is raised. When HLH is left untreated the hypersecretion of cytokines leads to pancytopenia and disseminated intravascular coagulation (DIC) develops rapidly, followed by multiple organ failure such as pulmonary dysfunction, liver failure, coagulopathies, sepsis and CNS disease. HLH (primary + secondary) is diagnosed as per HLH-2004 protocol (Henter 2007) based on the presence of:

- a. A molecular diagnosis or familial history consistent with pHLH
- b. Five out of the eight criteria below are fulfilled:
3. -Fever
4. -Splenomegaly
5. -Cytopenias affecting 2 of 3 lineages in the peripheral blood (haemoglobin &lt; 90 g/L; platelets &lt; 100 x 10 9 /L; neutrophils &lt; 1 x 10 9 /L)
6. -Hypertriglycerida emia (fasting triglycerides ≥ 3 mmol/L or ≥ 265 mg/dL) and/or hypofibrinogena emia (≤ 1.5 g/L)
7. -Haemophagocytosis in bone marrow, spleen or lymph nodes, with no evidence of malignancy
8. -Low or absent natural killer (NK)-cell activity
9. -Ferritin ≥ 500 µg/L
10. -Soluble CD25 (sCD25; i.e. soluble IL2 receptor) ≥ 2400 U/mL.

## 2.1.5. Management

There is no approved therapy for the treatment of primary HLH. However, the current standard of care for treatment naive HLH patients consists of the HLH-1994 or 2004 treatment protocol (etopside, dexamethasone with or without upfront cyclosporine A). The aim of HLH-94/04 treatment is to suppress the hyper-inflammatory state, kill the exuberant lymphocytes and pathogen-infected antigenpresenting cells. This will break the vicious loop of ineffective activation of cytotoxic cells. This treatment also aims to bridge to haematopoietic stem cell transplantation (HSCT), which is the only curative treatment for patients with primary HLH (Jordan 2011). For pHLH patient continuation therapy is recommended to keep the patient in remission until an allogeneic HSCT can be performed, this consists of pulses of dexamethasone in combination with etoposide and cyclosporine A (CSA). Importantly, even if HLH is not in remission, allogeneic HCT should still be attempted (Marsh 2018). Moreover, in published experiences around 30% to 60% of patients have been transplanted with active disease, indicating that complete responses are difficult to obtain HLH patients (Messina 2018).

HLH disease activity and the overall patient condition, as well as time between diagnosis and transplant are considered prognostic factors for a successful transplantation. Whether disease status at transplant is predictive of outcome, is debated (Messina 2018). Recent experience suggests that reduced intensity conditioning may improve the outcomes compared to a myeloablative regimen but

OR

<div style=\"page-break-after: always\"></div>

might be at the cost of higher mixed chimerism (Marsh 2010). Appropriate antibiotic treatment and supportive care are required.

Figure 1 Schematic Overview of the HLH-94 Treatment Regimen

<!-- image -->

CSA = cyclosporine-A; IT = intrathecal; VP-16 = etoposide. Source: Henter et al, 1997.

Other treatment regimens described are the HLH 2004 (HLH-94 but with upfront Cyslosporine-A) and HIT Regimen (anti-thymocyte globulin with dexamethasone and etoposide), but these have not shown to give better outcomes compared to the HLH-94 regimen.

No uniform definition exists for pHLH patients who require treatment beyond first line. Patients who initially respond to therapy may experience a relapse of HLH. Relapses may respond to intensification of standard-of-care therapy. The intensification was not (yet) described in HLH-94; but included in HLH-04 protocol. No standard definition of refractory HLH exists. The HLH society considered refractory HLH as failing to experience an adequate response to conventional therapy (Marsh 2017). In literature, patients refractory to steroids and etoposide or steroids and ATG have been described. In patients who are refractory to treatment, the addition of alemtuzumab is recommended (Marsch 2017). Other products that have been used as 'salvage therapy' in pHLH are anakinra, or ATG.

## Course of disease/prognosis

If left untreated, the disease is lethal with a median survival less than 2 months after diagnosis (Janka, 1983). For treatment naive patients treated with the HLH 94-04 treatment the estimated 5-year survival in patients with suspected or diagnosed pHLH is 56-59%. Most deaths occur in the first 9 weeks of treatment (Trottestam 2011).

At the time of introduction of the HLH-94 regimen, genetic testing was not possible. Overall survival at 5 years post-HSCT for pHLH was reported to be up to 70%. Survival of patients with refractory HLH is not clearly described in the literature, but the clinical experience strongly suggests that patients who fail to response adequately to conventional therapies have 'poor' survival, but the overall survival is not specified.

The drugs currently used to treat HLH may worsen some of the disease parameters, as it is the case for etoposide (decrease in blood cell counts) and for the prolonged use of glucocorticoids (bleeding and rash). Drugs used for conditioning and after HSCT can significantly impact on HLH parameters and increase the risk for infections. HSCT itself is a procedure which triggers significant complications, including failure of engraftment or secondary rejection, acute and chronic graft versus host diseases, venous occlusive disease, thrombotic microangiopathy, pulmonary complications, infections including

<div style=\"page-break-after: always\"></div>

CMV reactivation and BK virus with haemorrhagic cystitis and fungal infections. Therefore, interpretation of the safety profile in the absence of a direct comparison may be hampered due to overlap between treatment and disease-related complications.

Table 1 provides an overview of the reported efficacy outcome as reported for the HLH-94 and HLH2004 studies and in the retrospective review of the use of alemtuzumab in refractory HLH. Please note, that no uniform response criteria are used and that over time, the selection of HLH patients that proceed to HSCT and treatment of HSCT have improved and HLH definitions changed. If left untreated or unresponsive to therapy, pHLH is invariably lethal. Overall, there is still an unmet medical need in the treatment of pHLH.

Table 1 Published efficacy data for HLH: treatment naive and refractory patients

|                                                                                                                         | Previously untreated patients                                                                         | Previously untreated patients                                                                       | Refractory patients treated with alemtuzumab   |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------|
|                                                                                                                         | HLH 94 n=249                                                                                          | HLH-2004 n=369                                                                                      | Marsch et al 2013 4 n=22                       |
| Number of familial/ primary HLH cases- Note that at the time of HLH-94 no genetic testing was possible at time of study | n=52 cases of familial HLH 1                                                                          | n=168 pHLH cases 1                                                                                  | n=? pHLH cases                                 |
| single arm                                                                                                              | prospective                                                                                           | prospective                                                                                         | retrospective review tert. Centr               |
| Time frame                                                                                                              | 1994-1998                                                                                             | 2004-2011                                                                                           | 2004-2010                                      |
| 5-year OS                                                                                                               | 56 (44-71)% 1                                                                                         | 59% (52-67) 1                                                                                       |                                                |
| 2.5-year OS                                                                                                             |                                                                                                       |                                                                                                     | 64% 2                                          |
| Proceeding to HSCT (n, %)                                                                                               | n= 40 (76%) 1                                                                                         | n=135 (80%) 1                                                                                       | n=17 (77%) 2                                   |
| post HSCT survival at 5 years                                                                                           | 70% (57-86) 1                                                                                         | 70% (63-78) 1                                                                                       | not reported                                   |
| time to HSCT 2                                                                                                          | 165 days 1                                                                                            | 126 days 1                                                                                          | not reported                                   |
| Clinical response                                                                                                       | 59% reported to have nonactive disease after 8 weeks- number includes both pHLH and sHLH patients 2,3 | 51% reported to have nonactive disease after 8 weeks- number includes both pHLH and sHLH patients 1 | 86% at 2 weeks 2                               |

Data in bold specific for familial or primary HLH patients

1 Survival data of patients with sibling with HLH, from Bergsten 2017 1

2. no information available for pHLH patients; Non- active disease is defined as normalisation of diagnostic clinical and laboratory abnormalities including fever, cytopenia, splenomegaly, decreased fibrinogen, increased sCD25 and CNS symptoms. In the case of ferritin, normalisation or a 3-fold improvement in the pre-study level will be evidence of complete response provided the posttherapy level is also &lt; 1000 ng/ml

3. Data from Trottestam 2011.

The duration of alemtuzumab treatment in the referenced study was considerably shorter (median of 4 days; range 2-10 days) than the anticipated duration of NI-0501 treatment in the NI-0501-04 study

1  Bergsten E, Horn A et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long term results of the cooperative HLH-2004 study. Blood prepublished online September 21, 2017; DOI 10.1182/blood-2017-0678834

<div style=\"page-break-after: always\"></div>

(4-8 weeks). Moreover, the partial response in the referenced study was defined at the endpoint of 2 weeks and not at 8 weeks.

## About the product

Emapalumab is a high affinity fully human IgG1 anti-human interfero n gamma (IFNγ) monoclonal antibody (mAb) which binds to soluble and receptorbound forms of IFNγ. Pharmacotherapeutic group: selective immunosuppressants, ATC code: L04AA39

The initially claimed indication is: Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary Haemophagocytic Lymphohistiocytosis (HLH).

The proposed posology is: The recommended starting dose of emapalumab is 1 mg/kg given as an intravenous infusion over 1 hour. Emapalumab should be administered twice a week (every 3 to 4 days) until haematopoietic stem cell transplantation (HSCT) is performed. The emapalumab dose may be increased to 3 mg/kg, then to 6 mg/kg and up to 10 mg/kg depending on clinical conditions. After the patient's clinical condition is stabilised, the dose may be decreased to the previous level to maintain clinical response until HSCT.

## Concomitant medications

Emapalumab should be given concomitantly with dexamethasone. Administer dexamethasone with emapalumab at a starting daily dose of 10 mg/m 2 . Dexamethasone can be tapered according to the judgment of the treating physician.

Antibiotic prophylaxis for Pneumocystis Jiroveci, fungal infections and varicella zoster and tuberculosis (if required according institutional guidelines) were given from the day prior to initiation of emapalumab treatment until the end of the study.

## Type of Application and aspects on development

The CHMP did not agree to the applicant's request for an accelerated assessment as the product was not considered to be of major public health interest. This was based on the low methodological quality of the data, which precluded the identification of an evident benefit of emapalumab over the existing therapies.

The applicant requested consideration of its application for a Conditional Marketing Authorisation in accordance with Article 14-a of Regulation (EC) No 726/2004, at day 180 of the procedure, based on the following criteria:

## · The benefit-risk balance is positive.

The applicant considers the B/R for the second line patient population positive because the study met its primary endpoint in the second line treated patients with 17/27 (63%) of patients responding (95% CI: 0.42-0.81; p=0.0134). The effect was supported with several sensitivity analyses and with a reduction in the glucocorticosteroid therapy while maintaining response.

Safety data are available from just over 80 patients treated with emapalumab in clinical trials and just over 100 patients treated post-marketing in the US. The applicant claimed that the totality of these data demonstrates that emapalumab has a manageable safety profile favourably differentiated from conventional therapies.

- It is likely that the applicant will be able to provide comprehensive data.

<div style=\"page-break-after: always\"></div>

Study NI-0501-09 is an on-going open-label, single arm, multicentre study to assess efficacy, safety, impact on quality of life, and long-term outcome in paediatric patients with primary pHLH treated with emapalumab that will provide further understanding of the efficacy and safety of the medicinal product.

The primary efficacy parameter is as the NI-0501-04 study, Overall Response, i.e., achievement of either Complete or Partial Response or HLH Improvement, at EOT or Week 8 (whichever occurs earlier). Secondary efficacy parameters are, amongst others, the Overall survival, including survival to HSCT and survival after either HSCT or last emapalumab infusion (if HSCT is not performed).

Safety will also be evaluated (adverse events, laboratory parameters and number of patients who discontinued emapalumab treatment for safety reasons).

The study is ongoing with 22/34 enrolled (EU:20 and US:2), and preliminary data suggest 15/22 patients are in second line (all EU). The applicant is confident that the study will complete enrolment, and Last Patient Last Visit is estimated to be October 2022.

## · Unmet medical needs will be addressed

The applicant claimed that emapalumab will address an unmet medical need in pHLH. Primary Haemophagocytic Lymphohistiocytosis (HLH) patients are a fragile paediatric patient population suffering from a life-threatening disease with high mortality in spite of conventional therapy. There is currently no approved treatment available in the EU.

Treatments with a different mode of action are needed - no single treatment can obtain complete response in all patients.

Second line patients, the target patient population in the proposed indication statement, are in a particularly susceptible situation as conventional therapy has failed and no well documented treatment choices exist.

- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required.

Based on the high unmet medical need, the positive benefit/risk profile and the manageable and favourably differentiated safety profile of emapalumab, the applicant believes that the benefit of the immediate approval outweigh the risks that still additional data are required.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as concentrate for solution for infusion containing 5 mg/ml of emapalumab as active substance. Two presentations are applied for: 2 ml and 10 ml.

Other ingredients are histidine, histidine monohydrochloride monohydrate, sodium chloride, polysorbate 80 and water for injections.

The product is available in a vial (type I glass) with a stopper (bromobutyl rubber) and a seal (aluminium) with a flip-off cap.

Although this dossier is not considered a Quality by Design application, certain elements of an enhanced approached were applied.

<div style=\"page-break-after: always\"></div>

## 2.2.2. Active Substance

## General information

Emapalumab (INN) is a 147,987 Da fully human immunoglobulin G1 λ2 monoclonal antibody comprising two heavy chains and two light chains covalently associated by disulphide bridges and a single N-linked glycosylation site in each heavy chain. The predicted amino acid sequence for heavy and light chains is presented in Figure 2. This was predicted from the translation of the nucleotide sequence for the gene of emapalumab active substance. This sequence is unique to emapalumab.

## HeavyChain

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

N-terminal=E（Glutamate);C-terminal=K(Lysine)

## LightChain

NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYY CQSYDGSNRWMFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNK YAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

N-terminal =N(Asparagine); C-terminal =S (Serine)

The complementarity determining regions(CDR)are shown inred, and the fragment crystallizable (Fc) glycosylation sitein blue.

## Figure 2: Predicted amino acid sequence for emapalumab active substance

Emapalumab neutralises the biological activity of and therefore cellular responses to interferon gamma (IFNγ) by disrupting its interaction with the IFNγ receptor 1|2 co mplex therefore inhibiting subsequent activation of the JAK-STAT signalling pathway. The complementarity dependent regions (CDR) highlighted above are therefore important for the mechanism of action. The mechanism of action of emapalumab does not require Fc effector function.

## Manufacture, process controls and characterisation Description of manufacturing process and process controls

All active substance manufacturing sites are GMP-authorised for the relevant activities.

The active substance manufacturing process is appropriately described. It contains the critical steps typically used for the manufacture of a therapeutic monoclonal antibody. The container closure system for the active substance is a 4 L or 500 mL high density polyethylene (HDPE) screw cap container with a polypropylene closure. Specifications have been provided for the packaging which meets Ph. Eur. requirements. Results of extractable and leachable studies have been provided in S.2.5 and are deemed adequate.

## Control of materials

Raw materials and reagents used in the manufacture of the active substance are listed identifying where each material is used in the process. Most of the materials are compliant to Ph. Eur. or national pharmacopoeias. A control strategy is specified for non-compendial materials which was considered acceptable. No excipients, cell culture media components or purification resins of animal origin are used in the emapalumab active substance manufacturing process.

## Control of critical steps and intermediates

No intermediates are registered to the manufacturing process.

<div style=\"page-break-after: always\"></div>

Following scale down model (SDM) process characterisation studies (PCS, described below), a failure modes and effects analysis (FMEA) was then carried out to evaluate the impact of failure of each process parameter on process performance and/or product quality (severity score), the likelihood of an excursion from the acceptable range (occurrence score) and how such an excursion is monitored (detectability score). The FMEA identified critical process parameters (CPPs); process parameters whose variability has an impact on a CQA and should be monitored or controlled to ensure that the process produces the desired product quality. The steps in the process where CPPs were identified and the defined target or acceptable range for each of these critical parameters are provided and reflect data obtained in PCS studies.

Quality attributes will be monitored at each step as in process controls (IPCs).

## Process validation

Process performance qualification (PPQ) batches were run using the proposed commercial process and adequately demonstrate that consistent process performance and acceptable product quality are achieved during routine commercial scale manufacturing. CPPs and non-CPPs were run within their acceptance criteria. All quality attributes (QAs) and performance attributes (PAs) monitored met the acceptance criteria. All active substance batches met release acceptance criteria. Hold times executed during process validation exceed and therefore support those registered in the dossier.

## Manufacturing process development

Quality attributes (QAs) commonly used for monoclonal antibodies were ranked for criticality based on their impact on biological activity/efficacy, pharmacokinetics/pharmacodynamics, immunogenicity and safety. The scoring system used has been outlined and also accounts for uncertainly around the impact. Appropriate rationale is given for those QAs that were ranked as non-critical. A PP was evaluated using a qualified scale-down model (SDM) in process characterisation studies (PCS) if it was deemed to have a high risk of impacting on a CQA/PA, no manufacturing data was available to support its range and no scientific justification can be made to support it (score =8). PPs with a high risk of impact and therefore technically critical but with manufacturing data available to support their ranges, are not controlled, monitored or evaluated further. The applicant has registered a complete list of critical PPs. During PCS evaluation of PPs, PAs and QAs were monitored as outputs and compared to equivalence ranges based on 95% confidence intervals of data obtained from control / set point PCS runs. The PCS studies described are deemed appropriate. A wide range of PPs have been comprehensively evaluated. For the PCS of several manufacturing steps, numerous PPs are evaluated in a multi-variate fashion. However, a design space is not claimed and it is the intention that during manufacture, all PPs will be operated at their target set points and within their PARs. The overall control strategy (including in process controls, testing of starting material, monitoring of process parameters) is considered sufficiently adequate to control the process leading to an active substance of intended and consistent quality.

## Characterisation

Characterisation of emapalumab has been performed. The methodology used is deemed adequate. Emapalumab has been physicochemically characterised for primary and secondary structure, mass heterogeneity, size purity, charge heterogeneity, glycosylation, free thiol content and disulphide mapping. Biological activity was characterised using a cell-based assay that captures the proposed clinically-relevant mechanism of action; i.e. it monitors the ability for emapalumab to neutralise the bi ological activity of, and therefore cellular responses to IFNγ. The immunological properties of emapalumab have been fully characterised. Emapalumab did not have complement dependent cytotoxicity (CDC) activity. Emapalumab includes several molecular entities or variants which are considered product-related substances, these have been appropriately characterised and include,

<div style=\"page-break-after: always\"></div>

charge variants, fragments, aggregates and oxidised species. Process-related impurities have been outlined. The control strategy for these has been described and is acceptable. Specified impurities have been included in product used in clinical studies.

## Specification

The active substance specification includes tests for characteristics, identity, purity, activity, impurities and safety parameters.

Testing is included for molecular and biological characteristics to confirm the quality of emapalumab. The end of shelf life specification is the same as the batch release specification. The proposed active substance specifications tests and methods are currently acceptable.

## Analytical methods

The proposed procedures have been satisfactorily validated and are, adequate to control the active substance on a routine basis, i.e. as release tests.

## Batch analysis

The applicant has provided batch data for clinical and PPQ batches manufactured at scale. Batch-tobatch consistency has been demonstrated.

## Reference materials

The applicant has appropriately characterised an in-house primary reference material and prepared a working standard. The working standard will be used in analytical testing for batch release and stability studies. This approach is acceptable.

## Stability

An active substance shelf-life of 36 months at -65ºC is claimed.

24-month data for 3 PPQ batches and 72-month data for 1 clinical batch are provided in support of this shelf-life. All batches were at commercial scale. Studies were carried out in accordance with ICH requirements. All results remain within specification and no trends are observed.

The stress conditions were shown to be suitable to provide an appropriate level of degradation without product decomposition. The studies also confirm the stability-indicating nature of the analytical methods which are the same as those used for routine analysis.

Photostability studies were carried out in line with ICH guidelines.

Based on the provided data the claimed shelf-life and storage conditions are acceptable.

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is a concentrate for solution for infusion, which is presented as a clear or slightly opalescent, colourless to slightly yellow liquid and free from visible particles. Gamifant is manufactured in two presentations, 2 ml and 10 ml, each presentation containing 5 mg/ml of emapalumab in formulation buffer. The composition of emapalumab is presented below. The primary container is a type I colourless glass vial with a flurotec-coated bromobutyl rubber stopper and an aluminium overseal.

Comparability data has been provided which includes batch release data, IPCs and some additional characterisation studies. The data support the comparability of batches manufactured at both sites.

<div style=\"page-break-after: always\"></div>

The applicant has applied QbD principles in the development of the finished product and their manufacturing process. However, no design spaces were claimed for the manufacturing process of the finished product. A standard risk assessment was performed which uses a system of risk ranking and filtering to evaluate individual process parameters. Critical process parameters (CPPs) are defined in line with ICH Q8 as a process parameter whose variability has an impact on a critical quality attribute (CQA) and therefore should be monitored or controlled to ensure the process produces the desired quality. All process parameters that fall outside of the definition for CPPs are non-CPPs. Extractable and leachable studies were conducted on the container closure and appropriate toxicological justification was provided which justifies that there is no risk to patient safety.

The container closure systems are Type I colourless 10 mL and 2 mL vials. Specifications for each of these components are registered in the dossier. The proposed specifications are comprehensive and the container closure complies with relevant Ph. Eur. standards.

## Manufacture of the product and process controls

All finished product substance manufacturing sites are GMP-authorised for the relevant activities.

The manufacturing process is straightforward and standard for a biological parenteral product. The manufacturing process is described in sufficient detail and is appropriate for the manufacture of a biological concentrate for solution for infusion.

## Process controls

These IPCs are appropriate for routine control of a biological finished product. CPPs for each manufacturing step have been listed; criticality was assigned based on risk assessment. The ranges were defined based on process characterisation studies and are considered appropriately supported by data.

Traditional process validation was performed on several consecutive PPQ batches for both fill volumes. Two batches were manufactured at the proposed minimum commercial production scale and one at the proposed maximum commercial production scale. For each manufacturing step, results are provided for CPPs, non-CPPs and IPCs. The majority of results were within the acceptance criteria and demonstrated that the manufacturing process can be run in a consistent manner. Extractable and leachable studies have also been provided for material which comes into contact with the finished product during manufacture. A toxicological justification has been provided to support the safety of the identified compounds. Shipping validation studies are described which support transport of finished product from the site of manufacture.

## Product specification

Finished product specifications cover the relevant aspects of identity, purity, potency and sterility.

The panel of tests are in accordance with ICH Q6B and Ph. Eur. 2031 monoclonal antibodies for human use and are therefore considered appropriate for routine control of emapalumab. The release and shelf life specifications have been justified based on batch data from clinical and PPQ batches.

## Analytical methods

The analytical procedures are sufficiently well described in the dossier. Details of method validation have been provided for the product specific methods as well as the Ph. Eur. methods for sterility and endotoxin. The level of detail provided for the validation is in general considered sufficient. Methods

<div style=\"page-break-after: always\"></div>

have been validated according to ICH Q2(R1) and cover the relevant parameters of accuracy, precision, specificity, limit of detection, limit of quantitation, linearity and range.

## Batch analysis

Batch data has been provided for several PPQ and clinical batches. Overall, the batch data show that the finished product batches are consistent and well within specification. This demonstrates the manufacturing process is capable of producing a consistent finished product.

## Reference materials

The reference standard used for the finished product testing is the same as for active substance.

## Stability of the product

The proposed shelf life of the finished product is 3 years when stored in a refrigerator (2ºC to 8ºC).

The product should not be frozen and the vial should be kept in the outer carton to protect from light (due to photosensitivity of the active substance).

Stability data was presented at real time (36 months at 5ºC), accelerated (36 months at 25ºC) and force degradation conditions (degradation by oxidation, high pH, low pH and agitation), in line with ICH guidelines. Stability indicating nature of the methods has been confirmed.

Photostability results carried out in line with ICH guidelines have been presented

The proposed shelf life of 36 months at 50°C is supported by two batches with 36 months data and 7 batches with 24 months data.

## Adventitious agents

The various controls in place to minimise the risk of contamination with non-viral adventitious agents are described. The strategy includes control of raw materials and testing of the master cell bank/inprocess bulk/active substance to demonstrate the absence of contamination with bacteria, mycoplasma or fungi. The suitability of the non-pharmacopoeial methods used to screen the MCB for non-viral adventitious agents has been addressed. Raw materials have been evaluated to assess their risk of Transmissible Spongiform Encephalopathy; no materials of animal origin are used during the manufacturing process and it is confirmed that all materials used are compliant with EMEA/410/01. No raw materials of human or animal origin were used in the preparation and cryopreservation of the master cell bank. With respect to the early developmental cell bank a statement of low TSE/BSE risk was provided from the cell line developer along with confirmation that the risk assessment was performed in accordance with EMA/410/01 rev.3. This information provides sufficient assurance given the parental cell line is standard and taking into account the testing summaries of the host cell banks in 3.2.S.2.3.

The MCB and unprocessed bulk have been tested for viral contamination in accordance with ICH Q5A and results are acceptable. The methods used to evaluate the MCB for viral contamination have been briefly described and their suitability substantiated. A summary of the viral clearance studies has been provided and, complies with ICH Q5A. The background reports for the viral clearance studies were provided. Sufficient information has been provided to support the validity of the approach taken during viral clearance studies and the suitability of methods used.

## GMO

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

The manufacturing process of emapalumab active substance is well described and controlled. The manufacturing process is considered standard for a monoclonal antibody and an appropriate control strategy has been registered. The control strategy was developed based on small-scale evaluation of process parameters as inputs with quality attributes and performance attributes as outputs. Subsequently three PPQ lots were manufactured at scale and show that consistent process performance and acceptable product quality are achieved during routine commercial scale manufacturing. Minor changes to the process between clinical and PPQ are supported by batch data, extensive characterisation and forced stability data and demonstrate negligible impact on quality. The panel of release tests is considered appropriate and the specifications are acceptable. The current shelf-life claim of 36 months is sufficiently supported by stability data.

The finished product manufacturing process is sufficiently well described, is under a sufficient level of control and has been appropriately validated. The panel of analytical tests is considered appropriate to control the release of the finished product and the specifications are acceptable. The stability data provided support the claimed shelf life.

The controls in place to minimise the risk of non-viral/viral adventitious agent contamination are adequately described. Overall, acceptable viral clearance has been demonstrated for the downstream purification process.

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.2.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation, in the case of a positive opinion:

- for the host cell protein assay, a revised specification based on a validated revised method should be registered within 1 year of approval;
- the active substance specifications should be re-evaluated after manufacture of a total of 20 batches or by December 2021;
- the finished product specifications should be re-evaluated after manufacture of a total of 30 batches or by December 2021.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The applicant submitted an adequate non-clinical package based on the nature of the medicinal product in support of their applied indication.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

Emapalumab is a high affinity antibody against human IFNγ with a dissociation constant of 1.4 pM. Once formed, emapalumabIFNγ complex could still bind to IFNγR1 ( 10.7 nM), albeit with a much lower affinity than IFNγ alone ( 0.59nM). Nevertheless, emapalumabfacilitated inhibition of IFNγ binding to its receptor led to a dose dependent in vitro interference of IFNγ dependent STAT1 signalling. Emapalumab is a non-competitive inhibitor, as it was unable to reduce STAT1 signalling after IFNγ was preincubated with cells expressing STAT1 -luc. Co-incubation of emapalumab with huIFNγ showed a potent and dose -dependent reduction of STAT-1 activity (IC50 = 1.23nM). Complete inhibition was reached after roughly equimolar incubation of IFNγ with emapalumab. The ability to inhibit INFγ functioning of emapalum ab was further investigated in an in vitro model of protection against infection by encephalomyocarditis virus (EMCV). Emapalumab dose dependently increased viral activity, with an IC50 of 6 nM.

Emapalumab has a low picomolar affinity for cynomolgus IFNγ ( 49.3 pM). The applicant justifies the approximately 40-fold difference in affinity as being a result of a combination of both very high affinity as well as avidity, which makes calculating an accurate dissociation constant challenging. Considering that both human and cynomolgus dissociation constants are in the low picomolar range, emapalumab is considered to be a high affinity ligand for huIFNγ and cynoIFNγ. Emapalumab also bound to rhesus IFNγ and with low affinity to porcine IFNγ. Little to no cross -reactivity is observed for most other common laboratory animals with the exception of pig. The lack of cross-reactivity in rodent was demonstrated in an in vitro model of EMCV infection, where emapalumab was unable to neutralise the protective effects of rat o r mouse IFNγ. In contrast, protective effects of human INFγ were effectively inhibited by emapalumab.

Because no animal models of HLH exist, a mouse specific anti IFNγ (XMG1.2) was used to establish proof of concept. XMG1.2 binds with high affinity to mIF Nγ (KD=15 pM) and is highly potent in neutralising IFNγ -mediated upregulation of MCH II (IC50=0.4 nM). Because potency of emapalumab was established using STAT1 activity, it would have been preferable to use this for XMG1.2 as well. However, published and applicant's studies in mouse models of HLH showed improvement of clinical and laboratory features of the disease, suggesting that emapalumab could elicit comparable effects. The applicant has sufficiently demonstrated the validity of XMG1.2 as a surrogate antibody of emapalumab.

Perforin deficient (pfp-/-) mice infected with lymphocytic choriomeningitis virus (LCMV) were used in an applicant driven proof of concept study. These mice develop characteristic clinical (fever, splenomegaly, pancytopenia, hypertrigliceridaemia, hypofibrinogenaemia and haemophagocytosis) and histological features (activated lymphohistiocytic infiltrates, splenic/lymph node follicular depletion, periportal infiltrates, bone marrow hyperplasia, and meningeal infiltrates) of human HLH. XMG1.2 improved control overweight loss and hypothermia, reduced ferritin and triglyceride levels, reduced

<div style=\"page-break-after: always\"></div>

cytopenia, and reduced cytokine levels (IL-6, IL10 and TNFα) in a more or less dose dependent manner. Optimal results were achieved from 30 mg/kg onwards. As a proof of concept that an antiIFNγ antibody can improve disease pathology of HLH, the provided study is adequate. Further evidence not examined in the applicant study was presented in the form of published literature, which showed that neutralisation of INFγ was able to improve further clinical and histological features in a mouse model for HLH. Notable observations include:

- Increased survival in LCMV infected pfp-/mice after IFNγ neutralisation, but not after TNF -α, IL-12, IL-18, M-CSF, and GM-CSF (Jordan et al. 2004)
- Normalisation of neutrophil, platelet and haemoglobin levels in LCMV infected pfp-/- mice after IFNγ neutralisation (Jordan et al. 2004)
- Abrogation of haemophagocytosis in LCMV infected pfp-/- mice a fter IFNγ neutralisation (Pachlopnik Schid et al. 2009)
- Decreased splenomegaly and liver inflammation, increased RBC and platelet, inhibition of CXCL9 and CXCL10 production. CXCL9 and CXCL10 levels correlated with disease activity in paediatric sHLH patients (Bautois et al. 2017)

Overall, there is sufficient nonclinical evidence to suggest that neutralisation of IFNγ by emapalumab would lead to an improvement of the disease pathology of HLH mouse models of disease. As such, the non-clinical proof of concept and mode of action is adequately demonstrated in this model. However, translatability of MoA and PoC to the human setting should be confirmed in clinical studies. Gene mutations associated with inherited HLH also influence other proteins than perforin and/or other processes involved in HLH.

## Secondary pharmacodynamic studies

The applicant demonstrated that emapalumab does not have intrinsic Fc effector functions, including antibody-dependent cytotoxicity (ADCC) and complement dependent toxicity (CDC). There was no offtarget binding of emapalumab to human tissue shown.

## Safety pharmacology programme

The absence of dedicated safety pharmacology studies has been adequately justified based on the nature of the product. Incorporation of relevant functional parameters in repeat dose toxicity studies in cynomolgus monkeys did not reveal any findings of concern.

## Pharmacodynamic drug interactions

The absence of a pharmacodynamic drug interaction study has been adequately justified based on the physiologic nature of emapalumab. Downregulation of CYPs as a result of circulating cytokines was considered by the applicant. Although this is related more to the disease pathology of HLH than that it is an effect of emapalumab, it is agreed that emapalumab could have the potential to restore CYP downregulation.

## 2.3.3. Pharmacokinetics

The pharmacokinetic profile of emapalumab was characterised following single intravenous administration to cynomolgus monkeys. Toxicokinetic profiles were characterised in cynomolgus

<div style=\"page-break-after: always\"></div>

monkeys following once weekly intravenous dosing for a total duration of up to 13 weeks. Foetal exposure was characterised in the embryo-foetal development study in mice using rat antimouse IFNγ mAb, XMG1.2, as a functional surrogate for emapalumab. Emapalumab in cynomolgus serum was measured by sandwich ELISA assays. A complete validation was provided for the method used in the 8-week monkey repeated dose study, while the method used in the 13-week study was considered a preliminary assay and only partially validated. A validated method was also provided for the determination of anti-emapalumab antibodies in monkey serum. The method used for the measurement of XMG1.2 in mouse plasma was fit for purpose. Single dose pharmacokinetics was characterised following an intravenous infusion of emapalumab at 10 and 30 mg/kg to cynomolgus monkeys. Volume of distribution was 0.062 - 0.134 L/kg, corresponding to approximately the 1 - 2-fold the serum volume, which is as expected for a monoclonal antibody. Serum clearance was 0.21 - 0.30 mL/h/kg, which is higher than in humans (0.0875 mL/h/kg in healthy volunteers, based on 80 kg body weight and estimated linear clearance in adult patients 0.17 mL/h/kg based on 70 kg body weight). Elimination half-life was lower at 30 mg/kg (7 - 11 days) than at 10 mg/kg (11 - 15 days). Systemic exposure increased approximately doseproportionally between 10 and 30 mg/kg. There were no consistent gender differences. Multiple dose studies were performed in cynomolgus monkeys at 3 - 30 mg/kg/week for 8 weeks and 10 - 200 mg/kg/week for 13 weeks. Exposure multiples achieved in the studies were up to approximately 2x human exposure in the 8-week study and up to 14-18x the human exposure in the 13-week study. In the 8-week study, systemic exposure increased approximately dose-proportionally. In the 13-week study, the increase was less than dose-proportionally after day 36. In the 8-week study, exposure was lower in females than in males at 10 and 30 mg/kg. This was most obvious at 10 mg/kg. In the 13-week study, no consistent differences between males and females were found. Clearance was low (0.08 - 0.17 mL/h/kg), which is as expected for an antibody with a long half-life, and comparable to clearance in humans. Clearance was slightly higher at higher dose (0.17 mL/h/kg at 200 mg/kg) than at lower doses. The half-life was estimated as 7 - 10 days in the 8-week study. This half-life is lower than the half-life in healthy volunteers (approximately 22 days). However, the washout time of 7 days in the monkey study was too short to estimate the half-life reliably. Half-life in HLH patients varies widely depending on IFNγ concentrations. Accumulation was observed, of approximately 2 - 3-fold in the 8-week study. In the 13-week study, accumulation of up to nearly 5fold was observed at 10 mg/kg, whereas accumulation was maximally 2fold at doses ≥ 100 mg/kg. Evidence of neutralising antibodies against emapalumab was found only in the 8-week study, and only in 1 out of 22 monkeys. In the 13-week study, no ADAs were found, but emapalumab levels were too high to measure ADAs reliably. However, the pharmacokinetic profiles in the 13-week study do not indicate the formation of neutralising antibodies. Formal tissue distribution and protein binding studies were not conducted with emapalumab, which is agreed. The volume of distribution of 0.034 - 0.042 L/kg in cynomolgus monkeys indicates that emapalumab was primarily confined to the vascular compartment. This is consistent with the known biodistribution of a monoclonal antibody. In an embryo-foetal toxicity study in mice, in which rat antimouse IFNγ mAb was administered instead of emapalumab, this antibody was found in the foetuses on gestation day 18. No metabolism studies were conducted with emapalumab. The expected metabolism of antibodies consists of degradation to small peptides and individual amino acids. According to ICH S6 (R1), classical biotransformation studies do not need to be conducted. No excretion studies have been conducted since emapalumab is degraded to small peptides and amino acids similar to endogenous immunoglobulins.

Gamifant

<div style=\"page-break-after: always\"></div>

No non-clinical interaction studies have been performed. Pharmacokinetic drug interactions are unlikely because emapalumab is not metabolised via CYP P450 enzymes. However, cytokines, including IFNγ, which are overproduced in HLH, are known to downregulate cytochromes P450 (CYPs), resulting in suppression of CYP activity during active disease. Emapalumab, targeting IFNγ, will have the potential to restore CYP activity back to normal. Thus, attenuation of IFNγ in HLH patients by emapalumab may contribute to the restoration of CYP activity and potentially influence the metabolism of drugs used concomitantly. Section 4.5 of the SmPC contains a warning regarding this effect.

## 2.3.4. Toxicology

## Single dose toxicity

No single dose toxicity studies have been performed which can be accepted.

## Repeat dose toxicity

The repeat dose toxicity of emapalumab was investigated in cynomolgus monkey dosed up to 200 mg/kg/day for up to 13 weeks duration. The only adverse effects noted were those related to GI tract infection, consisted of liquid faeces at all dose groups leading to dehydration at the high dose, and increases in plasma white blood cells, lymphocytes and neutrophils. Increases in inflammatory cells were also observed in kidney and lung. There were mortalities at all dose groups. GI tract infection was confirmed as caused by Shigella sp. and Campylobacter sp., which are commonly found in cynomolgus monkeys. It seems likely that the pharmacological effect of IFNγ inhibition results in these opportunistic infections. This was further confirmed by an additional 8-week study using monkeys which were confirmed pathogen free, in which no treatment-related effects including infections occurred. The exposure in the toxicology studies was sufficiently high (up to approximately 2x human exposure in the 8-week study and up to 14-18x the human exposure in the 13-week study. Evidence of neutralising antibodies against emapalumab was found only in the 8-week study, and only in 1 out of 22 monkeys. In the 13-week study, no ADAs were found. These results indicated that formation of ADAs does not interfere with the interpretation of the study results.

Immunotoxicity was examined in both 13 and 8-week studies, although in the 8-week study the analytical methods were considered not reliable. In the 13-week study, the T-cell dependent antibody response to the antigen Keyhole Limpet Haemocyanin (KLH), was slightly reduced in the treated animals as compared to controls, where the levels of anti-KLH IgG antibodies were reduced after the first challenge. This is not unexpected and could be due to the reduction of IF Nγ in these animals. Upon a secondary boost with KLH, the levels of anti-KLH IgG were comparable to controls, indicating no impairment in generating the B cell memory pool or ability to mount a response following reexposure to antigen. These results indicate that emapalumab is not immunotoxic, but it is clear from the pre-clinical and clinical data that the immune function is supressed.

The toxicity studies with emapalumab have been conducted in juvenile, adolescent, and young adult monkeys. There was no difference between target organs between the different ages of the animals, and no target organs were identified that play a role in development. The outcome of the repeated dose studies is therefore applicable to all ages of patients.

<div style=\"page-break-after: always\"></div>

## Genotoxicity / Carcinogenicity

No genotoxicity or carcinogenicity studies have been performed. Considering the physiologic nature of the product, this is agreed.

## Reproduction Toxicity

No reproduction toxicity studies were performed with emapalumab. Instead, a murine surrogate antimouse IFNγ antibody, XMG1.2, was used in a mouse model. The applicant justifies its choice of species and use of surrogate by the GI tract infections and subsequent problems observed in monkeys, which would make a reproduction toxicity study in monkeys not possible. Although this is endorsed, the applicant has also performed a repeated dose study in pathogen free monkeys that did not develop any infections, and these animals could therefore also be used for the reproduction toxicity studies. Nevertheless, the use of mice and the surrogate product was agreed in the PRIME procedure and is agreed in the current MAA.

In a fertility and early embryonic development study male and female mice were treated with XMG1.2 from before cohabitation, through mating, and implantation (females), at doses up to 150 mg/kg/week which is 5-fold higher than the therapeutic dose in a mouse model of HLH. There were no harmful effects for male and female fertility and early embryonic development at the dose-levels tested.

In the embryo-foetal development study no treatment-related effects on dams or foetuses were observed after treatment with XMG1.2 at doses up to 150 mg/kg bolus i.v. on four occasions during gestation. XMG1.2 was found in foetuses of mice at gestation day 18.

in the pre- and postnatal development (PPND) studies pregnant female mice were treated with XMG1.2, at doses up to 150 mg/kg twice weekly which is 5-fold higher than the therapeutic dose in a mouse model of HLH, from implantation through lactation and weaning of the of the offspring. There were no effects on maternal reproductive function at the dose-levels tested nor any effects on sexual maturation, organ weights, learning and memory, reproductive or immunological functions evaluated in the F1 generation mice (offspring exposed in utero and through lactation).

## Local Tolerance

Local tolerance was studied as part of the 8 week and the 13-week repeat dose toxicity studies in cynomolgus monkeys and a subcutaneous and paravenous local tolerance study in rabbits. Slight and transient erythema was seen after paravenous injection of both emapalumab and placebo in some rabbits. Therefore, slight reactions could occur after misdosing in patients.

Increasing concentrations of emapalumab did not induce ADCC or CDC in vitro . In contrast, dose dependent ADCC and CDC was achieved after incubation with alemtuzumab, a positive control antibody. The potential of emapalumab to induce ADCP was not investigated.

No remarkable or relevant staining was observed in a tissue cross-reactivity study using a panel of 35 standard human tissues. When staining was observed, this was also seen in controls and is nonspecific. No additional TCR assay using animal tissue is necessary.

## Other toxicity studies

There are no impurities or degradation products of toxicological concern based on the physiological nature of the product.

<div style=\"page-break-after: always\"></div>

## 2.3.5. Ecotoxicity/environmental risk assessment

The active substance is a natural substance, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, emapalumab is not expected to pose a risk to the environment.

## 2.3.6. Discussion on non-clinical aspects

The sequence homology of nonhuman primate (NHP) IFNγ is 95% identical to human IFNγ. Between NHP species, sequence homology is 100%. As a result, emapalumab shows high affinity binding to human, cynomolgus and rhesus IFNγ. Further supporting evidence for the activity of emapalumab is the fact that in the toxicology studies, cynomolgus monkeys frequently developed GI tract infections as a result of reduced protection of IFNγ on Shigella, Campylobacter or Salmonella, commonly present in cynomolgus monkeys.

The applicant conducted the embryo-foetal development study in mice using the surrogate antibody XMG1.2. Because most, if not all, adverse effects of mAbs are induced by the pharmacological action and immune responses, the conduct of an embryo-foetal development study in mice is considered acceptable from a pharmacological perspective. Antibody dependent phagocytosis (ADPC) has not been investigated by the applicant. However, in the absence of antibody-dependent cytotoxicity in the pivotal toxicology studies, this can be accepted by CHMP.

Emapalumab in cynomolgus serum was measured by validated sandwich ELISA assays. The method for the determination of anti-emapalumab antibodies was sufficiently validated. The method used for the analysis of the surrogate XMG1.2 in mouse plasma was acceptable. The non-clinical pharmacokinetics of emapalumab are considered to be sufficiently characterised.

Results from immunotoxicity tests indicate that emapalumab is not immunotoxic, however as the immune function is supressed, based on the pre-clinical and clinical data showing opportunistic infections in monkeys treated with emapalumab, and infections in patients in the clinical trials have been observed. However, due to the single arm design and the immunosuppressed status of the patients, it remained unclear whether infections are increased due to treatment with emapalumab. The mechanism of action is not completely clear and it is unknown whether only opportunistic infections are likely to occur, or whether there is also a risk of other infections related to IFNγ reduction.

## 2.3.7. Conclusion on the non-clinical aspects

Overall, there is sufficient nonclinical evidence to suggest that neutralisation of IFNγ by emapalumab would lead to an improvement of the disease pathology of HLH mouse models of disease. As such, the non-clinical proof of concept and mode of action is considered adequately demonstrated. However, translatability of mechanism of action and proof of concept to the human setting should be confirmed in clinical studies. The non-clinical pharmacokinetics of emapalumab were characterised sufficiently. The toxicology programme revealed the occurrence of opportunistic infections, probably due to immunosuppression related to IFNγ reduction.

<div style=\"page-break-after: always\"></div>

## 3. Clinical aspects

## 3.1.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

The clinical development programme for emapalumab was designed to examine the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of emapalumab in controlling disease activity in patients with either primary or secondary HLH. The primary focus is on primary HLH, while the development for secondary HLH is recently initiated.

The clinical package contains of the following studies to support the application (Table 2):

- PK study in healthy volunteers NI-0501-03
- One single arm pivotal study NI-0501-04
- One extension study NI-0501-05
- Compassionate use
- Historical controls

<div style=\"page-break-after: always\"></div>

Table 2: Overview of Emapalumab Clinical Development Programme (Clinical Studies part of the MAA)

| Study Grouping Study No.   | Phase                     | Study Design                                                                                                                                                                                                                                                  | No. of Centres Location              | Treatment Dose, Regimen, and Duration                                                                                                                                     | Total No. Pts Sex (M/F)   | Age (Range)               | Diagnosis                 | Prim endpoint             |
|----------------------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Pivotal Study              | Pivotal Study             | Pivotal Study                                                                                                                                                                                                                                                 | Pivotal Study                        | Pivotal Study                                                                                                                                                             | Pivotal Study             | Pivotal Study             | Pivotal Study             | Pivotal Study             |
| NI-0501-04 a               | 2/3                       | Open-label, single-arm, multicentre study in paediatric patients (≤18 years of age at the time of HLH diagnosis) with long- term follow-up in the NI-0501-05 study                                                                                            | 21 centres Germany, Italy, Spain, US | Starting dose: 1 mg/kg emapalumab IV every 3 days with possible adaptation of dose (3 mg/kg or 6 mg/kg up to 10 mg/kg) for up to 8 weeks                                  | 34 b 16/18                | 0.1-13 yrs                | pHLH                      | Overall response rate     |
| Long-Term Follow-Up Study  | Long-Term Follow-Up Study | Long-Term Follow-Up Study                                                                                                                                                                                                                                     | Long-Term Follow-Up Study            | Long-Term Follow-Up Study                                                                                                                                                 | Long-Term Follow-Up Study | Long-Term Follow-Up Study | Long-Term Follow-Up Study | Long-Term Follow-Up Study |
| NI-0501-05 a               |                           | International, multicentre, follow-up study to collect safety and outcome data c for patients who received emapalumab in either NI-0501-04 or CU. Patients were monitored for 1 year after HSCT or after emapalumab last infusion (if HSCT was not performed) | 21 centres Germany, Italy, Spain, US | Emapalumab is not being administered in the NI-0501-05 study, unless when there is a need to continue treatment with emapalumab for > 8 weeks                             | 38 d                      |                           |                           |                           |
| Healthy Volunteer Study    | Healthy Volunteer Study   | Healthy Volunteer Study                                                                                                                                                                                                                                       | Healthy Volunteer Study              | Healthy Volunteer Study                                                                                                                                                   | Healthy Volunteer Study   | Healthy Volunteer Study   | Healthy Volunteer Study   | Healthy Volunteer Study   |
| NI-0501-03                 | 1                         | Randomised, placebo-controlled study in healthy adults                                                                                                                                                                                                        | 2 centres UK                         | Single-ascending doses of emapalumab at doses of 0.01, 0.1, 1.0, or 3.0 mg/kg or placebo, over a 2-hour infusion period                                                   | 20 17/3                   | 22-49 yrs                 |                           |                           |
| Compassionate Use          | Compassionate Use         | Compassionate Use                                                                                                                                                                                                                                             | Compassionate Use                    | Compassionate Use                                                                                                                                                         | Compassionate Use         | Compassionate Use         | Compassionate Use         | Compassionate Use         |
| CU                         | NA                        | NA                                                                                                                                                                                                                                                            | Ireland, Italy, UK, US               | Starting dose: 1 mg/kg emapalumab IV every 3 days with possible adaptation of dose (and frequency of administration) based on PK and clinical response for up to 13 weeks | 17 5/3                    | 0.02-56 yrs               | primary and secondary HLH |                           |
| Historical controls        | Historical controls       | Historical controls                                                                                                                                                                                                                                           | Historical controls                  | Historical controls                                                                                                                                                       | Historical controls       | Historical controls       | Historical controls       | Historical controls       |
| NI-0501-HC                 | NA                        | Retrospective collection of primary HLH patients` clinical data                                                                                                                                                                                               | US and EU                            | NA                                                                                                                                                                        | 72 39/33                  | 0.1-18.9 YERS             |                           |                           |

· a  Both studies are ongoing. A single CSR that presents data collected in both studies at the database cut-off date of 20 July 2017 is provided in the MAA; this CSR is identified as the NI-050104 CSR.  b Includes 27 patients who had previously failed conventional treatment for HLH (ie, second-line patients) and 7 patients who were treatment-naïve (I,e., first-line patients).

<div style=\"page-break-after: always\"></div>

- c Including duration of response, the number of patients who undergo HSCT, post HSCT outcomes, and overall survival.  d Includes 28 patients from the NI-0501-04 study and 10 CU patients. CU = compassionate use; IV = intravenous; HSCT = haematopoietic stem cell transplantation; US = United States; UK = United Kingdom

<div style=\"page-break-after: always\"></div>

## 3.1.2. Pharmacokinetics

Pharmacokinetics were studied in adult healthy volunteers (one phase 1 study) and in HLH patients (2 phase 2/3 studies as well as a number of compassionate use patients).

In healthy volunteers, complete sampling was performed, and data were analysed by noncompartmental analysis and by population pharmacokinetic modelling. In HLH patients, sampling was sparse, but still relatively frequent, and data was analysed by population pharmacokinetic modelling.

Immunogenicity assays: A three-tiered approach was used for immunogenicity testing, which is consistent with regulatory guidelines. Antibodies against emapalumab were measured with electrochemiluminescent immunoassays. In healthy volunteers, evidence of ADA formation was found only in one sample from one subject. In HLH patients, sustained presence of ADAs occurred in 2 out of 50 patients. In one of these patients, neutralising ADAs were found. However, in this subject, the PK of emapalumab was not influenced by the ADAs.

PopPK analysis: Two population pharmacokinetic models were developed by the applicant. One model was developed from healthy volunteer data, which accurately described the pharmacokinetics of emapalumab using a two-compartmental model. This healthy volunteer model was used as a basis for the development of a population pharmacokinetic model in HLH patients. Allometric scaling was used to bridge the pharmacokinetic data to the paediatric population. Furthermore, a non-linear clearance pathway mediated by IFNγ was included in the model. No other significant covariates were identified during the model development. The final pharmacokinetic model was adequate in describing the pharmacokinetics of emapalumab.

## Absorption

Not relevant due to the nature of the medicinal product. Emapalumab is dosed via the IV route and therefore completely bioavailable.

## Distribution

Estimated volume of distribution seems to be around 5.5 L in healthy volunteers and 9.5 L in HLH patients of 70 kg. Emapalumab is therefore largely confined to the blood compartment which is normal for an IgG mAb.

## Metabolism

Because emapalumab is an antibody and antibodies are generally catabolised by proteases to small peptides and amino acids that are either incorporated into the endogenous pool or excreted, no traditional in vitro drug metabolism studies with human hepatocytes were performed for emapalumab and none were needed.

## Elimination

No excretion studies were performed, which is agreed as emapalumab is an antibody degraded into small peptides and amino acids. Estimated clearance in healthy volunteers seemed to be around 0.007 L/h. Half-life in healthy volunteers was approximately 22 days. Estimated linear clearance in patients of 70 kg was 0.0124 L/h. Estimated non-linear clearance in 70 kg patients was 0.141 L/h. Total clearance increased with increasing IFNγ due to target -mediated drug disposition and also with

<div style=\"page-break-after: always\"></div>

increasing body weight: At 5 kg body weight, estimated total clearance varied from 0.00112 L/h (IFNγ = 0) to 0.0140 L/h (IFNγ = 1000 ng/mL) an d at 70 kg body weight, estimated total clearance varied from 0.0116 L/h (IFNγ = 0) to 0.145 L/h (IFNγ = 1000 ng/mL). Terminal half -life varied from 19 - 25 days (IFNγ = 0) to 2 -3 days (IFNγ = 1000 ng/mL).

## Dose proportionality and time dependency

In healthy subjects following a single dose, no apparent deviation from dose-proportional pharmacokinetics was observed over a 0.1 3 mg/kg range. At doses ≤0.1 mg/kg, target mediated disposition might have an influence on the PK. In patients at steady state, emapalumab concentrations increased approximately dose-proportionally from 1 - 3 mg/kg and less than dose-proportionally from 3 - 10 mg/kg. The less than dose-proportionality may be explained by target mediated drug disposition in patients with high IFNγ (these are the patients requiring higher doses of emapalumab, see Figure 3).

Emapalumab concentrations fluctuated from peak to trough and increased towards an equilibrium. Peak and trough concentrations at a dose of 1 mg/kg at steady state were 2.9 and 4.3 times higher than after the first dose. Steady state was reached approximately after the 7 th  administration. However, it should be noted that the steady state concentrations and time to reach steady-state depends heavily on total IFNγ concentrations.

Figure 3 Concentration-time profiles of free emapalumab (blue, left log axis) and total IFNγ (red, left log axis in two illustrative patients. Administrations are indicated by vertical orange lines and doses expressed in mg/kg are indicated above the x-axis. The dots indicate BLQ values. The left graph for the second patient is a widening of the first 10 days.

<!-- image -->

Target population: Due to the inclusion of total dose as covariate in the healthy volunteer model and inclusion of allometric scaling and the non-linear clearance mediated by total IFNγ in the population

<div style=\"page-break-after: always\"></div>

pharmacokinetic model of HLH patients, it is difficult to compare the pharmacokinetic characteristics in both populations. However, it is noted that the mean observed emapalumab concentrations in HLH patients were almost 2 times lower than expected based on healthy volunteer data and therefore also the originally intended ceiling concentration.

Figure 4 Estimated apparent total clearance versus total IFN-γ concentrations in HLH patients. Semi-log graph on the left. Log-log graph on the right. The dots are individual predicted clearances in patients. The green line is the population predicted clearance. The orange dotted line is the clearance in healthy volunteers.

<!-- image -->

The estimated non-linear clearance in an HLH patient was highly dependent on the total IFNγ concentrations (see Figure 4). The half-life ranges from 3.1 to 25.1 days in patients with a bodyweight of 70 kg and IFNγ concentrations ranging from 0 - 1000000 pg/mL. Furthermore, clearance also appears to increase with increasing bodyweight. Therefore, a bodyweight-based dosing regimen can be supported.

## Special populations:

Overall, bodyweight and total IFNγ are the main predictors for explaining variability in pharmacokinetics of emapalumab. The applicant justified that including bodyweight in the population pharmacokinetic model was more appropriate than including age in the population pharmacokinetic model. None of the other evaluated covariates contributed to a significant improvement of the population pharmacokinetic model. Therefore, currently, no dose adjustments are necessary for gender, renal function and hepatic function. It should however be noted that the patient population is very small. Some trends were observed for elevated hepatic laboratory values in African-American patients. However, none of these trends were significant.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic interaction studies

Emapalumab is an IgG1 monoclonal antibody, which is likely eliminated by non-specific catabolism in the reticuloendothelial system. The enzymes involved are not known to be inhibited or induced by drugs, and therefore it is unlikely that other drugs will have an impact on the PK of emapalumab.

Other medicinal products administered concomitantly with emapalumab may potentially be affected due to the restoring effect of emapalumab on cytokine-induced inhibition of P450 enzymes. Section 4.5 of the SmPC contains a warning for the potential effect of Gamifant on CYP450 (i.e. the normalizing effect on cytokine-induced depression of CYP450), which is acceptable.

## Dosing regimen:

The currently proposed posology recommends a starting dose of emapalumab of 1 mg/kg administered intravenously over 1 hour. After which, emapalumab is administered bi-weekly. From day 3 onwards, the emapalumab dose may be increased to 3 or 6 mg/kg based on clinical response. From day 9 onwards, the emapalumab dose may be further increased to 10 mg/kg. There are many uncertainties associated with this posology, see discussion on clinical pharmacology.

## 3.1.3. Pharmacodynamics

## Mechanism of action

The disease mechanism in HLH is generally described in the literature as a vicious cycle of cytokine secretion by CTL, NK cells, and macrophages, generating a cytokine storm, caused by failure of the cytotoxic function of CTL and NK cells. The proinflammatory cytokines include amongst others IFNγ, TNFα, IL -6, and M-CSF (Xu 2012, Henter 1991). The mechanism of action of emapalumab is to neutralise IFN ɣ in HLH patients to reduce clinical symptoms.

For PK-PD analyses samples were taken at peak and/or trough of each administration and at days 1, 2, 5 and 8 after the start of the treatment. Available serum concentrations of free emapalumab, total IFNγ (trough), CXCL9 (trough) and CXCL10 (trough) were us ed in the analysis. In few cases when trough was not available, peak values were used. In addition, as indicators of HLH disease activity ferritin and sIL2R (serum concentrations (as available during treatment) were selected for the analysis.

Free IFNy cannot be measured independently after the administration of emapalumab. No direct relationship between emapalumab and free IFNγ concentration could be made, due to interference in the assay of free IFNγ. To confirm the neutral isation of IFNγ by emapalumab, the decrease in serum concentration of CXCL9, a chemokine almost exclusively produced through the activation of the free IFNγ, is monitored. As such, CXCL9 is considered as a biomarker of free IFNγ activity to show the pharmacological activity of emapalumab in neutralising IFNγ ( Figure 5 ).

<div style=\"page-break-after: always\"></div>

Figure 5. Proposed representation of the immune system components involved in HLH

<!-- image -->

Study NI-0501-04 was conducted to demonstrate efficacy of neutralising IFNy by emapalumab and reducing the clinical syndrome of hyperinflammation in HLH patients. An individualised dose escalation approach was used to account for the high variability of IFNγ production in HLH patients, the target -mediated drug disposition (TMDD) of emapalumab influencing the half-life of emapalumab and thus exposure of emapalumab, and the need to allow timely dose adjustments to account for the severity of the disease.

Individual PK-PD-effect time profiles indicated that after administration of emapalumab, the concentrations of total IFNγ (free+bound) increased and reached equilibrium between production and elimination within 3 days of treatment. There appeared to be a weak correlation between CXCL9 concentration and total IFN ɣ concentration at baseline (R-squared =0.34), and total IFN ɣ concentration at day 3 (Rsquared =0.52). At moderate levels of total IFNγ concentrations, the concentrations of CXCL9 and CXCL10 decreased rapidly after the first administrations of emapalumab, indicating an effective 'neutralisation ' of IFNγ activity. At high total IFNγ concentration and relatively low concentrations of emapalumab, the CXCL9 and CXCL10 concentrations could still increase, indicating an incomplete 'neutralisation ' of IFNγ activity.

The applicant conducted an exposure-efficacy analysis and an exposure-safety analysis, although not all patients were included in the conducted exposure-response/safety analyses (n=34).

PK-PD modelling has demonstrated that the dose of emapalumab needs to be adapted to the production of IFNy for optimal inhibition of its biological activity. Exploratory analyses indicated that the higher the IFNγ production the higher the dose and c oncentration of emapalumab required to achieve the same level of neutralisation . This implies that, depending on the IFNγ production, best chances of clinical response could be expected at very different doses and exposures of emapalumab. Since the production of IFN-y is highly variable and unpredictable between and within patients over time, a dose adaptation strategy has been developed to ensure the best possible neutralisation of IFNy.

At the end of treatment, the univariate logistic regression analysis suggested biomarkers CXCL9, CXCL10 and total IFNγ as prognostic indicators of r esponse (p&lt;0.10). Multivariate analyses were not conclusive for response.

The current proposed posology is starting with 1mg/kg twice weekly and up-titration according to clinical response on the basis or worsening of symptoms (fever, platelet count, neutrophil count,

<div style=\"page-break-after: always\"></div>

ferritin, splenomegaly or coagulopathy (both D-Dimer and Fibrinogen). The starting dose is 1 mg/kg regardless of baseline symptoms and IFN-Y level. A total of 32.2 % patients maintained the 1 mg/kg dose in the study, but in a total of 61.8% further increase of doses from 1 to 3 mg/kg was needed. Due to the various modifications in the protocol, it is unclear whether the patients who kept the 1 mg/kg dosing were monitored using CXCL9/IFNy or monitored on their clinical symptoms. After the first dose of emapalumab, a significant decrease in CXCL9, sIL2 and ferritin concentration occurred indicating inhibition of IFN-Y.

However, during the study, no correlation was investigated between the occurrence of clinical symptoms and emapalumab, CXCL9, ferritin, total IFN-Y or sIL2 over time, despite the variable course of the disease. In some patients, the CXCL9 level and ferritin remained low indicating sufficient IFN-Y neutralisation, but the dose was increased, suggesting a clinical worsening of symptoms.

## 3.1.4. Discussion on clinical pharmacology

## Analytical assays:

Sandwich immunoassays with fluorescence detection were used to measure free emapalumab in serum. The analytical method for the measurement of emapalumab concentrations shows a lack of robustness, which is evident by frequent failure of QC samples. The applicant showed however that all failed runs have been retested until valid. In studies NI-0105-04 and NI-0501-05, adequate incurred sample analyses were performed, which is a sign that analysed data are sufficiently reliable. In study NI-0501-03, some runs which were already passed, were rerun. Reasons for this have been reported, which included that some runs were repeated inadvertently. It appears however that in most of these cases the original results were reported.

Long-term stability of CXCL9 in the patient samples is not guaranteed after 12 months. For up to 12 months, CXCL9 seems reasonably stable. After 12 months, stability of CXCL9 is not established because many QCs exceeded the acceptance criteria at 18, 21 and 24 months. For CXCL9 in matrix, at 12 months and longer, an overestimation seems to occur more often than an underestimation. This could be relevant for the analysis of CXCL9 in patients because CXCL9 analysis started on 3 May 2016, while samples were collected from August 2014. This implies that there may have been samples which were stored for more than 12 months before analysis for CXCL9. Additional analyses were conducted, which demonstrated that over-estimation of CXCL9 concentration in clinical samples could be up to 109%. Therefore, the results obtained with CXCL9 should be interpreted with caution.

There are also questions regarding the analytical methods for IFNγ and the markers sIL2Ra. The longterm stability of CXCL10 in human serum up to 36 months was considered sufficient.

Although IFNγ -mediated inflammation is likely a significant feature of HLH, the spectrum of mechanisms that potentially lead to pathologic inflammation are likely more complex. IFNy-mediated inflammation is not always detectable from IFNy concentrations in plasma as more than half of the patients in the clinical development programme of emapalumab did not have any elevated IFNy concentrations at baseline. Therefore, peripheral IFNy also plays a role in the treatment with emapalumab.

Preclinical models have shown that an antiIFNγ antibody can improve disease pathology in an animal model of HLH. However, it remains unclear whether in humans IFNγ -mediated inflammation is the only relevant pathway (e.g. TNFα, IL6 are described to also be involved). It is also not known whether the animal model (perforin knock-out mice) represents all genetic pHLH variants. Indeed, gene mutations associated with inherited HLH also influence other proteins than perforin, and some mutations even influence other metabolic processes than the cytotoxic function of NK/CT cells.

<div style=\"page-break-after: always\"></div>

Based on the assumed pathophysiology of disease (i.e. with a key function for the elevated IFN-y and the proposed mechanism of action of emapalumab) (see below), acceptable PD markers have been selected. However, it should be emphasised that all relationships between PK/PD and clinical symptoms are only indirectly established in the current analyses introducing limitations:

- -In the population pharmacokinetic model, the observed IFNy concentration was used to describe the plasma-concentrations of emapalumab. Therefore, this model can be used to describe the pharmacokinetics of emapalumab, but is not predictive for the effect of emapalumab on IFNy.
- -Furthermore, in the PK/PD analysis, the observed total IFNy and emapalumab concentration were used to describe the concentration of CXCL9. Also, this model cannot be used to describe the concentrations of CXCL9 over time.
- -In the exposure-response analysis, CXCL9 concentrations (as measure of exposure) were correlated to clinical symptoms at the end of treatment using a logistic regression, but the correlation with symptoms during treatment has not been established.

All of these models cannot handle the dynamic nature of the disease. Furthermore, as emapalumab is a symptomatic treatment, it is important to demonstrate that emapalumab reduces clinical symptoms over time and not only at the end of treatment.

It should also be noted that concomitant medication was allowed in study NI-0501-04. The applicant stated to have excluded observations obtained after conditioning or intake of drugs such as alemtuzumab, etoposide or anti-thymocyte globulin (ATG) from the PK-PD analysis, except for CU patients in whom this information was not available. The treatment with dexamethasone and cyclosporine A may also influence the hypercytokinaemia. In conclusion, the influence of co-medication on the pharmacodynamic parameters is unclear.

As mentioned above, the relationships between indicators of disease activity (sIL2R and ferritin) and emapalumab, CXCL9 and total IFNγ are not clear as these were only measured at the end of treatment and were not further quantified over time. The correlation between CXCL9, IFNγ and emapalumab and parameters used to modify the dose (fever, platelet counts, neutrophil counts and splenomegaly) has also not been established.

Overall, it is considered that the current approach to analyse the data of study NI-0501-04/05 and CU patients is not supportive for the proposed dosing regimen. There is an uncertainty whether the starting dose of emapalumab is appropriate based on the following considerations:

- The starting dose is not based on the baseline IFN-Y or clinical symptoms, while exploratory analyses indicate that the higher the IFNγ production , the higher the dose and concentration of emapalumab required to achieve complete neutralisation of IFNy levels.

- After the first week of treatment, most patients required an increase in dosing regimen, indicating that no optimal disease control has been achieved and that these patients are likely underdosed.

Indeed, whilst the overall split is 2:1 for dose increase vs dose maintenance with the current posology, in 1 st  line cases the split is 6:1 in favour of dose increase. Within the 1 st  week of treatment 6/7 (22%) of 2 nd  line cases and 3/7 (43%) of 1 st  line cases required an increase in emapalumab dose. The frequent need to increase the starting dose of emapalumab in 1 st  line cases is matched by the lower rate of clinical responses observed in this group. Further CHMP requests to clarify the intended posology, the applicant has not sufficiently addressed the rationale for no prompt neutralisation of IFN-y levels which could favour starting a higher dose then titrating down or up as required.

<div style=\"page-break-after: always\"></div>

Furthermore, the dosing frequency has not been substantiated, because the elimination half-life depends heavily on the amount of free IFNy and can be much longer in patients where complete neutralisation of IFNy has already been achieved. In those patients the apparent half-life will be approximately 22 days and the biweekly dosing regimen as currently proposed would result in severe accumulation of emapalumab without dose adjustments. The consequence of emapalumab accumulation for safety is unknown, due to the single arm design of the pivotal study and the limited number of patients included. Furthermore, no additional benefit can be expected as complete neutralisation of IFNy has already been achieved in these patients. It is therefore strongly advised to determine emapalumab concentrations in patients treated with emapalumab in future studies.

In addition, the proposal to dose emapalumab based on the proposed clinical symptoms i.e. fever, platelet count, neutrophil count, ferritin, splenomegaly or coagulopathy (both D-Dimer and Fibrinogen)) is also not supported. On a population level, CXCL9 lowering demonstrated favourable effects on clinical symptoms. However, there is substantial variability between and within patients, there are additional stability issues with CXCL9 in the samples collected and the influence of time has not been taken into account in any of the analyses. During the study, no direct correlation was identified between the occurrence of clinical symptoms, emapalumab administration or CXCL9 over time.

Furthermore, dosing on clinical symptoms involves several uncertainties. It is unclear:

- -whether the panel of markers that was used is sensitive to detect the requirement for dose adaptions and what cut-off points should be used,
- -whether IFNy neutralisation creates a direct effect on clinical symptoms or whether effects can be delayed (which would imply that dose adaptions are not timely),
- -whether IFNy neutralisation follows a similar relationship for all clinical symptoms,
- -how dose adaptions are influenced by the administration of concomitant medication (as these can also affect multiple clinical symptoms). As a consequence, it is currently still questioned if clinical symptoms are a valid marker for the need to adapt the dose as these symptoms do not necessarily indicate incomplete neutralisation of IFNy. This concern is supported because symptom driven dose increase occurred without an apparent increase in CXCL9, during the study, and almost no dose reductions were observed in the study. These considerations do question if the current posology based on symptoms is sufficiently justified.

In the responses to the questions regarding the dosing strategy, the applicant remained of the opinion that the starting dose of 1 mg/kg and dose adjustments based on clinical symptoms is adequate. On the other hand, the applicant indicated that additional data will be provided from the NI-0501-09 study that will be studying a starting dose of 3 mg/kg. The applicant proposes this study as a confirmatory study if a conditional authorisation would be approvable. Although additional data including a change in starting dose are considered necessary, it should be remembered that not only the starting dose but also the dosing frequency, dosing based on clinical symptoms and stopping/continuing emapalumab before HSCT are questioned. Therefore, uncertainties still remain on the posology and dosing regimen.

The above considerations raise the question whether in humans, unlike in animal, other cytokines might be involved in the pathophysiology of pHLH. So, although emapalumab significantly decreases the amount of IFN-Y as shown by a reduction in CXCL9, symptoms remained. Dose increases were necessary despite the low, stable concentration of CXCL9 and no additional increases in total IFNy were observed. This might only be explained by the involvement of other pathways in the development of signs and symptoms of pHLH .

<div style=\"page-break-after: always\"></div>

Therefore, dose adaptions based on clinical outcome has not been justified by the current analyses.

It also remains unclear when emapalumab needs to be stopped before conditioning prior to HSCT. In patients with accumulation, significant emapalumab exposure may still be present at the time of HSCT (due to the potential long half-life of emapalumab). Furthermore, in patients with a relatively short half-life (high production of IFNy), clinical symptoms significantly increase after termination of emapalumab, which could imply that some of the beneficial effects of emapalumab are lost before HSCT.

The applicant has collected a large amount of both PK/PD samples in a very sick paediatric patient population and has already shown that there is a relationship between IFNγ, CXCL9 and emapalumab. To support the dosing regimen, it is still envisioned that a more mechanistic approach should be used, which directly relates emapalumab dose to the clinical symptoms.

PopPK analysis: Two population pharmacokinetic models were developed by the applicant. One model was developed from healthy volunteer data, which accurately described the pharmacokinetics of emapalumab using a two-compartmental model. This healthy volunteer model was used as a basis for the development of a population pharmacokinetic model in HLH patients. Allometric scaling was used to bridge the pharmacokinetic data to the paediatric population. Furthermore, a non-linear clearance pathway mediated by IFNγ was included in the model. No other significant covariates were identified during the model development. The final pharmacokinetic model was adequate in describing the pharmacokinetics of emapalumab.

## Immunogenicity assays

The method validation suggests that low concentrations of neutralising antibodies cannot be detected. Interference by emapalumab in patients reported as negative for ADAs cannot be completely excluded. In 6 patients reported negative for immunogenicity, none of the immunogenicity samples taken had emapalumab levels lower than 20000 ng/mL at the time of sampling. Only high concentrations of ADAs could therefore have been detected. Therefore, the presence of low concentrations of anti-emapalumab antibodies may have been underestimated. Moreover, it is difficult to conclude regarding the occurrence of ADAs as patients are immunocompromised.

The immunogenicity of emapalumab appears to be low (&lt;5% of subjects had persistent ADA positivity) but can be somewhat underestimated because of interference in the ADA assay with emapalumab and the fact that patients are immunocompromised. One subject developed neutralising anti-bodies, however, no effect on pharmacokinetics of emapalumab was apparent.

## 3.1.5. Conclusion clinical pharmacology

In healthy volunteers, the PK of emapalumab is typical of monoclonal antibodies with a long half-life of approximately 22 days. In HLH patients, clearance of emapalumab is strongly dependent on IFNy production/concentration. At high total interferon concentration, emapalumab is mainly characterised by non-linear clearance mediated by interferon concentrations. Total clearance is approximately 10fold higher at high IFNγ concentrations than at low IFNγ concentrations. Bodyweight is a covariate on clearance and on distribution volume. This supports dosing based on body weight

The applicant demonstrated that the administration of emapalumab resulted in a decrease of CXCL9 concentr ations, which can be accepted as a biomarker for free IFNγ. There were however issues with the stability of CXCL9 after 12 months. Plasma samples will need to be measured before 12 months in clinical practice.

<div style=\"page-break-after: always\"></div>

The correlation between clinical symptoms and IFN-Y over time has not been clearly shown. Moreover, the central role of IFN-Y in the disease can be questioned as other pathways might also be involved.

The proposed posology, i.e. starting dose, dosing frequency and dosing based on clinical symptoms and stopping/continuing emapalumab treatment before HSCT, has not been adequately justified.

## 3.2. Clinical efficacy

## 3.2.1. Dose response study

No formal dose-response studies have been performed. Dose titration was performed in the main clinical study.

## 3.2.1. Main studies

The pivotal trial to establish the efficacy and safety is trial NI-0501-04. This study was originally designed as a single-arm, dose finding, pilot study in 10 reactivating primary HLH patients. The study was subsequently amended to broaden the study population and include all treated patients and to continue as a single arm Phase 2/3 study.

Upon completion of the NI-0501-04 study, patients were invited to participate in Study NI-0501-05 for long-term follow-up for 1 year, either after HSCT or after the last infusion of emapalumab. Study NI0501-05 could also include patients from compassionate use (CU). Study NI-0501-05 essentially provides the long-term follow-up and safety data.

Supportive efficacy data have been provided by the patients that received emapalumab in CU. The collection of historical data from primary HLH patients to serve as an external control cohort for study NI-0501-04 has been undertaken (in accordance with the emapalumab PIP).

See below the design of the NI-0501-04 and NI-0501-05 studies.

## Clinical Efficacy Studies

| Study / Phase        | Design                | Centres                                                                       | Treatment                                                                                  | Subjects                                                                                                                             |
|----------------------|-----------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| NI0501-04 phase 2/3  | Open label single arm | 21 in Austria, Czech Republic, Germany, Italy, Spain, Sweden, Turkey, UK, USA | 1 mg/kg emapalumab IV every 3 days increased as required to 3 or 6 mg/kg for up to 8 weeks | 34 HLH patients (7 1 st line, Rx naive) (27 2 nd line, failed conventional Rx) 16M:18F Age <18 yrs. at diagnosis Range 0.1 - 13 yrs. |
| CU compassionate use | Open label single arm | 12 physicians in Ireland, Italy, USA                                          | 1 mg/kg emapalumab IV every 3 days increased as required to 3 or 6 mg/kg for up to 8 weeks | 17 HLH patients 5M:3F Age 0.02 - 56 yrs.                                                                                             |

<div style=\"page-break-after: always\"></div>

| NI0501-05   | Open label single arm   | 21 Germany, Italy, Spain, USA   | Emapalumab iv given if need to treat for >8 weeks Long term, 1yr follow-up of NI-501-04 or CU cases after HSCT or last dose   | 38 patients (28 from NI-0501-04) (10, CU)   |
|-------------|-------------------------|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|

Study NI-0501-04: A phase 2/3, open-label, single arm, multicentre study to assess safety, tolerability, pharmacokinetics and efficacy of intravenous multiple administrations of NI-0501, an antiinterferon gamma (anti-IFNy) monoclonal antibody, in paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH).

The discussion of the methods and results from study NI-0501-05 are integrated in the methods and results on study NI-0501-04.

Methods

## Figure 6 Study design schematic for NI-0501-04 and NI-0501-05

<!-- image -->

If no appropriate donor was identified by Week 8 or HSCT was delayed for reasons unrelated to emapalumab administration, emapalumab treatment could be continued beyond Week 8 in Study NI0501-05, provided that a favourable benefit-risk was established for the patient by the Investigator. In these circumstances, the patients transitioned to the NI-0501-05 study directly after the last infusion of emapalumab in the NI-0501-04 study.

## Study Participants

The main inclusion criteria were

1. Primary HLH aged ≤ 18 years, fulfilling the criteria for the diagnosis of HLH provided by the HLH-2004 protocol:
- a. A molecular diagnosis or familial history consistent with primary HLH OR
- b. Five of the following 8 criteria:
- i. Fever
- ii. Splenomegaly

<div style=\"page-break-after: always\"></div>

iii. Cytopenias affecting 2 of 3 lineages in the peripheral blood (Hb &lt;90 g/L; platelets &lt;100 x10 9 /L; neutrophils &lt; 1 x 10 9 /L)

iv. Hypertriglyceridaemia (fasting triglycerides ≥ 3 mmol/L) and/or hypofibrinogenaemia ( ≤ 1.5 g/L)

v. Haemophagocytosis in bone marrow, spleen or lymph nodes, with no evidence of malignancy

- vi. Low or absent NK-cell activity

vii. Ferritin ≥ 500 μ g/L

viii. Soluble CD25 (sCD25; i.e., soluble IL-2 receptor) ≥ 2400 U/mL

2. Active disease
3. Patients having already received HLH conventional therapy must have fulfilled 1 of the following criteria as assessed by the treating physician:
- Having not responded
- Having not achieved a satisfactory response
- Having not maintained a satisfactory response
- Showing intolerance to conventional treatment of HLH

The main exclusion criteria were:

1. Diagnosis of secondary HLH consequent to a proven rheumatic or neoplastic disease
2. Body weight &lt; 3 kg
3. Patients treated with:

- any T-cell depleting agents (such as ATG, anti-CD52) during the previous 2 weeks prior to screening

- any other biologic drug within 5 times their defined half-life period, except for rituximab in case of Documented B-cell Epstein- Barr virus (EBV) infection (a list of some of the most commonly used biologic half-lives is included in the Study Specific Risk Management Plan)

4. Active mycobacteria, Histoplasma Capsulatum, Shigella, Campylobacter, Leishmania or Salmonella Infections
5. Evidence of past history of tuberculosis or of latent tuberculosis
6. Positive serology for HIV antibodies, hepatitis B surface antigen or hepatitis C antibodies
7. Vaccination with a live or attenuated live (including Bacillus Calmette-Guérin [BCG]) vaccine within the previous 12 weeks prior to screening

Conventional therapy is defined as: treatment for HLH according to the conventional therapy at the site (e.g. corticosteroids alone or in combination with etoposide, CsA, methotrexate, etc.) '.

For the definitions used for patients having not responded, having not achieved a satisfactory response and patients having not maintained a satisfactory response and patients showing intolerance to conventional treatment of HLH, see Table 3.

<div style=\"page-break-after: always\"></div>

Table 3. Definitions responses to prior therapies

| Protocolv.5.0 and6.0                                         | Protocolv.4.0                                                                                                                                            | Protocolv.2.1 and 3.0                         | Clinicalconsiderations                                                                                                                                                    |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patient having not responded                                 | No Response (for at least 2 weeks from initiation of treatment) and including worsening of the disease (without previous partial or incomplete response) | n.a.                                          | Patienthasnever experienced a response to previous HLH treatments, rather HLH may be worsening                                                                            |
| Patient having not achieved a satisfactory response          | Worsening or no further improvement after incomplete response                                                                                            | n.a.                                          | Patient has experienced somedegreeofresponse, although incomplete. However,HLH disease mayreactivate or show someworsening.                                               |
| Patient having not maintained a satisfactory response        | Reactivationor worsening after a partial response                                                                                                        | Reactivationafter at least a partial response | Patienthasexperienceda partial or complete response,however response was lost due to HLH reactivation or worsening(e.g.forother aSpects of HLH, such as CNS disease)      |
| Patient showing intolerance to conventional treatment of HLH | Intolerance to conventional treatmentof HLH                                                                                                              | n.a.                                          | Patient presents signs and symptoms of drug toxicities,which preclude continuing treatment with previous therapeutic agents and prompt search fortherapeutic alternatives |

## Treatments

Emapalumab was supplied in 2, 3 and/or 10 mL filled preservative free, single-use glass vials at a concentration of 5 mg/mL, for dilution prior to administration.

The treatment regimen underwent subsequent modifications, driven by the information acquired from the analysis of the data collected in treated patients. In the original protocol, the initial dose of emapalumab was 1 mg/kg/3 days and administration were allowed during the first 2 weeks of treatment based on PK and the parameters of fever and platelet counts. When the study was amended to a phase 2/3 study, another dosing scheme was defined. The latest treatment regimen, currently used in the ongoing study, is described in detail below.

Emapalumab was administered for 8 weeks as induction treatment of HLH. The treatment period will be divided in 2 separate periods, period 1 and period 2. During period 1 (up till study day 15) patients received therapy every 3 days, while in period 2, the administration of emapalumab occurred on a twice-a-week schedule. Elongation of the dosing interval to 1 week can occur after 4 weeks of treatment, if the patient has achieved Complete Response and maintained it for at least one week. Emapalumab treatment can be shortened, although not less than 4 weeks, if patient's condition and donor availability allow an earlier HSCT. Emapalumab treatment could also be continued beyond week 8 in the NI-501-05 study, provided that a favourable benefit/risk has been established for the patient.

Emapalumab was administered at a starting dose of 1 mg/kg every 3 days by IV infusion over a period of one hour. Doses subsequent to the initial dose could be increased to 3 mg/kg, if required, based on clinical and laboratory criteria. If, after a minimum of 2 infusions at 3 mg/kg, upon re-assessment, the same clinical and laboratory criteria (fever, platelets, absolute neutrophil count, ferritin, splenomegaly, hepatomegaly, see Table 4) were found to still apply, the dose of emapalumab could be increased to 6 mg/kg for up to 4 infusions. After which the dose could be reduced to 3mg/kg; continued at 6 mg/kg or increased above 6 mg/kg, if PK and PD evidence indicated e xtremely high IFNγ levels and, consequently, fast emapalumab elimination. An initial dose of 1mg/kg was predicted to inhibit for 3

<div style=\"page-break-after: always\"></div>

days at least 99% of IFNγ effect in patients with baseline IFNγ &lt;/= 3,400 pg/mL, following simulations based on the calculated neutralising concentrations of NI-0501 and PK parameters of NI-0501 in healthy volunteers and PK information from recombinant IFNγ in humans.

In the NI-0501-05 study, patients from study NI-0501-04-EU could continue receiving NI-0501 treatment beyond the foreseen 8 weeks upon request of the Investigator, providing a favourable benefit/risk has been established. The last administered emapalumab dose from the NI-0501-04 study was carried forward.

Table 4 Clinical and Laboratory Criteria to Guide Dose Increase

<!-- image -->

- NI-0501 dose was increased from 1 to 3 mg/kg if these criteria applied after SD6.

Depending on whether dose increase to 3 mg/kg occured on SD3 or SD6.

bIfNI-0501 dose was already increased on SD3, at least 2 infusions at the dose of 3 mg/kg were performed before criteria re-assessment.

dFor a maximum of 4 infusions.

Abbreviations: bsl. = baseline; ANC = absolute neutrophil count; US = ultrasound

It is estimated that roughly 15-12 patients (44%-35% all treated patients) were dosed based on the final dosing scheme.

## Additional treatments

## Background therapy with dexamethasone

Treatment-naïve patients also received 10 mg/m 2  of dexamethasone whilst 2 nd  line cases received at least 5 mg/m 2  dexamethasone starting at least 1 day before emapalumab administration.

Dexamethasone could be tapered or increased by the Investigator according to the patient`s condition,

<div style=\"page-break-after: always\"></div>

provided that the dexamethasone dose, at each step, is not more than halved and frequency of change is not more than weekly.

## Prophylactic therapy

Patients received prophylactic treatments starting from the day prior to initiation of emapalumab treatment (i.e., SD-1) until the end of the study (NI-0501-04) as recommended by the HLH treatment guidelines for Pneumocystis jiroveci, fungal infections, varicella zoster and tuberculosis.

Vaccination with a live or attenuated-live (including BCG) vaccine was avoided during the whole study including the 4-week follow-up period.

iii. Other disease modifying concomitant therapy

- Cyclosporin A could be continued (not initiated) or withdrawn at any time, by the Investigator.
- Intrathecal methotrexate and glucocorticoids could be continued as clinically required.
- IVIG could be given at 0.5 g/kg, every 4 weeks or more to maintain adequate IgG levels

iv. Full supportive care measures including blood products were allowed v. Based on recommendations from the DMC the protocol was amended to allow:

- G-CSF, in case of prolonged neutropenia
- Rituximab, in case of documented B-cell EBV infection
- Additional HLH treatments were allowed if at maximum NI-0501 dose level:
- o Unable to maintain at &gt; 50% improvement from baseline in 3 HLH parameters on &gt;2 consecutive measurements
- o Limited improvement: &lt;50% improvement in &gt;3 HLH clinical and laboratory criteria

For Study NI -0501-05: There was no restriction in the use of additional medication, except for live or attenuated live vaccinations which should be avoided as long as emapalumab concentrations are detectable in serum.

Some situations were planned to trigger an immediate decision to permanently discontinue study treatment:

- Treatment discontinuation for a Safety Reason

A patient was to be discontinued from study treatment if an SAE occurred after emapalumab administration that was 1. considered by the Investigator to be related to emapalumab (with guidance from the DMC if needed) and 2. was a life-threatening event.

- Treatment Discontinuation for Lack of Efficacy

A patient was to be withdrawn from Study NI-0501-04 if, after additional HLH therapy concomitantly to emapalumab, no response or lack of improvement was observed. However, at the request of the Investigator, the DMC could agree to maintain the patient in the study if it was considered that loss of neutralisation of IFNγ could expose patien t to the risk of further HLH worsening.

## Objectives

The objectives of the study NI-0501-04 include the following:

- -To determine the safety and tolerability profile of multiple IV administrations of emapalumab -To determine emapalumab efficacy and benefit/risk profile in HLH patients

<div style=\"page-break-after: always\"></div>

- -To describe the pharmacokinetics (PK) profile of emapalumab in HLH patients
- -To define an appropriate emapalumab therapeutic dose regimen for HLH
- -To assess the immunogenicity of emapalumab.
- -To determine the PD effects (l evels of circulating total IFNγ and biomarkers of its neutralisation, namely chemokine CXCL9 [C-X-C motif ligand 9] and CXCL10)
- -To determine other biomarkers, e.g., sCD25, IL-10

Additional objectives of study NI-0501-05 were:

- -To monitor the long-term safety profile of emapalumab
- -To assess HLH patients' survival after emapalumab treatment
- -To assess duration of response to emapalumab treatment (i.e. maintenance of HLH control)
- -To assess post-HSCT outcome measures, if applicable
- -To assess background disease activity, in patients with secondary forms of HLH
- -To study the elimination profile of emapalumab

## Outcomes/endpoints

The primary efficacy endpoint of the study was:

Overall Response, i.e., achievement of either Complete or Partial Response or HLH Improvement, at End of Treatment of Study NI-0501-04 (EOT 04).

Criteria for the definition of Overall Response are reported in Table 5. The response was assessed by an algorithm applied by a SAS programmer of the CRO, based on laboratory outcomes and data derived from clinical visits.

## Table 5 Definitions of Response

| Overall Response Rate   | Overall Response Rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Conplete Response       | Complete Response (CR) was assigmedif No fever = body tenperatue < 37.5°C Normal spleen size as measuured by 3D abdominal ulhrasoumd No cytopenia = Absolute Neutrophil Coumts ≥ 1.0x10°/L and platelet coumt ≥ 100x10°/L [absence of G-CSF and tansfision support mst be documented for at least 4 days to report no cytopenia] No hyperfemitinemia = serum levelis < 2000 μig/L No evidence of coagulopathy, ie, normal D-Dimer and/or normal (> 150 mg/dL) fibrinogen levels No neuwological and CSF abnormalities athibuted to HLH No sustained worsening of sCD25 (as indicated by at least 2 consecutive measurements that were > 2-fold higher than baseline) |
| Partial Response        | Partial Response (PR) was assigued if: At least 3 of the HLH climical and laboratory abnomalities (including CNS abnormalities) met the aforementioned criteria for “Complete Response\". In the case of \"reactivated patient” who entered the study with 3 abnormal HLH featues, at least 2 critenia were to meet the definition given There was no progression of other aspects of HLH disease pathology (eg, jaumdice, liver size, edema, CNS clinical alterations)                                                                                                                                                                                                |
| HLH Improvement         | HLH improvement (Hl) was assigned if: Aiojeioqel pue [eorup HTH f iseal 1e jo (auleseq moy aaueqp %os) juamanondim abnormalihies(includingCNSimvolvement).In the case of teachivatedpatientswho entered the shudy with 2 abnormal HLH featues, a change firom baseline greater than 50% for both defined HLH as inproved.                                                                                                                                                                                                                                                                                                                                            |

Secondary efficacy endpoints included:

<div style=\"page-break-after: always\"></div>

- -Time to response, defined as elapsed time from the date of the first dose of emapalumab to first achievement of at least HLH improvement
- -Durability of Response, i.e. maintenance of response achieved any time during the study until End of Treatment (EoT) and beyond (including data collected in the long-term follow-up study NI-0501-05) different follow-up periods will be considered, firstly censoring at i) EoT and ii) the day prior to starting conditioning; and secondly by taking the complete follow-up period beyond HSCT.
- -Percentage of patients with a ≥50% reduction in glucocorticoids from Baseline to EOT 04.
- -Number of patients able to proceed to HSCT, when deemed indicated
- -Survival at Week 8 (or EoT) and at the end of the study. Long-term survival (in particular D+30 and D+100 post-HSCT survival

Additional endpoints for study NI-0501-05 included:

- -Clinical Response: just before the start of conditioning and prior to Transplantation
- -Survival time up to one year post-HSCT (including survival to HSCT and survival post- HSCT) or one year after last NI-0501 infusion (if transplant is not performed)
- -Post-HSCT outcome indices, e.g. engraftment rate, donor chimerism achieved, incidence of acute and chronic Graft versus Host Disease (GvHD) (it applies to patients who receive HSCT)
- -Overall Response has been assessed at EOT 04/05, defined as the end of emapalumab treatment overall, i.e. considering EOT in Study NI-0501-05 for those patients who continued treatment after the 8 weeks envisaged in Study NI-0501-04.
- -Duration of First Response was assessed until the time of HSCT conditioning, i.e., including data from long-term follow-up study NI-0501-05.

The following analyses were not described in the protocol, but the data was provided in the CSR.

- -Investigator assessed response rate
- -Overall Response at Week 2
- -Overall Response Rate at EOT in NI-0501-04 Study in the Evaluable Analyses Sets
- -Duration of First Response until EOT 04 - total elapsed time from first achievement of response to first loss of response. First response was defined as the occurrence of at least an HLH improvement, with response maintained for at least 4 consecutive days, and loss of first response was the time when no response (criteria for at least HLH improvement no longer met) was assessed for at least 4 consecutive days.
- -Cumulative duration of first response- as the total number of days the patient was in response from SD0 until start of HSCT conditioning. In this analysis, all days in response (i.e. when the criteria of at least an HLH improvement applied) were counted. Patients who never responded had a value of 0 days in this analysis
- -Post-HSCT event-free survival, i.e., from the date of HSCT to the date of any pre-specified event (graft failure, HLH reactivation, or death of any cause) or to the date of last assessment (either in Study NI-0501-04 or NI-0501-05)
- -Cox regression model was fitted to the data on Overall Survival with a time-dependent covariate signalling transplantation

## Randomisation and blinding (masking)

Not applicable. It was a single arm, open label study.

<div style=\"page-break-after: always\"></div>

Table 6. Summary of Bioanalytical Methods and Labs Performing Validation &amp; Sample Analysis

| Analyte          | adai A9s5y                                           | Assay Validation                                                                                                                                              | Serum Samples Analyzed by                                                                                                                                                                                                                                      | LLOQ                            |
|------------------|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| Emapalumab       | Sandwich immunoassay using the Gyrolab platform      | Novimmune SA (Geneva, Switzerland) and 1CON Development Solutions (Manchester, United Kingdom) with cross-validation by BioAgilytix Laboratories (Durham, NC) | Sam ples from NI-0501-03 at ICON Development Solutions (Manchester, United Kingdom) Sam ples from NI-0501-04, NI-0501-05, and CU from European sites at Novimmune, SA (Geneva, Switzerland) and samples from US sites at BioAgilytix Laboratories (Durham, NC) | 62.5 ng/mL                      |
| ATA              | ECLIA using the Meso-Scale Delivery platform         | LGC Drug Development Services (Fordham, United Kingdom)                                                                                                       | All samples (NI-0501-04, NI-0501-05, and CU) analyzed by LGC Drug Development Services (Fordham, United Kingdom)                                                                                                                                               | 6.1 ng/mL of positive control   |
| ATA              | Bridging immunoassay using the Gyrolab platform      | Covance Laboratories (Harrogate, United Kingdom)                                                                                                              | All samples (NI-0501-04, NI-0501-05, and CU) analyzed by Covance Laboratories (Harrogate, United Kingdom)                                                                                                                                                      | 20.00 ng/mL of positive control |
| ATA              | ECLIA using the Meso-Scale Delivery platform         | ICON Development Solutions (Manchester, United Kingdom)                                                                                                       | All samples (NI-0501-03) analyzed by ICON Derelopment Solutions (Manchester, United Kingdom)                                                                                                                                                                   | 23.9 ng/mL of positive control  |
| Neutralizing ATA | Cell-based assay and a luciferase reporter gene      | LG C Drug Development Services (Fordham, United Kingdom)                                                                                                      | All samples (Ni-0501-04, N1-0501-05, and CU) analyzed by LGC Drug Development Services (Fordham , United Kingdom)                                                                                                                                              | 73.1 ng/mL of positive control  |
| Total IFNY       | Sandwich immunoassay using the Gyrol ab platform     | Novimmune SA (Geneva, Switzerland)                                                                                                                            | NI-0501-04, NI-0501-05, and CU samples by Novimmune SA (Geneva, Switzerland)                                                                                                                                                                                   | 0.211 ng/mL                     |
| Total IFNY       | ECLIA using the Meso-Scale Delivery platform         | Novimmune SA (Geneva, Switzerland)                                                                                                                            | NI-0501-03, NI-0501-04, NI-0501-05, and CU samples by Novimmune SA (Geneva, Switzerland)                                                                                                                                                                       | 50.0 pg/mL                      |
| CXCL9            | Sandwich ECuA using the Meso-Scale Delivery platform | Norimmune SA (Geneva, Switzerland)                                                                                                                            | NI-0501-04, NI-0501-05, and CU samples by Novimmune SA (Geneva, Switzerland)                                                                                                                                                                                   | 80.0 pg/mL                      |
| CXCL10           | Sandwich ECuA using the Meso-Scale Delivery platform | Novimmune SA (Geneva, Switzerland)                                                                                                                            | NI-0501-04, NI-0501-05, and CU samples by Novimmune SA (Geneva, S witzerland)                                                                                                                                                                                  | 50.0 pg/mL                      |
| sIL2R            | Sandwich ECuA using the Meso-Scale wo,ped Aueaijaa   | Novimmune SA (Geneva, Switzerland)                                                                                                                            | NI-0501-04, NI-0501-05, and CU studies samples by Novimmune SA. (Geneva, Switzerland)                                                                                                                                                                          | 50.0 pg/mL                      |

## Statistical methods

A minimum of 28 evaluable patients treated with NI-0501 as 2 nd  line was to be enrolled to provide 90% power to show a 70% Overall Response Rate, ORR, was significantly greater than 40% using an exact binomial test at a one-sided significance level of 2.5%.

All analysis sets were defined prior to final database closure; analysis sets included the following:

- -All Treated Analysis Set : defined as all patients who received any part of an emapalumab infusion
- -Second-line All Treated Analysis Set (pivotal cohort), defined as all patients within the All Treated Analysis Set who received conventional HLH therapy prior to enrolment in the study
- -Evaluable Analysis Sets , including patients, within the All Treated Analysis Sets as defined above, who were assessed as evaluable for efficacy. Adjudication to the Evaluable Analysis Set was made through a Joint Review performed by the Independent DMC physicians and the Principal Investigators of the study.
- -Additionally, some analyses for selected efficacy and safety endpoints were conducted on the subgroup of patients receiving NI-0501 as first-line treatment and by-continent (as relevant).

The primary efficacy endpoint was analysed with an exact binomial test to evaluate the null hypothesis that the Overall Response Rate was at most 40%. This test was performed at the one sided 0.025

<div style=\"page-break-after: always\"></div>

significance level. The primary efficacy analysis was performed on the 2nd line All treated analysis set with supportive evidence derived from the 2nd line Evaluable analysis set.

The time to response, durability of response and survival time were presented using Kaplan Meier curves with median calculated (where available) together with an associated two-sided 95% confidence interval (CI).

If parameters for determination of Overall Response were missing, the following imputation rules were used:

1. Missing data at EOT for the parameters necessary for determination of Overall Response were imputed using the closest available value within -3 days and +5 days before and after the EOT date, respectively, provided that the upper limit was before the start of HSCT conditioning.
2. Values recorded at both scheduled and unscheduled visits were considered. For example, a value measured at an unscheduled visit could have been used to replace a missing value at a scheduled visit.
3. If data were missing for any of the response criteria, after imputation, the patient could not be classified as a Complete Response, with the exception of missing cerebrospinal fluid (CSF) data at EOT for patients without central nervous system (CNS) involvement at study entry and new CNS symptoms during the study, since analysis of CSF was not required unless clinically indicated.

The secondary efficacy endpoints were supportive, and no formal statistical testing was conducted.

An unplanned, informal descriptive interim analysis was performed to apply for an FDA Breakthrough designation and an EMA PRIME designation. Of 11 patients in the study and 4 non-study, compassionate use patients the following were provided: demographics, evolution of time of HLH-2004 diagnostic laboratory criteria, number of patients with improvement/normalisation of HLH relevant laboratory parameters, and individual trajectories of HLH relevant laboratory parameters.

## Results

## Participant flow

A total of n=53 patients were assessed for eligibility. A total of n=35 patients were allocated to treatment. One patient experienced an SAE just before initiation of treatment and did not meet the criteria anymore. Most patients completed study NI-0501-04 (n=26, 76.5%); a total of n=8 subjects withdrew prematurely (see Figure 7).

Overall, 12 investigational sites in 4 Countries (i.e. Germany, Italy, Spain and US) treated at least 1 patient in Study NI-0501-04. The first patients enrolled was on 28 July 2013, the last patient completed was on 20 July 2017 for the NI-0501-04 study.

A total of N=27 patients were identified as second line patients and a total of n=7 patients as treatment naive (first line).

<div style=\"page-break-after: always\"></div>

## Figure 7 Disposition of patients treated in the NI-0501-04 study (including enrolment in study NI-0501-05 )

## Screened N=53

Entered N=35

Treated N=34

Completed N=26

not fulfilling in /exclusion criteria (n=15), other (n=3)

1 onset of SAE qualifying as exclusion criterion immediately prior to first emapalumabinfusion

Withdrawn during study: n=8: adverse event (n=1), death (n=2), informed consent (n=1), use of additional HLH medication* (n=4), * these patients were included in study Nl0501-05

Continuing treatment in study NI-0501-05: n=24/26 from the 04 study (1 patient denied consent and 1 died after study completion) + 4 withdrawn patients

Completed N=20

Withdrawn during 05 study; N=8 Informed consent (=1) Died (n=5) Entered Cu programme (n=2)

During study NI-0501-04, a total of n= 26 patients completed Study NI-0501-04, (first line, second line). During study NI-0501-05, a total of N= 16 patients received treatment (source table 5 SoCE).

Figure 8 Disposition flow of patients who originated in NI-0501-04 in Study NI-0501-05 (All Treated)

<!-- image -->

The database cut off is 20 July 2017, when 34 patients received emapalumab. At the time of Day180 data from an additional 11 patients recruited was provided.

## Conduct of the study

The initial study NI-0501-04 was designed and conducted as a pilot Phase 2 study (version 1.1. dated 27 Sept 2012), with the target of enrolling 10 evaluable patients with only reactivating pHLH, i.e. patients in whom, after achievement of at least a partial response to conventional therapy, the disease presented again or worsened.

<div style=\"page-break-after: always\"></div>

The first patient was enrolled on 28 July 2013 and last patient completed on 20 July 2017, with 27 investigators. The original protocol NI-0501-04 was for EU sites v1.1 27 Sep 2012, extended to US sites v1.0 05 Jul 2013.

The study included 6 amendments while the study was ongoing. In the original protocol, the study population was limited to patients with a recurrence that showed at least Partial Response to conventional induction treatment of primary HLH. In amendment 04 (dated 7 May 2014) and amendment 05 (dated 15 December 2014), the study was broadened to the currently defined study population including the first line patient population. Amendment 04 come into force after the study had enrolled n=2 patients, amendment 05 came into force after the inclusion of n=3 patients.

In September 2015, an unplanned, informal descriptive analysis was conducted on the first n=11 entered patients to support the breakthrough therapy designation at FDA, followed by an application for the PRIME scheme at EMA. Results of this analyses were shared with the FDA and EMA and all study staff involved in decision making and conduct of the trial (including the Scientific steering committee (SSC), Data Monitoring Committee (DMC) and investigators.

After this analysis, the protocol was amended, while study was still continuing. In February 2016 (amendment 6), the protocol was amended to continue as a Phase 2/3 study in the same patient population as included by amendment 5. In this amendment, additional HLH treatments were allowed, the definitive dosing scheme became based on clinical symptoms and the response criteria, and the primary and secondary outcome measures were defined.

Initially, the response and disease activity assessment had consisted of the separate measurement of criteria such as CR, PR, etc and also included a response criterion defined as non-active disease, which is more or less in line with the HLH-94/04 protocol, however the latter criterion was removed upon amendment 6. The primary endpoint was, from then on, defined by combining several of the prior used response measurements (CR, PR, HLH improvement). Also, all the secondary endpoints were newly introduced.

When amendment 06 came into force, a total on n=19 patients had been enrolled. The data base lock was after n=34 patients were enrolled.

<div style=\"page-break-after: always\"></div>

Table 7 Key changes of the protocol amendments

<!-- image -->

| ProtocolAmendment Date                                          | Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EU version 2.1 11 January 2013                                  | + Addition of advice on contraception, and exclusion of preguancy and lactation  Clarification on the dose escalation process Revision of the IMP preparation fonm ● Clarification of the 4-week follow-up period after treatment discontinuation                                                                                                                                                                                                                                                                                                                                                                                      |
| US version 2.1 05 December 2013                                 | + Clarification of a few protocol sections (eg, treatment periods and follow-up period, dosing regimen, prophylactic and concomitant therapies, monitoring of NI-0501 concentalion, DMC role) dnug action on lymphocytes (ie, CBC with differential coumt at certain time points) · Differentiation between infusion visits and safety/efficacy assessment visits during treatment period 2                                                                                                                                                                                                                                            |
| EU version 3.0 13 December 2013                                 | Amendment of the protocol number to reflect the introduction of the US twin protocol + Implementation of a combined analysis of the data generated by the EU and US protocol  Clarifications of a few protocol sections (eg, Inclusion/Exclusion Criteria, study design, study outline and stopping nules) and introducing few additional clinical assessments (non-invasive), as well as PK and laboratory measuurements, aimed at facilitating the analysis of the data                                                                                                                                                              |
| US version 3.0 16 April 2014 EU version 4.0 07 May 2014         | Broadening of the patient population eligible to receive NI-0501 in the study. In addition to primary HLH patients reactivating after having achieved Partial Response following conventional therapy, the protocol allowed the inclusion of primary HLH patients who received conventional therapy and: 1. Worsened or showed no futher improvement for at least 4 weeks firom initiation of treatment after achieving at least Partial orIncomplete Response 2. Showed no response after at least 2 weeks from initiation of conventional therapy or worsening of the disease 3. Showed intolerance to conventional treahment of HLH |
| US version 4.0 17 November 2014 EU version 5.0                  | Broadening of the target patient population to include patients naive to HLH treatment + Revision of the title of the shudy to reflect the changes made to the Study Population                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 15 December 2014 EU version 6.0 26 February 2016 US Version 5.1 | Revision of the dose regimen, the dose detemmination criteria, and the background therapy requirements Prolongation of the study to continue as Phase 2/3, with detenmination of sample size for the pivotal cohort (defined as patients who receive NI-0501 in second line) Definition of primary and secondary efficacy endpoints, consistently with the amended phase of the study consistently with the amended phase of the study                                                                                                                                                                                                 |
| 24 March 2016                                                   | + Revision of the dosing regimen and implementation of a standardized approach to dose increase. Clinical criteria were indicated to guide the dose increase by the Investigator. Dose increase was allowed at any time duwing the course of the shudy  Possibility to add other HLH treatments, primarily etoposide, if pre-defined criteria Were met + Update to the stopping nules to reflect the experience gathered with the dnug and the amended phase of the study                                                                                                                                                              |

## Statistical analysis plan

The study had no official statistical analyses plan (SAP) until the descriptive analyses was conducted. The first version of the SAP is dated 12-10-2015. The SAP 1.0 was drafted with reference to the NI0501-04 pilot protocol (US protocol version 4.0; EU protocol version 5.0) and was therefore replaced by SAP 2.0 (dd 02-11-2016) after the protocol was amended to continue as a Phase 2/3 study.

The main modifications affecting the SAP can be summarised as follows:

- a. Definition of the efficacy endpoints (primary and secondary) that were exploratory in the pilot protocol
- b. Revision of criteria for the definition of response to treatment
- c. Definition of the null hypothesis in the context of formal sample size estimation
- d. Change from Bayesian to frequentist statistics.

<div style=\"page-break-after: always\"></div>

The study had a database cut of 20 Jul 2017, and the database lock was 29 Sept 2019. After the database lock, the SAP was modified twice. The first modification resulted in Version 3, dated 01-102017. Main modification to version V2 the DOR was defined as main secondary outcome measure and specific criteria for derivation of ORR were defined.

The final SAP was version 04, dated 27-10-2017. This version specified imputation rules on DOR, and additional details for derivation of the ORR and the identification of the second line patients.

On overview of the timelines of the various versions of the protocol, the number of enrolled patients and the SAP is provided in Table 8 .

Table 8 Overview of the various amendments, statistical analyses plan, and the number of enrolled patients.

| Protocol number                     | Total number of enrolled            | Statistical analyses plan           | Enrolled under statistical analyses plan   |
|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------------------------|
| V1 27-09-2012                       |                                     |                                     |                                            |
| V2 11-01-2013                       | N=1                                 |                                     |                                            |
| V3 13-12-2013                       | N=1                                 |                                     |                                            |
| V4 07-05-2014                       | N=1                                 |                                     |                                            |
| V5 15-12-2014                       | N=16                                | analyses Sept 2015                  | N=11                                       |
|                                     |                                     | V1 12-10-2015                       | N=17                                       |
| V6 26-02-2016                       | N=15                                | V1 12-10-2015                       | N=17                                       |
|                                     | N=15                                | V2 02-11-2016                       | N=3                                        |
| Data base lock dd 29 September 2017 | Data base lock dd 29 September 2017 | Data base lock dd 29 September 2017 | Data base lock dd 29 September 2017        |
|                                     |                                     | V3 01-10-2017                       |                                            |
|                                     |                                     | V4 27-10-2017                       |                                            |

The descriptive analyses were based on 11 patients with a data base lock of September 2015. A total of n=3 patients are enrolled between the database lock of the descriptive analyses and when the first version of the statistical protocol came into force.

In Bold the phase III study and corresponding associated SAPs are highlighted.

## GCP inspection

The pivotal trial study NI-0501-04 was also subject of a triggered GCP inspection further to CHMP request. The inspection was conducted from August 2019 until December 2019. The scope of the inspection were documentation and the consistency of reported data with source documents, referring to the pharmacokinetics and pharmacodynamics.

Moreover, the compliance with GCP and applicable regulations was to be verified, in particular where it may have had an impact on the validity of the data.

The Inspection took place at one laboratory site, two clinical sites and at the sponsor site. The Inspection resulted towards important critical and major findings related to the patient's rights and the data integrity .

The Inspection resulted important critical and major findings related to the integrity of the patient's rights such as:

- -deviations regarding to informed consents as for example, no translated informed consent available;
- -the collection of more medical data and storage of patient samples than was foreseen by the protocol or informed consent
- -the transfer to the sponsor of personal data like race, ethnicity, and sometimes patient's identity;

<div style=\"page-break-after: always\"></div>

- -the Data Monitoring Committee was not independent as a sponsor representative was always present.

Important Critical/ major findings related to the issues referring to the data integrity were mainly attributable to a lack of trial oversight by the Sponsor.

The critical findings found at the Sponsor site, impacted the whole clinical trial. In this case it negatively affected the data collection, data handling, the planning of the transition of the phase II to a phase III trial, statistical analyses, etc. The Sponsor's CAPA's were also considered insufficient and needed to be updated to an adequate level to enhance the data quality, resulting in a strong recommendation for a full GCP inspection (including computerised systems) in the context of a future MAA of the sponsor.

The most important critical/ major GCP findings directly affecting the collection and analysis of the efficacy and safety results of the 04 Study were:

- -The transition from an exploratory phase II to a confirmatory phase III trial was not pre-planned by well-defined criteria. The original protocol also did not foresee in pre-planned analyses. The preliminary results were shared with clinical and strategic decision makers and this may have influenced the design of the confirmatory part of the trial. Moreover, extensive sponsor involvement in the conduct of the trial was noted: e.g. several and one particular sponsor attendee attended all DMC meetings and was involved in discussions regarding waivers and exceptions for the inclusion and treatment of patients;
- -The statistical analyses plan was not finalised before the transition to a phase III trial, and not until almost all patients were included. Also, after data base lock, the SAP was amended twice. These amendments included specification for the identification of the second line population (pivotal study population), derivation of the overall response (primary outcome) and imputation rules for response analyses thus affecting the primary endpoint.
- -The set up and validation of the eCRF was not sufficiently GCP compliant.
- o E.g. the eCRF was not validated at the start of the trial. the Sponsor only relied on the statements of the supplier. This is regarded as insufficient, because some systems, e.g. Oracle, have deficiencies regarding key functionalities like time stamp and audit trail.
- o The eCRF was tested, but systems (Software) updates were (again) not validated and the effect. As a result, the effect of the software update on the eCRF is not established.
- -The eCRF did not align with protocol (eligibility criteria, definition of AEs) and this contributed to the incomplete collection of safety data that was repaired retrospectively.
- -The trial was subject to an inappropriate data management process. The findings that could have been of influence on the quality of the collected data relate to:
- o The electronic audit trail could not provide adequate information on who/when and why a change in the data base was made.
- o The management of the safety data base had many users (n=15) with privileged administration rights to the data base. Several of these users were involved in the conduct of the trial. These privileged users had more rights on the system (operating system or application), including but not limited to changing any system setting (e.g. system time), defining or removing users (incl. 'admin users'), activate or deactivate audit trail functionality (and sometimes even edit audit trail information) and making changes to data that are not captured in the audit trail (e.g. backend table changes in the database).
- -The electronic Trial Master Files and Investigator Study file did not align and were incomplete showing that the Sponsor lacked trial oversight.

<div style=\"page-break-after: always\"></div>

- -No clear GCP and study specific training took place at the start of the trial. The GCP training results in a proper data collection and trial conduct; the lack of study specific training may result in a less uniform interpretation of the protocol and conduct of trial, which may affect the data collection and data quality
- -A retrospective analysis was conducted by the applicant to show that the data handling procedures did not affect the data. However, this has limitations since a retrospective system validation can only validate the available data and the extent of missing data or unknown cannot be corrected retrospectively.

## Protocol violations and deviations

In study NI-0501-04 non-compliance to the protocol schedule of assessment represented more than half of all deviations.

Table 9. Overview of protocol deviations occurring in study NI-0501-04

| Deviation category                         | Number of patients (%) (N=34)   | Total Number of deviations (%) (N=96) [1]   |
|--------------------------------------------|---------------------------------|---------------------------------------------|
| Eligibility Major Minor Not applicable [2] | 4 (11.8) 2 1 1                  | 4 (4.2) 2 1 1                               |
| Co-medication Major Minor Exceptions       | 12 (35.3) 2 5 8                 | 15 (15.6) 2 5 8                             |
| Study drug Major Minor                     | 15 (44.1) 2 1                   | 17 (17.7) 2 1                               |
| Minor Exceptions                           | 26 (76.5) 13 22                 | 52 17 34                                    |
| Exceptions Assessments Major               | 13                              | 14 (54.2)                                   |
| Others Major Minor                         | 1 2 (5.9)                       | 1 2 (2.1)                                   |
| Exceptions Time point                      | 2                               | 0 2                                         |
| window                                     | (5.9)                           |                                             |
| Exceptions ICF                             | 1 1 0                           | 1 1                                         |
| Major Minor                                | 4 (11.8) 3 1 0                  | 0 4 (4.2)                                   |
|                                            | 1                               | 1                                           |
|                                            | 1                               | 0 1                                         |
|                                            | 0                               |                                             |
|                                            |                                 | 3 1                                         |
| Major                                      |                                 |                                             |
| Exceptions                                 |                                 |                                             |
| Minor                                      |                                 |                                             |
|                                            |                                 | (2.1)                                       |

[1] Total number of deviations reported in Study NI-0501-04

[2] Refers to post-mortem diagnosis of an exclusion criterion (NK/T cell lymphoma)

In the category of Eligibility Criteria, it should be noted that two patients were listed who both  met the eligibility criteria at the time of study entry. Only during the course of the study, did new information become available, based on which these 2 patients were excluded from the Evaluable Analysis Set, namely:

<div style=\"page-break-after: always\"></div>

-One patient (second line): although at the time of enrolment the eligibility criteria were met, a post-mortem histological analysis revealed the presence of NK/T-cell lymphoma, therefore classifying the patient's disease as a secondary form of HLH.

-Another patient (second line): at study entry the presence of CNS disease was diagnosed by the investigator in this patient with genetically confirmed FHL2. However, the final centralised experts' review of clinical, laboratory and radiographic characteristics did not confirm CNS involvement. Hence, there were no sufficient signs of systemic HLH activity, and the patient was assessed not to have met the inclusion criterion 'Presence of active disease', which prevented a full evaluation of emapalumab efficacy.

## Baseline data

## Baseline demographic data

- All treated

A total of N=34 patients entered study NI-0501-04. The median age at study entry was 1.0 year, with a range of 0.1 years to 13.0 years. A total of n=16 (47%) were male, and most patients n=22 (64%) were white. The median weight at consent was 10 kg ranging from 3.3 to 53 kg.

- Second line

A total of N= 27 (79%) patients entered study NI-0501-04. The median ages at study entry was 1.0 year, with a range of 0.2 to 13 years. A total of n= 11 (51%) were male, and most patients n=17 (63%) were white. The median weight was 11.65 kg ranging from 3.3 to 53 kg.

- First line

A total of n=7 (21) treatment naive patients entered study NI-0501-04. A total of n=5 were male and most patients were white (n=5, 71%). The median age was 0.73 years (range 0.1-4.7).

## Baseline disease characteristics

Median age at diagnosis of the second line patient group with HLH was 0.91 years. Most patients (79.4%) in the NI-0501-04 study had a genetic mutation known to cause HLH. The most frequent causative mutations were in the MUNC13-4 (23.5%) and PRF1 (20.6%) genes.

At baseline, most second line patients had elevated ferritin levels ( 78 % with ferritin &gt; 500 µg), thrombocytopenia (70% with a platelet count of &lt; 100 x10 9  cells/L), hypertriglyceridaemia (67% with a triglyceride level &gt; 3 mmol/L), elevated D-dimers ( 70% with Ddimers level &gt; 500 μg/L) and splenomegaly (56%) (Table 10). Central nervous system (CNS) findings were present in 37% of patients.

Overall the baseline characteristics between the all treated, and second line patients were comparable (see Table 10).

<div style=\"page-break-after: always\"></div>

Table 10 HLH disease characteristics at Baseline (All treated patients) (Table made by assessor)

| Parameter                                            | Treatment naive (n=7)               | Second line (n=27)                    | All treated (n=34 (%)                  |
|------------------------------------------------------|-------------------------------------|---------------------------------------|----------------------------------------|
| Age at HLH diagnosis (years) [1]                     |                                     |                                       |                                        |
| - Mean (SD)                                          | 1.178 (1.623(                       | 2.354 (3.43)                          | 2.089 (3.16)                           |
| - Median                                             | 0.73                                | 0.91                                  | 0.85                                   |
| - Min, max                                           | 0.04, 4.69                          | 0.03, 13.81                           | 0.03, 13.81                            |
| Race                                                 |                                     |                                       |                                        |
| White Asian African Descent Mixed/multi-racial Other | 5 (71.4) 2 (28.6)                   | 22 (64.7) 5 (14.7) 3 (8.8) 0 4 (11.8) | 17 (63.0) 3 (11.1) 3 (11.1) 0 4 (14.8) |
| Country of Origin                                    |                                     |                                       |                                        |
| US Italy Others Missing                              | 1 (14.3) 1 (14.3) 4 (57.1) 1 (14.3) | 7 (25.9) 3 (11.1) 12 (44.5) 5.(18.5)  | 8 (23.5) 4 (11.8) 16 (47.1) 6 (17.6)   |
| Mutation known to cause HLH                          | 5 (71.4)                            | 22 (81.5)                             | 27 (79.4)                              |
| - FLH                                                | 2 (28.6)                            | 0                                     | 2 (5.9)                                |
| 1 - FHL                                              | 2 (28.6)                            | 5 (18.5)                              | 7 (20.6)                               |
| 2 - FLH 3                                            | 1 (14.3)                            | 7 (25.9)                              | 8 (23.5)                               |
| - FLH 4                                              | 0                                   | 1 (3.7)                               | 1 (2.9)                                |
| - FLH 5                                              | 0                                   | 2 (7.4)                               | 2 (2.9)                                |
| - Griscelly syndrome type 2                          | 0                                   | 5 (18.5)                              | 5 (14.7)                               |
| - X linked proliferative disorder 1                  | 0                                   | 1 (3.7)                               | 1 (2.9)                                |
| - X linked proliferative disorder 2                  | 0                                   | 1 (3.7)                               | 1 (2.9)                                |
| HLH-2004 diagnostic criteria                         |                                     |                                       |                                        |
| - Fever                                              | 2 (29)                              | 4 (15)                                |                                        |
| - Splenomegaly                                       | 5 (71)                              | 15 (56)                               | 20 (59)                                |
| - Platelet count < 100 x 10 9 cells/L                | 4 (58)                              | 19 (70)                               | 23(68)                                 |
| - Neutrophil count t< 1 x 10 9 cells/L               | 3 (42)                              | 14 (52)                               | 17 (50)                                |
| - Ferritin >500 µg/L [2]                             | 6 (85)                              | 21 (78)                               | 27(79)                                 |
| - Fibrinogen<1.5 g/L                                 | 4 (58)                              | 11 (41)                               | 15 (44)                                |
| Other HLH abnormalities                              |                                     |                                       |                                        |
| • Ferritin > 2000 µg/L [2]                           | 4 (58)                              | 17 (63)                               | 21 (62)                                |
| • D Dimeer >500 µg/L                                 | 4 (58)                              | 19 (70)                               | 23 (68)                                |
| • ALT > 125 IU/L [3]                                 | 1 (14)                              | 10 (38)                               | 11 (33)                                |
| • total bilirubin>25 µmolg/L                         | 1 (14)                              | 7 (26)                                | 8 (24)                                 |
| • LDH > 1000 IU/L                                    | 3 (42)                              | 3 (11)                                | 6 (18)                                 |
| • Triglycerides > 3 mmol/L                           | 5 (58)                              | 18 (67)                               | 23 (68)                                |
| • CNS involvement [4]                                | 1 (14)                              | 10 (37)                               | 11 (32)                                |

· Note: baseline in NI-0501-04

- [1] age at initial HLH diagnosis is defined as (date of diagnoses - Date of birth)+1/365.25

[2] thresholds for ferritin are the one in the HLH 2004 diagnostic criteria (500 µg/L) and the one in the algorithm for response assessment in this study 2000 g/L

- [3] threshold for parameters are approximation of 2.5 x ULN for ALT, 1.5 x ULN for total bilirubin and ULN for LDH

[4] Patients who were assesses as CNS diseases by Medical Experts

ALT = alanine aminotransferase, CNS is central nervous system. HLH = Haemophagocytic lymphohistiocytosis. LDH lactate dehydrogenase ULN = upper limit of normal

There were 7 patients for whom the Investigator did not indicate the presence of a familial form of HLH e.g. a total of n=5 in the second line and n=2 in the first line.

<div style=\"page-break-after: always\"></div>

## Second line patients

Most of the second-line patients had a genetically confirmed diagnosis of pHLH. Additionally, in 2 patients a heterozygous mutation in a known HLH gene(s) (with impaired functional tests in 1 of them) supported the diagnosis of primary HLH; in 2 patients the diagnosis of secondary HLH was excluded although no mutations were found in known HLH genes (17-03 and 04-01); and for 1 patient (15-01) the diagnosis was post-mortem established as secondary HLH due to the presence of an haematological malignancy undiagnosed at study entry.

## First line patients

Two patients did not have a genetically confirmed diagnosis. However, one patient had a heterozygous mutation in a known HLH gene and another subject had an impaired functional test confirming the diagnosis of pHLH.

## Previously treated pHLH (Second line patients)

A total of n = 27 second line patients were included. Most of them received Dexamethasone + etoposide (n= 23; 85.2%) before commencing emapalumab. A total of N=1 patient received only dexamethasone, a total of N=3 the combination of dexamethasone + cyclosporine before the start of emapalumab. These four patients did not have a reported intolerance or contraindication for etoposide.

The HLH regimens that had been most frequently administered were HLH-94 (37.0%) and HLH-2004 (33.3%), followed by the HIT (14.8%), however few patients received additional HLH drugs on top of the main regimen to better control the disease (Table 11).

Two patients received HSCT prior to study NI-0501-04 and were considered for the study due to HLH reactivation following graft failure.

Table 11 Previous treatments for the treatment of HLH in before the administration of emapalumab \\_Second line treated population

| Parameter                                      | Second Line (N=27)   |
|------------------------------------------------|----------------------|
| Type of drug, n (96)                           |                      |
| Dexamethasone                                  | 27 (100)             |
| Etoposide                                      | 23 (85.2)            |
| Cyclosporine A                                 | 13 (48.1)            |
| Antithymocyte Immumoglobulin                   | 5 (18.5)             |
| Methylprednisolone (IV/oral)                   | 4 (14.8)             |
| Alemhzumab                                     | 1(3.7)               |
| Auakinra                                       | 1 (3.7)              |
| Glucocorticoids (intrathecal)                  | 7 (25.9)             |
| Methotrexate (intrathecal)                     | 9 (33.3)             |
| Previous HLH regimen [1]                       |                      |
| HLH-94 (dexamethasone, etoposide) [2]          | 10 (37.0)            |
| HLH-2004 (dexamethasone, etoposide, CsA) [3]   | 9(33.3)              |
| HLH-HIT (dexamethasone, ATG and etoposide) [4] | 4 (14.8)             |
| Dexamethasone + MPN + CsA                      | 2 (7.4)              |
| Dexamethasone + CsA                            | 1 (3.7)              |
| Dexamethasone >10 mg/m/day                     | 1 (3.71              |

[]Assigued based on the reported dnugs thepatient received

[2] 1 patient also received MPN and anakinra; 1 patient also received alemtuzumab

[3]1 patient also received MPN and ATG

[4] 1 patient also received CsA

HLH = hemaphagocytic lymphohistiocytosis; MPN = methylprednisolone; CsA = Cyclosporin A;

ATG = antithymocyte immumoglobulin

<div style=\"page-break-after: always\"></div>

The reasons for entering study NI-0501-04 were HLH reactivation (n=15, 55%), or incomplete response/no response or HLH worsening (n=14, 52%). A total of N=7 (26%) were intolerant to conventional HLH treatment (see Table 12).

## Patients not having received prior HSCT:

The applicant clarified that there was difficulty in identification of a suitable donor and/or need for referral to other hospitals in order to access the best expertise on HLH treatment and transplant, therefore some patients did not receive prior HSCT.

The applicant provided the treatment protocols of second line patients who had their first line treatment in another country than the study site.

A Venn diagram for 2nd line cases was provided upon CHMP request, to highlight the breakdown of cases where retreating with conventional therapy or physician's choice was a potential option according to these criteria.

<div style=\"page-break-after: always\"></div>

Figure 9. Venn diagram representing second-line patients enrolled in Study NI-0501-04

<!-- image -->

## Definitions:

- -Relapsed: patients who had some degree of response to prior conventional therapy (including an incomplete response) however this response was not sustained either because of a reactivation of the disease or because some aspects of HLH disease worsen
- -Refractory: patients who never showed any sign of improvement with conventional therapy, instead HLH disease was progressively worsening
- -Intolerant: Patients who may have responded to previous therapy, however present signs and symptoms of drug toxicities, which preclude treatment continuation or re-intensification and prompt search for therapeutic alternatives

A total of 7 (25.9%) of the 27 second-line patients who had failed prior conventional HLH therapies were recorded as being intolerant to prior HLH treatments, namely dexamethasone and etoposide.

<div style=\"page-break-after: always\"></div>

Table 12 Previous response to conventional HLH treatment and reasons for entering study NI-0501-04

| Historieally reported outcome of previous conventional HLH therapy   |                        |                            |
|----------------------------------------------------------------------|------------------------|----------------------------|
| Patients Achieved Response to Conventional HLH Treatments            |                        |                            |
| Complete Response Partial Response Incomplete Response               | (%) N N(%) (%) N       | 7 (25.9) 7 (25.9) 8 (29.6) |
| Time to Response (days) [1]                                          | N Median Min, Max      | 22 51.5 4,517              |
| Patients Experienced Worsening Under Conventional HLH Treatments     |                        | 5 (18.5)                   |
|                                                                      | N(%)                   |                            |
|                                                                      | Median Min, Max Median | 54.0 1, 693 5 (18.5)       |
| Patient Experienced a Worsening                                      | N (%) N                | 5                          |
| Time to Worsening (days) [3]                                         | Min, Max               | 5.0                        |
|                                                                      |                        | 7 (25.9)                   |
| Reasons Patients Enter the Study after Previous HLH Ireatment [4]    | N(%)                   |                            |
| HLH Reactivation Incomplete Response/ No Response / HLH Worsening    | (%) N                  |                            |
| Patients Experienced Intolerance to Conventional HLH Treatment       |                        |                            |
|                                                                      |                        | 1, 30                      |
|                                                                      | N(%)                   |                            |
|                                                                      |                        | 15 (55.6)                  |
| Intolerance to Conventional HLH Treatment                            |                        |                            |
| 7 (25.9)                                                             | 7 (25.9)               | 7 (25.9)                   |
| 14 (51.9)                                                            | 14 (51.9)              | 14 (51.9)                  |
| N (%)                                                                | N (%)                  | N (%)                      |

[1] Time to Response is defined as (date of response achieved -- date of HLH diagnosis +l).

[2] Time to Reactivation defined as (date of reactivation - date of response to previous treatment +l)

[3] Time to Worsening defined as (date of worsening - date of response to previous treatment +l)

[4] Patients who entered shudy with multiple reasons are presented in each reason.

Source: Table 14.1.4.2.1

<div style=\"page-break-after: always\"></div>

Table 13. Intolerant patients in the pivotal study

| Patient ID   | Drug                     | Comments by the Investigator                                                               |
|--------------|--------------------------|--------------------------------------------------------------------------------------------|
|              | Etoposide                | After8 weeksoftreatment and maintenance for 5 months, the pt. could not tolerate etoposide |
|              | Etoposide Cyclosporine A | Etoposide and CsA stopped for renal failure                                                |
|              | Etoposide                | n.a.                                                                                       |
|              | Etoposide                | Etoposide approaching max cumulative dose                                                  |
|              | Dexamethasone            | n.a.                                                                                       |
|              | Etoposide                | Pancytopenia                                                                               |
|              | Etoposide Dexamethasone  | n.a.                                                                                       |

## Concomitant therapy during the NI0501-04 study

All patients (n=34) received dexamethasone as background HLH treatment at a per-protocol starting dose between 5 and 10 mg/m2/day. In the majority of patients (66.7%), the dexamethasone dose was 10 mg/m2/day at initiation of emapalumab treatment.

None of the first line patients received concomitant HLH therapy. A total of N=9 second patients used concomitant HLH therapy during study NI-501-04. These treatments were etoposide, alemtuzumab, anakinra and cyclosporine.

A new treatment was newly initiated in 6 patients. Seven patients used etoposide, alemtuzumab or ATG and 5 patients used cyclosporine prior to measuring the primary endpoint. Most patients which received concomitant HLH treatments during study 04, had no response to treatment except for 3 patients as discussed below:

- The first patient achieved a PR but was administered alemtuzumab prior to the measuring of the primary endpoint. Note that this patient was included in the sensitivity analysis in which additional HLH treatments were classified as non-responders.
- The second patient achieved a PR and was administered cyclosporine (until SD 6) prior to the measuring of the primary endpoint (at SD 61).
- The third patient achieved a PR and was administered cyclosporine (until SD 36) prior to the measuring of the primary endpoint (at SD 60).Intrathecal therapy (methotrexate alone or in combination with either hydrocortisone or methylprednisolone) was administered to n=12 (35.3%) patients during Study NI-0501-04.

In 5 patients in whom cyclosporine-A was in place prior to study entry, this treatment was continued, as allowed by the protocol; treatment with cyclosporine A was discontinued during the first week in one patient, by week 3 in 2 patients, and continued until end of treatment in the NI -501-04 in 2 subjects.

In eleven patients G-SCF was administered during study 04-05, response measurements were performed when Pharmacodynamic effects of G-SCF could still be expected.

<div style=\"page-break-after: always\"></div>

Two patients received rituximab in study 04.

Before the end of emapalumab treatment in the NI-0501-04 study, 5 patients were administered HLH treatments, specifically etoposide and alemtuzumab, due to insufficient control of HLH.

A total of N =15 patients were identified who used concomitant HLH treatments (etoposide, alemtuzumab, ATG and/or CSA) prior to the measurement of the secondary endpoints (EoT 04/05).

Nearly all patients (97.0%) received anti-infective treatment, including anti-bacterial (97%), antimycotics (82.4%), and antivirals (67.6%). All most all patients received prophylactic anti-infective therapy. Most patients also received anti-infectious agent for adverse events treatment. Approximately half of patients were treated with cardiovascular agents, among which diuretics and calcium channel blockers were the most represented. Anti-convulsive for the treatment of CNS disease were taken by 26.5% of patients.

Table 14. Emapalumab Dosing in Study NI-501-04

| Parameter                         | Statistic                   | NI-0501-04 (N=34)                  |
|-----------------------------------|-----------------------------|------------------------------------|
| Duration of Dosing (days) [1]     | N Mean (SD) Median Min, Max | 44.6 (16.94) 54.0 4,60             |
| Cumulative Dose (mg/kg) [2]       | N Mean (SD) Median Min, Max | 34 38.5 (42.66) 19.0 4,210         |
| Average Dose Frequency (days) [3] | N Mean (SD) Median Min, Max | E 3.416 (0.9607) 3.165 1.35, 6.00  |
| Average Dose per Day (mg/kg) [4]  | N Mean (SD) Median Min, Max | 34 0.909 (1.1580) 0.695 0.17, 6.77 |

In study NI-0501-04 38.2% off patients received emapalumab 1 mg/kg every 3 to 4 days during the entire duration of the study, with the interval between infusions elongated to 6-7 days in some. The dose of emapalumab was increased in 62% of patients, to 3-4 mg/kg in 10 (29.4%), and 6 - 10 mg/kg daily in 11 patients (32.3%).

## Numbers analysed

The All Treated Analysis Set included n=34 (100%) patients, with n=27 being subjects treated as second line (79.4%) and n=7 cases as first line.

## Outcomes and estimation

## · Primary outcome: overall response rate at end of treatment study NI0501-04

Overall, N=17 (63%, 95% CI: 0.42, 0.81)  and n=22 ( 64.7%, 95% CI: 0.44, 0.78)  patients in the Second-Line Analysis  Sets (n=27) and All-Treated (n=34), respectively, had an Overall Response at end of treatment in the NI-0501-04 study (Table 15).

For both the second line and the first line analyses set, the lower limit of the 95% CI was higher than the hypothesised null hypothesis of 40% (p=0.0134 and p=0.0031, respectively, see Table 15.

<div style=\"page-break-after: always\"></div>

The Overall Response rate in the second -Line Analysis Set was n=17 63% (95% CI 0.42, 0.81) p=0.0134 (Table 15).

Table 15 Overall response rate- EOT

|                                 | All Treated (N=34)   | Second Line (N=27)   | First Line (N=)   |
|---------------------------------|----------------------|----------------------|-------------------|
| OverallResponse                 |                      |                      |                   |
| Complete response, n (96)       | 7 (20.6)             | 7 (25.9)             | 0                 |
| Partialresponse                 | 11 (32.4)            | 8 (29.6)             | 3 (42.9)          |
| HLHimprovement                  | 4 (11.8)             | 2 (7.4)              | 2 (28.6)          |
| Overall Response Rate [1] N (%) | 22 (64.7)            | 17 (63.0)            | 5 (71.4)          |
| (959% C1)                       | (0.46, 0.80)         | (0.42, 0.81)         | (0.29, 0.96)      |
| p-value [2]                     | 0.0031               | 0.0134               | 0.0963            |

CI=confidence interval;EOT=End-of-Treaiment.

[1] Comprised of complete response, partial response, and HLH improvement.

[2] p-value based on Exact Binomial Test at a one-sided siguificance level of 2.5%6 comparing proportion ofpatients

With Overall Response to hypothesized null hypothesis of 40%6.

Sensitivity analyses for Overall Response rate were performed to explore the impact of the following on the robustness of the conclusions from the primary analysis (Table 16):

- 1) a narrower time window at EOT (i.e., -3/+3 days rather than -3/+5 days)
- 2) administration of additional HLH treatments i.e. etoposide and alemtuzumab upon the Investigator's assessment of unsatisfactory response; and
- 3) continuation of emapalumab treatment in the NI-0501-05 study

These analyses confirmed the conclusions of the primary analyses (Table 16).

Table 16 Sensitivity Analyses of Overall Response- (table prepared by assessors)

| Overall Response Rate [1]                                                        | First line**   | Second line   | All Treated   |
|----------------------------------------------------------------------------------|----------------|---------------|---------------|
| Missing data imputation window of -3/+3 days [2]                                 |                |               |               |
| N                                                                                | 7              | 27            | 34            |
| n (%)                                                                            | 5              | 17 (63.0)     | 22 (64.7)     |
| (95% CI)                                                                         |                | (0.42, 0.81)  | (0.46, 0.80)  |
| p-value [3]                                                                      |                | 0.0134        | 0.0031        |
| Started concomitant HLH treatment in NI- 0501-04 study considered non-responders |                |               |               |
| N                                                                                | 7              | 27            | 34            |
| n (%)                                                                            | 5              | 16 (59.3)     | 21 (61.8)     |
| (95% CI)                                                                         |                | (0.39, 0.78)  | (0.44, 0.78)  |
| p-value [3]                                                                      |                | 0.0337        | 0.0085        |
| No other HLH treatments added during study NI-0501-04                            |                |               |               |
| N                                                                                | 7              | 22            | 29            |
| n (%)                                                                            | 5 (71)         | 16 (72.7)     | 21 (72.4)     |
| (95% CI)                                                                         |                | (0.50, 0.89   | (0.53, 0.87)  |
| p-value [3]                                                                      |                | 0.0019        | 0.0004        |
| At EOT 04/05 [4]                                                                 |                |               |               |
| N                                                                                | 7              | 27            | 34            |
| n (%)                                                                            | 3 (43)         | 16 (59.3)     | 19 (55.9)     |
| (95% CI)                                                                         |                | (0.39, 0.78   | (0.38, 0.73)  |
| p-value [3]                                                                      |                | 0.0337        | 0.0444        |

[1] Overall Response Rate comprised of Complete Response, Partial Response or HLH improvement as defined in SAP. Percentages, 95% CI, and p-value were based on patients with non-missing response at EOT.

[2] Primary efficacy analysis used a data imputation window of -3/+5 days at EOT in the NI-0501-04 study.

[3] One-sided p-value based on a one-sided Exact Binomial Test comparing proportion of patients with Overall Response to

<div style=\"page-break-after: always\"></div>

hypothesised value of 40%.

[4] Using the -3/+5 day time window.

CI = confidence interval; EOT 04/05 = the end of emapalumab treatment occurred in either the NI-0501-04 or NI-0501-05 studies. Source: CSR NI-0501-04 Table 14.2.2.7 and Table 14.2.2.8 (imputation window -3/+3 days), Table 14.2.2.11 and Table 14.2.2.12 (patients who started concomitant HLH treatments in the NI-0501-04 study were considered non-responders), and Table 14.2.2.15 and Table 14.2.2.16 (patients with no concomitant HLH treatments during the NI-0501-04 study).

** data not provided by the applicant

## · Secondary outcomes

## Characterisation of response

## Time to first response

Time to response was defined as the time from date of first dose to achievement of first maintained response (either Complete or Partial Response, or HLH Improvement maintained for at least 4 days) occurring prior to or at EOT 04. A total of n=24 (88.9%) and n= 30 (88.2%)of patients in the SecondLine Analysis Sets and in the All-Treated and respectively, responded to emapalumab treatment; the median time to the initial response was 8.0 days (95% CI 7.0-14.0) for the treatment experienced set and 8.0 days (95% CI 5.0, 10) for the all treated. No data has been provided for the first line treatment separately.

## Duration of response

Duration of first response was defined as the total elapsed time from first achievement of response to first loss of response. The median time to loss of the initial treatment response was not estimable for the Second-Line Analysis Set and 58.0 days in the All-Treated Analysis Set.

## Cumulative duration of response

Cumulative duration of response represents the total time in response from the achievement of a first response up to HSCT conditioning, calculated by adding together the separate time periods in which patients have remained 'in response'; patients who never responded had a value of 0 days in this analysis.

From start of treatment until HSCT conditioning, median cumulative response duration was 31.0 days in Second-Line Analysis Sets and 33.5 days in the All Treated set, respectively. Patients in each analysis set remained in response with HLH under control for a median of 75% of the time.

## Swimmer plots

A comprehensive review of response to emapalumab on a patient basis is given in second line patients given in Figure 10 (second-line patients) and in

Figure 11 (first-line patients).

<div style=\"page-break-after: always\"></div>

Figure 10. Swimmer Plot of Response Duration until HSCT conditioning in Second Line

<!-- image -->

Note:  One patient continued emapalumab treatment in CU after premature withdrawal from Study NI0501-04 due to administration of additional HLH treatments. The dotted vertical line indicates the latest timepoint at which response assessment at EoT 04 (3 days after last infusion in Study NI-0501-04) was performed.

Figure 11.Swimmer Plot of Response Duration until HSCT conditioning in First-Line Patients

<!-- image -->

## Glucocorticosteroids tapering

In the All treated set the dexamethasone dose was 10 mg/m 2 /day or higher in 24 (70.6%) patients at initiation of emapalumab treatment decreasing to 5 mg/m 2  at EOT04. Sixteen (47.1%) patients could reduce the dose of glucocorticoids by at least 50% during Study NI-0501- 04, and 5 (14.7%) additional patients could reduce the dose of glucocorticoids received by at least 30% (Table 17).

<div style=\"page-break-after: always\"></div>

Table 17 Dexamethasone dose over time and glucocorticoid tapering in study NI-0501-04 all treated and second line all treated analysis set

|                                                                        | First line (n=7)   | Second Line (Pivotal Cohort) (N=27)   | All Treated (N=34)   |
|------------------------------------------------------------------------|--------------------|---------------------------------------|----------------------|
| Median daily dexamethasone dose (mg/m 2 )                              |                    |                                       |                      |
| Baseline                                                               | 10.2               | 10.0                                  | 10.0                 |
| Week 2                                                                 | -                  | 5.7                                   | 7.3                  |
| EOT 04                                                                 | 5.0                | 5.3                                   | 5.2                  |
| (N, %) Percentage of patients with a glucocorticoid dose reduction [1] |                    |                                       |                      |
| <30%                                                                   | 3 (42.9)           | 10 (37.0)                             | 13 (38.2)            |
| ≥30% -50%                                                              | 0                  | 5 (18.5)                              | 5 (14.7)             |
| ≥50%                                                                   | 4 (57.1)           | 12 (44.4)                             | 16 (47.1)            |

[1] From Baseline to end of treatment in the NI-0501-04 study, with EOT defined as 3 days after the last emapalumab infusion in the NI-0501-04 study.

EOT = end-of-treatment.

## Patients who underwent HSCT and HSCT outcomes

In the all treatment set, a total of n=23 patients entered the preconditioning period.

A total of n=22/34 (64.7%) proceeded to transplant, one patient died in the preconditioning period. The median time between the last time of emapalumab infusion and initiation of the preconditioning period was 3 days (0-28 days). Responses at time of conditioning for second line patients (n= 19) were: 5 in CR, 5 in PR 3 had HLH improvement (ORR of 68.4 % (95% CI 0.43-0.97) Six second line patients (and 2 first line patients) underwent a HSCT with no response on emapalumab

The median time interval between the last emapalumab dose and HSCT was 16 days (8-35). The assessment of clinical response on HSCT is not performed, given the impact of the conditioning agent on the response algorithm.

Complete information on transplants outcome is available for n=21 patients.

The median time to HSCT was 100 days (95% CI: 73, 155) in the All Treated and 83 days (95% CI: 64, 139) in the Second-Line analysis sets, respectively. In first line three patients (43%) proceeded to HSCT at a median time of 233 (89.0, NE) days= 7.6 months. The engraftment rates were n=19 (86.4%) and (n=17) 89.5%, and n=2 (67%) for the all treated, second and first line respectively.

The 3 patients who failed to engraft were the ones who received haploidentical transplantation. Clinical manifestation of GVHD were observed in 7 patients, all in the second line population.

## Patients not undergoing HSCT

A total of 4 surviving patients did not undergo HSCT. In two patients a complete response was achieved, another patient received a partial response. Three of these patients did not have a known HLH causative gene mutation, while the other patient failed a previous transplant and experienced episodes of HLH reactivation.

## Survival post-HSCT

The median follow-up for post HSCT survival was 11.06 [1.0-18.1 in the all treated population and 11.76 [1.6-18.1] in the second line population, and 1.87 [1.0-12.0] in first line patients.

In the Second Line All Treated population, survival probability estimates were 0.89 (95% CI:0.64, 0.97) at 3 months and afterwards. In the All Treated populations, survival probability estimates were 0.90 (95% CI: 0.66, 0.97) at 3 months and afterwards (see Figure 12).

<div style=\"page-break-after: always\"></div>

In the Second line All Treated Analysis Set, 16 of the 19 transplanted patients (84.2%) undergoing HSCT were event-free: 2 patients died post-HSCT and 1 patient had HLH relapse after graft failure. In the All Treated Analysis Set, 18 of 22 transplanted patients (81.8%) were event-free: 2 patients died post-HSCT and 2 patients had HLH relapse after graft failure (Table 18).

Table 18 Hematopoietic Stem Cell Transplantation

| Parameter                                            | All-Treated (n=34)   | Treatment- Experienced (n=27)   | Treatment naive N=7   |
|------------------------------------------------------|----------------------|---------------------------------|-----------------------|
| Underwent HSCT, n (%)                                | 22 (64.7)            | 19 (70.4)                       | 3 (42.8)              |
| Median time to HSCT (95% CI), days                   | 100 (73, 155)        | 83 (64, 139)                    | NP                    |
| Post HSCT engraftment rates ,1 , n (%)               | 19 (86.4)            | 17 (89.5)                       | 2 (66.7)              |
| Post HSCT acute and chronic GVHD incidence 1 , n (%) | 7 (31.8)             | 7 (36.8)                        | 0                     |
| Post HSCT HLH relapse rates 3 , n (%)                | 3 (13.6)             | 2 (10.5)                        | 1 (33.3)              |
| Post HSCT event-free survival 4 , n (%)              | 18 (81.8)            | 16 (84.2)                       | 2 (66.7)              |

Note: percentages for post-HSCT events calculated on the number pf patients undergoing HSCT

1 Based on the number of patients experiencing primary or secondary graft failure as reported in the AEs.

2 Based on occurrence of GVHD as reported in AEs.

3 As reported in AEs.

4 Events include graft failure, relapse, or death of any cause. Only patients who went through transplant were included.

AE = adverse event; CI = confidence interval; EOT = end of treatment; GVHD = graft versus host disease.

Table 19. Survival post HSCT

|                                             | Statistic                | All patients (N=22)   | 2nd line patients (N=19)   | 1st line patients (N=3)   |
|---------------------------------------------|--------------------------|-----------------------|----------------------------|---------------------------|
| Censored Observations                       | N (%)                    | 20 (90.9)             | 17 (89.5)                  | 3 (100.0)                 |
| Event Rate                                  | N (%)                    | 2 (9.1)               | 2 (10.5)                   | 0                         |
| K-M Survival Time Estimates in Days         | 75th Percentile (95% CI) | NE (NE, NE)           | NE (NE, NE)                | NE (NE, NE)               |
| K-M Survival Time Estimates in Days         | Median (95% CI)          | NE (NE, NE)           | NE (NE. NE)                | NE (NE, NE)               |
| K-M Survival Time Estimates in Days         | 25th Percentile (95% CI) | NE (48.00, NE)        | NE (48.00, NE)             | NE (NE, NE)               |
| K-M Survival Probability Estimates (95% CI) |                          |                       |                            |                           |
| Month 3                                     | Probability (95% C1)     | 0.90 (0.662, 0.975)   | 0.89 (0.641, 0.973)        | NE (NE, NE)               |
| Month 6                                     | Probability (95% C1)     | 0.90 (0.662, 0.975)   | 0.89 (0.641, 0.973)        | NE (NE, NE)               |
| Month 12                                    | Probability (95% C1)     | 0.90 (0.662, 0.975)   | 0.89 (0.641, 0.973)        | NE (NE, NE)               |

Source for first-line patients: Table 14.2.9.14.2

Notes: Survival Post-HSCT defined as the time from the date of HSCT to the date of death. Patients without an event were censored at the date of last contact. Patients who did not proceed to HsCT were excluded from this analysis.

<div style=\"page-break-after: always\"></div>

Figure 12 Survival Following HSCT (All-Treated Analysis Set)

<!-- image -->

Time (Days)

Total: 22; Died: 2 (9.1%); Censored: 20 (90.9%)

Note: Number at risk provided at each time point.

## Overall Survival

Median follow up time for Overall Survival was 13.37 [0.1-20.0] in second line patients and 4.90 [1.120.9] in first line patients. Median survival pre-and post HSCT was not yet reached. Overall, n=24/34 (70.6%) and N=20 (74.1%) of patients in the All-Treated and Second-Line Analysis Sets, respectively, were alive at last observation (see Table 20 , Figure 13 , and Figure 14.

## Table 20 Overall survival

|                                             | First line (n=7)    | Second Line (N=27)   | All Treated (N=34)   |
|---------------------------------------------|---------------------|----------------------|----------------------|
| Overall Survival 1                          |                     |                      |                      |
| Censored Observations, n (%)                | 4 (57.1)            | 20 (74.1)            | 24 (70.6)            |
| Event Rate, n (%)                           | 3 (42.8)            | 7 (25.9)             | 10 (29.4)            |
| Kaplan-Meier Survival Probability Estimates |                     |                      |                      |
| Month 6 Probability (95% CI)                | 0.69 (0.213- 0.912) | 0.73 (0.522, 0.864)  | 0.73 (0.541, 0.848)  |
| Month 12 Probability (95% CI)               | 0.46 (0.069, 0.795) | 0.73 (0.522, 0.864)  | 0.69 (0.503, 0.822)  |

Overall survival was defined as time from the date of first dose to the date of death or to the date of the last assessment in either the NI-0501-04 or NI-0501-05 studies. Patients without an event were censored at end of NI-0501-04 and NI-0501-05 studies or at the time of last contact. Kaplan-Meier methodology was used for estimation. CI = confidence interval; NE = not estimable

<div style=\"page-break-after: always\"></div>

Figure 13 Overall survival - all treated analysis set

<!-- image -->

Total: 34; Died: 10 (29.4%6): Cens0red: 24 (70.6%6)

Note:Numberat riskprovided ateach timepoint.

Figure 14 Overall survival - second line all treated analyses set

<!-- image -->

Total: 27; Died: 7 (25.9%6); Cens0red: 20 (74.196)

Note: Number at risk provided at each timepoint.

A Cox regression model of Overall Survival with HSCT as a time-dependent covariate indicated HSCT reduced risk of death in the all treated patients by 69% HR 0.31 (95% CI 0.05 to 1.79) and 44% HR 0.56 (0.08 to 3.74) in 2 nd  -line patients.

## Post-HSCT Event Free Survival

In the 2 nd  line all treated analysis set 16 of 19 (84.2%) were event-free with 2 deaths post-HSCT and 1 patient with HLH relapse after graft failure. In first line patients one event was seen (33.3%).

In the All Treated Analysis Set, 18 of 22 (81.8%) were event-free with 2 deaths and 2 patients with HLH relapses after graft failure.

## Ancillary analyses

As ancillary analyses, the applicant provided the Investigator assessed response rate, Overall response rate at week 2 of treatment and Overall Response Rate at EOT in NI-0501-04 Study in the Evaluable Analyses Sets (

<div style=\"page-break-after: always\"></div>

Table 21 and Table 22). In the response to the 1 st  RSI, the applicant provided the response rate for the patients who were included prior to and after the final protocol.

Table 21 Investigator-assessed response rates at Week 2 and EOT 04 - All treated setassessor's table

|                                | Week 2              | Week 2                  | EoT                 | EoT                     |
|--------------------------------|---------------------|-------------------------|---------------------|-------------------------|
|                                | investigator (n=34) | primary analysis (n=34) | Investigator (N=34) | primary analysis (n=34) |
| All treated                    |                     |                         |                     |                         |
| Overall response rate          | 27 (80%)            | 18 (53%)                | 24 (70.6)           | 22 (65)                 |
| Complete Response (n, %)       | 3 (9)               | 4 (12)                  | 5 (15)              | 7 (21)                  |
| Partial Response (n, %)        | 23 (67)             | 6 (18)                  | 17 (50)             | 11 (32)                 |
| non-active disease (NAD) n, %) | 1 (3)               |                         | 2 (6)               |                         |
| None of the above (n, %)       | 1 (3)               |                         | 4 (12)              |                         |
| Missing (n, %)                 | 5 (15)              |                         | 6 (18)              |                         |
| HLH improvement                |                     | 8 (24)                  |                     | 4 (12)                  |

Table 22 Overall Response Rate at EOT in NI-0501-04 Study in the Evaluable Analyses Sets

|                           | First line evaluable (n=7)   | Second Line Evaluable (N=24)   | All Treated Evaluable (N=31)   |
|---------------------------|------------------------------|--------------------------------|--------------------------------|
| Overall Response, n (%)   |                              |                                |                                |
| Complete response         | 0                            | 6 (25.0)                       | 6 (19.4)                       |
| Partial response          | 3                            | 8 (33.3)                       | 11 (35.5)                      |
| HLH improvement           | 2                            | 2 (8.3)                        | 4 (12.9)                       |
| Overall Response Rate [1] |                              |                                |                                |
| N (%)                     | 5                            | 16 (66.7)                      | 21 (67.7)                      |
| (95% CI)                  |                              | (0.45, 0.84)                   | (0.49, 0.83)                   |
| p-value [2]               | np                           | 0.0075                         | 0.0017                         |

In the first RSI a post-hoc analysis of ORR at EoT 04 is provided for patients enrolled before and after finalisation of the pivotal protocol (EU protocol Version 6) in February 2016 in the All Treated and in the Second-Line populations ( Table 23 ).

Response at start of conditioning for the second line patients was: 5 in CR, 5 in PR and 3 had HLH improvement. Six second line patients (and 2 first line patients) underwent a HSCT with no response.

Also, a post-hoc analysis for efficacy outcomes in patients assumed to be or not eligible for retreatment or re-escalation of prior conventional therapy was presented ( Table 24 ).

The time between completion of emapalumab treatment and conditioning start/HSCT was also provided in the response to the 1 st  Request of supplementary information.

<div style=\"page-break-after: always\"></div>

Table 23. ORR at EoT 04 (post-hoc analyses) patients treated before and after the finalisation of the pivotal study

|                                                                                      | Statistics   | All Treated             | All Treated Second-Line   |
|--------------------------------------------------------------------------------------|--------------|-------------------------|---------------------------|
| Post-hoc alalysis                                                                    |              |                         |                           |
| Pts.enrolledbefore finalization ofthe pivotal protocol in Februany 20i6 ORR atEoT 04 | N n (%)      | 19 13 (68) (0.46, 0.85) | 17 11 (65)                |
| Pts.enrolledafterfinalizationofthe pivotalprotocol inFebruary 2016 ORR.atEoT 04      | N 10 %656    | 15 9 (60.0) (0.36,0.80) | 10                        |
|                                                                                      | 10 %656      |                         | (0.41, 0.83)              |
|                                                                                      | n (%)        |                         | 6 (60.0)                  |
|                                                                                      |              |                         | (0.31, 0.83)              |

Table 24. Efficacy outcomes in patients assumed to be or not eligible for re-treatment or reescalation of prior conventional therapy

|                                                          | Re-treatmentorre-escalationofprior conventionaltherapy   | Re-treatmentorre-escalationofprior conventionaltherapy   |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                          | Patientspotentiallyeligible (n=15)                       | Patientsnoteligible (n=12)                               |
| ORREoT04(byalgorithm)                                    | 11 (73.3%)                                               | 6 (50.0%)                                                |
| Clinicalresponse atEoT04 (asstatedbytheInvestigator) [1] | 13 (86.7%)                                               | 8 (66.7%)                                                |
| Patientsaliveatendof04/05 studies                        | 13 (86.7%)                                               | 8 (58.3%)                                                |
| PatientsreceivingHSCT[2]                                 | 12 (80.0%)                                               | 7 (58.3%)                                                |
| ORR atstartofconditioning                                | 9 (75.0%)                                                | 5 (71.4%)                                                |
| Patients alive post-HSCT[3]                              | 11 (91.7%)                                               | 6 (85.7%)                                                |

[1]Include completeresponse,partial response and non-active disease.Missingrecords（n=2in eachofthesubgroups)countedasnoresponse

[2] of thepatients alive,2patientswere notmovedtoHScTasperInvestigator's decisionbased onindividualbenefit/riskassessmentoftheprocedure

[3]PercentagecalculatedwiththenumberofpatientsreceivingHScTasdenominator

Table 25. Time between completion of emapalumab treatment and conditioning start/HSCT

| All Treated patients receiving HSCT (N=22)             | All Treated patients receiving HSCT (N=22)             | All Treated patients receiving HSCT (N=22)     | All Treated patients receiving HSCT (N=22)     |
|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Time between last emapalumab infusion and conditioning | Time between last emapalumab infusion and conditioning | Time between last emapalumab infusion and HSCT | Time between last emapalumab infusion and HSCT |
| 0-3 days^                                              | 14 (63.6%)                                             | Up to 14 days^                                 | 6 (27.3%)                                      |
| 4-10 days                                              | 5 (22.7%)                                              | 15-21 days                                     | 13 (59.1%)                                     |
| 11-14 days                                             | 2 (9.1%)                                               | 22-28 days                                     | 2 (9.1%)                                       |
| > 14 days*                                             | 1 (4.5%)                                               | > 28 days*                                     | 1 (4.5%)                                       |

^ One patient  was discontinued from study NI-0501-04 due to administration of additional HLH treatments, but emapalumab was reinstated in compassionate use, upon the investigator's request. Conditioning started the same day of last emapalumab infusion in CU, therefore the patient is counted under this category.

* In this patient  the pre-HSCT work-up revealed an asymptomatic pulmonary thromboembolism which was treated with enoxaparin and resolved before starting conditioning.

<div style=\"page-break-after: always\"></div>

## Updated data

Since the data base lock of 20 July 2017, an additional n=13 patients were screened and an additional n=11 patients have been treated. The results of these additional 11 patients are provided with a data cut off of 31 Jan 2019.

## Results

Of these additional n=11 patients, a total of n=7 patients were marked as second line treatment patients and a total of n=4 patients as treatment naïve; two patients prematurely left trial NI-501-04. One second line patient because of death (n=1) and one first line patient because of an adverse event (i.e. respiratory failure n=1), possibly not related to study medication. A total of n=6 patients received emapalumab in study NI-0501-05.

During the procedure the applicant changed the applied indication to a second line target population. Therefore, the focus of the current assessment will be on the additional second line pHLH patients.

## Demographics

Second line pHLH patients

Most of the seven additional patients were male (n=4) and white (n=6). A total of n=3 patients had the mutation that could be classified as FLH5, one patient had a FLH2 mutation and n=3 patients had an unidentified mutation. None of these 3 patients had a family history of pHLH, but 2/3 patients had an impaired functional test. Together with the young age, this confirms the diagnosis of pHLH. The functional test of one patient is left un-interpreted.

Most of these patients (4/7) received dexamethasone + etoposide as first line treatment. The other n=3 patients only received pre-treatment with dexamethasone: none of these patients were reported as having experienced an adverse event for etoposide or being intolerant to etoposide (Table 26).

The response of previous therapy was reported for n=5 patients with n=3 patients experiencing a complete response. The reason for starting emapalumab was reactive disease (n=3), no response to previous therapy (n=1) or reasons not reported (n=3) (Table 27).

During the emapalumab treatment, a total of n=3 patients received concomitant therapy with etoposide. Of these patients, n=2 also received alemtuzumab (Table 28).

A total of n=2 patients achieved a complete response; One additional patient achieved a partial response; all these patients had not received etoposide before the start of emapalumab. A total of n=4 had no response at the end of treatment, all these patients had previously been treated with etoposide. A total of n=3 received also concomitant HLH treatment during the trial (Table 29).

A total of 2 of these additional 7 patients also received emapalumab administration in the follow up study NI-0501-05. A total of n=5 patients underwent HSCT and are still alive. The other two patients died before they could commence HSCT (Table 26).

<div style=\"page-break-after: always\"></div>

Table 26 Summary of main demographic and disease characteristics of the additional 7 second line patients entering the study NI-501-04 between 20 Jul 2017 and with data cut of 31 Jan 2019.

| Patient   |      | First line HLH treatment   | Response on previous HLH therapy   | Reason start Emapalumab   | Response EoT by algorhythm   | Additional med during study NI- 0501-04   | HSCT   | Alive   |
|-----------|------|----------------------------|------------------------------------|---------------------------|------------------------------|-------------------------------------------|--------|---------|
| A         | FLH5 | D+ methylpred              | NA                                 | NA                        | CR                           |                                           | Y      | Y       |
| B         | UNK  | D                          | No reseponse                       | NA                        | CR                           |                                           | Y      | Y       |
| C         | FLH2 | D                          | CR                                 | NA                        | PR                           |                                           | Y      | Y       |
| D         | FLH5 | D + E                      | CR                                 | React                     | None                         | E                                         | Y      | Y       |
| E         | FLH5 | D + E                      | PR                                 | React                     | None                         | E + alem + aba                            | Y      | Y       |
| F         | UNK  | D + E                      | CR                                 | React                     | None                         |                                           | Died   | Died    |
| G         | UNK  | D + E                      | None                               | None                      | None                         | E + alem                                  | Died   | Died    |

Table by assessor: source: narratives, listing

D= dexamethasone, Methylp= methylpredsnison, E = etoposide, alem = alemtuzumab, aba = aba NA is not available, CR is completer response, PR = partial response, none = no response, Aba = abatacept. 2 patients were treated with dexamethasone for 1 week before emapalumab was started.

## First line patients

A total of n=4 patients were identified as first line patients and included 2 white males and 2 Asian females. All patients had a different mutation, one patient had a FLH2, one patient FLH3, one patient FLH4 and one patient Grisselli syndrome type -2 mutation.

These patients received dexamethasone a short time before treatment with emapalumab was started. One patient received additional etoposide treatment during the emapalumab administration.

The reported outcome at the end of treatment was partial response (n=1), HLH improvement (n=1) and none (n=2).

All patients received emapalumab treatment in study NI-0501-05. A total of N=3 underwent a HSCT, 2 died after HSCT and one is still alive. One patient died before commencing HSCT.

Table 27 An overview of the data is provided in the table below.

| Patient   | HLH treatment received before emapalumab administration   | Response EoT 04 by criteria   | Additional medication   | HSCT   | Alive   |
|-----------|-----------------------------------------------------------|-------------------------------|-------------------------|--------|---------|
| AA        | D                                                         | PR                            |                         | Y      | N       |
| AB        | D                                                         | None                          |                         | Y      | N       |
| AC        | D                                                         | HI                            |                         | Y      | Y       |
| AD        | D                                                         | none                          | Etoposide               | N      | N       |

3 patients were treated with Dexamethasone for 1 day, 2 days or 3 days before E was started. Duration of treatment for patient AC is not clear. PR= partial response HI = HLH improvement

## Efficacy results

The applicant provided the integrated efficacy of the all treated (first line and second line) and the second line treated population, where the results of these additional patients are combined with the previously presented analyses with the cut off base of 20 July 2017.

With these additional N=11 patients, the total number of all treated patients is n=45 (n=34 + n=11) and the number of second line patients is n= 34 (n=27 + n=7).

<div style=\"page-break-after: always\"></div>

Table 28 The integrated analyses for the second line and first line patients are provided below: Second line patients

|                                                                                    | Updated NI-0501-04 analysis Second-Line All Treated (database cut-off date: 31st Jan 2019)   | Primary/interim NI-0501- 04 analysis, Second-Line All Treated (database cut-off date 20th July 2017)   |
|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Number                                                                             | N=34                                                                                         | N=27                                                                                                   |
| Genetic confirmation                                                               | 26/34                                                                                        | 22/27                                                                                                  |
| ORR 95% CI, p-value                                                                | 20 (58.8%) 40.7, 75.4; p=0.0205                                                              | 17 (63.0%) 42.0, 0.81, p=0.013                                                                         |
| CR                                                                                 | 9 (26.5)                                                                                     | 7 (25.9)                                                                                               |
| PR                                                                                 | 9 (26.5)                                                                                     | 8 (29.6)                                                                                               |
| HLH-improvement                                                                    | 2 (5.9)                                                                                      | 2 (7.4)                                                                                                |
| None                                                                               | 14                                                                                           | 10                                                                                                     |
| Sensitivity analyses by excluding the patients who received additional HLH therapy | Sensitivity analyses by excluding the patients who received additional HLH therapy           | Sensitivity analyses by excluding the patients who received additional HLH therapy                     |
| ORR 95% CI                                                                         | 19 (55.9) [37.9, 72.8]; p= 0.0444                                                            | 16 (59.3) [0.39, 0.78]; p=0.0337                                                                       |
| Proceed to HSCT                                                                    | 24/34 (71%)                                                                                  | 19/27 (70%)                                                                                            |
| Month 12 probability                                                               | 0.73 (0.551, 0.852)                                                                          | 0.73 (0.522, 0.864)                                                                                    |
| Median FU time (months)for censored patients                                       | 14.6 [4.6-20.0)                                                                              | 13.37 [0.1-20.0]                                                                                       |
| Post HSCT survival probability                                                     | 0.91 [0.68, 0.98]                                                                            | [ 0.89 [0.64,0.97]                                                                                     |

## Additional sensitivity analyses

At the 2 nd  day 180, the indication was again amended, to patients with refractory or recurrent disease or intolerance with conventional HLH therapy (combination of dexamethasone and etoposide). For the data cut of 31 Jan 2019, no additional post hoc efficacy analyses were provided to align with the study population with the amended indication. A total of n=4 second line patients fulfilled the criteria for the applied application as they received first line dexamethasone + etoposide.

In order to align with the newly applied indication, the applicant provided additional post hoc responses using database lock 20 July 2017 excluding the n=4 patients that were eligible for etoposide in the first line but did not receive it. The overall response rate in this population was 60.9% (95% CI: 0.385, 0.803); N= (14/23) .

The overall 12-month survival probability is 0.70 (95% CI: 0.46, 0.84; N=23)) and the 12-month survival probability post HSCT in patients undergoing HSCT of 0.88 (95% CI: 0.60, 0.97; N=17).

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following table summarises the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 29

Title : A phase 2/3 open label, single arm, multicentre Study to assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple administrations of NI-0501, an inti-interferon gamma (anti IFNγ) monoclonal antibody, in Paediatric patients with Primary Haemophagocytic Lymphohistiocytosis (HLH)

| Study identifier          | NI-0501-04 EudraCT 2012-003632-23. US-P-IND#111015. NCT 01818492 NI-0501-05 follow up study   | NI-0501-04 EudraCT 2012-003632-23. US-P-IND#111015. NCT 01818492 NI-0501-05 follow up study                                                     | NI-0501-04 EudraCT 2012-003632-23. US-P-IND#111015. NCT 01818492 NI-0501-05 follow up study   |
|---------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Design                    | Open label, single arm, multicentre study                                                     | Open label, single arm, multicentre study                                                                                                       | Open label, single arm, multicentre study                                                     |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: Follow up      | 4- 12 weeks <7 days from screening to 1 st infusion Further infusions may be given within the follow-up study NI-0501-05 up to 1 year           |                                                                                               |
| Hypothesis                | Exploratory/ response rate is above most 40%.                                                 | Exploratory/ response rate is above most 40%.                                                                                                   | Exploratory/ response rate is above most 40%.                                                 |
| Treatments groups         | All Treated Analysis Set                                                                      | defined as all patients who received any part of an emapalumab infusion, ≤ 1mg/kg for at least 4-8 weeks, n=34                                  |                                                                                               |
| Treatments groups         | 2 nd line All treated Analysis set (2 nd line)                                                | Above patient population limited to those with recurrent, worsening, refractory disease or intolerant to current treatment N=27                 |                                                                                               |
| Treatments groups         | 1 st line All treated Analysis set                                                            | Treatment-naïve patient population N=7                                                                                                          |                                                                                               |
| Endpoints and definitions | Overall response rate                                                                         | Overall Response Rate, ie, achievement of either Complete or Partial Response or HLH Improvement, at End of Treatment (EoT) of study NI-0501-04 |                                                                                               |
| Endpoints and definitions | Time to response                                                                              | Elapsed time from the date of the first dose of emapalumab to first achievement of at least HLH improvement                                     |                                                                                               |
| Endpoints and definitions | Durability of Response                                                                        | Maintenance of response achieved any time during the study until EoT and beyond                                                                 |                                                                                               |
| Endpoints and definitions | Glucocorticoid Tapering                                                                       | Percentage of patients with a ≥50% reduction in glucocorticoids from Baseline to EOT 04.                                                        |                                                                                               |
| Endpoints and definitions | Patients able to proceed to HSCT                                                              | Percentage of patients able to proceed to HSCT                                                                                                  |                                                                                               |
| Endpoints and definitions | Survival at Week 8 (or EoT) and at the end of the study                                       | Survival at Week 8 (or EoT) and at the end of the study and long-term survival (in particular D+30 and D+100 post-HSCT survival).               |                                                                                               |
| Database lock             | 20 July 2017                                                                                  |                                                                                                                                                 |                                                                                               |

<div style=\"page-break-after: always\"></div>

| Results and Analysis (based on study NI-0501-04 and follow up study NI-0501-05)   | Results and Analysis (based on study NI-0501-04 and follow up study NI-0501-05)                                                                  | Results and Analysis (based on study NI-0501-04 and follow up study NI-0501-05)   | Results and Analysis (based on study NI-0501-04 and follow up study NI-0501-05)   | Results and Analysis (based on study NI-0501-04 and follow up study NI-0501-05)   |
|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Analysis description                                                              | Primary Analysis                                                                                                                                 | Primary Analysis                                                                  | Primary Analysis                                                                  | Primary Analysis                                                                  |
| Analysis population and time point                                                | The primary analysis is performed on the 2nd line analysis set                                                                                   | The primary analysis is performed on the 2nd line analysis set                    | The primary analysis is performed on the 2nd line analysis set                    | The primary analysis is performed on the 2nd line analysis set                    |
| description Descriptive statistics and estimate variability                       | Treatment group                                                                                                                                  | All treated set                                                                   | second line                                                                       | treatment naive                                                                   |
| description Descriptive statistics and estimate variability                       | Number of subjects                                                                                                                               | 34                                                                                | 27                                                                                | 7                                                                                 |
| description Descriptive statistics and estimate variability                       | Overall response at the EoT                                                                                                                      | 22 (65%)                                                                          | 17 (63%)                                                                          | 5 (71%)                                                                           |
| description Descriptive statistics and estimate variability                       | Time to response (median)                                                                                                                        | 8 days                                                                            | 8 days                                                                            | NP                                                                                |
| description Descriptive statistics and estimate variability                       | 95% CI                                                                                                                                           | 5-10                                                                              | 7,14                                                                              |                                                                                   |
| description Descriptive statistics and estimate variability                       | Durability of Response                                                                                                                           | NP                                                                                | NP                                                                                | NP                                                                                |
| description Descriptive statistics and estimate variability                       | Glucocorticoid Tapering                                                                                                                          | 16 (47.1%)                                                                        | 12 (44%)                                                                          | 3 (43%)                                                                           |
| description Descriptive statistics and estimate variability                       | Patients able to proceed to HSCT                                                                                                                 | 23/34 (67.7%)                                                                     | 19/27 (70.4%)                                                                     | 4/7 (57.1%)                                                                       |
| description Descriptive statistics and estimate variability                       | Survival at Week 8 (or EoT) and at the end of the study (Ni-0501- 04) and long- term survival (in particular D+30 and D+100 post- HSCT survival) | NP                                                                                | NP                                                                                | NP                                                                                |
| Notes                                                                             | NP=not provided                                                                                                                                  | NP=not provided                                                                   | NP=not provided                                                                   | NP=not provided                                                                   |

## Analysis performed across trials (pooled analyses and meta-analysis)

The historical control group provided by the applicant is discussed in the section 'Supportive studies'.

The historical obtained in the HLH-94 and HLH-04 trials data have been summarised to contextualize the primary outcome, the overall response rate, and some additional important secondary outcome measures. However, it should be noted that there are several factors which provide a significant level of uncertainty regarding this cross-study comparison.

<div style=\"page-break-after: always\"></div>

## Applicant's Review of Prospective/Retrospective Studies in HLH

## Table 30.Summary of Prospective Studies with Data on HLH Induction Therapies (8 weeks)

| Study/ study design             | Drugs                          | HLH diagnosis                                                             |   No. of pts | Publication                 |
|---------------------------------|--------------------------------|---------------------------------------------------------------------------|--------------|-----------------------------|
| 6-H7H Single arm (1994-2003)    | Dexa.+ etoposide               | HLH-94 diagnostic criteria* JO Affected sibling                           |          249 | Henter,2002 Trottestam,2011 |
| HLH-2004 Single arm (2004-2011) | Dexa+ etoposide + cyclosporine | HLH-2004 diagnostic criteria Affected sibling And/or a molecular sisoubep |          369 | Bergsten, 2017              |
| HIT Single arm (2010-2016)      | ATG+ dexa + etoposide          | HLH-2004 diagnostic criteria And/or a molecular diagnosis                 |           31 | Jordan,2016(abstract)       |

*No genetic diagnosis available during the course of this study.

Table 31. Summary of Efficacy Results (8 wks) from Prospective HLH Studies

| Study   | Response rate   | Reactiva tion   | Duration of response   | 0%of pts undergoing HSCT                                        | Time to HSCT                                         | Comments   |
|---------|-----------------|-----------------|------------------------|-----------------------------------------------------------------|------------------------------------------------------|------------|
| 59%*0   | 12A             | NA              | 50%                    | (164 days in pts with affected                                  |                                                      | HLH-94     |
| 51%**   | 37.4A           | NA              | 50%                    | 148 days (129 days in pts with affectedsibling and/oramolecular |                                                      | HLH-2004   |
| NA      | NA              | NA              | NA                     | NA                                                              | 39%ofptsundergoing HSCTreportedatthe 2016 HS Meeting | HIT        |

*Response as defined by the treating physician. ^ No definition of reactivation available. ° 37 responders reported of 60 patients with an affected sibling (61%). # No information on response rate is available specifically for the 188 patients with an HLH causative mutation or an affected sibling, representing 45% of the population studied.

Table 32. Summary: Survival from Prospective HLH Studies

| Study Overall survival                                                  | Survival post-HSCT                                                             | Comments   |
|-------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------|
| 54% 5 yrs PoS (50% in pts with affected sibling)                        | 66%                                                                            | HLH-94     |
| 61% 5 yrs PoS (59% in in familial cases or with proven genetic disease) | 66%                                                                            | HLH-2004   |
| No significant improv. in OS compared to the HLH-94 study               | 65% survival at last follow-up reported at the 2016 Histiocyte Society Meeting | HIT        |

PoS: Probability of Survival. OS: Overall Survival

<div style=\"page-break-after: always\"></div>

## Survival in Observational cohorts

Survival after HSCT in 109 children with HLH undergoing allogeneic HSCT in Italy between 2000 and 2014, 74% with a genetic diagnosis confirmed, the 5-year survival post HSCT was 71%, event free survival 60% (Messina 2018).

Table 33.Summary: HLH Induction Therapies in Retrospective Studies

| /Apms study design                                                     | Drugs                                                     | HLH diagnosis                                                                                                                         | No. of pts                            | Publication   |
|------------------------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|---------------|
| Report from the HLH International Registry (1989-1995)                 | Etoposide or teniposide (77%) No specific treatment (20%) | -5 HLH criteria Affectedsibling(48%)                                                                                                  | 122                                   | Arico'1996    |
| Salvage therapy of refractory HLH with alemtuzumab (2004-2011)         | Aemtuzumab                                                | Pts with persistent or worsening HLH symptoms and lab. abnormalities despite treatment*o Genetic diagnosis available in 7/22 patients | 22                                    | Marsh, 2013   |
| Geneticand mechanistic diversity inpediatricHLH Single arm (1999-2016) | All available therapies                                   | HLH-2004 diagnostic criteria -Genetic tests                                                                                           | 122 (19 pts with a genetic diagnosis) | Chinn,2018    |

# Fever, splenomegaly, cytopenia affecting at least 2 lineages, hypertrigliceridaemia and/or hyperfibrinogenaemia, haemophagocytosis. Diagnosis of familial/primary HLH required positive family history of HLH. 97% of patients had an impaired natural killer cell activity, 58% had cerebrospinal fluid pleocytosis. *As defined by the treating physician. ° Only 8/22 pts had a genetic diagnosis and 5/22 pts were &gt; 18 yrs old.

Table 34. Summary: Efficacy results from Retrospective Studies

| Study                                              | Response rate                                            | Duration of response   | % of pts undergoing HSCT            | Time to HSCT   | Comments                                                                                                                                                                                                                                                                      |
|----------------------------------------------------|----------------------------------------------------------|------------------------|-------------------------------------|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Report from the HLH Intermational Registry         | NA                                                       | NA                     | 24%                                 | 6.4 mo.        |                                                                                                                                                                                                                                                                               |
| Salvage therapy of refractory HLH with alemtuzumab | 64%* (only Partial Response obtained assessed at week 2) | See comments           | 77%                                 |                | Pts received other HLH therapiesthanalemtuzumab Duration of response wasonly available in 3 pts as: most pts recelved additional courses of alembuzumab, patients received additional salvage therapies, died or began HSCT conditioning within 28 days following alemtuzumab |
| Genetic and mechanistic diversity in pediatric HLH | NA                                                       | NA                     | 73.7% in pts with genetic diagnosis | NA             |                                                                                                                                                                                                                                                                               |

*None achieved CR. PR defined as &gt;/=25% improvement in 2 or more quantifiable symptoms and laboratory markers of HLH by 2 weeks following alemtuzumab. Platelet count, fibrinogen, fever, liver and spleen size were not considered in the calculation of the response.

<div style=\"page-break-after: always\"></div>

Table 35. Summary: Survival from retrospective studies of HLH

| Study                                              | Overall survival                                                        | Survival post- HSCT   | Comments                                       |
|----------------------------------------------------|-------------------------------------------------------------------------|-----------------------|------------------------------------------------|
| Report from the HLH International Registry         | 21.8% at 5 yrs withHSCT66%andwithout HSCT 10%)                          | 66% at 5 yrs          | AllsurvivorswithoutHSCTwere non familial cases |
| Salvage therapy of refractory HLH with alemtuzumab | 64% at a median of 870 days following first alemtuzumab administra tion | NA                    |                                                |
| Genetic and mechanistic diversity in pediatric HLH | overall survival 45% (estimated 54% in pts with genetic diagnosis)      | NA                    |                                                |

## Clinical studies in special populations

As pHLH is primary a paediatric disease, no studies are needed in the elderly.

## Supportive studies

## Compassionate use

Compassionate use enabled access to treatment with emapalumab for:

- HLH patients with a serious debilitating disease or immediately life-threatening disease or condition which cannot be treated satisfactorily by conventional therapy AND
- Have a favourable benefit/risk of receiving NI-0501 as assessed by the treating physician

## Main Exclusion criteria

- Qualify to participate in an ongoing NI-0501 clinical trial
- Receipt of a biologic treatment within 5x half-life prior to first infusion of NI-0501
- o Except rituximab used to treat an EBV infection (within one week), OR
- o Except ATG and alemtuzumab (2 weeks).
- Clinically active mycobacteria, Shigella, Salmonella, Campylobacter, Leishmania infections
- Clinical or historical evidence of past or active TB; HIV; HBV, HCV infection

As of the 20 July 2017, 17 patients entered Compassionate use (CU): 8 patients with primary HLH and 9 patients with secondary HLH. All patients received emapalumab after having failed HLH conventional treatments.

## primary HLH

The median age at start of emapalumab in the primary HLH patients (n=8) was 0.48 years with a range of 0.02 (2 days) to 5 years. Most patients were white (n=6, 75%) and n= 5 (62.5%) were males. In 7/8 patients (87%) a mutation in one of the known HLH causative genes was detected. CNS disease was present in n=4 (50% of patients).

<div style=\"page-break-after: always\"></div>

All patients previously received HLH treatment. The most frequently reported drug was dexamethasone n=8 (100%), followed by etoposide n=7 (87%), cyclosporine n=2 (25%). Anakinra and alemtuzumab were used in n=1 patient.

All patients received emapalumab at the initial dose of 1 mg/kg and the frequency of administration was, at least initially, every 3 days. In some patients, it was possible to elongate the interval between emapalumab infusions, particularly in patients who required relatively long treatment duration. The median duration of dosing was 36.5 days, and the median average dose per day and the median cumulative dose were 0.68 and 14 mg/kg, respectively. Subjects also received a background dose of glucocorticoids tapered according to the treating physician's judgement, prophylaxis for Pneumocystis jiroveci, varicella zoster and fungal infections, continued conventional intrathecal therapy for CNS involved if required and standard supportive care including transfusion of blood products and antimicrobials. Four patients are still alive at the cut of data of 20 July 2017, 3 of them underwent HSCT and survived. HSCT was not deemed necessary for 1 primary HLH patient who achieved complete HLH disease control. A total of n=4 patients died during the during the precondition (Gamifant) period, in two patients an infection was considered the cause of death. An attempt for an overall response assessment was made primarily on the laboratory data, as the clinical features were not available. Based on the evaluation of the lab values over time, an overall response was observed in 3 patients from week 2 until the end of treatment. One other patient had persistent cytopenia, this patient underwent HSCT and survived. All other patients failed to achieve an overall response and died. secondary HLH A total of n=9 patients with secondary HLH entered CU. The median age at start of emapalumab in secondary HLH patients was 5.22 years with a range of 0.1 (1 month) to 56 years. In secondary HLH patients, an auto-inflammatory rheumatic disease was present in 4 (44%) of patients and the underlying cause of HLH was unknown in 3 (33%) patients. One other patient had an EBV infection and one patient was initially affected by Wegener's granulomatosis. The four patients with auto-immune related HLH had a favourable response as defined by the treating -splenic lymphoma, after a long physician and survived. All patients with an unknown cause of sHLH died. One patient affected by Wegener's granulomatosis died soon after the diagnosis of γ/δ hepato history of recurrences of HLH. One of the patients with an EBV infection, died despite having experienced an initial improvement in HLH parameters and general condition.

## Historical control

Retrospective data collection has been undertaken by the applicant to generate a historical cohort aimed to be contemporaneous to Study NI-0501-04 and its long-term follow-up Study NI-0501-05, literature data.

NI-0501-04. Data collection concerned primary HLH (pHLH) patients who were diagnosed with HLH (patients qualified for the analysis based on a confirmed or suspected diagnosis of primary HLH (including FHL1 i.e. genetic disease considered likely but specific gene not yet identified: not a known collection was open both to patients naïve to HLH treatment (first line patients) and to patients who received more than one course of conventional HLH treatments (second line patients). The applicant and to serve as support to the interpretation of efficacy evidence, thus complementing the available Data has been obtained in collaboration with the European and the US Principal Investigators for Study HLH causative gene) and received HLH available therapies from January 2010 onwards. Historical data

<div style=\"page-break-after: always\"></div>

clarified that the clinical status; i.e. treatment naïve or treatment experienced cannot reliably determined in the historical control cohort (n=72). The applicant defined 6 probable second line patients.

The primary analysis of the key endpoints of Overall Survival (OS) and Post-HSCT Survival have utilised propensity score modelling to correct for baseline imbalances. The following covariates were included in the propensity score logistic regression models: age, gender, CNS involvement (reported/not reported) and genetic disease (confirmed/not confirmed). A complementary analysis of these same endpoints based on a Cox Regression Model including baseline covariates was performed.

This model predicted the probability of being in the NI-0501-04 study population based on the baseline covariates. For each of the transplant/no transplant subgroups, patients were then stratified into two strata in each case according to the propensity score. The cut-point for this stratification was determined by the median propensity score among the NI-0501-04 patients who died. This process produced four strata according to the transplant/no transplant and propensity score &lt;/ ≥ cut-point breakdowns. The HC and NI-0501-04 patient treatment groups were then compared using a stratified Cox model analysis, stratified according to the four strata with a term for HC/NI-0501-04. Hazard ratios (adjusted for baseline imbalances) with 95% confidence intervals and corresponding p-values provided information on the effect of treatment group on OS.

An additional Stratified Cox model, stratified by transplant/no transplant and including terms for treatment group and the covariates as listed above, was also fitted to these data without any adjustment for propensity scores. Hazard ratios for each covariate and treatment were provided based on this model together with 95% confidence intervals and a p-value comparison for treatment group.

Comparison of Post-HSCT survival used a similar approach but with a single propensity score model based on the sub-group of patients who received HSCT.

## Dataset

The historical cohort is comprised of 72 patients.

The conventional HLH therapy received in the historical control group was mostly represented by either HLH-2004 or HIT regimen (about 40% of the patients each). Information on HLH therapy was not specified in 14% of patients, and a minority (about 5%) received other steroid-based therapy (variously associated to cyclosporine, tacrolimus and sirolimus).

<div style=\"page-break-after: always\"></div>

T able 36. Demographic and HLH characteristics of Study\\_04/05 patients and Historical controls (HCs)

| Parameter                    | Statistics                | Study_04/05 (N=34)          | HCs (N=72)                 |
|------------------------------|---------------------------|-----------------------------|----------------------------|
| Age at HLH diagnosis (years) | Mean (SD) Median Min, Max | 2.5 (3.17) 1.1 0.03 - 13.90 | 5.0 (5.36) 2.5 0.05 -18.94 |
| Age Category                 |                           |                             |                            |
| <2years                      | N (%)                     | 21 (61.8%)                  | 33 (45.8%)                 |
| ≥ 2 -<12 years               | (%N                       | 12 (35.3%)                  | 28 (38.9%)                 |
| ≥12 -≤18years                | N (%)                     | 1 (2.9%)                    | 11 (15.3%)                 |
| Gender                       |                           |                             |                            |
| Female                       | N (%)                     | 18 (52.9)                   | 33 (45.8)                  |
| Male                         | (%)N                      | 16 (47.1)                   | 39 (54.2)                  |
| HLH genetic confirmation     |                           |                             |                            |
|                              | (%N                       | 27 (79.4)                   | 45 (62.5)                  |
| No                           | N (%)                     | 7(20.6)                     | 27 (37.5)                  |
| CNS Disease reported         |                           |                             |                            |
| s                            | (%N                       | 12 (35.3)                   | 15 (20.8)                  |
| No                           | (%N                       | 22 (64.7)                   | 57 (79.2)                  |
| HSCT                         |                           |                             |                            |
| Yes                          | (%) N                     | 22 (64.7)                   | 51 (70.8)                  |
| No                           | (% N                      | 12 (35.3)                   | 21 (29.2)                  |

The most frequent mutations involved PRF1 (FHL2) and MUNC13-4 (FHL3) genes in about 20% and 25% respectively in each treatment group.

Table 37. HLH Treatment in Historical Controls

| Parameter                                       | Statistics   | HCs (N =72)   |
|-------------------------------------------------|--------------|---------------|
| Dexamethasone/etoposide/cyclosporineA           | N (%)        | 27 (37.5)     |
| Dexamethasone/etoposide/anti-thymocyte globulin | N (%)        | 31 (43.1)     |
| Others [1]                                      | (%) N        | 4 (5.6)       |
| Notreported                                     | N (%)        | 10 (13.9)     |

[1] Includes: dexamethasone 10 mg/m?; dexamethasone and cyclosporine A; steroids associated with tacrolimus and sirolimus; regimen not further specified.

Table 38. Year of HLH diagnosis for patients enrolled in Study 04/05 and for the HC cohort.

| Diagnosed in year   | NI-0501-04 (patients number)   |   Historical Controls (patients number) |
|---------------------|--------------------------------|-----------------------------------------|
| Jan2010-Dec 2012    |                                |                                      44 |
| 2013                | 3                              |                                      13 |
| 2014                | 7                              |                                       6 |
| 2015                | 13                             |                                       7 |
| 2016                | 8                              |                                       0 |
| 2017                | 3                              |                                       2 |

## HSCT

Fifty-one (70.8%) patients in the HC cohort versus 22 (64.7%) in study NI-0501-04/05 underwent HSCT. Median time to HSCT was 166 days (95% CI: 127, 185) in the HC cohort and 100 days (95%CI: 73, 155) in Study\\_04 patients.

Non-randomised comparison of Overall Survival (OS)

<div style=\"page-break-after: always\"></div>

Survival at week 8 (or HSCT if performed earlier) was 88.2% (30/34) in study NI-0501-04 vs 82.9% (24/29) in the historical controls. Survival at HSCT (or Week 24 when HSCT had not been performed) was 79.4% (27/34) in Study NI-0501-04 versus 75.9% (22/29) in the historical controls.

## Propensity Score Modelling for survival analyses

The propensity score logistic regression model used age, gender, presence of confirmed genetic disease (confirmed/not confirmed) and CNS involvement (reported/not reported) as variables, with a separate model for patients undergoing or not undergoing HSCT to account for imbalances between treatment groups. Propensity score was calculated as the probability of being in Study NI-0501-04.

PS strata were formed by choosing the median propensity score among the patients who died in the Study\\_04/05 group, separately by 'transplant' and 'no transplant'.

## Analysis of Maximum Likelihood Estimates

Gender: 1 = Female, 0 = Male; Genetic disease: 1 = Confirmed, 0 = Not confirmed; CNS disease: 1= Reported, 0 = Not reported

Table 39. Number of Patients by Propensity Score strata

| Study Type      | PS Strata   | PS Strata   | PS Strata     | PS Strata     | PS Strata   |
|-----------------|-------------|-------------|---------------|---------------|-------------|
|                 | Transplant  | Transplant  | No transplant | No transplant | Total       |
|                 | PS Low      | PS High     | PS Low        | PS High       |             |
| StudyNI-0501-04 |             |             |               |               |             |
| N               | 3           | 19          | 7             | 5             | 34          |
| Event (%)       | 1 (33%)     | 1 (5%)      | 4(57%)        | 4(80%)        | 10 (29%)    |
| Censored(e%o)   | 2 (67%)     | 18 (95%)    | 3(43%)        | 1(20%)        | 24 (71%)    |
| HC cohort       |             |             |               |               |             |
| N               | 22          | 29          | 19            | 2             | 72          |
| Event (%)       | 8 (36%)     | 5 (17%)     | 8(42%)        | 2 (100%)      | 23 (32%)    |
| Censored (%)    | 14 (64%)    | 24 (83%)    | 11 (58%)      | 0             | 49 (68%)    |
| Total           | 25          | 48          | 26            | 7             | 106         |

Table 40. Cox regression for Overall Survival stratified by Propensity score: High vs Low

| Statistical significance: ALL Pts   |
|-------------------------------------|
| ** Cox model                        |
| # Stratified Log Rank test          |
| ** p=0.389                          |
| # p=0.387                           |

## Post-HSCT Survival

A single propensity score model was fitted using the same variables as for Overall Survival.

<div style=\"page-break-after: always\"></div>

Table 41. Baseline characteristics of Patients undergoing HSCT

| Parameter                    | Statistics                | Study_04/05 (N = 22)      | HCs (N =51)              |
|------------------------------|---------------------------|---------------------------|--------------------------|
| Age at HLH diagnosis (years) | Mean (SD) Median Min, Max | 2.7 (3.51) 1.0 0.1 - 13.9 | 4.5 (5.36) 1.5 0.1 -18.9 |
| Gender                       |                           |                           |                          |
| Female                       | N (%)                     | 12 (54.5)                 | 23 (45.1)                |
| Male                         | N (%)                     | 10 (45.5)                 | 28 (54.9)                |
| HLH genetic confirmation     |                           |                           |                          |
| Yes                          | N (%)                     | 19 (86.4)                 | 35 (68.6)                |
| No                           | N (%)                     | 3 (13.6)                  | 16 (31.4)                |
| CNS disease reported         |                           |                           |                          |
| Yes                          | N (%)                     | 8 (36.4)                  | 11 (21.6)                |
| No                           | N (%)                     | 14 (63.6)                 | 40 (78.4)                |

Propensity score strata were formed by choosing the median propensity score among patients who died in Study NI-0501-04.

Table 42. Analysis of Maximum Likelihood Estimates

| Parameter       | Coefficient (SE)   |
|-----------------|--------------------|
| Intercept       | -1.857 (0.7912)    |
| Age             | -0.098 (0.0677)    |
| Gender          | 0.429 (0.5572)     |
| Genetic disease | 1.188 (0.7237)     |
| CNS disease     | 0.741 (0.5941)     |

Gender: 1 = Female, 0 = Male; Genetic disease: 1 = Confirmed, 0 = Not confirmed; CNS disease: 1= Reported, 0 = Not reported

Table 43. Number of Patients by Propensity Score strata

| Study Type      | PS strata         | PS strata          | PS strata   |
|-----------------|-------------------|--------------------|-------------|
|                 | Transplant PS Low | Transplant PS High | Total       |
| StudyNI-0501-04 |                   |                    |             |
| N               | 3                 | 19                 | 22          |
| Event (%)       | 1 (33%)           | 1 (5%)             | 2( 9%)      |
| Censored (%)    | 2 (67%)           | 18 (95%)           | 20 (91%)    |
| HC cohort       |                   |                    |             |
| N               | 22                | 29                 | 51          |
| Event (%)       | 8 (36%)           | 5 (17%)            | 13 (25%)    |
| Censored (%)    | 14 (64%)          | 24 (83%)           | 38 (75%)    |
| Total           | 25                | 48                 | 73          |

Table 44. Cox Regression for Post-HSCT Survival stratified by Propensity Score: high vs. low

| ** p=0.397   |
|--------------|
| ** p=0.397   |
| ** p=0.397   |

** Cox model. ## Stratified log rank test

<div style=\"page-break-after: always\"></div>

## Cox regression analyses

Cox regression analyses model, stratified by transplant/no transplant for Overall Survival, unstratified for Post-HSCT Survival, included treatment group and adjusted for the same covariates as in the propensity score model. Overall survival is defined as time from the date of HLH diagnosis (HCs) or time of first emapalumab dose (Study\\_04/05) to the date of death. Post-HSCT survival is defined as time from the date of HSCT to the date of death. Patients without an event were censored at the time of last contact.

Table 45. Stratified Cox Regression Analyses of Overall Survival

| Parameter       |   DF |   Parameter Estimate |   Standard Error |   Chi- Square |   Pr > ChiSq |   Hazard Ratio [1] |   95% Hazard Ratio CIs |   95% Hazard Ratio CIs |
|-----------------|------|----------------------|------------------|---------------|--------------|--------------------|------------------------|------------------------|
| Study type*     |    1 |             -0.25799 |          0.42357 |        0.371  |       0.5425 |              0.773 |                  0.337 |                  1.772 |
| Age             |    1 |             -0.03195 |          0.0421  |        0.576  |       0.4479 |              0.969 |                  0.892 |                  1.052 |
| Gender          |    1 |             -0.39824 |          0.38773 |        1.0549 |       0.3044 |              0.672 |                  0.314 |                  1.436 |
| Genetic Disease |    1 |             -0.3194  |          0.40832 |        0.6119 |       0.4341 |              0.727 |                  0.326 |                  1.618 |
| CNS Disease     |    1 |              0.24564 |          0.41782 |        0.3456 |       0.5566 |              1.278 |                  0.564 |                  2.9   |

* Historical control is the reference

Table 46. Cox Regression Analyses of Post-HSCT Survival

| Parameter       |   Parameter Estimate |   Standard Error |   Chi- Square |   ChiSq |   pezH Ratio [1] |   95% Hazard Ratio CIs |   95% Hazard Ratio CIs |
|-----------------|----------------------|------------------|---------------|---------|------------------|------------------------|------------------------|
| Study type*     |             -0.69866 |          0.81425 |        0.7362 |  0.3909 |            0.497 |                  0.101 |                  2.453 |
| Age             |              0.05389 |          0.04621 |        1.36   |  0.2435 |            1.055 |                960     |                  1.155 |
| Gender          |              0.22193 |          0.55709 |        0.1587 |  0.6904 |            1.248 |                  0.419 |                  3.72  |
| Genetic Disease |             -1.25708 |          0.56304 |        4.9849 |  0.0256 |            0.284 |                  0.094 |                  0.858 |
| CNS Disease     |              0.07487 |          0.60722 |        0.0152 |  0.9019 |            1.078 |                  0.328 |                  3.543 |

*Historical control is the reference

Similar results were obtained from the Cox model versus Propensity score models, with HR for death of 0.773 (95%CI 0.337, 1.772, p=0.543) vs 0.657 (0.252, 1.711, p=0.389) and HR for post-HSCT survival of 0.497 (0.101, 2.453, p=0.391) vs 0.505 (0.104, 2.452, p=0.397) respectively.

## Response to Treatment

Response to treatment based on HLH disease control as assessed by the treating physicians was available for most patients at conditioning for HSCT, whereas in study\\_04/05 patients' response to treatment was assessed at several time points based on both the Investigator`s clinical judgement and the protocol pre-defined algorithm including at conditioning.

Table 47. HLH Disease Control at HSCT (as reported by the physician)

|                              | Statistics   | HCs (n=51)       | Study_04/05 (m=22)   |
|------------------------------|--------------|------------------|----------------------|
| HLH Disease Control Rate [1] | % [95%CI]    | 62.7 [49.4,76.0] | 77.3 [59.8,94.8]     |
| Yes                          | N (%)        | 32(62.7)         | 17 (77.3)            |
| No                           | N (%)        | 18 (35.3)        | 1 (4.5)              |
| Missing                      | N (%)        | 1 (1.9)          | 4 (18.2)             |

[1] Missing records counted as no HLH disease control; CI derived using normal approximation to the binomial

<div style=\"page-break-after: always\"></div>

## Ancillary data

The applicant provided additional post hoc responses excluding the n=4 patients that were eligible for 1L etoposide but did not receive it. The overall response rate in this population was 60.9% (95% CI: 0.385, 0.803); N= (14/23) .

The overall 12-month survival probability is 0.70 (95% CI: 0.46, 0.84; N=23)) and the 12-month survival probability post HSCT in patients undergoing HSCT of 0.88 (95% CI: 0.60, 0.97; N=17).

## 3.2.2. Discussion on clinical efficacy

## Indication

Initially the applicant proposed the following indication:

'Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).'

At the first D180 the applicant amended the indication to 'treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or intolerance to conventional HLH therapy'.

At the second D180 the applicant amended the indication to 'treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide)'.

## Design and conduct of clinical studies

Design: The current application is based on a single arm trial NI-0501-04 (4-12 weeks) and NI-050105 (up to 1 year follow up). A single arm trial (SAT) carries important intrinsic limitations which may be overcome in specific circumstances, which include a predictable course of the disease, a welldescribed patient population and compelling results indicative of clinical benefit, for which a well understood MoA is deemed helpful. In addition, adequate historical controls can be used to contextualise the data.

The applicant conducted a single arm trial despite the recommendation to conduct a randomised controlled trial by the EMA. Although it is acknowledged that no treatment is approved for pHLH, the HLH-1994 or HLH-2004 protocol represent standard of care (SoC) for pHLH in the first line. In case of disease recurrence/relapse the SoC is re-intensification/re-treatment with the first line regimen according to the HLH-2004. For refractory disease alemtuzumab, anakinra or ATG have been described.

It should be noted that emapalumab was administered on a background of dexamethasone, and other concomitant HLH treatments were allowed as well. This hampered the evaluation of the effect of emapalumab treatment in the context of a single arm study, in particular considering the variable course of the disease.

Conduct of the study: The study NI-0501-04 was initially designed as a phase II, dose-finding study using Bayesian explorative statistics. During the study, the study was amended several times based on the clinical experience and was finally upgraded to a single arm, open-label confirmatory study (protocol EU version 6.0). Amendment 4 and 5 broadened the patient population however only few patients were included prior to these amendments.

<div style=\"page-break-after: always\"></div>

The transition to the phase III trial appeared not to be carefully pre-planned as no criteria appeared to be predefined before commencing the phase III trial. The transition to phase III was based on descriptive analyses of the first n=11 patients.

Amendment 6.0 transited the study from a phase II to the phase III trial. The amendment 6.0 affected dosing schemes, allowed the permission of additional concomitant HLH treatment, redefined the criteria for the response rate (primary efficacy parameter), defined the primary and secondary endpoints, statistical methods, goal of the study. The statistical analyses plan for the phase III trial was defined &gt; 8 months after the transition, when about &gt; 80% of patients were included. After data base lock, the statistical analyses plan was amended twice. These amendments affected amongst others, the secondary outcomes, specifications were made for the derivation of overall response, imputation rules for response analyses and additional information was added for the identification of the second line population.

These amendments of the study protocol and statistical analyses plans give rise to concerns on the interpretability of the data as the changes to the trial might be based on the knowledge of the initial results of this trial. A post hoc analysis indicated that response rates are comparable between patients who were included before and after the finalisation for the final protocol (amendment 6.0), but the small size of the subgroups hinders definitive conclusions.

A triggered GCP inspection was initiated for the clinical studies NI-0501-04. The inspectors visited one analytical laboratory site, two investigator's sites and the sponsor site. The inspectors concluded that critical and major findings were reported related to the violation of patients' rights and integrity of the data. The latter findings refer mainly to a lack of trial oversight by the Sponsor which affect the data collection, data management and analyses of trial results. Due to these findings, the Inspectors /CHMP concluded that the study NI-0501-04 was not considered GCP compliant and the integrity of the data is impaired. The Inspectors/CHMP concluded that the data of study NI-501-04 should not be used for evaluation and assessment of the MAA of emapalumab.

## Study participants:

The inclusion of pHLH patients was not limited to those patients that showed an affected patient family and a genetic confirmation of known causative gene. HLH with an impaired functional test, or HLH with the absence of secondary forms of HLH was also allowed. However, not all forms of secondary HLH were considered as an exclusion criterion and the diagnosis of sHLH can be challenging once the external trigger has been eliminated.

The study population included treatment naive (first line) and patients that were treated with conventional therapy (second line). The primary analysis set are the second line patients, i.e. patients who insufficiently responded to conventional HLH therapy being the combination of dexamethasone with etoposide. The 2nd line patients with primary HLH are described as relapsed, worsening, 'refractory', or intolerant, which are unconventional terms for pHLH and are not necessarily applicable where the option of retreating with conventional therapy is available.

Overall, the eligibility criteria allowed for the inclusion of a heterogeneous population.

It should be noted that patients with reactivating/ worsening of disease are also considered eligible for re-intensification/re-treatment with first line SoC, as they are not considered refractory to treatment.

For patients who are refractory to treatment or intolerant to treatment, salvage therapy could be used like alemtuzumab, CSA, etc.

Treatment: Dosing schemes before the final protocol were guided by PK &amp; clinical data and the maximum dose was 3mg, while in the final dosing scheme dosing was guided by clinical data only with

<div style=\"page-break-after: always\"></div>

a maximum dose of 10 mg allowed. It is estimated that roughly 15-12 patients (44%-35% all treated patients) were dosed using that final dosing scheme.

The proposed posology (starting dose, dosing frequency and dosing based on clinical symptoms) has not been adequately justified from a PK perspective (refer to discussion on clinical pharmacology). Based on the proposed mode of action, a higher starting dose would have been expected. Moreover, as commented on in scientific advice (EMA/CHMP/SAWP/97018/2017), there are concerns whether the up-titration according to clinical response is the most appropriate dosing strategy, given the apparent need for fast responses in the target population. Up-titration as dosing strategy has not been sufficiently justified by the applicant. Furthermore, no recommendations for dose reduction are made. In addition, the dosing strategy also does not allow for an appropriate distinction between being refractory to emapalumab and not receiving a sufficient amount of medicinal product.

Many concomitant HLH treatments were allowed during the study, which prevented the isolation of the treatment effect of emapalumab (see below).

Dexamethasone and prophylactic anti-infectious treatments were given during the study, which needs to be reflected in the SmPC. Dexamethasone was reduced on the judgement of the treating physician but no more than halving the dose /once weekly. Eligibility criteria for HSCT have not been provided. This may impact the external validity of the trial.

## Endpoints:

Primary endpoint: Trial NI-0501-04 used a new definition for the primary outcome measure, the overall response rate (ORR). Upon a protocol amendment for the final protocol the applicant disregarded criteria more in line with literature from the endpoints. This newly defined ORR is measured by an improvement in clinical and laboratory outcome measures at week 8 (or earlier if a donor for HSCT was available).

However, it is unknown whether this clinical endpoint translates into patient benefit i.e. the clinical relevance of this outcome is not clear, because:

- 1) It is unclear whether a relation exists between the measured ORR at week 8 and the chance to proceed to HSCT or improved HSCT outcome.
- 2) A response may lead to an improvement of Quality of Life (QoL). However, QoL was not measured in the clinical trial.
- 3) Also, the new definition of ORR differs (is less strict) from the ones used in historical trials. This hampers the understanding of the results and may lead to an overestimation of the effect.

Secondary endpoints: The study NI-0501-04, included several key secondary endpoints such as the time to response, duration of response and reduction in glucocorticoids. These endpoints are considered appropriate to determine anti-disease activity of the product however it is unclear how they relate to patient benefit and are affected by the use of concomitant HLH therapy.

Generally, OS and HSCT outcomes, as all patient with pHLH should proceed to HSCT, are considered relevant for determining patient benefit. However, it needs to be considered that these time-dependent endpoints are not readily interpretable in single-arm trials, as prognostic and predictive factors cannot be separated, and control of bias cannot be ascertained in cross-study comparisons. Likewise, many factors may influence the choice to perform a HSCT, including availability of a donor further, further hampering a full understanding of the HSCT rate data. The mixing of results for the induction study NI0501-04 and the follow-up study NI-0501-05 is confusing.

<div style=\"page-break-after: always\"></div>

Of note, some of the endpoints were selected from either the prespecified secondary endpoints in the protocol of study NI-0501-04 or of study NI-0501-05, while other endpoints reported in the CSR were not prespecified in any protocol or not reported according to methods reported in the protocol. This raise concerns that reporting of some of the secondary outcomes may be data driven.

Statistical analyses: The primary analysis set for efficacy constituted of all patients who received any part of an emapalumab infusion in the second line and the analysis of the treatment naïve patients is exploratory. Statistical tests to investigate whether the overall response rate was at least 40% in the second line treated population are considered appropriate. However, starting new treatment or additional medication was not counted as non-response, which may result in an overestimation of efficacy.

## Efficacy data and additional analyses

## Study population:

The primary study population included N=34 patients. The number of treatment-naive patients included in the study (n=7) is too small for a sound assessment. The primary analysis set consists of the second line all treated set (=27). The small sample size severely limits the ability to extrapolate the study outcomes to the heterogeneous pHLH population. The applicant did not adhere to the ITT principle, but restricted the analyses to all patients who received emapalumab. One patient who entered the trial was not treated, but the exclusion of this patient is not expected to have a large influence on the outcomes.

The study included a total of n=27 second line patients for whom a total of n=15 patients re escalation/ re intensification of treatment of previous HLH treatment might be an option, a total of n=7 were intolerant to treatment and a total of n=5 showed refractory disease. For these latter n=12 patients, salvage therapy could be considered.

Concerns were raised regarding how well this included study patient population represents the broad target pHLH population as proposed in the current indication. The following concerns are raised:

## -No strict definition of pHLH

The included study population included a total of N=3 patients who did not have an affected family history, no molecular causative mutation, or heterozygous mutation in known HLH genes, or impaired functional tests. The diagnosis of pHLH was made after the exclusion of some forms of secondary HLH.

However, the exclusion of secondary forms of HLH might be challenging as the diagnosis of one of these three patients was confirmed post-mortem as secondary HLH due to the presence of a haematological malignancy undiagnosed at study entry.

Of the two other patients, one patient died after HSCT and the last patient recovered without the need for HSCT. In view of the absence of genetic of functional confirmation, it cannot be excluded that this patient might also have had a secondary form of HLH. Considering the overall limited number of patients, there is uncertainty whether the diagnosis of these 3 patients may have impacted the results.

## Not all second line patients were treated with etoposide

The conventional HLH treatment is the combination of dexamethasone + etoposide. A total of n=4 (15%) of patients were included, who had not received pre-treatment with etoposide. These patients did not have an apparent contra-indication or intolerance for etoposide. Therefore, these patients should not have been included in the second line treatment population but should have been treated with etoposide first.

<div style=\"page-break-after: always\"></div>

## -Reactivating after prior HSCT

Also, two second line patients were included who had received a prior HSCT. The two patients are not considered to be representative of patients who require work up to HSCT.

The inclusion of patients with possible secondary HLH, the inclusion of patients without pretreament of etoposide and patients who received priort HSCT results add to a very heterogeneous noncomprehensive second line study population, for which it is difficult assess the representativeness for the proposed target population e.g. like proposed in the current indication. Concerns are raised on the internal and external validity of the study.

## Concomitant HLH and G-CSF treatment and impact on the results:

During the single arm trial, the concomitant use of other HLH treatments and G-CSF was allowed. Dexamethasone as background therapy may have influenced the primary endpoint as HLH is reactive to immunosuppression. In addition, nine patients used additional HLH treatments prior to measuring of the primary endpoint and in a total of n=5 patient the additional HLH treatment was newly introduced. In 3 patients (one used alemtuzumab, two used CsA and this treatment may have affected the ORR (other patients had no response to treatment). A total of n =15 patients were identified who used concomitant HLH treatments (etoposide, alemtuzumab, ATG and/or CSA) prior to the measurement of the secondary endpoints (EoT 04/05).  Also, the use of G-CSF (in 11 patients) may have affected the primary and secondary outcome measures, as these were not stopped in a timely manner prior to measuring the ORR at EoT04. This concomitant use of the HLH therapies and G-CSF could have influenced the number of patients proceeding to HSCT and survival outcomes.

Overall, due to the use of concomitant therapies the contribution of emapalumab to primary and secondary efficacy outcomes cannot be isolated.

## ORR at end of NI-0501-04 study and updated efficacy data :

The ORR for 2 nd  line cases at end of trial NI-0501-04 is 63.0% (95% CI 0.42, 0.81), reducing to 59.3% (0.39, 0.78) when subjects receiving additional, newly initiated HLH treatments (n=5) are classified as non-responders.

However, not all patients classified as second line patients received upfront dexamethasone and etoposide as first line therapy. When the second line patients who did not receive upfront etoposide were excluded (n=4), the ORR was reduced to 60.9% (95% CI: 0.385, 0.803; N=23) with the lower limit of the 95% CI being less than the pre-set limit of 40%. This result together with other sensitivity analyses including ORR at end of trial NI-0501-04/05, fail to meet the target of demonstrating the ORR is &gt;40% (p-values &gt;0.025 and CI not entirely above 0.40).

Since the data base lock of 20 July 2017, an additional n=13 patients were screened and an additional n=11 patients have been treated in the NI-0501-04 study. The results of these additional 11 patients (including at least n=4 first line patients) are provided with a data cut- off of 31 Jan 2019. A total of n=7 treatment experienced patients were included. A total of n= 3 did not receive upfront etoposide and cannot be regarded as supportive for the applied application. The other n=4 patients received upfront etoposide, but none of them showed a response to emapalumab. Hence, these updated data do not appear to be in line with the previously reported results and it remains that the study has not robustly demonstrated a response rate that exceeds 40%. Moreover, these data were collected under the same circumstances as the primary analysis data, as the GCP inspections took place after this cutoff date. Thus, the same GCP findings apply.

Secondary endpoints : The applicant had not pre-specified the measurement of the duration of response and therefore it is not extensively discussed here. Median time to response was 8 days.

<div style=\"page-break-after: always\"></div>

Noteworthy is that not all responses are maintained throughout the study. In some patients, response status through time is highly variable. This is mostly due to the waxing and waning character of HLH, but also by using response criteria in which minor changes may induce a change in the response classification. Almost half of the patients achieved a 50% reduction glucocorticoid use at EoT 04, which might be indicative of disease activity of emapalumab, but it is not known how far the dose has to be reduced to be regarded as a benefit.

HSCT : Overall, a total of n=19 (70%) of the second line patients entered the preconditioning period (n=4 (57.1%) in first line). Responses at conditioning for second line patients were: 5 in CR, 5 in PR and 3 had HLH improvement. Six second line patients (and 2 first line patients) underwent a HSCT the HSCT outcome and what was the influence of concomitant HLH medication, or patient characteristics, on the HSCT outcome (see above).

Survival : For the second line patients the median follow-up for OS was 13.4 months. In 2 nd  line treatment cases the Kaplan-Meier estimate for survival at 6 and 12 months is 73% (95% CI 52% 86%). After the data cut-off, one first line patient died and several deaths under newly recruited HLH treatments may have influenced these outcomes.

with a reported 'no response'.  Of note, it is not clear how emapalumab administration contributed to Median time to HSCT was 84 (2.8 months) in the 2nd line patients and 233 days=7.6 months in first line patients. A total of 4 surviving patients did not undergo HSCT. Three of these patients did not have a known HLH causative gene mutation, while the other patient failed a previous transplant and experienced episodes of HLH reactivation. patients occurred. The study is insufficiently mature to provide 5-year OS data. Note that additional

When efficacy results are compared between patients not eligible and eligible for re-intensification with prior SoC, outcomes appear to be driven by the latter type of patients (ORR (50% vs 73%), proceeding to HSCT (58% vs 80%).

## Use of external controls, including Historical Controls:

Retrospectively collected primary HLH patients (n=72) who received HLH available therapies from January 2010 onwards were presented as historical controls to compare survival rates. The selection methods for the historical controls (HCs) are not considered appropriate (i.e. concurrent with NI-050104 study, by same investigators) as they are prone for selection bias. The non-randomised comparison of OS and post-HSCT Survival between the HC study and pivotal study indicated extremely wide confidence intervals, showing that even if all important covariates and sources of bias are addressed by these analyses, considerable uncertainty remains regarding comparison between treatments. The wide confidence intervals cross the 1 indicating substantial superiority of either treatment as a reasonable possibility.

When comparing first line pivotal study patients with the literature (HLH-94/04 patients), pivotal study patients appear to compare numerically worse (respectively 57% vs 76-80% proceed to HSCT; 12month OS probability 46% vs 5-year OS 56-59%). It should be noted that comparisons to any historical controls carry inherent biases which hinder adequate comparison.

All in all, the historical controls data are considered of little relevance for the understanding of the 04/05 study also because of the differences in line of treatment, time frame and level of supportive care and lack of data on prognostic variables, which the applicant has not adjusted for in the analyses.

<div style=\"page-break-after: always\"></div>

## Supportive data from Compassionate Use :

Data from patients from compassionate use (CU) have been presented as supportive data for the NI0501-04/05 study. Eight subjects with primary HLH not previously treated with emapalumab and ineligible for study NI-0501-04 are presented. The data on CU cases are insufficiently robust to draw any conclusions on efficacy.

## Conditional marketing authorisation

At the second day 180, the applicant applied for a Conditional Marketing authorisation for 'treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH) with refractory or recurrent disease or intolerance with conventional HLH therapy (combination of dexamethasone and etoposide)', with the proposal that the Study NI-0501-09 would provide confirmatory data for the B/R assessment. Study NI-504-01-09 is a single arm trial with almost a comparable design as study NI-0501-04. The expected end date of this study is October 2022.

However, as stated above, due to the use of concomitant therapies the contribution of emapalumab to primary and secondary efficacy outcomes cannot be isolated. As study NI-0501-09 is almost a replication from study NI-0501-04, the CHMP considers that this study will not provide confirmatory efficacy data, as the data will face the same uncertainties as identified in study NI-0501-04 as discussed above.

## 3.2.3. Conclusions on the clinical efficacy

Efficacy data for emapalumab in pHLH patients have been derived from pivotal study NI-0501-04/ and its extension NI-0501-05. In the pivotal study 45 patients with primary haemophagocytic lymphohistiocytosis (pHLH), of whom 27 patients were treatment-experienced. were treated with emapalumab, in combination with concomitant conventional therapy as considered clinically appropriate. The primary endpoint was ORR as defined by complete or partial response or HLH improvement.

Concerns have been raised about the various amendments in the study protocol and statistical analyses, as these might be data driven. The study has been subject to a triggered GCP inspection. The outcome of the GCP inspection recommended not to use the data to support the MAA, as the quality of the data could not be confirmed.

Even if the quality of the gathered data could be confirmed, given that emapalumab was used in combination with other HLH therapies, as well as due to the known variability in the course of pHLH, the key issue is that responses seen in the study cannot be causally attributed to treatment with emapalumab. Similarly, the contribution of emapalumab to patient eligibility for HSCT, and its impact on OS, could not be ascertained. Updated efficacy results from 7 additional patients could not resolve this key issue, as these were obtained in the same setting. The benefit of emapalumab is not considered demonstrated.

No substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since the role of IFN-gamma is the pathogenesis of pHLH is incompletely understood.

The proposed study NI-0501-09 is almost a replication from study NI-0501-04. Therefore, this study will not provide confirmatory efficacy data for the benefit, as the data will face the same uncertainties as identified in study NI-0501-04 as discussed above.

<div style=\"page-break-after: always\"></div>

## 3.3. Clinical safety

## Patient exposure

The primary analysis of safety for emabalumab in pHLH was based on data from the NI-0501-04 study with data cut-off 20-07-2017and its long-term follow-up study NI-0501-05, both of which were open label and uncontrolled. The pivotal safety population consists of n=34 patients.

Initially the following supportive safety analyses were provided:

- Data from the patients that received emapalumab in compassionate use (n=17). The safety data available from CU is limited to serious adverse events, fatal events and adverse events assessed as related to emapalumab administration by the treating physician.
- Relevant safety data from the 14 healthy volunteers who received a single infusion of emapalumab in study NI-0501-03 is presented separately. Six of the 14 subjects received an emapalumab dose lower than 1 mg/kg. Due to their very low production of IFNγ, healthy volunteers have a different PK profile compared with HLH patients.

According to the applicant the main safety data of study NI-0501-04/05 consists of N=34 patients, plus compassionate use in 17 primary and secondary HLH patients and a total of N=14 healthy volunteers exposed to emapalumab in study NI-0501-03.The main safety data in the submission documentation is provided up to the data cut-off point of 20 July 2017. The median follow-up time for the safety database is 11 months. (min 0.1-max 20.9 months). At the initial application limited additional safety reporting the number of deaths has been provided with additional data up to 31 January 2018.

At day 180 and 2 nd  day 180 the following additional safety data was provided by the applicant:

- safety  data  on  N=11  pHLH  patients  further  enrolled  in  the  NI-0501-04  study  after  the  primary analysis with cut-of 24-Nov-2019.
- a  summary  of  safety  data  from  n=22  pHLH  patients  in  ongoing  study  NI-0501-09  in  a  similar population  as  the  NI-0501-04  study  population  and  a  short  summary  of  n=14  patients  with secondary HLH from the NI-0501-06 study.
- safety data from N=102 primary HLH patients (cut-off 19 May 2020) treated post-marketing in the US (showing no additional safety concerns).

Safety data were available for Historical Controls with regard to the causes of death (except in 4 patients) only.

The applicant has acknowledged the limitations of the safety data currently available for emapalumab in the treatment of primary HLH and is proposing to initiate and maintain a disease registry with the aim to further characterize emapalumab potential risks, its long-term safety and the benefit risk profile of treatment.

An AE (classified by preferred term) occurring after initiation of study medication was counted as a treatment-emergent AE (TEAE) if it was not present before initiation of study medication. All AEs reported spontaneously by the patients or his/her relatives or observed by the Investigator or his/her staff during the clinical study were to be reported on the AE data collection form. Note that AEs (e.g. haematological toxicity, pyrexia, infections) already present at start of treatment were not reported. The on-study AEs were separately provided by the applicant in the AR.

Intensity of adverse events was graded on a three-points scale (mild, moderate, severe) using the modified WHO (World Health Organization) toxicity scale (Grade 3 and 4 are considered to be the

<div style=\"page-break-after: always\"></div>

severe grade). If AE severity was not mentioned in the scale, assessment was to be made using the following definitions: Mild: Discomfort noticed but no disruption of normal activity. Moderate: Discomfort sufficient to reduce or affect normal daily activity. Severe: Inability to work or perform normal daily activity.

The main safety data of study NI-0501-04/05 consists of N=34 patients, CU of primary and secondary HLH consists of n=17 patients. The total number of patients exposed to emapalumab is n=51. A total of N=14 healthy volunteers were exposed to NI-0501-04. Therefore, the total number of subjects exposed to emapalumab is n=65 (Table 48).

Table 48.Number of subjects exposed to emapalumab

|                                 | Any emapalumab dose up to 10 July 2017   |   Any emapalumab dose up to 31 January 2018 |
|---------------------------------|------------------------------------------|---------------------------------------------|
| NI-0501-04 (primary HLH)        | 34                                       |                                          37 |
| CU (primary and secondary HLH)  | 17 b                                     |                                          19 |
| NI-0501-03 (healthy volunteers) | 14 a                                     |                                          14 |
| Total                           | 65                                       |                                          70 |

a Emapalumab doses of 0.01 (3 subjects), 0.1 (3 subjects), 1.0 (4 subjects), or 3.0mg/kg (4 subjects) b 8 patients with primary HLH and 9 patients with secondary HLH

Up to 31 January 2018, 694 infusions of emapalumab have been given in the NI-0501-04/05 studies and &gt;1100 have been given in total.

## Studies NI-00501-04/05 and CU

Emapalumab was administered to patients at an initial dose of 1 mg/kg every 3 days. The dose of emapalumab could be increased according to pre-defined protocol criteria that were guided by clinical and laboratory response data obtained from each patient. The highest dose administered in the NI 0501-04/05 studies or in CU patients was 10 mg/kg daily.

All patients (n=34) were exposed to a dose of 1mg/kg. A total of n=23 were exposed to the 3 mg/kg, n=10 to the 6 mg/kg and n=5 to the 10 mg/kg.

Table 49. Extent of exposure (up to 31 January 2018)

<!-- image -->

|                                  |                            | NI-0501-04/05                      | NI-0501-04/05                     | NI-0501-04/05/                     | CU A11/05 (pHLH and                |                                    |
|----------------------------------|----------------------------|------------------------------------|-----------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                  | Statistic                  | A11 (N=37)                         | 2nd line (N=28)                   | PHLH CU (N=48)                     | SHLH) (N=23)                       | All Patients (N=58)                |
| Duration of Dosing （days）[1]     | n Nean (SD) Modian Min,Max | 37 72.6(57.94) 52.0 4,245          | 28 59.5(42.86) 47.0 4,157         | 48 68.1（55.32) 47.0 4,245          | 23 65.7(77.42) 34.0 4,318          | 58 71.8(65.92) 47.0 4,318          |
| Duration of Dosing （weeks) [2]   | n Mean(SD) Median Min,Max  | 37 10.378(8.2773) 7.430 0.57,35.00 | 28 8.505(6.1230) 6.715 0.57,22.43 | 48 9.726 (7.9030) 6.715 0.57,35.00 | 23 9.385(11.0608) 4.860 0.57,45.43 | 58 10.256(9.4178) 6.715 0.57,45.43 |
| Cumulative Dose （mg/kg）[3]       | n Mean (SD) Median Min,Max | 37 61.6(62.40) 29.0 4,254          | 28 43.1(45.92) 19.0 4,142         | 48 62.6(64.93) 40.5 4,254          | 23 61.6(70.88) 39.0 2,236          | 58 63.2(65.72) 38.5 2.254          |
| Average Dose Frequency (days)[4] | n Mean(SD) Median Min,Max  | 37 3.689(1.4380) 3.230 1.35,8.72   | 28 3.683(1.3461) 3.235 2.00,8.72  | 48 3.604(1.3426) 3.205 1.35,8.72   | 23 3.321(1.0115) 3.060 2.00,5.95   | 58 3.559(1.3114) 3.150 1.35,8.72   |

<div style=\"page-break-after: always\"></div>

```
pHlH = Primary Hemophagocytic lymphohistiocytosis disease.sHLH = Secondary Hemophagocytic lymphohiatiocytosis disease. Notes: 2nd Line: Patients that have already received conventional HlH therapy without having obtained a satisfactory response accordingtothetreating physician orhavingshown signs ofintolerance toit. [i]Last infusion date in study oforigin or 05 （or date of start of HscT conditioning if earlier)-first infusion date+1. [2] [Last infusion date in study of origin or 05 （or date ofstart of HscT conditioning if earlier)-first infusion date +1]/7 [3] Sum of total actual dose per kg aciministered from first infusion date until last NI-05ol infusion date in study oforigin or 05 (ordateofstartofHscTconditioningifearlier). [4] [Duration of dosing （days)]/ [Total number of infusions until last infusion date in any study or start of Hscr conditioning if [5]Cumulativedose/Durationofdosing.
```

## Study NI-0501-03

A total of 14 subjects received a single dose of emapalumab at doses of 0.01 mg/kg (3 subjects), 0.1 mg/kg (3 subjects), 1 mg/kg (4 subjects), and 3 mg/kg (4 subjects). Six subjects received placebo. All 20 subjects received the full infusion at the planned dose.

A total of 15 subjects participated in the follow-up period beyond 8 weeks: 5, 3, 4 and 3 patients from the placebo, 0.1 mg/kg, 1 mg/kg and 3 mg/kg groups, respectively.

## Adverse events

The pivotal safety data set to provide the adverse event profile is study NI-0501-04/05 (n=34), because in this study the events were systematically collected, and this analysis set does not contain double counted patients or non-treated patients. Note, that the AEs reported below are TEAE. The primary safety group that provided the AE profile is study NI-0501-04/04. Safety data from CU and healthy volunteers are reported in section 'safety in special populations' of this AR.

Overall most AEs were assessed as mild (53.2%) while 28.1% and 18.7% were assessed as moderate or severe. In Table 50 an overview of TEAEs is provided.

Table 50 Treatment emerging adverse events pre-post conditioning NI-0501-04/05

| Adverse Event, N (%)                                               | NI-0501-04/05            | NI-0501-04/05            | NI-0501-04/05                    |
|--------------------------------------------------------------------|--------------------------|--------------------------|----------------------------------|
|                                                                    | Pre- Conditioning (N=34) | Post Conditioning (N=23) | Pre and Post Conditioning (N=34) |
| At Least 1 AE                                                      | 32 (94.1)                | 23 (100.0)               | 34 (100.0)                       |
| At Least 1 AE Related to Study Drug [1]                            | 10 (29.4)                | 1 (4.3)                  | 11 (32.4)                        |
| At Least 1 Serious AE                                              | 21 (61.8)                | 15 (65.2)                | 30 (88.2)                        |
| At Least 1 Serious drug related AE                                 | 2 (5.9)                  | 0                        | 2 (5.9)                          |
| Deaths [2]                                                         | 8 (23.5)                 | 2 (8.7)                  | 10 (29.4)                        |
| At Least 1 Serious AE with Fatal Outcome                           | 7 (20.6)                 | 2 (8.7)                  | 9 (26.5)                         |
| At Least 1 Serious AE Related to Study Drug and with Fatal Outcome | 0                        | 0                        | 0                                |
| At Least 1 AE Leading to Withdrawal                                | 2 (5.9)                  | 0                        | 2 (5.9)                          |

AE=Adverse Event

Notes: Data from both Study NI-0501-04 and NI-0501-05 are included.

[1] Highest relationship to treatment is counted as assessed by Sponsor or Investigator.

[2] One first-line patient who died after the database cut-off date of 20th July 2017 is not included.

Source: NI-0501-04 CSR Table 14.3.1.1

## Pre-conditioning

During the preconditioning period, 32 out of 34 patients reported a TEAE; approximately half of the patients reported one severe TEAE.

<div style=\"page-break-after: always\"></div>

The most commonly reported TE-AEs during the pre-conditioning period were condition aggravated n=17 (50.0%), hypertension n=14 (41.2%), pyrexia n=8 (23.5%), constipation n=5 (14.7%), hypokalaemia n=5 (14.7%), lymphocytosis n=4 (11.8 %), tachycardia n=4 (11.8%), abdominal pain n=4 (11.8%), diarrhoea n=4 (11.8%), cytomegalovirus infection n=4 (11.8%), irritability n=4 (11.8%), cough n=4 (11.8%), tachypnoea n=4 (11.8%), rash 4 (11.8).

At the end of the cut of date of 20 July 2017, more than 90% of the mild and moderate events were resolved or resolving. Those who did not resolve were mainly reported in the patients that died. A total of n=6 patients who reported not resolved TEAEs and included hypothyroidism (n=1), glucocorticoid deficiency (n=1), decreased of Ig G in patient (n=1), hypertension (n=2) and intermittent constipation (n=1), delayed gastric emptying (n=1) and mild peripheral oedema (n=1)

## Severe Adverse events

The most frequently reported SOCs with more than 10% of the patients having reported a severe TEAE) were 'Infections and infestations' (29.4%), (17.6%), 'Respiratory, thoracic and mediastinal disorders' (17.6%), \"General disorders and administration site conditions\" (14.7%) and hepato- biliary disorders (11.8%).

The PT terms of these severe AEs included the PT terms condition aggravated (HLH reactivation, an HLH flare, or HLH worsening; 4 patients; 11.8%), gastrointestinal haemorrhage (3 patients; 8.8%), respiratory failure (2 patients; 5.9%), and hypertension (2 patients; 5.9%, with pre-existing hypertension in medical history).

The applicant had also provided an overview of all on-study AEs in the pre-conditioning period. The most frequent on study-AEs were: Infections (56%; bacterial, fungal, and viral) and condition aggravated (50.0%). Other commonly reported AEs during the pre-conditioning period included hypertension (41.2%), infusion-related reactions (IRRs; 27%), and pyrexia (24%). The most frequent severe AEs reported were similar as to reported above for the TEAEs.

## Post-conditioning

There were 23 patients in the post conditioning period. During the post-conditioning period, 13 (56.5%) patients overall had a severe (TE) AE, 6 (26.1%) had a moderate event while 4 (17.4%) patients reported a mild AE as their AE of highest intensity.

The most commonly reported TE-AEs during the  post conditioning period were Pyrexia n=12 (52.25), hypertension n=10 (43.5 %), mucosal inflammation n=5 (21.7%), Graft versus host disease in skin n=5 (21.7%), thrombotic micro-angiopathy n=4 (17.4%), abdominal pain n=4 (17.4%), stomatitis n=4 (17.4%), Cytomegalovirus infection n=4 (17.4%), rash n=4 (17.4%), diarrhoea n=3 (13.0%), vomiting n=3 (13.0%), condition aggravated n=3 (13.0%), engraftment syndrome n=3 (13.0%), hypoalbuminemia n=3 (13.0%), hypokalaemia n=3 (13.0%), hypomagnesaemia n=3 (13.0%)

## Non resolved TAEs

A total of n=4 patients reported TEAS that had not resolved at the data of cut-of. These TEAS were mild skin and liver GvHD and loose stools (n=1), GvHD in skin (n=3), epilepsy (n=1) and human rhino virus test positive (n=1)

## Severe TEAE

A total of 24 TEAEs were reported in 21 patients. The most frequently reported SOCs with 10 % of patients having reported severe TEAE were 'General disorders and administration site conditions', and 'Immune system disorders' (21.7% each), 'Infection and infestations' (17.4%), SOCs \"Injury,

<div style=\"page-break-after: always\"></div>

poisoning and procedural complications, \"Respiratory, thoracic and mediastinal disorders\" and \"Cardiac Disorders\" (13% each).

The most frequently reported severe post-conditioning AEs were related to HSCT failures (3 patients; 13%) or HSCT complications (3 patients, with engraftment syndrome or GVHD-related events). The 3 patients with graft failure/failure to engraft also experienced HLH reactivation (coded to the preferred term condition aggravated); all of them had a haplo-identical bone marrow transplant.

## Non resolved severe TEAEs

During the post-conditioning period, 14 severe TEAEs with an outcome not resolved were reported. All occurred in 4 patients who died either during conditioning (n=1) or after transplant (n=3).

## All other severe TEAEs resolved without sequela

The applicant has provided an overview of all on study AEs in the post-conditioning period. The reported TEAEs are similar to all on study AEs in the post conditioning period.

An overview of TEAES per system organ class is provided in Table 51 . No details on the occurrence of TEAEs by the preferred terms was provided.

Most mild and moderate TE-AEs resolved in both the pre and post conditioning period. Severe TE-AEs did not resolve in 56% in the preconditioning period and 52% in the post conditioning period.

Table 51 Treatment Emerging Adverse events by System organ class (NI-0501-04/05 analysis set)

| SOC , n (%)                                     | All treated               | All treated              |
|-------------------------------------------------|---------------------------|--------------------------|
|                                                 | preconditioning (n=34, %) | Post conditioning (n=23) |
| Blood and lymphatic system disorders            | 8 (23. 5)                 | 6 (26.1)                 |
| Cardiac Disorders                               | 7 (20.6)                  | 5 (21.7)                 |
| Ear and labyrinth disorders                     | 0                         | 1 (4.3)                  |
| Endocrine Disorders                             | 2 (5.9)                   | 2 (8.7)                  |
| Eye disorders                                   | 3 (8.8)                   | 2 (8.7)                  |
| Gastrointestinal disorders                      | 19 (55.9)                 | 11 (47.8)                |
| General disorders                               | 23 (67.6)                 | 18 (78.3)                |
| Hepatobiliary disorders                         | 7 (20.6)                  | 1 (4.3)                  |
| Immune system disorders system                  | 3 (8.8)                   | 10 (43.5)                |
| Infections and infestations                     | 19 (55.9)                 | 16 (69.6)                |
| Injury, poisoning and procedural complications  | 8 (23.5)                  | 5 (21.7)                 |
| Investigations                                  | 11 (32.4)                 | 8 (34.8)                 |
| Metabolism and nutrition disorders              | 9 (26.5)                  | 7 (30.4)                 |
| Musculoskeletal and connective tissue disorders | 5 (14.7)                  | 2 (8.7)                  |
| Neoplasms, benign, malignant and unspecified    | 1 (2.9)                   | 0                        |
| Nervous system disorders                        | 10 (29.4)                 | 5 (21.7)                 |
| Psychiatric disorders                           | 5 (14.7)                  | 3 (13.0)                 |
| Renal and urinary disorders                     | 6 (17.6)                  | 2 (8.7)                  |

<div style=\"page-break-after: always\"></div>

| Reproductive system and breast disorders       | 1 (2.9)   | 0         |
|------------------------------------------------|-----------|-----------|
| Respiratory thoracic and mediastinal disorders | 17 (50) 8 | (34.8)    |
| Skin and subcutaneous disorder 13 (38.2)       |           | 9 (39.1)  |
| Vascular disorders                             | 15 (44.1) | 11 (47.8) |

Notes: Data of both study NI-0501-04 and NI-050105 are included. If a patient experiences more than 1 event in a given SOC, that patients is counted once for the SOC. IF a patient experiences more than 1 event with a given preferred term, that patient is counted only once for that preferred term

## Drug related Adverse Events

## Pre-condition period study NI-0501-04/05

Eleven patients had at least 1 AE that was considered by the Investigator or by the Sponsor to be related to study drug (pre-conditioning: 10 patients, 29.4%; post-conditioning: 1 patient, 4.3%)Most these pre-conditioning adverse drug reactions (ADRs) were infusion related reactions (n= 9); either pyrexia or skin/subcutaneous tissue disorders. None of the cutaneous reactions and pyrexia AEs were severe or serious, all events resolved, and the subjects completed all infusions.

Two infections (disseminated histoplasmosis and necrotising fasciitis) were considered by the investigator as possible related. These were also severe SAEs. Both events resolved upon treatments. The applicant has disputed the possible relation with treatment for the case of necrotising fasciitis. It should be noted that necrotising fasciitis caused by Pseudomonas aeruginosa is exceptionally uncommon with only 12 cases reported in the literature (Lota 2010).

## Post condition period study NI-0501-04/05

One patient with positive mycobacteria test in urine and in a gastric aspirate was reported. The patient was asymptomatic, and the event assessed as mild and probably related to emapalumab treatment.

## Events in healthy volunteers

In the Phase 1 NI-0501-03 study, herpes zoster was reported as a (treatment related) SAE with a 14 days latency after emapalumab infusion (dose administered 3 mg/kg) in one healthy volunteer (). Based on this patient, at entry viral prophylaxis was required in study NI-0501-04/05. See also Safety in special populations.

## Adverse events of special interest

## Infectious AEs

## Infections at a baseline study NI 050104/05

Thirteen of 34 patients entered the study with ongoing infections (n=10) or positive microbiological results (n=3). Most of these infections resolved during the study. Infections present before the study that were ongoing at the time of death were bacterial carrier disease, CMV infection, a EBV infection (n=3), human metapneumovirus and a human rhino virus.

## Infections (emerging) in the preconditioning period

From the initiation of emapalumab treatment until start of HSCT conditioning, 19 of 34 patients (55.9%) reported at least one infection. The most frequently reported infections were viral infections (seen in n=14 patients, 41.2%), followed by bacterial (n=12, 35.3%) and fungal (n=3). Among the 11 infections reported as SAEs, eight SAEs were assessed as severe. In 10 of these 11 patients the SAEs of infection resolved. and 1 patient had a fatal SAE of septic shock (Ps. aeruginosa) found to be multidrug resistant.

<div style=\"page-break-after: always\"></div>

From the viral infections, CMV and EBV were most frequently observed. The bacterial infections most commonly reported were C. Difficile, E coli. K pneumonia Ps. Aeruginosa. All but 1 infection resolved: One patient developed a necrotizing fasciitis consequent to Ps. Aeruginosa skin infection; and one patient reported a systemic fungal infection to a Histoplasmosis, which leaded to the preliminary termination of emapalumab administration. (see also drug related AEs). These were also severe SAEs, but both events resolved upon treatments. Two patients had oral/oropharyngeal candidiasis. These fungal infections resolved.

## Infections in the post-conditioning period.

After the start of HSCT conditioning, infections were reported in 16 of 23 patients (69.6%). In half of these patients the infection was reported as an SAE. Among the 15 infections reported as SAEs, 4 were assessed as severe (2 septic shock, 1 pneumonia and 1 K. Pneumoniae sepsis). Three of them occurred in 2 patients with severe HSCT complications. The fourth infection occurred 4 weeks after HSCT in a patient who developed severe pneumonia following Ps. Aeruginosa bacteraemia; this infection recovered. All other serious infections (the majority of which were viral) recovered. No systemic fungal infection was reported.

## Infusion-related reactions

Up to 31 January 2018 a total of 694 infusions of emapalumab were administered in studies NI-050104/05. Overall, 9 (26.5%) patients had at least one IRR. On later case review, 1 of these 9 events (lymphadenopathy) was no longer considered an IRR and instead was reported as an event associated with necrotising fasciitis. The majority of the events occurred with the 1 st  infusion of emapalumab and were all assessed as of mild intensity, except for one event of moderate pyrexia.

All infusions were completed, and no patients discontinued treatment due to IRRs. Two infusions were temporarily stopped in 2 patients at the first signs of a cutaneous IRR. One patient was administered diphenhydramine at the first occurrence of a rash however no premedication or treatment was given for the subsequent infusions. There was no evidence of anaphylaxis or anaphylactoid reactions, and no delayed hypersensitivity reactions were seen. During the studies there was one report of anaphylaxis. This occurred shortly after the 3 rd  infusion of etoposide and 3 days after the 38 th  dose of emapalumab. and was considered related to etoposide.

In the NI-0501-03 study, 9 IRRs were reported by emapalumab subjects and 4 by subjects that received placebo. All IRRs were assessed as mild, except for one case of moderate pyrexia. Pyrexia was the only noticeable trend and is proposed for inclusion in section 4.8 of the SmPC.

## Serious adverse events and deaths

## Pre-conditioning

During the pre-conditioning period, in the NI-0501-04/05 analysis set a total of 21 (65.6%) patients experienced at least 1 SAE. Data on frequent TE-SAEs in the preconditioning period in CU and the Healthy volunteers is reported in Table 52.

In a total of n=7, the reported SAEs were considered as the direct cause of death; a total of n=3 patients had an SAE reported as not resolved; n=2 patients recovered from one SAE with sequela and n=1 had an SAE assessed as resolving.

The most frequently reported SAEs were condition aggravated in 5 patients (14.7%), gastrointestinal haemorrhage in n=3 patients (8.8%), and multiple organ dysfunction in 2 patients (5.9%) each.

<div style=\"page-break-after: always\"></div>

## Not resolved SAEs

A total on n=3 patients experience no resolved SAE during the preconditioning period gastrointestinal haemorrhage (recurrent episodes) (n=1), a severe acute kidney injury attributed to the nephrotoxicity of concomitant medications (antibiotics and cyclosporine) N=1) and a severe subdural hygroma (n=1). These SAEs were considered to be unrelated to emapalumab administration

## Recovered with sequela

A total of n=2 patients reported SAE with sequelae i.e. cerebral disorder which occurred after completion with emapalumab (n=1), and a spinal compression fracture (n=1). Both SAEs were considered to but unrelated to treatment.

## Post conditioning

In the NI-0501-04/05 analysis set, a total of 15 (65.2%) patients experienced at least 1 serious AE during the post-conditioning period. A total of n=2 patients had fatal SAEs, 2 patients were reported that has not resolved, 2 patients were reported having recovered from an SAE with sequela and one patient was reported being in recovery.

The most frequently reported SAEs were consistent with commonly HSCT-related events, e.g., acute graft versus host disease, engraftment syndrome, graft failure, infections.

## Non resolved SAEs

One patient had a severe acute GvHD in intestine (grade IV) associated with non-serious liver and skin GvHD of moderate intensity, another patient had a Klebsiella pneumonia.

## SAE resolved with sequelae:

A total of N=2 patients reported two SAEs (7.5%) were also assessed as resolved with sequela during or at the end of the follow-up. The reported SAE was septic shock (n=1) and one SAE of eye movement disorder.

Table 52 Serious Adverse Events Reported in at least 2 Patients Overall in the PreConditioning by Preferred Term- NI-0501-04/05 analysis set

| Preferred Term                      | NI-0501- 04/05 (N=34)   | NI-0501- 04/05/ pHLH CU (N=44)   | CU AII (pHLH and SHLH) (N=21)   | AII Patients (N=53)   |
|-------------------------------------|-------------------------|----------------------------------|---------------------------------|-----------------------|
| At Least One SeriousAE              | 21 (61.8)               | 28 (63.6)                        | 15 (71.4)                       | 35* (66.0)            |
| Condition aggravated                | 5 (14.7)                | 7 (15.9)                         | 5 (23.8)                        | 10 (18.9)             |
| Respiratory failure                 | 1 (2.9)                 | 3 (6.8)                          | 4 (19.0)                        | 5 (9.4)               |
| Gastrointestinal hemorrhage         | 3 (8.8)                 | 3 (6.8)                          | 0                               | 3 (5.7)               |
| Multiple organ dysfunction syndrome | 2 (5.9)                 | 2 (4.5)                          | 2 (9.5)                         | 3* (5.7)              |
| Septic shock                        | 1 (2.9)                 | 1 (2.3)                          | 2 (9.5)                         | 3 (5.7)               |
| Acute kidney injury                 | 1 (2.9)                 | 2 (4.5)                          | 2 (9.5)                         | 3 (5.7)               |
| Circulatory collapse                | 1 (2.9)                 | 2 (4.5)                          | 1 (4.8)                         | 2 (3.8)               |
| Pulmonary edema                     | 0                       | 0                                | 2 (9.5)                         | 2 (3.8)               |
| Pneumonia                           | 2 (5.9)                 | 2 (4.5)                          | 0                               | 2 (3.8)               |
| Haemorrhage intracranial            | 0                       | 2 (4.5)                          | 2 (9.5)                         | 2 (3.8)               |

* The number of patients is not the sum of the patients in NI-0501-04/05and CU patients as one patient than 30 days after last infusion of emapalumab in the NI-0501-04 study. However in pooled group the patient is counted once.

A summary of SAEs in NI-0501-04/05 analysis group is provided below ( Table 53 ).

<div style=\"page-break-after: always\"></div>

No data were provided on the resolving of treatment emerging SAEs with or without sequelae.

Table 53 Serious Adverse Events by System Organ Class and Preferred Term- NI-050104/05 analysis set -second line and first line all treated

|                                      | Pre-conditioning   | Pre-conditioning   | Pre-conditioning      | Post conditioning   | Post conditioning    | Post conditioning    |
|--------------------------------------|--------------------|--------------------|-----------------------|---------------------|----------------------|----------------------|
| SOC, n (%) preferred term            | First line (n=7)** | Second line (n=27) | All treated (n=34, %) | First line (n=3) ** | Secon d line (n=19 ) | All treate d (n=23 ) |
| At least 1 SAE                       | 4 (57)             | 17 (63)            | 21 (62)               | 2 (67)              | 13 (68)              | 15 (65)              |
| Blood and lymphatic system disorders | 0 (0)              | 1 (4)              | 1(3)                  | 0 (0)               | 2 (11)               | 2 (9)                |
| Haemolytic anaemia                   | 0 (0)              | 1 (4)              | 0 (0)                 | 0 (0)               | 2 (11)               | 2 (9)                |
| Lymphocytosis                        | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 0                    | 0 (0)                |
| Thrombotic micro-angiopathy          | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Cardiac                              | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 2 (11)               | 2 (9)                |
| Disorders                            |                    |                    |                       |                     |                      |                      |
| Cardiac tamponade                    | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Cardiopulmonary failure              | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Right ventricular dysfunction        | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Ear and labyrinth disorders          | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| eye movement disorders               | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Gastrointestinal disorders           | 1 (14)             | 3 (11)             | 4 (12)                | 0(0)                | 2(11)                | 2 (9)                |
| abdominal pain                       | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Gastro-intestinal haemorrhage        | 1 (14)             | 2 (7)              | 3 (9)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Inguinal hernia                      | 0 (0)              | 0 (0)              | 0                     | 0 (0)               | 1 (5)                | 1 (4)                |
| pneumotosis intestinalis             | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| General disorders                    | 2 (28)             | 5 (19)             | 7 (21)                | 1 (33)              | 4 (20)               | 5 (22)               |
| Condition aggravated                 | 2 (28)             | 3 (11)             | 5 (15)                | 1 (33)              | 1 (5)                | 2 (9)                |
| Multiple organ failure               | 1 (14)             | 2 (8)              | 2 (6)                 | 0 (0)               | 2 (11)               | 1 (4)                |
| Pyrexia                              | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 2 (11)               | 2 (9)                |
| Immune system disorders system       | 1 (14)             | 0 (0)              | 1 (3)                 | 1 (33)              | 2 (11)               | 3 (11)               |
| Acute graft versus host in intestine | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 2 (11)               | 2 (9)                |

<div style=\"page-break-after: always\"></div>

|                                                | Pre-conditioning   | Pre-conditioning   | Pre-conditioning      | Post conditioning   | Post conditioning    | Post conditioning    |
|------------------------------------------------|--------------------|--------------------|-----------------------|---------------------|----------------------|----------------------|
| SOC, n (%) preferred term                      | First line (n=7)** | Second line (n=27) | All treated (n=34, %) | First line (n=3) ** | Secon d line (n=19 ) | All treate d (n=23 ) |
| anaphylactic reaction                          | 1 (14)             | 0 (0)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (00                |
| Engraftment syndrome                           | 0 (0)              | 0 (0)              | 0 (0)                 | 1 (33)              | 1 (5)                | 2 (9)                |
| Infections and infestations                    | 3 (42)             | 8 (30)             | 11 (32)               | 0 (0)               | 8 (30)               | 8 (35)               |
| Injury, poisoning and procedural complications | 0 (0)              | 1 (5)              | 1 (3)                 | 1 (33)              | 2 (11)               | 3 (13)               |
| blood stem cell transplant failure             | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| engraft failure                                | 0 (0)              | 0 (0)              | 0 (0)                 | 1 (33)              | 1 (5)                | 2 (8)                |
| spinal compression fracture                    | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Investigations                                 | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Blood creatinine increased                     | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Metabolism and nutrition disorders             | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Hypokalaemia                                   | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Nervous system disorders                       | 1 (14)             | 2 (7)              | 3 (9)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Cerebral disorders                             | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| neurological decompensation                    | 1 (14)             | 0                  | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Seizure                                        | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| subdural hygroma                               | 1 (14)             | 0 (0)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Renal and urinary disorders                    | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| acute kidney injury                            | 0 (0)              | 1 (5)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Respiratory thoracic and mediastinal disorders | 1 (14)             | 4 (15)             | 5 (15)                | 1 (33)              | 2 (11)               | 3 (13)               |
| Acute respiratory distress syndrome            | 0 (0)              | 1 (4)              | 1 (3)                 | 1 (33)              | 0 (0)                | 1 (4)                |
| acute respiratory failure                      | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Aspiration                                     | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Pulmonary artery thrombosis                    | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Pulmonary hypertension                         | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Respiratory distress                           | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Respiratory failure                            | 1 (14)             | 0 (0)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |

<div style=\"page-break-after: always\"></div>

|                           | Pre-conditioning   | Pre-conditioning   | Pre-conditioning      | Post conditioning   | Post conditioning    | Post conditioning    |
|---------------------------|--------------------|--------------------|-----------------------|---------------------|----------------------|----------------------|
| SOC, n (%) preferred term | First line (n=7)** | Second line (n=27) | All treated (n=34, %) | First line (n=3) ** | Secon d line (n=19 ) | All treate d (n=23 ) |
| Vascular disorders        | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 1 (5)                | 1 (4)                |
| Circulatory collapse      | 0 (0)              | 1 (4)              | 1 (3)                 | 0 (0)               | 0 (0)                | 0 (0)                |
| Hypertension              | 0 (0)              | 0 (0)              | 0 (0)                 | 0 (0)               | 1 (5)                | 1 (4)                |

Notes: For patients who entered Study NI-0501-05, SAEs observed while on the 05 study are included. [1] If a patient experienced more than 1 event in a given SOC, that patient is counted once for the SOC in that column. If a patient experienced more than 1 event with a given preferred term, that patient is counted only once for that preferred term in that column. [2]

## Deaths

As of the database cut-off date of 20th July 2017, 10 of 34 patients in the NI-0501-04/05 studies died.

A total of n=8 deaths occurred prior conditioning/HSCT and 2 after conditioning/HSCT. Between 20 July 2017 and 31 January 2018 two additional patients had a fatal outcome, one prior and one after conditioning/HSCT.

## Prior to HSCT

A total of N=9 patients died prior to the performance of HSCT. The most frequent cause of death were multi-organ dysfunction syndrome (n=3, 33%) and respiratory disorders (n=3, 33%) ( Table 54 ). In most patients, at the time of death, the HLH had worsened and may have contributed to the fatal outcome.

In a total of n=5, an ongoing infection was reported at the time of death. In most patients, refractory HLH contributed to the death. Most infections were of viral origin (EBV, CMV, adeno infections, parainfluenza), while bacterial causes were linked to pseudomonas or enterococci infection.

## Post conditioning period

In the post HSCT period, a total on n=3 patients died. Causes of death were related to HSCT failure (engraftment failure, GvHD). Additional contributing factors to death were an ongoing infection (n=2, Klebsiella pneumonia, CMV pneumonitis), and reactivation of the HLH (n=1).

<div style=\"page-break-after: always\"></div>

Table 54 Listing of Adverse Events with a Fatal Outcome (NI-0501-04/05 analysis set)

| HLH genetic confirmation                        | Event preferred term                                     | Time of onset since first emapalumab infusion (days)   | Time of death from onset of the event   |
|-------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------|-----------------------------------------|
| GS-2                                            | Septic shock                                             | 3 (pre-HSCT)                                           | Same day of the event                   |
| FHL1                                            | Gastrointestinal haemorrhage                             | 20 (pre-HSCT)                                          | 14 days                                 |
| None (NK-T cell lymphoma diagnosed post-mortem) | Multi-organ dysfunction syndrome                         | 34 (pre-HSCT)                                          | 3 days                                  |
| FHL3                                            | Multi-organ dysfunction syndrome                         | 51 (pre-HSCT)                                          | 26 days                                 |
| FHL5                                            | Acute respiratory distress syndrome Circulatory collapse | 61 (pre-HSCT) 95 (pre-HSCT)                            | 35 days Same day of the event           |
| FHL2                                            | Neurological decompensation                              | 126 (pre-HSCT)                                         | 7 days                                  |
| FHL3                                            | Respiratory failure                                      | 169 (pre-HSCT)                                         | 13 days                                 |
| None                                            | Multi-organ dysfunction syndrome and septic shock        | 115 (D+44 post-HSCT)                                   | 4 days                                  |
| FHL2                                            | Acute respiratory failure                                | 145 (D+65 post-HSCT)                                   | 4 days                                  |
| FHL2                                            | HLH                                                      | pre HSCT                                               |                                         |

*This death was reported after the database cut-off date of 20th July 2017.

CU=compassionate use; HLH=primary haemophagocytic lymphohistiocytosis; HSCT=haematopoietic stem cell transplantation; ** Added by assessor

Transplant/ infection related mortality at one year is 0.11 in the second line patients (event rate 2 (10.5%) patients).

## Updated data on deaths

In the updated data on NI-0501-04/05 study, n=15/45 (10 pre-HSCT, 5 post-HSCT) fatal cases were reported, of which 5 deaths occurred after the cut-off date of 20-July-2017. In the NI-0501-09 study 4/15 fatal cases (3 pre-HSCT, 1 post-HSCT) occurred prior to the cut-off date (24-Nov-2019) and 3/21 additional fatal events reported after the cut-off date. In all cases, the fatal events and other associated SAEs were assessed as not related to the use of emapalumab.

It is somewhat reassuring that no fatal cases were reported in the ongoing study NI-0501-06 in 9 patients with sHLH due to sJIA/MAS, however differences in disease between pHLH and sHLH should be considered.

<div style=\"page-break-after: always\"></div>

The most important causes for death in the NI-0501-09 and NI-0501-04 studies were multiple organ dysfunction syndrome or acute respiratory failure concurrent to infection or to HLH worsening or after HSCT. Also grade 5 haemorrhages and post-transplant complications were frequently seen. These causes appear to correspond to what can be expected for a pHLH population, however, the single arm trial in this very sick, co-medicated population does not allow to exclude whether emapalumab could have played a contributory role to these deaths.

## Deaths in historical control study

Whilst safety data were not collected systematically in the 72 patients in the historical control group, safety data was available with regards to causes of death in all but 4 patients. The most frequent causes of death were related to HLH progression and/or organ failure, which accounted for 74% of the deaths for which information was available in HCs (versus 60% in the Study NI-0501-04/05). Fatal infections were reported as cause of death in 4 patients. Death caused by haemorrhagic event was reported in 1 of HCs (pulmonary).

## Laboratory findings

The applicant has presented the haematology parameters and chemistry laboratory values as median worst/highest Post-Baseline values.

## Haematology, chemistry (including renal function test)

Investigators were requested to not report any emerging haematological abnormality or worsening related to the studied disease (HLH). The mean changes from baseline over time in haematology parameters were considered to generally reflect the underlying disease and the concomitant treatments commonly administered. No safety concerns were identified upon administration of emapalumab for haematology laboratory findings. According to the applicant there were no consistent, directional changes in chemistry laboratory values.

No change observed in creatinine or urea led to treatment discontinuation or change in dose or dosing interval for patients of the NI-0501-04/05 group. Three patients in CU developed renal failure while receiving emapalumab. They all required haemofiltration or haemodialysis; according to the investigators no renal failure was related to emapalumab and the administration of emapalumab was continued with no change in treatment regimen during the procedures. One patient recovered did not recover and died from another cause.

## Liver function test

During treatment, shifts in transaminases (more often ALT than AST) were seen towards worse high values. ( Table 55 Table 56 Table 57 ).

Table 55 Clinical Laboratory Shifts of Alanine Aminotransferase (ALT) Values from Baseline to Worst High On-Treatment and to End of Treatment (NI-0501-04/05 analysis set)

| Baseline Category   |                  | Worst High On-Treatment   | Worst High On-Treatment   | Worst High On-Treatment   | Worst High On-Treatment   |
|---------------------|------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| ALT                 | Total            | ≤ 2.6 xULN                | >2.6 to ≤5 xULN           | >5.1 to ≤20 xULN          | >20xULN                   |
| ≤ 2.6 xULN          | 24               | 8 (33.3)                  | 5 (20.8)                  | 7 (29.2)                  | 4 (16.7)                  |
| >2.6 to ≤5 xULN     | 4                | 0                         | 2 (50.0)                  | 1 (25.0)                  | 1 (25.0)                  |
| >5.1 to ≤20 xULN    | 5                | 0                         | 0                         | 4 (80.0)                  | 1 (20.0)                  |
| >20 xULN            | 0                | 0                         | 0                         | 0                         | 0                         |
| Missing             | 1                | 0                         | 0                         | 0                         | 1 (100.0)                 |
|                     | End of Treatment | End of Treatment          | End of Treatment          | End of Treatment          | End of Treatment          |
| ≤ 2.6 xULN [1]      | 24               | 19 (79.2)                 | 2 (8.3)                   | 2 (8.3)                   | 0                         |
| >2.6 to ≤5 xULN     | 4                | 4 (100.0)                 | 0                         | 0                         | 0                         |

<div style=\"page-break-after: always\"></div>

| >5.1 to ≤20 xULN [1]   |   5 | 2 (40.0)   |   0 |   2 (40.0) |   0 |
|------------------------|-----|------------|-----|------------|-----|
| >20 xULN               |   0 | 0          |   0 |          0 |   0 |
| Missing                |   1 | 1 (100.0)  |   0 |          0 |   0 |

ULN = Upper Limit Normal.

Note: N (%) is given. Subject is only counted once in the worst category for criteria with different cutoffs.

Denominator is number of subjects satisfying the particular baseline criteria with non-missing measurement.

[1] Post-baseline value missing for 1 patient

Table 56 Clinical Laboratory Shifts of Aspartate Aminotransferase (AST) Values from Baseline to Worst High On-Treatment and to End of Treatment (NI-0501-04/05 analysis set)

| Baseline Category    |                  | Worst High On-Treatment   | Worst High On-Treatment   | Worst High On-Treatment   | Worst High On-Treatment   |
|----------------------|------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| AST                  | Total            | ≤ 2.6 xULN                | >2.6 to ≤5 xULN           | >5.1 to ≤20 xULN          | >20xULN                   |
| ≤ 2.6 xULN [1]       | 25               | 15 (60.0)                 | 5 (20.0)                  | 3 (12.0)                  | 1 (4.0.7)                 |
| >2.6 to ≤5 xULN      | 3                | 0                         | 0                         | 3 (100.0)                 | 0                         |
| >5.1 to ≤20 xULN     | 5                | 0                         | 0                         | 4 (80.0)                  | 1 (20.0)                  |
| >20 xULN             | 0                | 0                         | 0                         | 0                         | 0                         |
| Missing              | 1                | 0                         | 1 (100.0)                 | 0                         | 0                         |
|                      | End of Treatment | End of Treatment          | End of Treatment          | End of Treatment          | End of Treatment          |
| ≤ 2.6 xULN [1]       | 25               | 22 (88.0)                 | 2 (8.0)                   | 1 (4.0)                   | 0                         |
| >2.6 to ≤5 xULN [2]  | 3                | 2 (66.7)                  | 0                         | 0                         | 0                         |
| >5.1 to ≤20 xULN [2] | 5                | 3 (60.0)                  | 1 (20.0)                  | 0                         | 0                         |
| >20 xULN             | 0                | 0                         | 0                         | 0                         | 0                         |
| Missing              | 1                | 1 (100)                   | 0                         | 0                         | 0                         |

ULN = Upper Limit Normal

Note: N (%) is given. Subject is only counted once in the worst category for criteria with different cut-offs.

Denominator is number of subjects satisfying the particular baseline criteria with non-missing measurement

[1] Post-baseline value missing for 1 patient

[2] End of Treatment value missing for 1 patient

Table 57 Clinical Laboratory Shifts of Total Bilirubin Values from Baseline to Worst High OnTreatment and to End of Treatment (NI-0501-04/05 analysis set)

| Baseline Category   |                  | Worst High On-Treatment   | Worst High On-Treatment   | Worst High On-Treatment   | Worst High On-Treatment   |
|---------------------|------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Total Bilirubin     | Total            | ≤ 1.5 xULN                | >1.5 to ≤3 xULN           | >3 xULN                   | Missing                   |
| ≤ 1.5 xULN          | 26               | 19 (73.1)                 | 4 (15.4)                  | 2 (7.7)                   | 1 (3.8)                   |
| >1.5 to ≤3 xULN     | 3                | 1 (33.3)                  | 1 (33.3)                  | 1 (33.3)                  | 0                         |
| >3 xULN             | 4                | 0                         | 0                         | 4 (100.0)                 | 0                         |
| Missing             | 1                | 0                         | 0                         | 0                         | 1 (100)                   |
|                     | End of Treatment | End of Treatment          | End of Treatment          | End of Treatment          | End of Treatment          |
| ≤ 1.5 xULN          | 26               | 23 (88.5)                 | 1 (3.8)                   | 0                         | 2 (7.7)                   |
| >1.5 to ≤3 xULN     | 3                | 3 (100.0)                 | 0                         | 0                         | 0                         |
| >3 xULN             | 4                | 0                         | 0                         | 3 (75.0)                  | 1 (25.0)                  |
| Missing             | 1                | 0                         | 0                         | 0                         | 1 (100)                   |

ULN = Upper Limit Normal.

Note: N (%) is given. Subject is only counted once in the worst category for criteria with different cut-offs.

Denominator is number of subjects satisfying the particular baseline criteria with non-missing measurement

The 4 patients with bilirubin levels &gt;3xULN at baseline had either very severe/refractory HLH (Patients) or a fulminant Pseudomonas sepsis (). Four patients had a 3-shift ALT increase resulting in ALT values greater than 20x ULN; probably related to veno-occlusive disease (n=1), or the concomitant administration of fluconazole (n=2).

<div style=\"page-break-after: always\"></div>

No change ALT, AST or bilirubin change has been related to emapalumab administration. No action has been taken about emapalumab treatment (drug withdrawal, drug decrease or elongation of the interval of administration).

## Vital signs and physical findings

In the NI-0501-04/05 studies in patients (and also in the NI-0501-03 study in healthy volunteers) some elevations in temperature were seen and AEs of pyrexia reported with a temporal relationship to emapalumab infusion. A blinded central review of the ECG recordings performed in the NI-0501-04/05 studies was undertaken by CardiaBase (France). The safety ECG report concluded that there were no relevant changes for the ECG intervals of interest (HR, QRS, PR, QTcF) after IV administration of emapalumab and no relevant changes were obvious from the categorical analysis or from the analysis of treatment-emergent morphological abnormalities after 1 dose or multiple doses of emapalumab.

Data from healthy volunteers showed that emapalumab might induce a trend in increase of temperature, with associated increase in heart rate. This might also have occurred in the patients but may be masked by the disease.

## Updated safety data from ongoing clinical studies

The applicant provided additional safety data up to the cut-off date of 24-Nov-2019 from an additional 11 patients in the NI-0501-04 study (N=45) and at Day 180. A short summary of a total of N=22 patients in the NI-0501-09 study was also provided. The latter study included a similar population as the NI-0501-04 study population. These additional data appear similar to what was previously reported.

A brief summary of additional safety data of n=14 was also collected from the single arm trial in patients with secondary HLH (sHLH), NI-0501-06. As stated by the applicant, the safety in this population was similar to what was previously reported.

The safety database has thus been enlarged beyond the original 34 patients and now includes just over 80 patients in clinical trials supported by N=17 patients in CU and N=14 healthy volunteers.

## Safety in special populations

pHLH is mainly a paediatric disease with a peak incidence of diagnosis between 1 and 6 months of age. Sporadic cases of FLH in older patients have been reported. The oldest reported patients to data are a Spanish man of 49 years-old and a 62 years-old Japanese man [Sieni 2014]. The disease is rare and even rarer in patients ≥ 65 years. No data in adults was presented by the applicant and this is accepted considering the disease epidemiology.

The data from CU, presented as supportive data, and data from trials in healthy volunteers are reported below.

## Intrinsic factors

No clinically relevant differences were seen in the incidence of AEs, SAEs, infection-related AEs, or IRRs for subgroups defined by age, race, gender, and geographic region (US/EU).

## Use in pregnancy and lactation

Primary HLH mostly occurs in infancy and early childhood. No clinical data on exposure in pregnancy or lactation is available for emapalumab.

<div style=\"page-break-after: always\"></div>

## Overdose

At least two patients were unintentionally overdosed. Daily doses of emapalumab up to 10 mg/kg have been given in clinical studies with no dose-limiting toxicity. The dose of emapalumab at which severe toxicity occurs is not known.

## CU

A total of n=21 patients entered CU, n=10 pHLH and n=11 sHLH. Four patients from CU were also in the NI-0501-04/05 analyses set. To consider the outcomes of CU as supportive of study NI-050104/05, there should be no overlap between the populations of the CU and pivotal study.

Further, the applicant indicates that the pHLH CU group includes n=10 patients, but it appears that n=2 patients were not treated (based on efficacy report).The inclusion of patients that were not treated to the safety database for CU (CU All) is not supported, as this will dilute the frequency of the adverse events. Also note that the number of patients with sHLH which were treated with emapalumab is n= 9, instead of 11 reported below.

A brief summary of AEs in CU is provided here. Data from pHLH patients from CU that were treated with emapalumab, but not in the context of study NI-0501-04/05 have not been provided.

None of the patients treated in CU had an AE assessed as related to emapalumab by the treating physician. A total of n=15 (71%) patients experienced an SAE. Among the pHLH patients, the most frequently reported SAE was condition aggravated (n=3, 27%), respiratory failure (n=2, 18%), and septic shock (n=2, 18%). SAEs leading to death occurred in 10 patients; including a total of 4 of the 8 treated pHLH patients (50%). The reasons for death in the pHLH were brain injury (n=1), respiratory failure (n=1), bronchopulmonary dysplasia (n=1) and condition aggravated (n=1).

Table 58 Listing of Adverse Events Leading to a Fatal Outcome in CU Patients

| Primary or secondary HLH   | Event preferred term                                                         |   Time of onset since first emapalumab infusion (days) | Time of death from onset of the event   |
|----------------------------|------------------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------|
| pHLH                       | Brain injury                                                                 |                                                      6 | On the same day of the event            |
| pHLH                       | Respiratory failure (suspected by progressive pneumothorax and barotrauma)** |                                                      1 | 10 days                                 |
| pHLH                       | Bronchopulmonary dysplasia                                                   |                                                     74 | 20 days                                 |
| pHLH                       | Condition aggravated Circulatory collapse                                    |                                                     13 | 2 days                                  |

** added by the assessor

Note that one patient had developed respiratory failure due to a pseudomonas sepsis. In the CSR it is reported that patient F or G was reported diagnosed with NK-T cell lymphoma post-mortem and is mentioned as death in the NI-0501-04/05 analysis set

<div style=\"page-break-after: always\"></div>

## Infections at start of the study

In the CU population, one patient was diagnosed with Trichosporon fungemia 1 week after starting emapalumab treatment. This event was considered to be serious and of severe intensity and resolved after approximately 3 months. Most of the 17 patients who received emapalumab in CU had an ongoing infection at start of therapy. A CMV and/or EBV infection was present in 3 patients; these infections resolved except the EBV infection in the patient diagnosed with Trichosporon fungemia.

## Infections in the Pre-conditioning period

Seven of the CU patients developed an infection that was considered as a serious event. They all resolved, but 2 who developed a septic shock following Candida Kefyr fungemia and a septicemia due to Pseudomonas Aeruginosa. None of these infections were reported as related to emapalumab administration.

## Infections in the Post-conditioning period

In CU patients no viral or fungal infections were reported as SAEs post-conditioning. Bacterial infections were reported in 3 patients and all resolved, but one, a septic shock after Ps. Aeruginosa sepsis, in a patient who had a disease reactivation post HSCT and a secondary graft failure resulting in death during the conditioning regimen for a second transplant. None were considered related to emapalumab.

## Healthy volunteers

Study NI-0501-03 was a Phase 1, randomised, double-blind, placebo-controlled, single-ascending dose study in 20 healthy adult volunteers, with a total of 14 subjects who received emapalumab at doses of 0.01 mg/kg (3 subjects), 0.1 mg/kg (3 subjects), 1 mg/kg (4 subjects), and 3 mg/kg (4 subjects) and 6 subjects who received placebo.

A total of 41 TEAEs were observed in 14 out of 20 subjects (70%), 10 of which were reported by 4 subjects having received placebo. Thirty-six (87.8%) of TEAEs were of mild intensity and 5 (12.2%) were of moderate intensity. No TEAEs of severe or life-threatening intensity were reported. The investigators considered 23 TEAEs (56.1%) in 10 of the 14 subjects who reported such events as being drug-related (at least with a reasonable possibility). AEs reported in &gt;1 subject treated with emapalumab included headache (n=4), pyrexia (n=3), viral and non-viral upper respiratory tract infection (n=2) 0 and myalgia (n=2). No deaths were reported in the NI-0501-03 single dose study in healthy volunteers.

## SAE

One patient experienced a herpes zoster infection. In the Phase 1 NI-0501-03 study, herpes zoster was reported as an SAE with a 14 days latency after emapalumab infusion (dose administered 3 mg/kg) in one subject . The subject was treated with oral acyclovir for 10 days. The infection had a normal course and resolved.

This AE is considered treatment related. After this AE, all patients in the NI-0501-04/05 viral prophylaxis at entry was required in study NI-0501-04/05.

## Laboratory parameters

There was a transient rise from baseline in mean level of neutrophils, total white cell count, CRP and fibrinogen from Day 2, in the 1 mg/kg and/or the 3 mg/kg emapalumab groups, with levels returning close to baseline within a few days for haematology parameters and within 2 weeks for the biochemistry parameters.

<div style=\"page-break-after: always\"></div>

## Vital signs

In the NI-0501-03 study, some elevations in temperature were seen and AEs of pyrexia reported with a temporal relationship to emapalumab infusion. An isolated case of non-sustained ventricular tachycardia was reported and was considered mild in intensity. This event occurred 8 hours after the start of infusion and was captured on the continuous ECG monitoring. The event was very transient (10 beats), self-terminating with no intervention and the subject reported no symptoms. All previous and subsequent ECGs for this subject were normal, and no abnormal vital signs were recorded. Additional cardiology investigations of this subject revealed no further abnormalities. No other ECG abnormalities seen in this study.

## Immunological events

At the cut-off date of 31 January 2018, a total of 4 patients (3 patients in NI-0501-04/05 studies and 1 patient treated in CU) out of 52 exposed to emapalumab and tested for ADA have shown at least one positive result during the systematic search for anti-emapalumab antibodies.

Transient effects on emapalumab exposure were seen in both of these patients, but there was no correlation with the treatment outcome since both patients had a complete response. Also, no apparent effect on safety could be detected.

For none of these 4 patients the positive testing of ADA changed the efficacy or safety of emapalumab or had impact on their pharmacokinetics profile. These patients were found to have no particular common features enabling the characterisation of a subpopulation with a higher risk of developing ADA.

## Table 59 ATA positive and response to treatment initial two patient with ADA

| PatientNunber   | ReponsetoEmapalumah                                                                                                                                                                                                |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 | Partal response at E0T in N1-0501-04 (Day 62) Complete respome at E0T in NI-0501-05 (Day 242) Complete respone based on mormalization of all HLH clhmical and laboratory sbnormalities and no disease reactivation |

[1] Firs-line HLH patient enralled in the NI-0501-04 shudy and who contimaed emapalwmab treatment in te NI-050l-05 shudy. Ths pahent was positive for nevhalizng antibodies.

[2] Secondary HLH patiemt treated in CU.

EOT =end-of-hreatment; HLH = hemophagocytic lymphohistiocytosi.

## Safety related to drug-drug interactions and other interactions

The potential for emapalumab to interact with the cytochrome P450 enzyme system or P-glycoprotein transport system has not been evaluated.

The applicant has not reported any safety experience obtained from concomitant medicinal use. the description of interactions appears sufficient.

## Discontinuation due to AES

## Study NI 501-04/05

Two patients had an AE leading to treatment withdrawal.

- One patient developed disseminated histoplasmosis 33 days after emapalumab initiation. Histoplasma infection was not ruled out prior to emapalumab initiation. The infection resolved with adequate antifungal therapy.

<div style=\"page-break-after: always\"></div>

- The second patient was diagnosed with HLH worsening and required the administration of etoposide and was therefore withdrawn from the study.

•

## CU and healthy volunteers

An additional sHLH patient treated in CU was discontinued to allow the administration of another investigational drug, while presenting with multi-organ failure in the context of a refractory HLH after 46 days of emapalumab treatment. This AE was not considered by the Investigator as being related to treatment. No subject discontinued treatment in the single dose healthy volunteer study NI-0501-03.

## AEs of specific interest

Based on the mechanism of action of emapalumab, the risk of infections caused by pathogens favoured by IFNγ neutral isation might be increased. In clinical package, two probably related cases have been described, one case of herpes zoster in a healthy volunteer NI-0501-03, and one case of disseminated histoplasmosis occurred in a patient with latent disease.

An additional case of necrotizing fasciitis by pseudomonas aeruginosa was considered treatment related by the investigator but not by the applicant.

All three events resolved after appropriate treatment.

## Comparison between the observed safety profile with emapalumab and reported safety profile with current standard of care focusses on etoposide

Safety data published on the experience gathered with standard of care in HLH are limited in the literature, as only 2 investigator, prospective studies are published. These studies were not aimed at obtaining marketing authorisation of the drugs investigated for the treatment of pHLH and so adverse events were not systemically collected. Furthermore, as the drugs used to treat HLH are not approved for the treatment of this disease, no information on the use of these drugs in pHLH patients is reported in the prescribing information.

The toxicity of etoposide is mainly related to myelosuppression and associated neutropenia, which makes patient vulnerable to infections. As emapalumab is a full antibody targeting IFNy, the use of emapalumab may results in an impaired IFN-Y function. In humans, deficiencies that result in decreased IFNγ production or signalling lead to selective susceptibility to a number of intracellular organisms like mycobacteria, Histoplasma, Salmonella, Shigella, Camplybacter, Leishmania or Salmonella infections.

An overview of the key toxicities associated with the use of etoposide, etoposide in the proposed target population, and the known toxicity of emapalumab is provided in Table 60.

<div style=\"page-break-after: always\"></div>

Table 60 Summary overview of key risks associated with the use of etoposide

|                  | Etoposide                                                                                              | Etoposide                                                                                                                                                                                                                                                                                                                                                                                                                       | Emapalumab                                                                                                                                                                                                                                                                                             |
|------------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | SmPC/other                                                                                             | HLH-94/2004studies                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                        |
| Myelosuppression | Very common; Leukopenia 91%, severe leukopenia (<1000 cells/mm3) in 17%, dose limiting, might be fatal | HLH-94: not described. Reference to neutropeniaasa major toxicity due to pre-BMT therapy, in particular during the first 2 months. HLH-2004: treatment toxicity was implicated in occurrence of infections and bleedings (thrombocytopenia) in the context of fatal outcomes.                                                                                                                                                   | No immunotoxicity observed in toxicity studies. No indication of myelotoxicity or effects on blood cells was identified in pivotal study                                                                                                                                                               |
| Infections       | Common,notfurther specified (etoposide SmPC)                                                           | HLH-94: described only in the context of HSCT-associated fatal outcomes including CMV infection in 5 patients, sepsis/septicaemia in 3 patients and 1 EBV driven lymphoproliferative disorder. HLH-2004: cause of death was provided for 7 patients who died early in the treatment due to septicaemia, infections and/or bleedings, possibly related to treatment toxicity. 1 patient discontinued etoposide due to infection. | 56%of patients enrolled in the pivotal study experienced infection; with exception of 2, all reported as unrelated. Infections caused by pathogens favored by IFNy neutralization. Hiosoplasmosis disseminated and herpes zoster was reported in 1 patient each, resolved after appropriate treatment. |

|                    | Etoposide                                                                                                                                                                                                                                              | Etoposide                                                                                                                                       | Emapalumab                                                                                                                                                             |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                    | SmPC/other                                                                                                                                                                                                                                             | HLH-94/2004studies                                                                                                                              |                                                                                                                                                                        |
| Liver toxicity     | ALT, AST, AP, bilirubin increased and hepatotoxicity, very common. Hepatic function monitoring in patients with liver impairment is recommended (etoposide SmPC) Reports of liver toxicity and severe hepatocellular injury (King 2001, LiverTox 2018) | HLH-2004:3 hepatobiliary SAEs of grade Ill and IV related to etoposide were reported during the study.                                          | No signal of liver toxicity observed in emapalumab studies                                                                                                             |
| Hypersensitivity   | Anaphylactic-type reactions reported in 3% in clinical trials, sometimes fatal (etoposide SmPC)                                                                                                                                                        | Not described                                                                                                                                   | Only mild to moderate IRRs were observed in 27% of patients No events of anaphylaxis and anaphylactoid reactions, and delayed hypersensitivity reactions were observed |
| Secondary leukemia | Acute leukaemia commonly observed (etoposide SmPC)                                                                                                                                                                                                     | 2 cases of AML occurred in patients participating in HLH-94 and LHL-2004 studies; after 2 years in 1 patient who received etoposide for 3 weeks | Not observed                                                                                                                                                           |
| Interactions       | Interactions with high dose cyclosporin and anti-epileptic medications (etoposide SmPC).                                                                                                                                                               | Not described                                                                                                                                   | Not observed Potential for pharmacodynamic interaction with substrates of CYp450 with narrow therapeutic index.                                                        |

<div style=\"page-break-after: always\"></div>

|                                       | Etoposide                                                                                                                                                                                                                                               | Etoposide          | Emapalumab                                                                                                                                                     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                       | SmPc/other                                                                                                                                                                                                                                              | HLH-94/2004studies |                                                                                                                                                                |
| Use with vaccines                     | Increased risk of fatal systemic vaccinal disease with the use of yellow fever vaccine, Live vaccines are contraindicated in immunosuppressed patients (etoposide SmPC)                                                                                 | Not described      | No data available. Live vaccines (such as Bacillus of Calmette and Guerin (BCG)) or attenuated live vaccines should not be given concurrently with emapalumab. |
| Mutagenicpotential                    | In animal studies, etoposide administered during organogenesis caused maternal toxicity. embryotoxicity and teratogenicity. Etoposide may damage spermatozoa and testicular tissue resulting in possible genetic foetal abnormalities (etoposide SmPC). | Not described      | In animal studies with emapalumab, no signal of maternal embryo-foetal toxicity and no effects on fertility. reproduction or development have been observed.   |
| Cardiovascular toxicity (hypotension) | Hypotension due to rapid i.v.injection has been reported, common (etoposide SmPC)                                                                                                                                                                       | Not described      | Not cases of hypotension reported during the treatment with emapalumab                                                                                         |
| Alopecia                              | Allopecia occurred in 33% of patients in patients receiving monotherapy at doses > 450 mg/m²(etoposide SmPC)                                                                                                                                            | Not described      | Not observed                                                                                                                                                   |

Note the emapalumab population includes a total of n=51 patients

## Post marketing experience

To  date,  102  patients  have  been  treated  in  the  US  following  FDA  approval  and  post-marketing surveillance. As stated by the applicant, the safety profile of this population is in line with previously reported and this new data has not revealed any additional safety concerns with the use of emapalumab in primary HLH (cut-off 19 May 2020).

## 3.3.1. Discussion on clinical safety

The pivotal safety data set is derived from 34 patients in the open-label uncontrolled studies NI-050104/05. During the application the applicant provided additional safety data up to the cut-off date of 24Nov-2019 from an additional N=11 patients in the NI-0501-04 study. The applicant also provided a short summary of the safety data in a total of N=22 patients in the NI-0501-09 study, in a similar population as the study NI-0501-04 population, and a short summary for N=14 patients obtained in study NI-0504-06 obtained in secondary HLH population. The total number of safety data derived from clinical trials is N=81 patients. These data indicate a similar safety profile to what is reported here for the primary safety dataset.

Supportive data is available from an additional 17 patients who received emapalumab in compassionate use in which a limited amount of data was collected (fatal events, SAEs and related AEs). The only controlled safety data available is from 14 healthy volunteers treated with a single dose of emapalumab in the NI-0501-03 study, of whom 8 received doses within the proposed therapeutic range (1 and 3 mg/kg). According to the applicant this dataset is supported by a post marketing US data obtained in n=102 patients which does not raise new safety concerns. Safety data available from the historical control cohort is limited to the causes of death reported.

The safety profile of emapalumab is mainly established in a single arm trial in patients with pHLH, a very sick, paediatric population. pHLH is variable disease showing a large disease heterogeneity both

<div style=\"page-break-after: always\"></div>

between patients as well as that symptoms waxes and wane over time. The disease is characterised with haematological signs and symptoms and with liver function abnormalities. Many patients are exposed to co- medications, and therefore, adverse events (AEs) might be obscured. The obtained safety database is small and lacks a comparison of a control arm with the current standard of care like intensification of therapy, the addition of alemtuzumab, anakinra or ATG. Due to the above considerations, it is difficult to interpret the observed safety profile as being related to emapalumab.

The database on primary safety analysis has a data cut of 20 July 2017. Updated safety data (24 Nov 2019) aligns with this safety base, and the remaining section of discussion is based on the pivotal dataset as the data could not be properly integrated.

## Exposure:

The pivotal safety data set is based the N=34 patients included in the pivotal study NI-0501-04/05 with a median follow up of 11 months (min 0.1 max 20.9 months) at the cut of data of 20 July 2017.

The total number of patients exposed was small and the duration of exposure was short for most subjects. The short duration of exposure can be accepted for now since emapalumab is not intended for chronic treatment in pHLH patients (these patients should precede to HSCT), however relatively long-term treatment might be envisaged for subjects not (yet) eligible for HSCT. A total of n=9 patients received treatment beyond 16 weeks because of the lack of available donor. One patient, without a genetic confirmation of pHLH, achieved a sustained control of pHLH and HSCT was not deemed necessary.

From a PK perspective, the dosing regimen is not considered suitable for patients with low IFNγ concentrations, as there is a potential for accumulation. The impact of this accumulation on the safety of the product is unknown. This remains an uncertainty, as a comparison of safety between subjects at risk of accumulation (low/normal IFNγ) and those in which accumulation is not as likely is not informative because of the limited patient numbers and the potential for confounding by indication.

The maximum dose given during the trial is 10 mg/kg which is also the maximal recommended dose in the SmPC. However, only few patients (n = 10 and n=5) were treated with doses of 6 and 10 mg/kg. Patients with a body weight &lt; 3 kg were excluded from the clinical studies because to protocol sampling procedures. A total of N=2 patients with a body weight &lt; 2 kg were treated in CU. The data obtained in patients with a body weight &lt; 2 kg is limited.

## AE profile:

AEs were reported according to modified WHO toxicity scale (a 3-point scale; mild, moderate, severe). Safety results were presented before (pre-conditioning period, n=34) and after start of conditioning/HSCT (post-conditioning period, n=23). There are multiple factors that differ between the pre- and post-conditioning treatment (e.g. emapalumab administration, the activity of HLH and the conditioning regimen). This makes it hard to determine if a difference in AEs pre and post-conditioning might be due to the emapalumab administration, HLH disease or other factors. Many differences might be attributed to HLH activity, co-medications, concomitant disease. The patient numbers are low and the lack of comparative data precludes definitive conclusions.

The most commonly observed treatment emerging AEs in the pre-conditioning period were condition aggravated (includes HLH reactivations, HLH flare or HLH worsening; in 50% of the patients), hypertension (41%) and pyrexia (24%). In addition, when all on-study AEs are counted, infections (56%) and infusion-related reactions (27%) are also frequently observed. Frequently observed severe treatment emerging AEs (overall, 53% of the patients) included condition aggravated (11.8%),

<div style=\"page-break-after: always\"></div>

gastrointestinal haemorrhage (8.8%), respiratory failure (5.9%), and hypertension (5.9%). The majority of the AEs were mild or moderate, when considering the AE of highest intensity, 52.9% of patients had a severe AE, 29.4% had a moderate AE and 11.8% had a mild AE. A similar pattern was seen in the post-conditioning period. It should be noted that most mild and moderate TEAEs resolved, but around half of the severe TEAEs do not resolve both in the pre- and post-conditioning period.

During the post-conditioning period, the most commonly reported (treatment emerging) AEs were pyrexia (52.2% of the patients) and hypertension (43.5%) and graft versus host disease (GVHD) (30%). The most frequently reported severe post-conditioning TEAEs (57% of the patients)) were related to HSCT failures (13%, 3 of 23) or HSCT complications (13%) with engraftment syndrome. A frequency of 3 of 23 transplanted subjects with graft failure seems rather high since the overall rate of graft failure in allo HSCT is 5.6%, but this may be confounded by the low frequency of haplotransplantation. The effect of emapalumab treatment on HSCT outcome is difficult to evaluate. Not only the lack of information on factors known to affect this outcome (graft source, conditioning regimen, patient age and condition at time of HSCT) hampers interpretation, also the low patient number and the presumed heterogeneity in these factors prohibit drawing any conclusions.

Treatment related TEAEs (in 29% and 4% of the patients pre - and post condition), consisted of infusion related events and infections which could potentially be favoured by IFNγ neutral isation. Most were non-severe and resolved.

Two severe treatment related infections were reported by the applicant; a patient with disseminated histoplasmosis and a healthy volunteer patient with a herpes zoster infection, the latter received no anti-viral prophylaxis. After this event, anti-viral prophylaxis was made part of the protocol. Also, a necrotizing fasciitis by pseudomonas aeruginosa was considered treatment related by the investigator but not by the applicant. It should be noted that necrotising fasciitis caused by Pseudomonas aeruginosa is exceptionally uncommon with only 12 cases reported in the literature (Lota 2010), thus a causal relationship cannot be excluded. All three events resolved after subsequent treatment.

In study NI-0501-03, the healthy volunteer study, 41 TEAEs were observed in 14 out of 20 subjects, 10 of which were in 4 subjects that received placebo. Thirty-six of the TEAEs were of mild intensity and the remaining 5 were of moderate intensity. Adverse events reported in more than one subject each were headache, pyrexia, viral and non-viral upper respiratory tract infection, and myalgia. No myelotoxicity was reported.

The treatment emerging AEs appear to be in line with what is expected seeing the nature of the disease and the side effects of concomittant medication.

The number of patients that discontinued the emapalumab administration was low (n=2) and were related to a course of disseminated histoplasmosis (probably due to treatment) and lack of efficacy (n=1). As reported by the applicant no action with regards to emapalumab treatment (drug withdrawal, dose decrease, elongation of the interval of administration) has been taken because of reported adverse events. Adverse events were properly treated and concomitant medications, when considered being related to the AE, were discontinued.

Due to the small sample size and short exposure, more rare AEs are left uncharacterised. The low number of patients that discontinued treatment (n=2) indicates that the treatment was tolerated in this sick population. Overall, the small sample size, the limited experience in the higher dose range, the lack of comparative data and absence of long-term safety data (i.e. 2 years after administration) hamper the evaluation of the safety profile. Therefore, the future safety profile should be carefully monitored, both in ongoing studies and within the post authorisation measures.

<div style=\"page-break-after: always\"></div>

## Death and SAEs:

The pivotal safety data set was used to characterize the SAE profile. Treatment emerging SAEs were observed during the pre-conditioning period in 21 (65.6%) patients, and in 15 (65.2%) patients in the post conditioning period. The most frequently reported TE-SAEs in the preconditioning period were condition aggravated (14.7%), gastrointestinal haemorrhage (8.8%), and multiple organ dysfunction (5.9%). The most frequently reported TE-SAEs in the post-conditioning period were acute graft versus host disease, engraftment syndrome, graft failure, infections. The vast majority of patients with SAEs recovered and few (surviving) patients had unresolved SAEs or recovered with sequelae.

During the NI-0501-04/05 study 10 patients (29%) died, and two additional study patients died after the data cut-off. In the CU 12 patients died and no deaths were reported among healthy volunteers. The cause of death was as expected in the treated population and none of the deaths was considered being related to emapalumab administration as many other confounders (e.g. underlying disease, infection, co-medication) could be identified.

The applicant has provided additional data on fatal cases from ongoing clinical studies with emapalumab. In the NI-0501-09 study 4/15 fatal cases (3 pre-HSCT, 1 post-HSCT) occurred prior to the cut-off date (24-Nov-2019) and 3/21 additional fatal events reported after the cut-off date. In the NI-0501-04/05 study n=15/45 (10 pre-HSCT, 5 post-HSCT) fatal cases were reported, of which 5 deaths occurred after the cut-off date of 20-July-2017. In all cases, the fatal events and other associated SAEs were assessed as not related to the use of emapalumab. The most important causes for death in these two studies appear to correspond to what can be expected for a pHLH population, however, however, the single arm trial in this very sick, co-medicated population caries the risk that these toxic deaths might be underreported and does not clarify the role of emapalumab.

No fatal cases were reported in the ongoing study NI-0501-06 in 9 patients with sHLH due to sJIA/MAS, however differences in disease between pHLH and sHLH should be considered.

When compared with the historical cohort data, the most frequent causes of death were related to HLH progression and/or organ failure, which accounted for 60% and 74% of the deaths for which information was available, in Study NI-0501-04/05 patients and in Historical Controls, respectively.

Nevertheless, as mentioned before, due to the limited sample size, the future safety profile needs to be carefully monitored, both in ongoing studies and within the post authorisation setting.

## Infections:

Patients with pHLH are vulnerable to infections; infections may trigger and maintain the disease. The supportive treatment of pHLH exists of anti-infectious prophylaxis, close monitoring of infections and prompt treatment of infections upon starting of treatment

All patients received anti-infectious prophylaxis throughout the study and probably around HSCT as recommended according to the current HLH treatment guideline. The use of anti-infectious prophylaxis is reflected in the SmPC.

The pivotal safety data set was used to characterize the AE profile. In the trial, many patient experience opportunistic infections, which was as expected seeing the nature of disease and effects of concomitant/prior treatment. In the pre-conditioning period, infectious events (55.9%) were mostly caused by opportunistic infections and in more than half of the patients' infectious events were considered to be SAEs. One systemic fungal infection (Histoplasmosis disseminated) was reported

<div style=\"page-break-after: always\"></div>

which might have been favoured by the use of emapalumab, one fatal bacterial infection was reported (pseudomonas) during preconditioning, which might also have been related to treatment. After the start of HSCT conditioning, infections were reported in 16 of 23 patients (69.6%), most of these infections also appear to be opportunistic infections. No systemic fungal infections were seen. Bacterial infections had a fatal outcome in one patient with graft failure and in one patient with GVHD.

Overall, the observed incidence of reported infections appears to be in line with previously reported data, but the lack of comparative data precludes a sound conclusion.

IRRs : Up to 20 July 2017, in studies NI-0501-04/05 26.5% patients had at least one IRR. The majority of the events occurred with the 1st infusion of emapalumab and were all assessed as of mild intensity, except for one event of moderate pyrexia. There was no evidence of anaphylaxis or and no delayed hypersensitivity reactions.

## ADA

The pivotal safety data set was used to characterize ADAs. A total of 4 patients out of 51 exposed to emapalumab and tested for ADA have shown at least one positive result. No apparent impact on efficacy and safety parameters was seen in these patients. The risk of immunogenicity with emapalumab in patients with primary HLH is considered low. This is based on the molecule's characteristics, the nature of the disease, the patient's characteristics, the route of administration of the drug and the short treatment duration. Immunogenicity data will be collected in the on-going studies with emapalumab and the applicant has confirmed that any new information that is not consistent with the current conclusions will trigger a new risk assessment, and consequently a possible modification of the RMP.

## Laboratory findings:

The pivotal safety data set was used to characterize the laboratory-based AE profile. Haematological and electrolyte abnormalities would have been expected to be seen frequently both in the pre- and post-conditioning period seeing the nature of the disease and effect of conditioning regimens. Improvements in laboratory measures were expected based on the response rates. Please note, that investigators have only reported abnormal haematological values without reporting the abnormalities related to the studied disease. This method might result to underreporting, as abnormalities will at first be attributed to concomitant medication or the disease. Also, during the trial the concomitant administration of G-CSF was allowed which may alleviate symptoms of haematopoietic toxicity, which also may result in underreporting. The haematological data provide a limited number of grade 3- 4 adverse events, however due to the above, the reliability of the data is questioned. On the other side, in the healthy volunteers, no myelosuppression was reported, but it remains somewhat uncertain whether the safety outcomes in healthy volunteers can be extrapolated to the very sick, paediatric pHLH population.

Methods for reporting chemical abnormalities are supported. The observed laboratory changes in electrolyte, liver and renal function could be attributed to the underlying disease, co-disease, concomitant medication etc. As reported by the applicant, no action with regards to emapalumab taken. Concomitant medications, when considered being related were discontinued.

treatment (drug withdrawal, dose decrease, elongation of the interval of administration) has been Therefore, although the safety profile is not clearly identified, the safety of emapalumab appears to be manageable in pHLH; although the single arm design in this sick population, small patient number and the lack of comparative data carries the risk of underreporting of AEs.

<div style=\"page-break-after: always\"></div>

Vital signs and physical findings: In the NI-0501-03 study an isolated case of non-sustained ventricular tachycardia was reported and was considered mild in intensity. Generally, monoclonal antibodies have a low likelihood of direct ion channel interactions. This event occurred in one of the low dose cohorts (0.1 mg/kg) and no cardiac rhythm abnormalities or ECG abnormalities were seen at any of the other doses in the study (up to 3 mg/kg).

## Drug-Drug interaction

During the clinical trial programme, no events of therapeutic protein DDI related to emapalumab were reported. However, the limited clinical trial data is not considered sensitive to identify DDIs due to the small numbers of patients, multiple concomitant medications and the uncontrolled open label setting. The potential for emapalumab to interact with the cytochrome P450 enzyme system or P-glycoprotein transport system has not been evaluated. Given the nature of the product (biological) this is agreed. However, neutralisation of IFNγ in HLH patients by emapalumab carries a potential risk of inflammation-mediated therapeutic protein-drug interactions as pro-inflammatory cytokines are known to down regulate cytochrome P450 (CYP), resulting in suppression of CYP activity during active disease. Thus, upon initiation or discontinuation of emapalumab in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g. cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.

## Contextualisation of safety data

Although no drugs are approved in the treatment of pHLH, currently well-established treatment exist. The applicant provided the safety profile of a historical cohort, but the provided data was limited to deaths while also concerns exist regarding the comparability of the included patient population.

The applicant provided a literature review of the available treatments. However, this comparison is severely hampered as only 2 investigator, prospective studies are published. The safety data in these studies has not been systemically collected. Further, these studies included treatment naive patients, patient that are underrepresented in the current study population. They also include a larger number of patients (HLH-94 N=249; HLH 2004 N=269), and might, therefore, be more sensitive to detect for less frequently occurring events, like for example toxicity related deaths. Moreover, over time, background therapy and procedures to proceed to HSCT might been changed, which will likely compromise the comparison. Based on these considerations, the comparison with historical data is clearly hampered.

The current treatment of pHLH (etoposide, cyclosporine, alemtuzumab) carry significant toxicities that may compromise treatment compliance and might in some case be fatal. No such cases have been described in the current trial, but these cases might be underreported due to the single arm design, disease characteristics, and frequent co-administration of other treatments which altogether carry a high risk of underreporting of events. Based on these considerations, it cannot be excluded that the use of emapalumab may have played a contributory role.

## Remaining points for discussion:

- -A triggered GCP inspection was initiated for the clinical studies NI-0501-04 and NI-0501-05. The outcome of the inspection concluded that critical and major findings were reported related to the integrity of the data. The latter findings refer mainly to a lack of trial oversight by the Sponsor which also affect the safety data collection.

For instance, the set up and validation of the eCRF was not sufficiently GCP compliant. Also, the CRF

<div style=\"page-break-after: always\"></div>

did not align with protocol (eligibility criteria, definition of AEs) and this contributed to the incomplete collection of safety data that was repaired retrospectively.

In addition, many users had admin rights to the safety database. Several of these users were involved in the conduct of the trial. As a result, the safety data is not collected in a sufficiently controlled data protected environment.

- The additional safety data from the NI-0501-04 study with a data cut off 31 Jan 2019 were collected prior to the GCP inspection and thus the GCP findings also apply to these data. It is uncertain to what extend the GCP findings apply for the NI-0501-09 study data. Further, all additional safety data including the post marketing data have similar limitations as those initially submitted as they were collected in a non-comparative setting, pertain to a heterogenous patient population known to have a variable course of the disease and concomitant (HLH) treatment was allowed.

- The applicant is proposing to initiate and maintain a disease registry with the aim to further characterize emapalumab potential risks, its long-term safety and the benefit risk profile of treatment. The applicant's proposal to initiate and maintain a disease registry as an additional pharmacovigilance activity is acknowledged.

## 3.3.2. Conclusions on the clinical safety

The primary safety data base of emapalumab consists of the safety data from the NI-0501-04 study with data cut-of 20-07-2017. After additional safety data received, the total number of safety data derived from clinical trials in primary and secondary HLH patients treated with emapalumab is N=81 and is therefore considered to be small. Supportive data is available from an additional 17 patients who received emapalumab in compassionate use and from 14 healthy volunteers.

All safety data are obtained in an insensitive population, as the data are obtained in a single arm open label study in a small population consisting of very sick paediatric patients. Also, the variable disease is characterised with haematological, hepatic, renal and CNS signs and symptoms and extensive comedication is used. Therefore, many adverse events (AEs) might be obscured and underreporting is likely to occur. Moreover, the lack of comparative data with the current SoC, leaves the safety profile of emapalumab undetermined.

Emapalumab is intended to replace etoposide in the treatment of pHLH. The overall safety profile of etoposide is well known but limited in patients with HLH. Etoposide and emapalumab have a different mode of action, which may result in a different safety profile in pHLH, however confirmation is lacking.

The number of patients who discontinued treatment in the overall treated population, which indicated that although the safety of the drug is not well characterised, the treatment was tolerated in this sick population. However, it remains uncertain whether the tolerability is due to the safety profile of the drug, or to the high tolerability or acceptability of not recognised adverse events in this sick population.

<div style=\"page-break-after: always\"></div>

## 3.4. Risk Management Plan

| Safety concern                                                                                                                                               | Risk minimisation measures                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks                                                                                                                                    | Important potential risks                                                                                                                                                                                                                     | Important potential risks                                                                                                                                                                                                                                                                                                      |
| Infections linked to lack of IFNγ biological activity (due to emapalumab mode of action)                                                                     | SmPC section 4.4 SmPC section 4.8 where advice is given on prophylaxis, monitoring for development of infection and appropriate treatment. PL section 2 (What you need to know before you are given emapalumab) and 4 (Possible side effects) | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Additional pharmacovigilance activities: A Non-Interventional, Postauthorization Safety Study of Emapalumab for the Treatment of Primary Hemophagocytic Lymphohistiocytosis to Estimate Survival and the Incidence of Infections |
| Missing information                                                                                                                                          | Missing information                                                                                                                                                                                                                           | Missing information                                                                                                                                                                                                                                                                                                            |
| Use of emapalumab in patients who received vaccination with a live or attenuated live (including Bacillus Calmette-Guérin [BCG]) vaccine prior to emapalumab | SmPC section 4.4 (Special Warnings and Precautions for Use) PL section 2 (What you need to know before you are given emapalumab)                                                                                                              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                               |
| Use of emapalumab in pregnant patients                                                                                                                       | SmPC section 4.6 (Fertility, pregnancy and lactation) PL section 2 (What you need to know before you are given emapalumab)                                                                                                                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                               |
| Use of emapalumab during breastfeeding                                                                                                                       | SmPC section 4.6 (Fertility, pregnancy and lactation) PL section 2 (What you need to know before you are given emapalumab)                                                                                                                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                               |

The PRAC considered that the risk management plan version 0.4 is acceptable.

However, the CHMP, having considered the data submitted in the application, was of the opinion that due to the concerns identified with this application, the risk management plan cannot be agreed at this stage.

## 3.5. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the

<div style=\"page-break-after: always\"></div>

requirements of Article 8(3) of Directive 2001/83/EC.

## 3.6. New Active Substance

The applicant declared that emapalumab has not been previously authorised in a medicinal product in the European Union.

The CHMP, based on the available data, considers emapalumab to be a new active substance as it is not a constituent of a medicinal product previously authorised within the Union.

## 3.7. Product information

## 3.7.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 4. Benefit-Risk Balance

## 4.1. Therapeutic Context

## 4.1.1. Disease or condition

Haemophagocytic lymphohistiocytosis (HLH) is a very rare group of disorders of uncontrolled immune activation associated with severe hypercytokinaemia. The symptoms of disease waxes and wanes over time and is sensitive to external factors like infections. HLH can be categorised as primary (familial) or secondary (acquired). Primary HLH corresponds to genetically inherited forms and secondary (acquired) HLH occurs in the setting of infectious, malignant, rheumatologic, or metabolic conditions. The incidence of HLH in paediatrics is estimated as 1 to 225 per 300 000 live births and HLH occurs mostly in infancy and early childhood. The incidence in the adult population is unknown. The current application targets paediatric patients with primary HLH.

Primary HLH (pHLH; or familial HLH) is caused by genetic mutations, of which most affect the cytotoxic function of T lymphocytes and natural killer (NK) cells. This ultimately results in a vicious cycle of amplified cytokine secretion (e.g. IFNγ, TNFα, IL -6, etc) and leads to pancytopenia, disseminated intravascular coagulation followed by multiple organ failure. Several underlying mechanisms for HLH have been proposed. Based on the observations in perforin knock-out mice one of them suggests a central role for IFNγ in cause of disease. Based on this model, n eutralisation of IFNγ has been proposed as a treatment strategy for pHLH, with the aims to provide a bridge to transplantation.

The applied indication has been amended during the procedure to: ' Treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide).

An Orphan drug designation has been granted for emapalumab in the treatment of HLH in the European Union (EU) (EU/3/10/749).

<div style=\"page-break-after: always\"></div>

## 4.1.2. Available therapies and unmet medical need

There is an unmet medical need in the treatment of pHLH. If left untreated pHLH has a dismal prognosis with a median survival of less than 2 months after diagnosis. There is no approved pharmacotherapy for the treatment of pHLH, however the current standard of care is the HLH-94 or HLH-04 treatment protocol which improved the survival of patients with HLH. These protocols exist of an 8-week treatment with etoposide plus backbone treatment of dexamethasone + with/or without cyclosporine-A (CSA). Continuation therapy should last until haematopoietic stem cell transplantation (HSCT), which is the only curative treatment for pHLH. While ideally performed when patients are in remission, around 30% to 60% of patients have been transplanted with active disease. For treatment naive patients treated according to HLH 94/04 protocol the estimated 5-year survival in patients with familial or pHLH is 56-59%. Around 76%-80% of the patients survive to HSCT, with overall survival is reported to be up to 70% at 5 years post HSCT.

Although the treatment of HLH therapy has improved the survival of patients with HLH, there is still a need for additional treatments. Patients with a relapse/reactivation who initially responded to therapy may respond to intensification of standard -of-care therapy, which is advised per HLH-04 protocol. For patients refractory to steroids and etoposide, there is limited evidence available, but most physicians recommend alemtuzumab. The prognosis pHLH patients who need treatment beyond first line is poorly described in the literature. Disease reactivation is common, particularly when the etoposide and dexamethasone is reduced. These reactivations usually respond to a re-intensification of therapy (Ehl, 2018). 2 Treatments that can be used as salvage therapy are alemtuzumab, anakinra or ATG. Specific recommendations for salvage therapy are difficult because of limited data. Consultation with an HLH expert is strongly encouraged before choosing and starting salvage therapy (Ehl, 2018.)

## 4.1.3. Main clinical studies

The main studies to support this application are the single arm, open label pivotal study NI-0501-04 and the follow-up study NI-0501-05. The pivotal study NI-0501-04 is a single arm study and was initially designed as pilot study in primary HLH patients with reactivating disease. Upon the final amendment, the study was changed to a single arm phase 2/3 study intended to support registration. After completion of study NI-0501-04, patients were invited to participate in the follow up study NI0501-05.

In study NI-0501-04, the starting dose of emapalumab was 1 mg/kg biweekly added to a continuous background treatment with dexamethasone. During the study the posology of emapalumab was modified. In the final posology, the dose could be increased based on clinical and laboratory criteria. HSCT was allowed after a minimum of 4 weeks of emapalumab. Upon protocol amendments, patients could use concomitant HLH medication in both the 04 (if meeting certain criteria) and 05 study (no limitations). The initial dataset comprised of in total 34 patients were treated with emapalumab in study NI-05-1-04/05, of which 7 were treatment naïve and 27 'second line'. The primary analysis set consists of the second line all treated set, which is regarded as the primary efficacy population from here on. The initially provided results were based on an interim analysis, as at Day180, additional data of N=11 treated patients from study NI-0501-04 were presented. These patients were treated after 20 Jul 2017 with a data cut off 31 Jan 2019. The data set included 7 second line and 4 treatment naive patients.

2  Ehl et al. Recommendations for the use of etoposid based therapy and bone marrow transplantation for the treatment of HLH: consensus statement by the HLH steering committee of the Histiocyte Society. J ALLERGY CLIN IMMUNOL PRACT: 1508-1517. https://doi.org/10.1016/j.jaip.2018.05.031

Gamifant

<div style=\"page-break-after: always\"></div>

The primary endpoint is the overall response rate measured at the end of treatment (week 8 or earlier) in study NI-0501-04 as defined by complete or partial response or HLH improvement.

The applicant has presented data from compassionate use (CU) (8 subjects with pHLH and 9 with sHLH) as supportive of study NI-0501-04/05. A historical cohort of 72 mainly treatment naïve patients with pHLH treated from 2010 onwards has been presented, seeking to indirectly demonstrate benefit over SOC. Also, additional safety data from 22 pHLH of study NI-0501-09 and n=14 patients in secondary HLH were provided.

## 4.2. Favourable effects

At the time of the interim analysis, the overall response rate at end of treatment in (EoT) study NI0501-04 (4-8 weeks) was 63% (0.42-0.81, n=17) in the second line treated set.

The ORR was 59.3% (n=16, 0.39-0.78) when treating subjects identified by the applicant as patients receiving additional HLH treatments (in addition to the dexamethasone background treatment) as nonresponders (n=5).

A CR was seen in 7 (26%), PR in 8 (30%) and HLH improvement in 2 (7%) patients.

The median time to first response was 8.0 days in the second line treated set.

The median duration of the first response until EoT NI-0501-04 was not estimated (NE) (22, NE) days in the second line. Note that the protocol defined a different definition for durability of response than was reported/calculated.

Twelve (44.4%) patients could reduce the dose of glucocorticoids by at least 50% at EoT Study NI0501-04 in the second-line set.

A total of n=19 (70%) proceeded to transplantation in the second line set. Median time to HSCT is 83 days and 100 days respectively. Responses at conditioning were: 5 in CR, 5 in PR and 3 had HLH improvement. Six second line patients (and 2 first line patients) underwent a HSCT with no response.

Twelve-month survival probability is 0.73 (0.522, 0.864).

The post HSCT survival 12-month probability estimate was 0.89 (0.641, 0.973).

A Cox regression model of Overall Survival with HSCT as a time-dependent covariate indicated HSCT reduced risk of death by 44% HR 0.56 (0.08 to 3.74) in 2 nd  line patients when they were compared to historical controls.

The final data from study NI-0501-04 included n=11 additional patients including n=7 treatment experienced. From the data presented, n=23 patients of the primary analyses are considered representing the latest applied indication i.e receiving dexamethasone and etoposide as first line treatment. The ORR was 20 /34 (59%), 95% CI 40.7, 75.4 p=0.02. Additional analyses excluding those patients who receive additional HLH therapy showed an ORR of 19/23 (55.9%) (95% CI 37.9, 72.8, p=0.04).

## 4.3. Uncertainties and limitations about favourable effects

The transition from an ongoing explorative phase II trial to a pivotal phase III trial was not preplanned. There is a concern that these changes were data driven since the corresponding amendments were made after a descriptive analysis conducted in the first n=11 patients which was shared with trial decision makers. These amendments changed the goal of the study, dosing scheme, concomitant HLH

<div style=\"page-break-after: always\"></div>

treatment and definitions of primary and secondary endpoints. Moreover, the statistical analyses plan has been amended twice after the data base lock.

On the patient population provided in the primary analyses set (20 July 2017) for a total of n=3/27 patients the pHLH diagnosis could not be confirmed.

The proposed posology is symptom based. The relationship between emapalumab and clinical symptoms was only indirectly demonstrated (via CXCL9) on a population level, without considering dose alterations, concomitant HLH medication and dynamic nature of the disease. Therefore, it remains unclear if emapalumab provides a complete neutralisation of the free and receptor bound IFN-Y and if this confers to symptom and disease improvement. From a pharmacokinetic and clinical perspective, the proposed posology (i.e. starting dose, dosing frequency, dosing on clinical symptoms, termination of emapalumab treatment before HSCT) has not been adequately justified and the central role of IFN Ɣ neutralisation in the overall pathophysiology of pHLH is not completely understood.Given that emapalumab was used in combination with other therapies, as well as due to the known variability in the course of pHLH, the responses seen in the study cannot be causally attributed to treatment with emapalumab. Similarly, the contribution of emapalumab to patient eligibility for HSCT, and its impact on OS, cannot be ascertained.

When subjects identified by the applicant as receiving some of these additional HLH treatments (added to a continuous background treatment with dexamethasone) are classified as non-responders, the 95% CI of the primary endpoint fails to meet the pre-specified target of ORR is &gt;40%.

The amended indication is not supported by the primary analyses (n=27 patients date 20 July 2017). A total of n=4 patients did not receive conventional first line HLH therapy without clear justification. With the exclusion of these second line patients that did not receive front line etoposide (although they were eligible), the ORR was 60.9% (95% CI: 0.385, 0.803), with the lower limit of the 95% CI being less than the pre-set limit of 40%.

From the updated data of study of Study NI-0501-04 (31 Jan 2019) a total of n=7 patients were identified as treatment experienced, but only 4/7 received upfront the combination of dexamethasone and etoposide. None of these n=4 patients showed a response on emapalumab.

Trial NI-0501-04 used an own, new definition for the ORR at week 8, which not corresponds to the usual definition, being less strict.  The clinical relevance of such a response remains unclear.

The long-term efficacy of emapalumab is unknown as the median FU time for the pivotal study is short (13.4 months) updated to (14.6 [4.6-20] months.

The selection methods for the historical controls (HCs) were not considered appropriate as they are prone for selection bias. Comparison of these controls to the pivotal study is considered inappropriate due to the differences in patient populations for which the analyses was not adjusted.

For the pHLH patients treated in CU it is not clear what dosing regimen and concomitant treatments these patients received and therefore they are not considered as supportive for the pivotal study outcomes.

The additional patient data for the NI-0501-04 study with a data cut off 31 Jan 2019 were collected under the same circumstances as the pivotal data. Thus, these were also subject to the GCP findings.

The application has been subject to a triggered GCP inspection. The conclusion of the inspection was that the clinical data of study NI-0501-04 should not be used for evaluation for the MAA of Gamifant. The deficiencies refer mainly to a lack of trial oversight by the Sponsor which affect the data collection, data management and analyses of trial results resulting in that the quality of the data could not be

<div style=\"page-break-after: always\"></div>

confirmed. This also relates to the data of the additional patients enrolled as the GCP inspection was performed after the data cut-off for these patients.

## 4.4. Unfavourable effects

The primary safety database consists of 34 treated HLH patients in study NI-0501-04/05 with a median FU of 14.6 months. Additional HLH patients (8 pHLH and 9 sHLH) were treated in compassionate use. In total, n=81 primary and secondary HLH patients were treated with emapalumab in clinical studies. Additional supportive data is obtained of n=102 patients treated in the post marketing setting.

Up to 31 January 2018, 95% of patients reported at least one AE in the pre-conditioning period. The most common treatment emerging and on-study AEs in the pre-conditioning period were infections (56%), condition aggravated (50%), hypertension (41%), infusion-related reactions (IRRs) (27%) and pyrexia (24%). During the post-conditioning period (n=23), the most commonly reported AEs were pyrexia (52.2%), hypertension (43.5%) and graft versus host disease (GVHD) (30%). During the preconditioning period, 52.9% of patients had a severe AE, 29.4% had a moderate AE and 11.8% had a mild AE. A similar pattern was seen in the post-conditioning period.

Reported treatment related TEAEs consisted of IRRs and infections potentially favoured by IFN γ neutralisation (mycobacteria (typical and atypical), salmonella, shigella, campylobacter, herpes zoster and histoplasma capsulatum). Most related TEAEs were non-severe and resolved. Two severe related infections were reported: a patient with disseminated histoplasmosis and a healthy volunteer with a herpes zoster infection. All these events resolved after appropriate treatment.

The number of patients that discontinued due to side effects was low (n=2, 6%). Only one patient withdrew treatment due to direct toxicity (disseminated histoplasmosis).

During the study, 10 patients died (29%) and two additional study patients died after the data cut-off (updated safety data till 31 Jan 2018). None of the deaths were considered related to treatment with emapalumab.

No anaphylactic/anaphylactoid reactions have been reported. Only mild and one moderate IRRs in 27% of patients (approximately 3% of the total number of infusions). The majority of events occurred during or after the first infusions and none led to premature withdrawal.

The applicant provided additional safety data up to the cut-off date of 24-Nov-2019 from n=11 additional patients in the NI-0501-04 study and 15 patients from the NI-0501-09 study in a comparable population. Additional data was also provided by N=22 patients from study NI-0501-06, a single arm study in secondary HLH. These data are supportive for the here reported safety profile.

The applicant stated that the safety profile of the post-marketing surveillance data provided from 102 US primary HLH patients has not revealed any additional safety concerns (data not provided - data cut of 19 May 2020).

## 4.5. Uncertainties and limitations about unfavourable effects

There are significant limitations to the safety database currently available for emapalumab. Upon inspection of the safety data base, the safety database appeared incomplete (i.e. not all (S)AEs were collected) and not validated in a timely manner. The methodological issues described above (under uncertainties and limitations about favourable effects) are also relevant for the safety data collected and hinder the interpretability of the data collected.

<div style=\"page-break-after: always\"></div>

The single arm design hinders conclusions on treatment related AEs. In this particular case, the distinction between treatment related AEs, disease related events, or the side effects of concomitant/prior medication is difficult to make and underreporting is likely to occur.

Moreover, the small sample size of the pivotal trial (n=34) and supportive trials preclude the characterisation of rare AEs, leaving the safety profile not properly characterised. This also pertains to the infections potentially favoured by INFγ neutralisation which cannot be verified clini cally.

The low number of discontinuations might indicate that the drug is well tolerated, but it remains uncertain if the tolerability is due to the safety profile of the drug.

Haematological abnormalities might be underreported in the current study because they were only reported if they were considered not being related to the studies disease (HLH).

No long-term safety data are available. The short duration of exposure might not be problematic since emapalumab is not intended for chronic treatment in pHLH patients, but it may be considered that relatively long-term treatment might be envisaged for subjects not (yet) eligible for HSCT.

The only safety data available from the historical control cohort is limited to the causes of death reported.

There may be accumulation of emapalumab with the currently proposed posology bearing an unknown safety risk.

All additional safety data including the post marketing data have similar limitations as those initially submitted as they were collected in a non-comparative setting, pertain to a heterogenous patient population and concomitant (HLH) treatment was allowed.

The additional safety data from the NI-0501-04 study with a data cut off 31 Jan 2019 were collected prior to the GCP inspection and thus the GCP findings also apply to these data.

<div style=\"page-break-after: always\"></div>

## Effects Table

Table 61 Effects Table for emapalumab in paediatric patients aged under 18 years with primary HLH (data cut-off: 20 July 2017)

| Effect                           | Short Description                                             | Unit               | Treatment                                                                              | Control            | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Refere nces        |
|----------------------------------|---------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects               | Favourable Effects                                            | Favourable Effects | Favourable Effects                                                                     | Favourable Effects | Favourable Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Favourable Effects |
| ORR at EOT4                      | Overall Response Rate at End of Treatment of study NI-0501-04 | n,%                | Primary analyses (data cut off 20 july 2017) n=17/27; 63% (0.42- 0.81) (1L: n=5, 71%)* | -                  | - no control arm, results cannot be contextualised -allowance of HLH co-medication upon transition to phase 2/3 study hinders the evaluation of the treatment effect - very heterogeneous study population which questions validity of outcomes: -unclear clinical relevance of a response - no contextualisation of ORR possible due to use of novel response criteria, and changes of treatments over time. So adequate external controls are missing. - dosing regimen not justified - central role of IFN-Y in the disease can be questioned as other pathways might also be involved. Updated data for the treatment experiences (data cut of 31 Jan 2019) se ORR 20/34 (58.8%) 95% CI 40.7, 75.4) Sensitivity analyses of the patients supporting applied indication Data cut of 20 Jul 2017: N=23 ORR 14/23 (60.9% (95% |                    |
| Patients able to proceed to HSCT | -                                                             | n,%                | n=19, 70% (1L: 4, 57.1%)*                                                              | -                  | - no control arm, influence of prognostic/predict factors on outcome cannot be excluded -allowance of HLH co-medication upon transition to phase 2/3 study hinders the evaluation of the treatment effect - very heterogeneous study population which questions validity of outcomes - dosing regimen not justified Updated data 31 Jan 2019 Treatment experienced. 27/34 (79%) Patients supporting the applied application; data not reported.                                                                                                                                                                                                                                                                                                                                                                                |                    |

<div style=\"page-break-after: always\"></div>

| Effect               | Short Description                                | Unit                 | Treatment                      | Control              | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Refere nces          |
|----------------------|--------------------------------------------------|----------------------|--------------------------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| OS                   | Overall survival - 12-month survival probability |                      | 0.73 (0.522, 0.864) (1L: 46%)* | -                    | - no control arm, influence of prognostic/predict factors on outcome cannot be excluded -allowance of HLH co-medication upon transition to phase 2/3 study hinders the evaluation of the treatment effect - very heterogeneous study population which questions validity of outcomes - dosing regimen not justified Updated data 31 Jan 2019 (treatment-experienced 0.73 (4.6-20.6)* Subgroup patients supporting the applied indication Data cut of 20 Jul 2017: 0.70 (95% CI 0.46, 0.83) Data cut of 31 Jan 2019: not provided |                      |
| Unfavourable Effects | Unfavourable Effects                             | Unfavourable Effects | Unfavourable Effects           | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Unfavourable Effects |
| TE-AE                | Patients with at Least 1 treatment emerging AE   | %                    | 100.0% (pre: 94% post: 100%)   |                      | Database on primary safety analyse data cut off 20 July 2017. - uncontrolled study for which the results cannot be contextualised - small sample size, short exposure and no long term follow up leave the safety profile not properly characterised - many AEs might be obscured due to the seriousness of the disease, concomitant medication, or concomitant diseases and underreporting is likely to occur. Updated safety data (24 Nov 2019                                                                                 |                      |
| TE-SAE               | At Least 1 treatment emerging Serious AE         | %                    | 88.2% (pre: 61.8) post: 65.2)  |                      | see above                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                      |
| deaths               |                                                  | %                    | 29% (pre: 24% post: 9%)        |                      | see above                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                      |
| Discontinu ations    | Patients who discontinued due to AEs             | n,%                  | (n=2, 6%)                      |                      | see above -uncertain if the tolerability is due to the safety profile of the drug or that in very sick patients more AEs may be accepted or are not recognised.                                                                                                                                                                                                                                                                                                                                                                  |                      |

Abbreviations: ORR= overall response rate, EOT4= end of study NI-0501-04, HSCT= haematopoietic stem cell transplantation, OS= overall survival TE= treatment emerging, AE= adverse event, SAE= serious adverse event. Notes: Favourable effects are reported for the second line treated analysis set.

* The outcomes for the all treated analysis set and first line analysis set are shown in brackets.

Unfavourable effects are reported for patients initially enrolled in the NI-0501-04 study and includes safety data from studies NI-0501-04 and NI-0501-05.

**In total 34 patients entered the preconditioning period and 23 the post conditioning period.

<div style=\"page-break-after: always\"></div>

## 4.6. Benefit-risk assessment and discussion

## 4.6.1. Importance of favourable and unfavourable effects

Primary HLH is a heterogeneous disease with a fluctuating course. HSCT is considered to be the ultimate treatment goal for pHLH patients and hence HSCT and OS outcomes are generally considered to determine patient benefit in this population. The improvement/resolution of disease may provide a better clinical condition before commencing to HSCT, however there is no general agreement regarding the need for achieving CR before HSCT in order to improve outcome.

The amended indication was limited to second line patients who received upfront etoposide and dexamethasone (n=23) (data cut-off 20-07-2017). Most second line pHLH patients had a response to emapalumab added to a continuous background treatment with dexamethasone, as well as most patients proceeded to transplantation and survived during the first year after treatment. No major safety concerns have been reported in the pivotal study.

There are several concerns to the efficacy data. The key issue is that the allowance of concomitant therapies in a single arm trial with patients known to have a variable disease course, prevent ascertaining of the treatment effect of emapalumab. Moreover, no substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since the role of IFN-gamma is the pathogenesis of pHLH is incompletely understood.  Also, the symptomsbased posology is not sufficiently justified. Finally, the amended indication is not robustly supported by the primary efficacy analyses. As a consequence, efficacy cannot be considered established.

The safety profile is insufficiently characterised due to an incomplete safety collection in the small data set; as outlined also in the GCP inspection and the non-comparative nature of the available data in a very sick population; which do not allow for definite conclusions on safety.

Importantly, the GCP inspection concluded that clinical data from study NI-0501-04 should not be used for evaluation for the MAA of emapalumab as data quality of this study could not be confirmed. The GCP findings also apply to the updated data provided by the applicant with a data cut of 31 Jan 2019.

Together, the above issues do not allow for determination of the benefit-risk balance for emapalumab.

## 4.6.2. Balance of benefits and risks

Given that emapalumab was used in combination with other therapies, as well as due to the known variability in the course of pHLH, the responses seen in the study cannot be causally attributed to treatment with emapalumab. Similarly, the contribution of emapalumab to patient eligibility for HSCT, and its impact on OS, cannot be ascertained.

No substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since the role of IFN-gamma is the pathogenesis of pHLH is incompletely understood.

Due to the study design and conduct, there are considerable uncertainties about the safety profile of emapalumab.

Further to these uncertainties, due to methodological problems, the findings of the triggered GCP inspection revealed substantial concerns on the integrity of study data and recommended that the results of this study should not be used to support the marketing authorisation application.

For these reasons, a positive B/R cannot be ascertained.

<div style=\"page-break-after: always\"></div>

An OE was held in July CHMP to address the Major objections raised. The arguments brought forward by the applicant were discussed; however the majority of the CHMP considered that the positive benefit risk was not demostrated. Divergent views were expressed by Members of the committee (see appendix).

## 4.6.3. Additional considerations on the benefit-risk balance

As comprehensive data on the product are not available, a conditional marketing authorisation was requested by the applicant at Day 180 of the application.

The applicant  argues in  line  with  the  requirements  as  laid  down  in  Notice  to  applicants  vol  2b  and 'Guideline  on  the  scientific  application  and  the  practical  arrangements  necessary  to  implement Commission  Regulation  (EC)  No  507/2006  on  the  conditional  marketing  authorisation  for  medicinal products for human use falling within the scope of Regulation (EC) No 726/2004' as advised.

The applicant considered that the product fulfilled all the criteria for a CMA based on the following:

## 1. B/R balance is positive

The applicant considers the B/R for the second line patient population positive because the study met its primary endpoint in the second line treated patients with 17/27 (63%) of patients responding (95% CI: 0.42-0.81; p=0.0134). The effect was supported with several sensitivity analyses and with a reduction in the glucocorticosteroid therapy while maintaining response.

Safety data are available from just over 80 patients treated with emapalumab in clinical trials and just over 100 patients treated post-marketing in the US. The applicant claimed that the totality of these data demonstrates that emapalumab has a manageable safety profile favourably differentiated from conventional therapies.

## 2. Comprehensive data will be provided by means of study NI-501-09.

Study NI-0501-09 is an on-going open-label, single arm, multicentre study to assess efficacy, safety, impact on quality of life, and long-term outcome in paediatric patients with primary pHLH treated with emapalumab that will provide further understanding of the efficacy and safety of the medicinal product.

The primary efficacy parameter is as the NI-0501-04 study, Overall Response, i.e., achievement of either Complete or Partial Response or HLH Improvement, at EOT or Week 8 (whichever occurs earlier). Secondary efficacy parameters are, amongst others, the Overall survival, including survival to HSCT and survival after either HSCT or last emapalumab infusion (if HSCT is not performed). Safety will also be evaluated (adverse events, laboratory parameters and number of patients who discontinued emapalumab treatment for safety reasons).

The study is ongoing with 22/34 enrolled (EU:20 and US:2), and preliminary data suggest 15/22 patients are in second line (all EU). The applicant is confident that the study will complete enrolment, and Last Patient Last Visit is estimated to be October 2022.

## 3. An unmet medical need will be addressed

The applicant claimed that Emapalumab will address an unmet medical need in pHLH. Primary Haemophagocytic Lymphohistiocytosis (HLH) patients are a fragile paediatric patient population suffering from a life-threatening disease with high mortality in spite of conventional therapy. There is currently no approved treatment available in the EU.

<div style=\"page-break-after: always\"></div>

Treatments with a different mode of action are needed - no single treatment can obtain complete response in all patients.

Second line patients, the target patient population in the proposed indication statement, are in a particularly susceptible situation as conventional therapy has failed and no well documented treatment choices exist.

## 4. The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required

Based on the high unmet medical need, the positive benefit/risk profile and the manageable and favourably differentiated safety profile of emapalumab, the applicant believes that the benefit of the immediate approval outweigh the risks that still additional data are required.

The CHMP after reviewing the comments of the applicant, was of the following view:

## · B/R is not positive

The B/R is considered negative, as efficacy and safety cannot be considered established due to:

- the use of concomitant therapy in a single arm trial with patients known to have a variable course of the disease prevent ascertainment of the treatment effect of emapalumab,

Moreover, the applied indication is insufficiently supported by the included second line study population, as additional analyses was conducted to align the study population with the newly proposed indication (n=23). This analysis showed however an ORR of 61% with the lower limit of the 95% CI crossing the preset limit of 40%. As such, the study did not robustly meet its primary endpoint.

Although it is acknowledged that up till now no large safety signal has emerged, the safety profile is considered  insufficiently  characterised  due  to  likely  underreporting  of  AEs  in  a  very  sick  population receiving  concomitant  medication  in  the  context  of  a  small  single  arm  trial  with  a  heterogenous population known to have a variable course of the disease.

## The study NI-0501-09 will not provide data to resolve the outstanding uncertainties on the efficacy and safety.

The single arm study NI-0501-09 proposed to provide confirmatory results will likely not provide the comprehensive data needed to support the application as the design is almost a replicate of the pivotal study NI-0501-04. Like study NI-0501-04, study NI-0501-09 is a single arm trial in pHLH, using the same primary outcome (ORR at week 8) and with the allowance of concomitant HLH treatment, although a higher starting dose (3mg/kg) and different recommendations for dose increases will be used. Thus, the NI-0501-09 study is associated with the same key limitation in terms of isolating drug effect.

## The unmet medical need is not considered fulfilled with this product

For patients with relapsed or worsening of disease, retreatment of re-intensification of dexamethasone and etoposide can be provided, while for refractory or intolerant patients alemtuzumab, ATG or anakinra can  be  provided.  Despite  these  treatment  options,  the  unmet  need  for  the  target  population  is acknowledged.

The data submitted as part of this MAA preclude a conclusion that emapalumab is able to fulfil an unmet meet in second line pHLH patients (in)eligible for SoC HLH therapy or who fail that treatment, in view of the benefit/risk considered negative.

<div style=\"page-break-after: always\"></div>

## The immediate availability of emapalumab is not in the benefit of public health

The efficacy for emapalumab has not been established and due to the small sample size of the safety database  and  issues  related  to  the  collection  of  safety  database,  the  safety  profile  has  not  been adequately characterised.

## In conclusion:

The current application for a CMA for emapalumab is not supported. A positive B/R cannot be concluded, and  the  applicant  is  unlikely  to  be  able  to  provide  comprehensive,  additional  data  to  resolve  the outstanding uncertainties regarding the efficacy and safety. Moreover, based on the available data, it is currently  not  possible  to  conclude  that  emapalumab  is  able  to  address  an  unmet  meet  in  patients (in)eligible for SoC HLH therapy or who fail that treatment.

## 4.7. - Conclusions

The overall B/R of Gamifant is negative.

## 5. Recommendations

## Outcome

Based on the CHMP review of data on efficacy and safety for Gamifant in the treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide) the CHMP considers by majority decision that the efficacy and safety of the above-mentioned medicinal product is not sufficiently demonstrated and, therefore recommends the refusal of the granting of the conditional marketing authorisation for the above-mentioned medicinal product.

Grounds for refusal

## Whereas

- in the single arm trial, the responses seen cannot be causally attributed to treatment with emapalumb given that emapalumab was used in combination with other therapies, as well as due to the known variability in the course of pHLH. Similarly, the contribution of emapalumab to patient eligibility for HSCT, and its impact on overall survival, cannot be ascertained;

- no substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since the role of IFN-gamma in the pathogenesis of pHLH is not completely understood;

- there are considerable uncertainties about the safety profile of emapalumab due to the study design and conduct;

- the triggered GCP inspection revealed substantial concerns on the integrity of study data and recommended that the results of this study should not be used to support the marketing authorisation application, thus adding to the above uncertainties;

- Further to these uncertainties, the triggered GCP inspection revealed substantial concerns on the integrity of study data and recommended that the results of this study should not be used to support the marketing authorisation application.

<div style=\"page-break-after: always\"></div>

For these reasons, a positive B/R cannot be ascertained thus the benefit risk is considered negative.

Due to the afore-mentioned concerns a satisfactory summary of product characteristics, labelling, package leaflet, pharmacovigilance system, risk management plan and follow-up measures to address other concerns as outlined in the list of outstanding issues cannot be agreed at this stage.

Furthermore, following review of the available data in the context of the applicant's claim of new active substance status, the CHMP position at the time of this report is reflected in section 2.9 (new active substance), and appendix 1. However, in light of the negative recommendation, the CHMP is of the opinion that it is not appropriate to conclude on the new active substance status at this time.

Divergent positions to the majority recommendation are appended to this report.

## 6. Re-examination of the CHMP opinion dated 23 July 2020

Following the CHMP conclusion that Gamifant was not approvable based on the grounds for negative opinion described in section 5 above, the applicant submitted grounds for re-examination as detailed in section 6.1.

## 6.1. Detailed grounds for re-examination submitted by the applicant

Following a request from the applicant at the time of the re-examination, the CHMP convened an AdHoc expert Group (AHEG) inviting the experts to provide their views on the CHMP grounds for refusal, taking into account the applicant's response detailed below:

## 6.1.1. Ground #1

## Overview of applicant's position on Ground #1

The applicant believes that there are inaccuracies and misinterpretation within the Assessment Report which may have had an impact on the underlying basis of the review of the marketing authorisation.

The applicant believes that CHMP has significantly underestimated the unmet medical need in patients with primary HLH who have not responded to first line therapy. This underestimation may be based on incorrect interpretation of the limited published literature regarding the use of unapproved therapies which, in the applicant's view, do not provide evidence that there are valid treatment options for a vulnerable paediatric population suffering from a rare disease with very high morbidity and mortality and having failed first line therapy.

Primary HLH is an acute hyperinflammatory syndrome primarily affecting young children. It is a rare, life-threatening disease with high morbidity and mortality, and is invariably lethal if left untreated. Even in patients receiving conventional therapy mortality is still high at 30 to 40% (Trottestam et al 2011a; Bergsten et al 2017; Bergsten et al 2020).

Dexamethasone and etoposide (HLH-94 protocol) are recommended as first line treatments by the Histiocyte Society, the leading medical association within this disease, but none of them are approved for the treatment of primary HLH. While these regimens may have improved survival of pHLH patients, the drugs have well-known toxic effects, particularly myelosuppression and generalised immunosuppression, leading to a high risk of a broad range of infections. Cyclosporine A and antithymocyte globulin are additional agents used in association with glucocorticoids and etoposide (Trottestam et al 2011a; Jordan et al 2016).

<div style=\"page-break-after: always\"></div>

A significant proportion of patients do not respond, or lose response to first line treatments, and there is no official recommendation by the Histiocyte Society on how to treat these second line patients. This is a consequence of the very limited data available on these agents. In patients with disease flares, reintensification with glucocorticoids and etoposide has been suggested (Marsh et al 2017). However, as stated by the Histiocyte Society, 'persistence of hyperinflammation and/or cytopenia warrants consideration of salvage therapy [Strong Consensus)' (Ehl et al 2018)].

Potential second line treatments have not been explored prospectively to ascertain their efficacy and safety, and none is approved for the treatment of pHLH, and none is formally recommended by the Histiocyte Society.

The unmet medical need for second line treatment is clearly articulated by the Histiocyte Society: 'Overall, there is a lack of adequate literature upon which to confidently base decisions regarding salvage therapy of HLH or predict outcomes of patients with refractory HLH. Prospective clinical trials of salvage and/or alternative therapies are urgently needed.' (Marsh et al 2017).

In conclusion, there are no regulatory approved treatments for primary HLH, neither first line, nor second line. Moreover, there is a significant unmet medical need in patients with primary HLH, in particular in the fragile paediatric population of second line patients in whom first line treatment has failed.

CHMP has incorrectly interpreted that emapalumab is intended to replace the first line treatment etoposide in the treatment of pHLH.

The pursued indication is 'Emapalumab is indicated for the treatment of paediatric patients aged under 18 years with primary HLH with refractory or recurrent disease or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide)'.

Emapalumab has been investigated with the objective to provide patients who fail first line treatment, including etoposide, with an additional treatment option, given the still high unmet medical need described above.

In conclusion, emapalumab is not intended to replace etoposide as first line treatment. The applicant stated that the benefit/risk of emapalumab should be evaluated against second line treatments, for which no robust evidence base exists, and that are not approved in any jurisdiction for this condition.

The applicant believes the inaccuracies and misinterpretation in the CHMP AR 2020 as described has negatively impacted the review of the emapalumab marketing application.

As a consequence, the applicant claimed that emapalumab was incorrectly evaluated against treatments for which no robust evidence base exists.

The applicant firmly believes that emapalumab contributes in addressing a significant unmet medical need in a disease for which there is no approved therapy today in Europe. This is done by tackling the disease with a mechanism of action different from those of the already available therapies and therefore offering patients an additional chance to control their disease (see ground 3: Pharmacokinetics/Pharmacodynamics for further information).

Based on the high unmet medical need (ground 1: Underestimated unmet medical need and misinterpretations in the assessment report) the mechanism of action of emapalumab being different from currently used off-label therapies ground 3: Pharmacokinetics/Pharmacodynamics, and its positive safety profile (ground 4: Safety), the applicant believes the benefits outweigh the risks and that the requirements for a conditional marketing authorisation are fulfilled with study NI-0501-09 providing comprehensive data.

<div style=\"page-break-after: always\"></div>

## Detailed Ground

## The applicant believes CHMP has incorrectly underestimated the unmet medical need in primary HLH, particularly for second line treatment

The applicant believes that CHMP has significantly underestimated the unmet medical need in patients with primary HLH who have not responded to first line therapy . This underestimation may be based on incorrect interpretation of the limited published literature regarding the use of unapproved therapies which, in the applicant's view, do not provide evidence that there are valid treatment options for a vulnerable paediatric population suffering from a rare disease with very high morbidity and mortality. The following section describes the features of the disease, the current standard of care and the data supporting treatment guidelines.

## The pHLH syndrome

Haemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation, for which high i nterferon gamma (IFNγ) production plays an important pathogenic role and is characterised by clinical signs and symptoms of extreme inflammation.

HLH is classified as primary or secondary, depending on the causes of the disease. Primary HLH (pHLH), refers to HLH associated with a number of genetic mutations. Secondary HLH refers to forms of HLH triggered by infections, rheumatologic conditions of autoimmune or autoinflammatory origin, and metabolic and neoplastic diseases which are the cause of immune dysregulation (Henter et al 1991b; Tang et al 2008; Jordan et al 2011).

pHLH occurs mostly in infancy and early childhood but can also be seen in adults, with the disease manifesting in most patients between 1 and 6 months of age (Henter et al 1991a; Aricò et al 1996; Janka and Lehmberg 2014). pHLH is an ultrarare syndrome with an estimated incidence of 0.15 per 100 000 per year (Meeths et al 2015).

Patients with pHLH suffer from signs and symptoms of severe inflammation such as hyperferritinaemia, fever, severe cytopenia, coagulation defects, organomegaly (spleen and liver), liver function impairment, and infections (Henter et al 1991a; Tang et al 2008; Xu et al 2012; Jordan et al 2011). Neurological findings are present in approximately 30% of the patients and they can be the only feature of pHLH (Henter et al 1997), although not part of current diagnostic criteria (Table 62).

The disease is invariably lethal if untreated with a median survival of less than 2 months after diagnosis (Janka 1983; Aricò et al 1996). With treatment, with conventional therapy mortality is still high at 30 to 40% (Trottenstam et al 2011; Bergsten et al 2017; Bergsten et al 2020). The morbidity is extremely high as patients require hospitalisation for extended periods due to a combination of factors including the need to reduce hyperinflammation, the management of multi-organ toxicities and the need to perform haematopoietic stem cell transplantation (HSCT) for cure (e.g. with initial treatment for 8 weeks followed by continuation of treatment until HSCT can be performed). The median time to HSCT is 148 days (range, 25-2105 days) (Bergsten et al 2017).

The toxicity of conventional treatments contributes to the remaining high mortality and morbidity in these fragile patients. These toxicities include myelosuppression and serious generalised infections (see ground 4: Safety).

## The diagnosis

Diagnosing HLH is challenging because of its rare occurrence and patients may be initially diagnosed with severe infections or with suspected malignancy; HLH is suspected when anticipated improvements are not seen or malignancy has been excluded and are referred to specialist care.

<div style=\"page-break-after: always\"></div>

Five diagnostic criteria for HLH were developed by the Histiocyte Society in 1991, based on common clinical signs and laboratory findings (Henter et al 1991a). These criteria were updated by the Histiocyte Society adding three new criteria Table 62 after analysis of patients enrolled in the HLH-94 study (Henter et al 2007). Based on the latest Histiocyte Society recommendation, the diagnosis of HLH is made when 5 of the 8 diagnostic criteria are present or when there is a molecular diagnosis consistent with HLH, namely the presence of a causative genetic mutation.

## Table 62 The HLH 2004 diagnostic criteria for HLH

## The diagnosis of HLH can be established if either of the following is present:

- A. molecular diagnosis consistent with HLH

Or

- B. five out of the eight diagnostic criteria below are fulfilled

Fever a

## Splenomegaly a

Cytopenias affecting ≥ 2 of 3 lineages in the peripheral blood: haemoglobin &lt; 90 g/L (in infants &lt; 4 weeks: haemoglobin &lt; 100 g/L); platelets &lt; 100 × 10 9 /L; neutrophils &lt; 1 × 10 9 /L a

Hypertriglyceridaemia and/or hypofibrinogenaemia (fasting triglycerides ≥ 3 mmol/L [≥ 265 mg/dL], fibrinogen ≤ 1.5 g/L a )

Haemophagocytosis in bone marrow, spleen or lymph nodes, with no evidence of malignancy a

Low or absent NK cell activity (according to local laboratory reference)

Ferritin ≥ 500 µg/L

Soluble CD25 (soluble IL-2 receptor) ≥ 2400 U/mL

a Indicates the 1991 criteria.

CD, cluster of differentiation; HLH, haemophagocytic lymphohistiocytosis; IL, interleukin; NK, natural killer.

Source: Henter et al 2007.

Once pHLH has been diagnosed or strongly suspected, even in the absence of a confirmed genetic diagnosis, therapy must be started as soon as possible, with the objective to reduce the hyperinflammation. The reduction of hyperinflammation is required to stabilize and improve the critical condition the patient is often in, and subsequently to allow the performance of haematopoietic stem cell transplantation (HSCT), which remains the only cure (Aricò et al 1996; Jordan et al 2011).

## History of treatment of HLH

During the last four decades, the progress in the understanding of the pathogenesis of the disease allowed the exploration of a number of different therapeutic options to improve survival, particularly through the use of chemo-immunotherapy/cytotoxic drugs and the performance of HSCT.

In 1983, Janka reported the mortality data of 101 pHLH patients for whom follow-up data were available: the mortality rates were 39% within 1 month, 59.4% within 2 months, 85% within 6 months, and 95% within 12 months. These patients were treated with glucocorticoids, splenectomy,

<div style=\"page-break-after: always\"></div>

exchange transfusions, cytotoxic drugs and, when possible, HSCT. Based on the data, it was concluded that glucocorticoids had an effect although with short duration, splenectomy only led to a transient clinical improvement, and exchange transfusions were only rarely successful to achieve a meaningful improvement (Janka 1983).

The first major improvement in the treatment of pHLH, was achieved with the use of the epipodophyllotoxin derivatives etoposide, and later teniposide, in combination with steroids. These combinations were shown to induce prolonged symptomatic resolution (Ambruso et al 1980; Henter et al 1986; Fischer et al 1985). In 1996 the pHLH Working Group of the Histiocyte Society reported data from the past Histiocyte Society HLH Registry (retrospective and prospective) showing that the majority of patients who received chemotherapy (mostly etoposide or teniposide), despite an initial response, relapsed and eventually died if they did not undergo HSCT (probability of 5 years survival was 21.8% for the entire cohort: 66% in patients undergoing HSCT and 10% in patients not undergoing HSCT) (Aricò et al 1996).

The experience reported above provided the basis for the establishment of the current standard of care of pHLH, which consists of a combination of glucocorticoids and etoposide (also denoted first line therapy). This was established on the basis of the outcome of two Histiocyte Society consecutive studies, the HLH-94 (Henter et al 1997; Trottestam et al 2011a) and the HLH-2004 studies (Henter et al 2007) (Table 63).

The cumulative knowledge has led to the current treatment of pHLH, which foresees two treatment steps:

Induction therapy, which has the objective of reducing inflammation and therefore reducing disease activity (see First-line treatments for more information) followed by continuation therapy, if required, aimed at keeping the patients alive and stable until HSCT, and Hematopoietic stem cell transplantation (HSCT), which represents the only curative treatment in pHLH.

## First-line treatments

The current first line treatments for the induction therapy are based on primarily two open, nonrandomised, single-arm studies:

the HLH-94 study (Henter et al 1997; Trottestam et al 2011a) and the HLH-2004 study (Henter et al 2007).

The HLH-94 study was the first study in pHLH to investigate the use of etoposide and dexamethasone in a more formal way (Henter et al 1997). The number of patients with pHLH was 60 and the total number of patients was 249. The 5-year cumulative survival was approximately 50% in patients with pHLH (none survived 5 years without HSCT) (Trottestam et al 2011a) (Table 63).

In the HLH-2004 study, attempts to improve the HLH-94-regimen were made by adding cyclosporine A to dexamethasone and etoposide at the start of the treatment regimen (Henter et al 2007). The number of patients with verified pHLH was 168 and the total number of patients was 369. The 5--year probability of survival rate was approximately 59% in the population including patients with verified pHLH (Bergsten et al 2017; Bergsten et al 2020) (Table 63).

In a third prospective, non-randomised, single-arm study, the Hybrid Immunotherapy study in HLH (HIT-HLH study) (Jordan et al 2016) ATG was added to the dexamethasone and etoposide regimen from the HLH-94 study. The 5-year probability of survival rate at last follow up was approximately 65% in the population including patients with verified pHLH (Table 63).

<div style=\"page-break-after: always\"></div>

The addition of cyclosporine A or ATG to the dexamethasone etoposide regimen was not considered to lead to significant improvement on overall probability of survival and post-HSCT survival compared to that observed during the HLH-94 study (Jordan et al 2016; Bergsten et al 2017). For this reason, the HLH scientific community, while highlighting the high unmet need in primary HLH, concurs that, on the basis of the available data, the HLH-94 regimen consisting of dexamethasone and etoposide should be considered the standard of care as first line treatment (Bergsten et al 2017; Ehl et al 2018).

A more recent single arm study by Moshous et al 2019 prospectively investigated the use of alemtuzumab in combination with methylprednisolone and cyclosporine A as first line therapy in a restricted subgroup of pHLH patients. Limited, preliminary data have been presented at congresses (no peer reviewed paper available). As expected, given the mechanism of action with eradication of all CD52 bearing lymphocytes and therefore that a donor needed to have been pre-identified, a favourable effect was reported in the primary endpoint (number of patients surviving until HSCT) in patients for whom a donor is already available and for patients who can rapidly undergo HSCT in very experienced centres. As alemtuzumab is not approved for pHLH, and given its toxicity profile, it is not readily available in a number of European countries, requiring a special procedure before it can be used in patients with pHLH.

As described above, glucocorticoids (GC) have been administered as background therapy in all pHLH treatment regimens tested during the last 40 years, the data of which have allowed the Histiocyte Society to issue recommendations on the first line treatment of pHLH (Henter et al 2002; Bergsten et al 2017; Jordan et al 2016; Moshous et al 2019.

Published data on drugs studied for the use of first line treatment in pHLH, identified in a literature search, including the HLH-94, HLH-2004, the HIT-study discussed above are summarised in Table 63.

<div style=\"page-break-after: always\"></div>

Table 63 Published data on treatments studied as first line treatment of pHLH

| Treatment regimen                                                                                                        | Available data and source                                                                                                                                             | Assessment of response                                                                                     | Survival                                                                                      | Toxicities                                                                                                                                                                                                | Comments                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chemotherapy (83% of pts, mostly etoposide or teniposide and a few vinblastine or vincristine) No treatment (16% of pts) | Histiocyte Society HLH Registry, prospective and retrospective No. of verified pHLH 1 59 (of a population of 122) Publication: Arico' 1996                            | Not performed                                                                                              | 5 yrs pSu: 21.8% of the total population 5 yrs pSu post-HSCT: 66% (only 29 pts received HSCT) | Myelodysplastic syndrome following etopo-/tenipo- side treatment in 1 pt.                                                                                                                                 | First evidence that patients with pHLH require both management of hyperinflammation and HSCT for survival and initiated the search for the best agents to be used to obtain an acceptable benefit risk profile.                                                           |
| Dexamethasone + etoposide                                                                                                | HLH-94 single arm prospective study No. of verified pHLH 1 pts: 60 (of a population of 249) Publications: Henter et al 2002, Horne et al 2005, Trottestam et al 2011a | Non-active disease (according to treating physician's assessment) at week 8: 37/54 (69%) verified pHLH pts | 5 yrs pSu: 50% in verified HLH pts and 54 %in the total population                            | 4 pts died of toxicity including 1 due to AML linked to etoposide, for 3 toxicity was not specified) (Henter et al 2002; Horne et al 2005), 1 pt. developed AML due to etoposide (Trottestam et al 2011a) | First evidence from a prospective study of the significant impact of chemotherapy in combination with glucocorticoid treatment on improving survival of pHLH pts. Etoposide proposed as the chemo-therapeutic agent to be used in combination with GC for pHLH treatment. |
| Glucocorticoids + cyclosporine A + anti- thymocyte globulin (ATG)                                                        | Retrospective, single centre consecutive cases                                                                                                                        | Calculated on ATG courses (total of 45), not per per pt                                                    | Overall survival: 17 (61%) of 28 after ATG was given as a first line                          | IRRs (fever, chills in 44.4% pts), infections (bacterial, fungal, and                                                                                                                                     | Data difficult to interpret due to the retrospective and monocentric nature                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Treatment regimen                          | Available data and source                                                                                                                             | Assessment of response                                                                                   | Survival                                                               | Toxicities                                                                                                                                                                                                                                                                                                                                                                                                                      | Comments                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                            | in first (28 pts) and second line (10 pts) No. of pHLH pts 3 : 38 (25, 66% with a genetic diagnosis) Publication: Mahlaoui et al 2007                 | CR: 33 (73%) of 45 courses PR 5 : 11 (24%) of 45 courses No response: 1 of 45 courses                    | treatment and 4 (40%) of 10 when ATG was used as a second line therapy | viral) with 4 fatal outcomes (3 with fungal infection, 1 with EBV B lymphoproliferative disorder)                                                                                                                                                                                                                                                                                                                               | of the study, the long period of time during which pts have been enrolled (1991-2005) and the use of ATG as first and as second line treatment.                                                                                                                                                                                                                                          |
| Dexamethasone + etoposide + cyclosporine A | HLH-2004 single arm prospective study No. of verified pHLH 2 pts: 168 (of a population of 369) Publications: Bergsten et al 2017; Bergsten et al 2020 | Resolution (according to treating physician's assessment) at wk 8: 51% in the total population (187/362) | 5 yrs pSu: 59% in verified HLH pts and 61% in the total population     | 7 patients died due to septicaemia, infections, and/or bleedings (possibly associated with treatment toxicity).13 had had SAEs due to CsA (mostly affecting CNS, 2 had PRES), 6 due to etoposide (3 hepatic AEs), 6 due to dexamethasone (5 hypertension); 11 patients reported SAE of cardiac hypertension due to CsA + dexamethasone); infection SAEs were reported in 5 patients involving combination of CsA, etoposide and | Evidence that increasing further general immunosuppression does not necessarily add benefit to survival of pHLH pts. The Histiocyte Society recommends treatment with dexamethasone and etoposide as first line treatment for pHLH. However, the significant amount of declared missing data represents a major limitation of this study (see Bergsten et al 2017; Bergsten et al 2020). |

<div style=\"page-break-after: always\"></div>

| Treatment regimen               | Available data and source                                                                                                        | Assessment of response   | Survival                        | Toxicities                                                                                 | Comments                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                 |                                                                                                                                  |                          |                                 | dexamethasone. 1 pt. developed AML 2 years after etoposide treatment (Bergsten et al 2017) |                                                                                                                                                                                                                                                                                                                                                                                      |
| Dexamethasone + etoposide + ATG | HIT-US single arm prospective study No. of pHLH pts: 31 (16, 52% with a genetic diagnosis) Publications: Jordan et al 2016 (abs) | Not available            | Survival at last follow-up: 65% | None reported.                                                                             | Although an extensive publication of these data is not yet available, the conclusion of the authors is that although an etoposide/ATG based regimen may provide effective therapy for pHLH, this has significant adverse effects The details about number of patients with a genetic diagnosis and the data on survival were presented at the Histiocyte Society conference in 2016. |

Abbreviations: AEs, Adverse Events; AML, Acute Myelogenous Leukaemia, ATG, Anti-Thymocyte Globulin, CNS, Central Nervous System, CsA, Cyclosporine A, EBV B, Epstein-Barr Virus B; GCs, Glucocorticoids; HIT-US, Hybrid Immunotherapy study-United States; HLH, Haemophagocytic Lymphohistiocytosis; HSCT, Haematopoietic stem cell transplant; IRRs, Infusion Related Reaction; pHLH, primary HLH; PRES, Posterior Reversible Encephalopathy Syndrome; pts, Patients; pSU, Probability of survival; no, Number; SAE, Serious Adverse Event; yrs, Years, wk, Week.

1 As no genetic testing was available at the time of study conduct, the presence of affected siblings in patients meeting the HLH-94 diagnostic criteria were used to define pHLH ('verified HLH').

<div style=\"page-break-after: always\"></div>

- 2 As genetic testing was only available during the last years of the study, the presence of affected siblings in patients meeting the HLH-2004 diagnostic criteria were used to define pHLH ('verified HLH') in subjects in whom the genetic tests were not performed. 3 As genetic testing was only available during the last years of the study, the presence of affected siblings and/or parental consanguinity and/or disease severity and relapses in the absence of secondary HLH in patients meeting the HLH criteria were used to define pHLH ('verified HLH') in subject in whom the genetic tests were not performed. PR and bleeding and/or biological manifestations) and/or biological (including cytopenia, hypertrigliceridaemia, hypofibrinaemia, and hyperferritinaemia; high

4 PR= Partial Response: defined by a significant but incomplete improvement of clinical (including mainly fever, hepatosplenomegaly, neurologic symptoms, blood levels of liver enzymes, pleocytosis, and hyperproteinorachy; and excess HLA DR+ /CD8+ T cells in the blood and/or cerebrospinal fluid) manifestations.

<div style=\"page-break-after: always\"></div>

The standard of care first line treatment, dexamethasone and etoposide, and other treatments used in pHLH are based on potent immunosuppressive and chemotherapeutic agents and they all display significant well-known toxicities based on their mechanism of action which can aggravate morbidity and mortality. This may limit their use and causes patients to have aggravated side effects potentially also affecting transplant outcomes and includes:

- an increased risk of infections (caused by neutropenia)
- an increased risk of bleedings (caused by thrombocytopenia)
- an increased risk of renal function impairment,
- difficulties in determining early on a favourable effect of treatment (because of the cytopenia, caused by the myelotoxicity)
- limitations in prolonging the use of these drugs while searching for a suitable donor or the emergence of toxicities which may require to postpone the time of transplant.

A summary of adverse drug reactions of standard of care first line treatments and other treatments used for pHLH, as presented in SmPCs/Product monographs and the emapalumab proposed SmPC special warnings and precautions is provided under Table 64. The originally approved, non-HLH indications together with their mechanism of action, based on SmPCs and Product Monographs, are presented in Table 64 and for additional drugs used as first line treatment although not according to the HLH-94 protocol in Table 65.

Table 64 Approved indications and mechanism of action of drugs recommended by the Histiocyte Society as standard of care / first line treatment of Primary HLH

| Drug (source)                      | Therapeutic indication(s)/Indications and clinical use                                                                                                     | Mechanism of action                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dexamethasone (dexamethasone SmPC) | For use in certain endocrine and non- endocrine disorders responsive to corticosteroid therapy                                                             | Adrenocortical steroids Cause profound and varied metabolic effects and in addition, they modify the body's immune responses to diverse stimuli.                                                                                                                                                                                                                                                                                                                           |
| Etoposide (Vepesid SmPC)           | Multiple tumour types including: Testicular cancer Small cell lung cancer Hodgkin's lymphoma Non-Hodgkin's lymphoma Acute myeloid Leukaemia Ovarian cancer | A semi-synthetic derivative of podophyllotoxin used in the treatment of certain neoplastic diseases. In vitro , etoposide has cytostatic action, which prevents the cells from entering mitosis or destroys them in the premitotic phase. Etoposide interferes with the synthesis of DNA and has a secondary effect on arresting cells in resting (G2) phase in experiments with human lymphoblastic cell lines. Etoposide has a marked action on human haemopoietic cells |

<div style=\"page-break-after: always\"></div>

| causing leukopenia and thrombocytopenia. Animal experiments have shown evidence of teratogenicity.   |
|------------------------------------------------------------------------------------------------------|

Table 65 Approved indications and mechanism of action for other drugs used for treatment of Primary HLH in first line (but not recommended by the Histiocyte Society for first line treatment or any other line of treatment)

| Drug (source)                                      | Therapeutic indication(s)/Indications and clinical use                                                                                                                                                                                         | Mechanism of action                                                                                                                                                                                                                                                                                                                                                                                                                             |
|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cyclosporine - A (Cyclosporine SmPC)               | Transplantation indications Solid Organ Transplantation Bone Marrow Transplantation Non-transplantation indications Endogenous uveitis Nephrotic syndrome Rheumatoid arthritis Psoriasis Atopic dermatitis                                     | Potent immunosuppressive agent strongly suppress cell mediated immunity                                                                                                                                                                                                                                                                                                                                                                         |
| Anti-Thymocyte Globulin (ATG) (thymoglobulin SmPC) | Immunosuppression in solid organ transplantation: - Prevention of graft rejection in renal transplantation - Treatment of steroid resistant graft rejection in renal transplantation - Prevention of graft rejection in heart transplantation. | The in vitro mechanism of action by which polyclonal anti- lymphocyte preparations suppress immune responses is not fully understood. The in vivo mechanism of action of Thymoglobulin is also not fully understood. The possible mechanisms by which Thymoglobulin may induce immunosuppression in vivo include the following: i. T cell clearance from the circulation. ii. Modulation of T cell activation, homing and cytotoxic activities. |

To summarise: drugs currently used as first line treatment of pHLH have been tested in open label, single arm, non-randomised studies. None are, however, approved for the treatment of pHLH and they all display severe adverse effects (e.g. severe systemic infections, myelosuppression, malignant hypertension), further adding to the high morbidity and mortality in this fragile paediatric patient population.

<div style=\"page-break-after: always\"></div>

## When first line treatment fails

Contrary to the suggestions in the CHMP AR 23 July 2020 (section 4.1.2), there are no treatment guidelines for patients having insufficient response to first line treatment, refractory disease or intolerance to first-line treatment. No drugs are approved for the treatment of pHLH either in the first or second line.

Approximately, 25 to 50% of patients with HLH fail to achieve a satisfactory response to first line treatment (Marsh et al 2017). Clinical experience strongly suggests that these patients who fail to respond adequately to first line treatment have very poor survival (Marsh et al 2013b). Additionally, patients may reactivate requiring re-intensification or alternative treatments (Marsh et al 2017).

Currently, the data regarding treatment of reactivation following first line therapy is scarce and does not allow physicians to make informed decisions (Trottestam et al 2011a; Bergsten et al 2017; Marsh et al 2013b; Marsh et al 2017). As noted previously, this is reiterated in the 2018 guideline in which there is no second line treatment recommendation (Ehl et al 2018).

The Salvage Therapy working group within the Histiocyte Society recently reviewed the existing literature regarding salvage therapy of patients with HLH who were refractory to conventional therapy. They concluded that insufficient evidence is found for anakinra, ATG, alemtuzumab and liposomal doxorubicin upon which to confidently base decisions regarding salvage therapy of HLH or predict outcomes of patients with refractory HLH. They stated that prospective clinical trials of salvage and/or alternative therapies are urgently needed (Marsh et al 2017).

The applicant has performed a literature search to identify potential additional data to what has already been identified by the Salvage Therapy working group but found no new data. Only two of the previously identified publications are relevant in the context of second line treatment. Details about these two studies are presented in Table 66.

In one retrospective case series, ATG, was administered together with methylprednisolone to 10 patients who failed other therapies (Mahlaoui et al 2007).

In the second publication, a retrospective case series of 22 children and young adults with refractory HLH (as per definition of the treating physician) who received alemtuzumab is described (Marsh et al 2013a). All patients in this series had previously received dexamethasone and etoposide. The evaluation of response was hampered by the availability of relevant data and the retrospective nature of the data collection.

Table 66 Published data on second line treatment of pHLH

| Treatment regimen          | Available data and source                                    | Assessment of response                           | Survival   | Adverse drug effects                                                                                                                                 | Comments                                                  |
|----------------------------|--------------------------------------------------------------|--------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| ATG and methylprednisolone | Retrospective case series No. of pts: 10 Mahlaoui et al 2007 | CR: 5/10 pts PR: 4/10 pts No response : 1/10 pts | OS: 40%    | 6 infections reported in 10 pts over 11 courses. Of note, the difference between the number of infections observed in second lime pts versus pts who | Cases were collected over 14 years and all in one centre. |

<div style=\"page-break-after: always\"></div>

|                                 |                                                                                                      |                                                                                                                           |                                                                             | received ATG as first line in the same case series (28 pts and 4 infections) was statistically significant.   |                                                                                                                                                           |
|---------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Alemtuzumab and glucocorticoids | Retrospective case series No. of pts: 22 (6 with a genetic diagnosis) Publication: Marsh et al 2013a | CR: none PR 1 : 14/22 pts (64%) Isolated improvement in one quantifiable symptom or laboratory marker of HLH: 5 pts (23%) | pSu at a median of 870 days following first alemtuzumab administration: 64% | None reported in the publication.                                                                             | Children and adults were enrolled and only a few pts had a genetic confirmation of pHLH. Evaluation of response was hampered by the lack of relevant data |

Abbreviations; CR, Complete Response; HLH, Haemophagocytic Lymphohistiocytosis; OS, Overall survival, pHLH, Primary HLH; PR, Partial Response, pSU, Probability of Survival.

1  response in two or more quantifiable symptoms or laboratory markers of HLH.

To summarise : 25 to 50% of patients do not respond adequately or lose response to the first line therapy. The data on second line therapy with other drugs or re-intensification therapy in case of reactivation of the disease after initial response is insufficient and not adequate enough to support a recommendation for use by the Histiocyte Society, despite the high mortality in these patients. There is therefore a significant unmet medical need in patients with pHLH in need of second line therapy. It is specifically this patient population in which emapalumab was studied and for which conditional marketing authorisation approval is sought.

## HSCT

Haematopoietic stem cell transplantation (HSCT) represents the only curative therapy in primary HLH due to the genetic background of the disease. However, HSCT is particularly challenging in primary HLH due to added risks of persistent immune activation and potential for systemic and CNS relapse (Allen et al 2018). It is therefore not surprising that the transplant-related mortality and morbidity (including HLH reactivation) is higher in HLH compared to other diseases requiring HSCT, with an overall survival between 45 and 65% (Baker et al 1997; Horne et al 2005; Ouachée-Chardin et al 2006).

The survival of patients with pHLH undergoing HSCT has not improved over the last 2 decades despite the considerable progress made in the management of transplant and transplant related morbidities. The 5-year post HSCT survival rate reported between 1996 and 2018 was:

- 66% for the Histiocyte Society Registry cohort (Arico' et al 1996) and the HLH-94 study (Trottestam et al 2011a).
- 61% for the HLH-2004 study (Bergsten et al 2017).

<div style=\"page-break-after: always\"></div>

- 71% in a cohort of pHLH patients from the European Bone Marrow Transplant Registry (Messina et al 2018).

Almost all deaths are reported to occur during the first year after HSCT and the cause of death have been described as transplant-related in the majority of patients (Trottestam et al 2011a; Bergsten et al 2017; Messina et al 2018). For example, of the 67 deaths occurred during the HLH-2004 study, approximately 50% died within 100 days from HSCT and almost 90% during the first year post-HSCT (Bergsten et al 2020).

Delaying HSCT in primary HLH patients (e.g. due to difficulties in reducing hyperinflammation and therefore decreasing disease activity and/or due to lack of donor availability) exposes patients to a higher risk of dying, mainly due to disease reactivation, irreversible CNS disease (which is more likely to occur following prolonged disease activity), but also to toxicities of the available HLH treatments (see GROUND 4: Severe adverse drug effects from current conventional pHLH treatment by adverse drug reaction for additional information).

It has to be underlined that HSCT outcomes in HLH depend also on variables related to the patients, including disease and performance status (so called fit for transplant status ), as well as infections occurring before the allograft. Data reported by Messina and colleagues (Messina et al 2018) indicate that the sole amelioration of transplant techniques, including supportive therapies, does not seem to be able to significantly improve HSCT outcomes in HLH. This is further supported by Bergsten et al 2020.

The use of reduced intensity conditioning (RIC) approaches instead of myeloablative conditioning (MAC) regimens have been shown to improve survival, however extremely high rates of post-HSCT mixed chimerism have been reported following RIC leading to secondary graft failure (Allen et al 2018). For this reason, innovative targeted treatments, such as emapalumab, which are able to improve disease control before the allograft and in particular to spare patients from toxicities related to the use of cytotoxic agents and high-dose steroids, are needed.

Chimerism is thought to be protective with respect to HLH relapse/flare when at least 20 to 30% of donor cells are present (Hartz et al 2016). Following emapalumab treatment complete donor chimerism was observed in all but 1 surviving patient at 1 year of follow-up (Locatelli et al 2020), as opposed to several reports documenting high rates of mixed and often unstable chimerism in transplanted HLH, especially when a RIC regimen is employed (Allen et al 2018; Wustrau et al 2020).

The reasons for the improved transplant outcomes of HLH patients treated with a monoclonal antibody neutralising IFNγ could be several and include:

- The possibility of tapering steroids before HSCT,
- The lower inciden ce of graft failure (either primary or secondary) or mixed chimerism (IFNγ has a detrimental effect on haematopoietic stem cells) (Merli et al 2019),
- The favourable safety profile due to the targeted mechanism of action, not causing myelosuppression and thus not associated with a generalised risk for infections.

Moreover, it is to be considered that IFNγ is involved in the pathophysiology of graft -versus-host disease and graft failure and its neutralisation could prevent the occurrence of these potentially fatal complications (Hakim et al 2016; Hess et al 2020).

To summarise: HSCT represents the only curative therapy in primary HLH. Despite the progress in the performance of HSCT, the survival of patients with pHLH undergoing HSCT has not improved during the last 2 decades and the post-transplant mortality rate in pHLH is still high. Reasons likely affecting survival is time to transplant, drug toxicities, fitness for transplant, and post-transplant chimerism.

<div style=\"page-break-after: always\"></div>

Innovative targeted treatments, such as emapalumab, that are able to reduce time to transplant, improve disease control before HSCT, to spare patients from toxicities and high-dose steroids, and reduce mixed chimerism are needed.

## CHMP has incorrectly interpreted that emapalumab is intended to replace etoposide in the treatment of pHLH

Referring to the CHMP AR 23 July 2020 (Section 3.3.2), the applicant wishes to clarify that there has never been an intention to replace etoposide with emapalumab for the treatment of pHLH but to provide an additional option for the treatment of pHLH. The primary focus of the NI-0501-04 trial and the currently proposed indication is in second line, in patients with refractory or recurrent disease or intolerance to conventional HLH therapy. Thus, the intent is not to replace etoposide in the treatment of pHLH.

The major contribution towards an improved survival of pHLH patients by etoposide (Henter et al 2002; Trottestam et al 2011a; Bergsten et al 2017) is fully acknowledged by the applicant. However, the high mortality and the complex pathogenesis of pHLH called for the investigation of additional ways to specifically address the unmet medical need in second line patients. As noted above, the data to support effective and safe treatment of this vulnerable patient population are insufficient and incomplete. This is particularly true as it is not possible to envisage a drug that could be efficacious and safe in all patients, given the different genetic mutations and the different complications present in pHLH patients.

## The applicant believes the inaccuracies and misinterpretation in the CHMP AR 2020 has negatively impacted the review of the emapalumab marketing application

The applicant believes the inaccuracies and misinterpretation in the CHMP AR 2020 23 July as described previously in this ground has negatively impacted the review of the emapalumab marketing application. As a consequence:

- Emapalumab was incorrectly evaluated against second line treatment regime for which no robust evidence base exists.
- The significant unmet medical need was incorrectly underestimated in this paediatric patient population with high mortality and morbidity, specifically in second line treatment.
- The CHMP underestimated the importance to patients and physicians of a novel targeted mode of action (see ground 3: Pharmacokinetics/Pharmacodynamics) with a favourable safety profile (see ground 4: Safety).

## Overall conclusions Ground 1

The applicant believes the inaccuracies and misinterpretations in the CHMP AR 23 July 2020 has negatively impacted the review of the emapalumab marketing authorisation application and has led to the incorrect conclusion that emapalumab does not fulfil the requirements for a conditional marketing authorisation.

The CHMP seems to have underestimated the importance to patients and physicians of a novel targeted mode of action (see ground 3: Pharmacokinetics/Pharmacodynamics) with a favourable safety profile (see ground 4: Safety). As outlined throughout this Ground, there is a high unmet need for drugs for the treatment of pHLH - specifically in second line patients. In the context of this rare and severe disease with high morbidity and mortality the applicant believes that a positive benefit risk ratio has been shown and that the benefit to public health of emapalumab's immediate availability on the market outweighs the risks due to a need for further data. Therefore, emapalumab meets the requirements for conditional authorisation and Study NI-0501-09 is proposed as a confirmatory study

<div style=\"page-break-after: always\"></div>

to provide comprehensive data. The efficacy and safety benefits of emapalumab are described in ground 2: Efficacy and study design and ground 4: Safety respectively.

## CHMP assessment of ground 1 defined by the applicant

Ground#1 defined by the applicant was not a ground for refusal of the CHMP. The applicant misinterpreted the CHMP; in fact, the CHMP indeed acknowledged an unmet medical need for the target population.

In the CHMP AR dated July 23 rd  2020, under section 4.1.2. Available therapies and unmet medical need, it is indeed noted that there is an unmet medical need in the treatment of pHLH. Additionally, under section 4.6.3. Additional considerations on the benefit-risk balance it is further noted that 'despite these treatment options, the unmet need for the target population is acknowledged' .

It is the applicant's belief that the CHMP has incorrectly interpreted that emapalumab is intended to replace the first line treatment etoposide in the treatment of pHLH.

It is the applicant's belief that the inaccuracies and misinterpretation in the final CHMP AR have negatively impacted the review of the emapalumab marketing application and consequently, emapalumab was incorrectly evaluated against treatments for which no robust evidence base exists.

Concerning the evaluation of emapalumab against treatments for which no robust evidence base exists, reference is made to the ground #2 that addresses the evaluation of emapalumab, ground #3 regarding discussion of the MoA and ground #4 regarding safety aspects.

## 6.1.2. Ground #2 - Efficacy and study design

In the single arm trial, the responses seen cannot be causally attributed to treatment with emapalumb given that emapalumab was used in combination with other therapies, as well as due to the known variability in the course of pHLH. Similarly, the contribution of emapalumab to patient eligibility for HSCT, and its impact on overall survival, cannot be ascertained;

The applicant believes the CHMP have incorrectly concluded that a single-arm trial in this disease does not allow causal attribution of the observed efficacy (response, bringing patients to HSCT and survival) to emapalumab given that emapalumab was used in combination with other therapies, as well as due to the known variability in the course of pHLH.

## Overview of Ground

A randomised controlled study is not feasible in pHLH, in second line patients; a single arm study is an appropriate mechanism by which to assess the benefit/risk profile of emapalumab in the proposed indication.

A randomised controlled study in second line pHLH patients was, and is not, feasible because of the rarity and severity of the disease and the absence of an adequate comparator. Such a design would pose an ethical challenge as patients would be randomised to an unapproved and unproven therapy. In addition, such a trial could take between 15-20 years to complete and is therefore clearly not feasible.

The NI-050104 study was designed to demonstrate that IFNγ neutralisation can reduce hyperinflammation in pHLH patients and therefore provide an additional therapeutic option to manage the disease prior to HSCT.

The drug effect was demonstrated by measurement of objective clinical and laboratory parameters of disease activity (Overall Response Rate) based on existing diagnostic criteria, in order to demonstrate

<div style=\"page-break-after: always\"></div>

efficacy independently of type of HSCT, the selection of donor, conditioning and supportive treatments. This was supported by analyses of HSCT and survival and comparison with historical control data.

A statistically significant and clinically relevant improvement in ORR was observed and was supported by multiple sensitivity analyses.

Emapalumab's demonstrated impact on clinical and laboratory HLH parameters were supported by the PK/PD data and correlated with the change in the IFNγ -specific PD marker (CXCL9).

The variability of the disease course does not preclude isolation and causal attribution of the observed efficacy to emapalumab. As the disease is lethal if untreated, and no drug alone has been proven to date to be sufficient in managing the disease, the characteristic unstable variability of pHLH does not, in itself, represent a barrier for the demonstration of the effect of emapalumab.

The observed efficacy can be attributed to emapalumab, despite the co-administration of glucocorticoids (GC); other potential HLH therapies (etoposide, alemtuzumab, ATG), cyclosporine A or supportive therapies. Administering emapalumab on a background of GC was required by a long lasting and consolidated experience on the use of GC in HLH.

The primary endpoint is supported by HSCT and survival data and comparison with historical control data.

The totality of the evidence supports the benefit of emapalumab in the treatment of pHLH in patients with refractory or recurrent disease or intolerance to conventional HLH therapy. The remaining uncertainties will be addressed through confirmatory study NI-0501-09 (ongoing) in the context of a conditional marketing authorisation.

## CHMP assessment

## Detailed Ground

## A randomised controlled study was and is not feasible in pHLH; a single arm study, is an appropriate mechanism by which to assess the benefit/risk profile of emapalumab in the proposed indication

## Challenges and feasibility of a randomised, controlled clinical trial

The applicant acknowledges that a randomised controlled clinical trial (RCT) provides the greatest internal validity and in many larger disease areas is considered the standard design for a registration study. However, in rare, life threatening paediatric diseases, this design is neither ethical not feasible as has been recognised in a number of approvals for medicinal products for rare diseases; indeed between 1999 and 2014, EMA issued approvals for 44 indications solely on the basis of uncontrolled trials (Hatswell et al 2016). As described in ground 1: Underestimated unmet medical need and misinterpretations in the assessment report there are no approved therapies for pHLH and no formal treatment recommendations for patients in whom first-line treatment has failed, largely due to paucity of data. Therefore, an RCT would require that patients would be randomised to an unapproved and undocumented therapy with potential significant toxicities. This in itself poses an ethical challenge which is further compounded by the severity of the disease and the vulnerability of the patient population affected namely paediatric patients, as parents may not accept the risk of their child being potentially randomised to an unproven, second line therapy or placebo plus current therapy. As supported by the statement by the patient representative, the fear that their child may receive chemotherapy, with the known toxicity profile, is real. This concern is even higher given that there is awareness that emapalumab is an approved drug in the treatment of pHLH in US.

<div style=\"page-break-after: always\"></div>

The lack of data on potential comparators also confounds the ability to effectively design such an RCT as this requires a comparator with known efficacy. However, in spite of these challenges the applicant has, at several points during the development of emapalumab, evaluated the potential of conducting such a clinical trial and has led to the conclusion that this would not be feasible.

Specifically, two potential clinical trial designs were proposed by the CHMP during review (see Figure 15).

Figure 15 Clinical trial designs proposed during initial assessment of Gamifant

<!-- image -->

The feasibility of conducting an RCT either as (1) a non-inferiority or (2) superiority trial with ORR or (3) survival as the primary endpoint has been assessed by the applicant under the assumptions shown in Table 7. Given the extreme rarity of the disease and based on the enrolment rate of the ongoing NI0501-09 study in pHLH (17 patients/year), which has 19 active sites, it will take 15-20 years to complete a non-inferiority trial with ORR as primary and significantly longer for a superiority study or one with OS as the primary endpoint. Furthermore, this assumes that US sites could be included which is unlikely to be feasible given the approval of emapalumab by the FDA. Requiring such a study in a disease like pHLH could therefore result in a lack of therapies being developed, even when there is a clear and urgent unmet medical need.

<div style=\"page-break-after: always\"></div>

Table 67 Feasibility of an RCT with emapalumab

| Study design   | 1) ORR primary endpoint Non-inferiority study                                                                                                                                       | 2) ORR primary endpoint Superiority study                                                                              | 3) OS primary endpoint Superiority study                                                                     |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| Assumptions    | Minimum response of 40% 70% response in active groups Non-inferiority margin 15% (50% of the potential or anticipated difference) 80% power, one-sided 2.5% significance level test | 70% response in emapalumab group 60% response in active control groups 80% power, two-sided 5% significance level test | 73% OS in emapalumab group 65% OS in active comparator group 80% power, two-sided 5% significance level test |
| Sample size    | 284                                                                                                                                                                                 | 748                                                                                                                    | 1100                                                                                                         |

Given the above considerations the applicant concludes that an RCT in this setting would not be feasible or ethically appropriate. It is noted that, throughout review, the CHMP assessment report erroneously stated that an RCT is recommended by relevant professional bodies including the European Society for Immunodeficiencies (ESID) and the Histiocyte Society. In fact, while the Histiocyte Society aspires to a randomised controlled study, there is recognition that this is not feasible and neither the Histiocyte Society nor ESID has made an official statement indicating that such a trial is feasible in this rare disease. This is supported further by Expert statements and demonstrated by the lack of historic RCTs in this disease area. The applicant asserts that a single arm study, such as NI0501-04 can be used to provide the required evidence of efficacy in the context of this rare disease with high unmet need and this is further justified in the following sections.

Study NI-0501-04 included an objective, measurable and clinically relevant endpoint in order to establish a drug effect before HSCT, and independently of type of HSCT, the selection of donor, conditioning and supportive treatments.

Study NI-0501-04 was designed to demonstrate that IFNy neutralisation can reduce hyperinflammation in pHLH patients and therefore provide an additional means to manage the disease prior to HSCT. In this context, the applicant believes that the primary endpoint used in study NI-050104 was valid, objective and clinically relevant and therefore as outlined below, can be used to assess the efficacy of emapalumab in the context of this single arm trial.

## Selection of the primary endpoint of ORR

There is no regulatory precedent in pHLH, therefore the primary endpoint was selected in order to demonstrate an effect of emapalumab on disease activity by assessing improvement or normalisation of the recognised pHLH clinical and laboratory parameters, prior to and independently of conditioning and HSCT. Overall response rate (ORR) at 8 weeks in second line patients was therefore selected as the primary endpoint with survival and performance of HSCT included as secondary endpoints to support the clinical relevance of the effect.

<div style=\"page-break-after: always\"></div>

The CHMP have commented that ' Trial NI-0501-04 used an own, new definition for the ORR at week 8, which not corresponds to the usual definition, being less strict.  The clinical relevance of such a response remains unclea r'. This is in fact not the case as outlined below. In collaboration with the Scientific Steering Committee (SSC), ORR was defined as Complete (CR), partial (PR) and HLH improvement (Table 68). The composite endpoint was proposed as all three responses were considered to provide meaningful benefit in a difficult to treat second line population given that the ultimate aim of therapy is to reach HCST and a reduction of HLH disease activity at the time of HSCT has been reported to be a favourable prognostic factor for the final transplant outcome (Horne et al 2005; Trottestam et al 2011; Messina et al 2018; Bergsten et al 2020). It is therefore relevant to at least reduce disease activity, but not necessarily treat longer to obtain CR, as delaying HSCT is also a negative prognostic factor (Horne et al 2005; Trottestam et al 2011; Messina et al 2018; Bergsten et al 2020). Of note, CR was not assessed as the primary endpoint in any of the HLH studies performed to date. Importantly given the single-arm nature of the trial, all parameters used were objective clinical and laboratory measures not susceptible to bias. The elements considered for the definition of ORR in NI-0501-04 were based upon the Histiocyte Society Diagnostic criteria for HLH (Henter et al 2007) with minor modifications as proposed by the NI0501-04 scientific steering committee (SSC) to address the latest understanding of the disease and to ensure that the diagnostic criteria were appropriate for use as a clinical trial endpoint, namely: setting the threshold of normalisation for ferritin at 2,000 µ g/L based on available literature supporting the clinical utility of this threshold value inclusion of D-Dimer in the assessment of coagulopathy in addition to fibrinogen The time-point (8 weeks) for the assessment of the primary endpoint was chosen based on the duration of the other conventional induction regimens (HLH-94, HLH-2004, HIT study), and to ascertain an effect of emapalumab prior to and independent of HSCT. Nonetheless, for completeness ORR was assessed also at a number of other timepoints during treatment, including at conditioning. Table 68 outlines the response definitions used in other prospective HLH trials including the HLH-94, HLH-2004 and HLH-HIT studies and the retrospective case review studying the effect of alemtuzumab as salvage therapy (Marsh et al 2013a). In comparing the NI-0501-04 response definition with those from other studies it should be noted that response data have not been reported at all (HIT-HLH) or have been published with response defined as non-active disease as reported/stated by the investigator (HLH-94, Trottestam et al 2011a and HLH-2004, Bergsten et al 2017). Where data are reported (response at HSCT, Bergsten et al 2020) a considerable proportion of the data are reported as missing. Furthermore, as demonstrated in Table 68, the response definitions across studies are comparable and, in some cases, can in fact be considered as less strict than those used in NI-0501-04. For example, the definition of non-active disease used in HLH-94 allows for some exceptions in normalisation of signs and symptoms (Horne et al 2005) and, in the most recent publication of the HLH-2004 data, (Bergsten et al 2020) D-Dimers and CNS status are also not considered which, due the nature of parameters, would be considered a less strict definition. In the retrospective case review of the effect of alemtuzumab as salvage therapy, some of the diagnostic criteria were not included in assessment of response including platelet count and fibrinogen, as these were not available consistently in patients; fever, because information was often lacking or difficult to interpret; and liver and spleen size, as examinations and imaging results were not

<div style=\"page-break-after: always\"></div>

consistently documented (Marsh et al 2013a). However, in response to CHMP questions, an analysis of the emapalumab data applying the criteria utilised in the alemtuzumab study has been conducted and supports the efficacy of emapalumab (see Emapalumab has demonstrated a consistently positive effect on ORR).

In conclusion, Study NI-0501-04 provides complete and appropriate data in order to assess response to treatment in pHLH that is consistent with or, in some cases, more robust than that of other studies.

Table 68 Clinical response definitions and data reported in HLH protocols

| HLH94                                                                                                                                                                                                                                                                                                                                    | HLH-2004                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | HIT-HLH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Marsh 2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NI0501-04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Response criteria Mon Active Disease No clinicall signs of se s om pe aseasp stated by the treating physician (Trottestam et al 201la; footnote to Table 3); i.e, no infection-induced, no hepato- splenomegaly, no fever exocept if dlinical signs of active CNS disease, and no cytopenias (except if drug-induced) (Horne et al 2005) | Mon Active Disease (Resolution)at Week.8 Normalisation of all HLH diaginostic criteria at wk 8 as reported by the 2017; footnote to Table 3) treating physician (Bergsten et al Specifically: No fever No splenomegaly (isolated moderate splenomegaly might persist in some pts) No cytopenia (Hb ≥90; Plt ≥100; ≥0.5 ANC) No hypertriglyceridemia (<265 mg/dL) Normal CSF, for pts with previously No hyperferritinemia ≥ 500 (or ≥ 200 Decrease in sIL2R, if available (HLH- abnormal CSF 200-i treatment Protocol) conditioning Complete response at stavt of - No fever  No splenomegaly  ANC ≥1.0 x 10°/L, platelets ≥100 x Fibrinogen >1.5 g/L 10%/L Ferritin analysed both for c500 mg/L or c2000 mg/L | Complete Response Normalisation of diagnostic clinical and laboratory abnormalities associated writh HLH at wk 8, including: or splenomegaly, decreased fibrinogen, - fever, cytopenias, increased sCD25, sCD163 (optlonally), In the case of and CNS symptoms. ferritin, normalisation OR a in the pre-study level complete response, 3-fold improvement will be evidence of therapy level is also provided the post may be artificially below 1000 ng/ml. Hb and plt counts increased with transfusion and may assessable (HIT-US not be lmmediately Protocol) | Comolete Response Normalisation of all quantifiable symptoms and laboratory markers including: - levels of soluble IL-2 receptor - ferritin, and triglyceride;  - neutrophil counts, - haemoglobin, - platelet counts - ALT - level of consciousness (documented in cEnical exams in patients with CNS HLH) Partlal Response At least a 25% improvement in 2 or - presence of haemophagocytosis in pathology specimens more quantifiable symptoms and following alemtuzumab laboratory markers by 2 weeks > 1.5-fold decrease in soluble IL- 2 Decrease of ≥ 25% in ferritin Decrease of 2 25% in triglyceride less than 50o, increase of ANC by For patients with an initial ANC off at least 100% to greater than 500 cells/mcL | Complete Response - No fever = body temperature < 37.5 <C - Normal spleen size - No cytopenla = Absolute Neutrophil Counts ≥ 1.0 x 100 x 109/L (absence of Granulocyte-Colony Stimulating Factor (G-CSF) 109/L and platelet count ≥ and transfusion support must be documented for at least 4 days to report no cytopenia) - No hyperferritinemia = serum level is c 2,000 pg/L mg/dL) fibrinogen levels - No evidence of coagulopathy, 1.e. normal D- Dimer and/or normal (> 150 - No neurologicall and Cerebrospinal Fluid (CSF) HLH - No sustained worsening of abnormalities attributed to sCD25 (as indicated by at least two consecutive measurements that are > 2- fold higher than baseline) Partial Response - Af laacf ? nf tha HI H |
|                                                                                                                                                                                                                                                                                                                                          | Onemissing parameter（ie,6of6or5 of5normalparameters)allowed （Bergstenetal2020) Partialresponseatstartof -3to5normalparameters of 6 conditioning measured,or3 to4of5measured, parameters(Bergsten et al2020) inadditionto1 to3abnormal NoResponseatstartofconditioning -Having>3 abnormalparameters (Bergsten et al2020)                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | ForpatientswithanANC500- 2000 cells/mcL,an increase by at least 100% to more than5000 cells/ mcL Forpatients with transaminitis with an ALT greater than 400, an ALT of at least 50%. ALTresponse wasadecrease of For patients with haemophagocytosis notedon a biopsy specimen within 4 weeks of alemtuzumab，resolution of haemophagocytosis following alemtuzumab. ForpatientswithrefractoryCNS HLH and altered level of consciousness,a response was defined as a normal level of consciousness following alemtuzumab(Marsh et al 2013a)                                                                                                                                                                                       | clinical and laboratory abnormalities (including CNS abnormalities)meetthe above-mentionedcriteriafor -There is no progression of “CompleteResponse pathology (e.g.,jaundice, liver size,oedema,CNS otheraspects of HLH disease clinical alterations) HLH improvement Improvement(>50 % change from baseline)of at least 3 HLH clinical and laboratory abnormalities (including CNSinvolvement)                                                                                                                                                                                                                                                                                                                                                |
| Published response data                                                                                                                                                                                                                                                                                                                  | Published response data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Published response data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Published response data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Published response data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| No data on elements of responsereported                                                                                                                                                                                                                                                                                                  | Responseatweek8 Non ActiveDisease(Resolution):no dataon elementof response reported (Bergsten et al2017) Responsesatstartofconditioning Dataonelementofresponse reportedinTable1ofBergstenetal 2020(although significant portion of data is reported as missing from the authors)                                                                                                                                                                                                                                                                                                                                                                                                                              | No response data reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Someelementsofresponsedata reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Allelements of response data reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

Clinical Relevance of the Primary Endpoint

Overall Response Rate, as defined in the NI-0501-04 study, is a clinically relevant endpoint that provides evidence of the medicinal product's efficacy in controlling the disease manifestations of HLH independently of type of HSCT, the selection of donor, conditioning and supportive treatments. Disease manifestations of HLH can result in direct morbidity, mortality and may preclude proceeding to HCST (the only available curative option). As such, low HLH activity at the time of HSCT has been reported to be a favourable prognostic factor for transplant outcome and therefore for survival (Horne et al 2005; Trottestam et al 2011; Messina et al 2018; Bergsten et al 2020). However, a complete response may be difficult to achieve and be maintained, as demonstrated by the need to re-intensify therapy after the initial 8 weeks of induction (Trottestam et al 2011a; Bergsten et al 2017) in some HLH patients. In this respect, the prolongation of treatment with the aim of obtaining the best possible complete disease control at transplantation should be weighed against the risk of delaying transplant and exposing patients to the risk of additional flares and side effects of chemotherapy and generalised immune-suppression leading to a potentially worse HSCT outcome. For these reasons, a composite ORR endpoint (Complete (CR), partial (PR) and HLH improvement) in a second line patient population is relevant.

Furthermore, the parameters chosen to assess the drug effect through ORR, namely platelet and neutrophil counts (cytopenia), ferritin and D-Dimer (hyperinflammation), spleen size (organomegaly), coagulopathy (fibrinogen), all represent a direct measure of the clinical benefit for the patients as when HLH is active, organ damage, coagulopathy and serious bleeding, and infections are a direct consequence of the presence of cytopenias, hyperinflammation and organomegaly.

In published experience it is reported that around 30% to 60% of patients are transplanted with active disease (Messina et al 2018), indicating that HLH control may be difficult to obtain in many HLH patients, and the pressing need to go to transplant given the limited therapeutic options available to control the disease. As such, in collaboration with the SSC, the null hypothesis based on a response rate of 40% was selected for the clinical trial.

In conclusion, the proposed primary endpoint of ORR is a clinically relevant endpoint that was selected to assess the efficacy of emapalumab in second line patients in the absence of confounding factors for pHLH patients such as HSCT, availability of a donor etc. It was based on the HLH diagnostic criteria that align with those used in other prospective clinical trials conducted in HLH and consists of objective, clinical and laboratory measures that are therefore not susceptible to bias. However, to further validate the clinically relevant efficacy of emapalumab, HSCT and survival were included as supporting secondary endpoints.

## Emapalumab has demonstrated a consistently positive effect on ORR

Emapalumab has shown a consistently positive effect on ORR in the primary analysis and in multiple pre-specified and post-hoc analyses (Figure 16).

The study met its pre-defined primary endpoint: ORR at EoT 04 in the pivotal cohort (second-line patients), with an ORR of 63% and the lower 95% CI above the pre-specified null hypothesis of 40%. The applicant further demonstrated the robustness of the efficacy outcome by performing a number of pre-specified or post-hoc sensitivity analysis. All analyses demonstrate a highly consistent effect on ORR which is remarkable for a rare disease trial sample size, although, as would be expected in a subgroup analysis in this context, the confidence intervals become wider when the number of patients is reduced. The efficacy observed is even more encouraging when considering that they have been generated in patients who have obtained an unsatisfactory response to previous first line treatments in whom it has been difficult to obtain disease control.

<div style=\"page-break-after: always\"></div>

The sensitivity analyses are discussed in more detail throughout this document as follows:

Patients with concomitant treatment treated as non-responders (see section below: The observed efficacy (ORR) can be causally attributed to emapalumab in the presence of concomitant medications).

Patients enrolled after the 2016 and protocol amendment (Transition from pilot to pivotal and design of the confirmatory trial).

Excluding patients from one US site (Source data).

In addition, the applicant undertook a post-hoc sensitivity analysis to understand if using the response criteria developed by Marsh and colleagues to retrospectively assess the efficacy of alemtuzumab in a case series of patients that failed conventional HLH therapy would yield a similar response to the prespecified primary endpoint in second line patients in the NI-0501-04 study (Marsh et al 2013a). A similar response rate to the primary analysis was indeed observed (excluding platelets) namely 70.4% (95% CI 0.50, 0.86; N=27) (Figure 16). When platelet count was added to the sensitivity analysis, the percentage of responders to emapalumab increased to 74.1% (95% CI 0.54, 0.89; N=27). In addition, the response rate as evaluated by the investigators in the NI-0501-04 study also supported the primary endpoint analysis in second line patients with a response of 70.4% (95% CI 0.50, 0.86; N=27) as did analyses including only patients who had previously received etoposide and dexamethasone and including all patients from the final database cut off (Figure 16).

In summary, a consistently positive effect of emapalumab on ORR has been demonstrated in the NI0501-04 study that clearly demonstrates the efficacy of emapalumab in the context of this rare and severe disease.

Figure 16 Overall Response Rate. The figure shows the primary endpoint (Overall Response Rate) and prespecified and post-hoc sensitivity analysis

<!-- image -->

## Emapalumab's demonstrated impact on clinical and laboratory HLH parameters is supported by PK/PD analyses.

The final CHMP opinion for Gamifant suggested that the efficacy data were not supported by the PK/PD profile. As outlined further in ground 3: Pharmacokinetics/Pharmacodynamics, the applicant asserts that this is incorrect and that the PK/PD profile is supportive of the efficacy of emapalumab.

The demonstrated amelioration of the typical clinical and laboratory HLH parameters, hence the improved control of HLH activity with emapalumab, was corroborated by the PK/PD analyses which demonstrate a clear relationship between the decrease in CXCL9 (a chemokine exclusively induced by IFNγ hence a measure of IFNγ neutralisation) and the improvement i n clinical and laboratory HLH parameters that form the basis of the objective primary endpoint of ORR. Moreover, the exposure

<div style=\"page-break-after: always\"></div>

response for efficacy shows that the likelihood of clinical response increases with decreasing CXCL9 plasma concentration and is clearly correlated to emapalumab exposure (ni-0501-04-05-exposureefficacy-safety.pdf). Please see ground 3: Pharmacokinetics/Pharmacodynamics for further details.

## The variability of the disease course does not preclude isolation and causal attribution of the observed efficacy to emapalumab

The applicant asserts that the efficacy seen in NI-0501-04 can be attributed to emapalumab regardless of the variability seen in the HLH disease course. As described further in GROUND 1: Underestimated unmet medical need and misinterpretations in the assessment report, HLH is a complex disease characterised by high variability both between patients and importantly, within an individual patient over time. As described by Jordan et al 2011 in 'How we treat HLH', 'therapy is complicated by dynamic clinical course' and that 'after starting therapy, patients should be monitored closely for signs of improvement as well as potential complications and toxicities. Patients may follow a highly unpredictable and dynamic clinical course which may require customisation of therapy'. This variability is therefore inherent and has been described in all clinical studies conducted in pHLH resulting in a need for adaptation of dose and dose frequency and the potential for administration of additional treatments to control disease (Trottestam et al 2011a; Bergsten et al 2017; Marsh et al 2013a; Moshous et al 2019). The variability therefore exists irrespective of the treatment regimen and is due to intrinsic (type of mutation) and extrinsic (e.g. infections and medical and surgical procedures) factors (Jordan et al 2011) and it is therefore unlikely that any single therapy will be effective in all patients. Ultimately the outcome for any patient with pHLH who does not receive a treatment that can bridge to HSCT is death.

In consideration of this variability, patients were closely monitored over time during the NI-0501-04 study for each of the clinical and laboratory measures that formed the components of the primary endpoint. This ensured that the effect of emapalumab was thoroughly documented and evaluated allowing the calculation of the total time in response for each patient. This is a clinically relevant measure as the amount of time in control of HLH manifestations can ensure more favourable clinical conditions to better overcome the challenges inherent to the transplant procedure itself. Thus, the study allowed the applicant to establish and adequately quantify the efficacy, safety, pharmacokinetics and pharmacodynamics of emapalumab using the small pool available of pHLH patients over an acceptable period of time.

The time spent in response during the study was calculated and visualised using Swimmer plots (Figure 17). The median time to response was 8 days and, despite the inherent variability in the disease, the median cumulative duration of response was 75% of days until transplantation. In some patients a transitory loss of response was noted, however response could be re-gained with continuation of treatment. However, this inherent variability in the disease underscores the necessity for a flexible approach to dosing as discussed further in GROUND 3:

Pharmacokinetics/Pharmacodynamics. As described in GROUND 3:

Pharmacokinetics/Pharmacodynamics, the temporal relationship of the PK/PD parameters to efficacy and emapalumab dose fully support the efficacy of emapalumab in the context of the high variability of the disease.

However, pHLH is lethal if untreated (Janka 1983) and prior to the use of a combination of GC and etoposide mortality was extremely high (12-month mortality of 95%). Hence there is no clinical evidence to support disease variability in the form of a temporary improvement to be sustainable, nor to happen spontaneously and therefore not to be associated with a therapeutic drug effect.

<div style=\"page-break-after: always\"></div>

In summary, the variability in disease course is inherent to the disease but does not preclude the ability to demonstrate efficacy of treatment. Efficacy of emapalumab has been clearly demonstrated in second line patients with pHLH, given the very high untreated morbidity and mortality seen.

Figure 17 Swimmer plot of response to emapalumab in individual patients over time

<!-- image -->

## The observed efficacy (ORR) can be causally attributed to emapalumab in the presence of concomitant medications

The applicant has clearly demonstrated that the efficacy observed in the NI-0501-04 study, and in the long-term follow up study NI-0501-05, can be attributed to emapalumab regardless of concomitant treatments allowed. The below discusses this in the context of:

- 1)  Glucocorticoids  (dexamethasone)  which  were  used  as  background  therapy  in  accordance  with standard of care

<div style=\"page-break-after: always\"></div>

- 2)  Other  potential  HLH  therapies  (as  proposed  by  CHMP  during  initial  review  of  the  MAA)  including alemtuzumab, etoposide, ATG and anakinra
- 3) Cyclosporine A used at baseline in a small number of patients (n=5)
- 4) supportive therapies.

## 1) Glucocorticoids

As described in ground 1: Underestimated unmet medical need and misinterpretations in the assessment report, glucocorticoids, notably dexamethasone, are insufficiently effective as monotherapy (Janka 1983; Arico' 1996) but do form the backbone of all recommended pHLH therapies in treatment guidelines and have been used as background therapy in all prospective clinical trials in pHLH (Bergsten 2017; Jordan 2016; Trottestam, 2011a). As such, dexamethasone was used as background in the NI-0501-04 study and the proposed SmPC section 4.2 posology recommends the use of dexamethasone during treatment with emapalumab (SmPC). The use of dexamethasone is therefore in alignment with clinical practice and appropriately represented in the proposed prescribing information.

This use of background glucocorticoid therapy did not confound the effect of emapalumab in the NI0501-04 study. Patients were insufficiently controlled before administered administering emapalumab while glucocorticoids could be tapered according to the treating physician's assessment of the patient's clinical condition after introduction emapalumab treatment. In 47% of the whole study population and in 44.4% of the second line population the dose of glucocorticoids was reduced by at least 50% at End of Treatment (EoT) -04 and an additional 18.5% could reduce the dose of glucocorticoids by at least 30% (CSR section 11.4). Patients who received higher or unchanged doses of dexamethasone at EoT 04 compared to baseline were non-responders to the combination of glucocorticoids and emapalumab, except for 1 patient who responded. This clearly supports that the efficacy seen was as a result of emapalamub and not the use of dexamethasone. In addition, as discussed in GROUND 3: Pharmacokinetics/Pharmacodynamics, the covariate effect of glucocorticoids (including the change in doses as a function of time) was specifically evaluated in the Population PK/PD modelling and it was concluded that the decrease in CXCL9 caused by glucocorticoids can be considered as marginal, certainly not essent ial, and the neutralisation of IFNγ activity can be attributed almost exclusively to emapalumab.

In conclusion, while dexamethasone has been shown to be insufficient to control the disease as monotherapy it forms the backbone of all proposed HLH treatments regimens, including emapalumab. The dose of glucocorticoids could be reduced in a substantial fraction of patients supporting that the efficacy shown in NI-0501-04 can be attributed to emapalumab, independently of dexamethasone. This is further supported by the PK/PD analyses presented in ground 3: PK/PD.

## 2) Other HLH therapies (Alemtuzumab, etoposide, ATG)

Throughout the CHMP review it was suggested that the potential addition of other HLH therapies prevented the clear delineation of the efficacy of emapalumab. The below demonstrates that this is not the case and the use of concomitant therapies was ethically appropriate in this disease and did not impact the ability to assess the efficacy of emapalumab. However, in order to ensure that the design of the study is properly represented in the SmPC, text has been added to section 4.2 to add that additional HLH medication (including etoposide) is allowed as proposed by the Rapporteurs during initial review of the application and this aspect of the study design and data are appropriately represented in section 5.1  of SmPC.

<div style=\"page-break-after: always\"></div>

As discussed in ground 1: Underestimated unmet medical need and misinterpretations in the assessment report, HLH is very complex and serious disease where patients may require multiple pharmacological interventions to maintain control. As such, in study NI-0501-04, additional HLH therapies could be administered for ethical reasons in the event of unsustained or limited HLH improvements on emapalumab. Given the limited data on other therapies, etoposide was the recommended agent, unless the investigator assessed this agent to be unlikely to be effective in an individual patient. Similarly, to NI-0501-04, additional therapies were also allowed in the HLH-94, HLH2004, and HIT studies Table 69.

<div style=\"page-break-after: always\"></div>

## Table 69 Use of additional HLH therapies during pHLH studies

| Study                                                                                                                                                                                                                                                                                                                                                                                                                         | Additional HLH therapies allowed by protocol                                                                                                                                                                                                        | Impact of additional HLH therapies on data analyses   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Introduction of cyclosporine A during initial therapy (first 8 wks of treatment) or administration of cytotoxic agents not prescribed in the protocol are allowed                                                                                                                                                                                                                                                             | All patients with major treatment changes were included in all outcome analyses                                                                                                                                                                     | HLH-94                                                |
| ' The protocol does not include a salvage protocol. We want to mention an alternative approach of inducing remission, with a regimen including a treatment with steroids (2-5 mg/kg/d methylprednisolone IV, following by progressive tapering) and ATG…. '.                                                                                                                                                                  | The publication from Bergsten and colleagues does not specify whether the reported outcomes do or do not account for additional HLH therapies                                                                                                       | HLH- 2004                                             |
| 'If patient is a non-responder,… after 2 weeks of treatment, then salvage therapy should be aggressively pursued. Though salvage therapy for HLH is not defined, options may include therapy per HLH-94, therapy with CAMPATH, pulse corticosteroids, or a repeat course of ATG, though no strategy is currently prescribed. Treating physicians are strongly encouraged to discuss salvage options with the study chairman.' | If salvage therapy is initiated, pts are considered to be off study. However, outcomes data will continue to be gathered on these patients, but may be analysed as a separate subset.                                                               | HIT                                                   |
| Additional HLH treatment are allowed in case of unsustained or limited HLH improvement. Etoposide is the recommended agent.                                                                                                                                                                                                                                                                                                   | All patients who received additional HLH treatments were included in outcome analyses. However, sensitivity analyses have been conducted to assess the impact of the additional treatments on the primary endpoint (ORR at EOT 04) and on survival. | NI- 0501- 04                                          |

<div style=\"page-break-after: always\"></div>

The potential concomitant agents for the treatment of pHLH discussed during review of the emapalumab MAA included etoposide, alemtuzumab, ATG and anakinra. No patients received anakinra during the NI-0501-04 study or the long-term extension study NI-0501-05. The patients receiving etoposide and/or alemtuzumab and/or ATG due to unsustained or limited HLH improvement in NI0501-04 and NI-0501-05 studies are presented in Table 70 and Table 71 respectively.

In total 12 patients received additional treatment during the 04/05 studies, and hereof 5 patients received additional treatment prior to the primary endpoint readout in the 04 study. Only one of these 5 patients recorded a response and sensitivity analyses did not demonstrate an effect of this additional therapy. Examination of the patient level data demonstrate that the majority of patients who received additional HLH therapies at any point in time remained non-responders (9 out of 12), and in the others a control of HLH had already been achieved, further supporting an independent effect of emapalumab. Further details are provided below.

Three patients received additional HLH treatments (etoposide and/or alemtuzumab and/or ATG) concomitantly to emapalumab, and 4 patients after either completion or withdrawal of emapalumab treatment. An additional patient (see note to Table 70) received alemtuzumab and etoposide because of HLH reactivation which occurred 3 weeks after emapalumab discontinuation due to disseminated histoplasmosis; in this patient the assessment of response to emapalumab occurred prior to the administration of etoposide and alemtuzumab. In 4 patients emapalumab was discontinued since administration of additional HLH treatments represented a withdrawal criterion in the protocol version current at that time. However, in 2 of these patients emapalumab treatment was re-initiated in compassionate use (CU) upon request of the treatment physician due to further worsening of the patients and the assessment of a favourable benefit risk.  In total there were 5 patients who received additional HLH treatments in Study NI-0501-04 either concomitantly to emapalumab or soon after last emapalumab infusion but prior to ORR assessment at EoT 04 (highlighted in grey in the below tables). All patients were second line with the exception of two first-line patients who received additional HLH therapy in the NI-0501-05 study (Table 70).

Table 70 Patients receiving etoposide/alemtuzumab/ATG during Study NI-0501-04 for unsustained or limited HLH improvement

## Concomitantly to emapalumab prior to Study Day (SD) of Overall Response Assessment

| Pt. ID   | Drug                  | Administered on (SD)                     | Last emapalumab infusion in 04 study (SD)   | Overall response at EoT 04 (SD)        | Additional comments                                         |
|----------|-----------------------|------------------------------------------|---------------------------------------------|----------------------------------------|-------------------------------------------------------------|
| AA       | Etoposide             | SD10 - SD13 (then SD32 - SD35 during CU) | SD18                                        | SD20 (incl. in sensitivity analysis) 1 | Withdrawn from study 2 (Emapalumab restarted in CU on SD21) |
| BB       | Etoposide Alemtuzumab | SD35 - SD49 - SD55 SD55 - SD56 - SD57    | SD59                                        | SD62 (incl. in sensitivity analysis) 1 |                                                             |
| CC       | Etoposide             | SD20 - SD27 - SD33                       | SD38                                        | SD39 (incl. in sensitivity analysis) 1 |                                                             |

After completion/withdrawal of emapalumab 5

<div style=\"page-break-after: always\"></div>

| Pt. ID   | Drug                      | Administered on (SD)                            | Last emapalumab infusion in 04 study (SD)   | Overall response at EoT 04 (SD)        | Additional comments                                         |
|----------|---------------------------|-------------------------------------------------|---------------------------------------------|----------------------------------------|-------------------------------------------------------------|
| DD       | Alemtuzumab Etoposide ATG | SD49 - SD51 SD55 - SD68 SD75                    | SD47                                        | SD50 (incl. in sensitivity analysis) 1 |                                                             |
| EE       | Etoposide 4               | SD19 (then SD24 - SD31 - SD60 - SD77 during CU) | SD15                                        | SD19                                   | Withdrawn from study 2 (Emapalumab restarted in CU on SD27) |
| FF       | Alemtuzumab               | SD31 - SD32 - SD33 (then SD36 - SD37)           | SD29                                        | SD33 (incl. in sensitivity analysis) 1 | Withdrawn from study 2                                      |
| GG       | Etoposide                 | SD12                                            | SD9                                         | SD12                                   | Withdrawn from study 2, 3                                   |

Note: SD0 is the day of first emapalumab administration

EOT 04 is defined as 3 days after last emapalumab infusion in Study NI-0501-04 (with a -3/+5 window)

1  Sensitivity analysis performed to evaluate the impact of additional HLH treatments on the primary efficacy endpoint (ORR at EoT 04).

2  Treatment with emapalumab was discontinued because the administration of additional HLH treatments was a withdrawal criterion in the protocol version current at the  time.

3  Patient continued on etoposide for a total of 9 doses.

4  Alemtuzumab was also administered during CU treatment.

5  Another patient, received alemtuzumab and etoposide (1 dose each) because of an HLH reactivation which occurred 3 weeks after emapalumab discontinuation. Treatment with emapalumab was discontinued due to disseminated histoplasmosis assessed as possibly related to the study drug (resolved upon antifungal treatment.

<div style=\"page-break-after: always\"></div>

Table 71 Patients receiving etoposide during Study NI-0501-05

| Pt. ID   | Drug      | Administered on (SD)                    | Last emapalum ab infusion (SD)   | Additional comments                                                                            |
|----------|-----------|-----------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------|
| HH       | Etoposide | SD131 - SD134 - SD137                   | SD141                            | Conditioning started on SD144                                                                  |
| II       | Etoposide | SD61 - SD64 - SD67 - SD69 - SD72 - SD75 | SD78                             | Conditioning started on SD80                                                                   |
| JJ       | Etoposide | SD84                                    | SD123                            | Single dose of etoposide administered due to increased WBC at SD82 CSF analysis, then resolved |
| KK       | Etoposide | SD121 - SD124 - SD128 SD131 - SD142     | SD167                            | Conditioning started on SD171. Patient died during conditioning                                |
| LL       | Etoposide | SD84 - SD88 - SD95 - SD109              | SD115                            | Etoposide administered due to occurrence of opisthotonus on SD77, then resolved                |

Impact of additional HLH therapies on response at end of treatment in the -04 study (primary efficacy endpoint)

Two sensitivity analyses have been conducted to evaluate the potential effect of concomitant HLH therapies on the efficacy of emapalumab. In these analyses, the 5 patients receiving concomitant therapy prior to the assessment of the primary endpoint were treated either as non-responders (sensitivity analysis 1) or were excluded from the analysis (sensitivity analysis 2).

The results of the sensitivity analyses are given in Table 72. The results of both sensitivity analyses are consistent with the primary endpoint in all second line patients.

Table 72 Sensitivity analyses on ORR at EOT 04 (primary efficacy endpoint) Sensitivity analysis 1

|                                                                     | Statistic         | All Patients (N=34)         | Second-Line Patients (N=27)   |
|---------------------------------------------------------------------|-------------------|-----------------------------|-------------------------------|
| Overall Response Complete response Partial response HLH Improvement | N (%) N (%) N (%) | 7 (20.6) 10 (29.4) 4 (11.1) | 7 (25.9) 7 (25.9) 2 (7.4)     |
| Overall Response Rate                                               | N (%) 95% CI      | 21 (61.8) (0.44, 0.78)      | 16 (59.3) (0.39, 0.78)        |
| p-value 1                                                           |                   | 0.0085                      | 0.0337                        |

1  p-value based on Exact Binomial Test at a one-sided significance levels of 2.5% comparing proportion of patients with Overall Response to null hypothesis of 40%

<div style=\"page-break-after: always\"></div>

## Sensitivity analysis 2

|                                                     | Statistic   | All Patients (N=29)    | Second-Line Patients (N=22)   |
|-----------------------------------------------------|-------------|------------------------|-------------------------------|
| Overall Response Complete response Partial response | N (%) N (%) | 7 (24.1) 10 (34.5)     | 7 (31.8) 7 (31.8)             |
| Overall Response Rate                               | N (%)       |                        |                               |
| HLH Improvement                                     | N (%)       | 4 (13.8)               | 2 (9.1)                       |
|                                                     | 95% CI      | 21 (72.4) (0.53, 0.87) | 16 (72.7) (0.50, 0.89)        |
| p-value 1                                           |             | 0.0004                 | 0.0019                        |

1  p-value based on Exact Binomial Test at a one-sided significance levels of 2.5% comparing proportion of patients with Overall Response to null hypothesis of 40%

Impact of additional HLH therapies on response at end of treatment in the -05 study

As mentioned above, during the extension Study NI-0501-05, 5 patients received etoposide concomitantly to emapalumab because of either insufficient control of HLH activity or concerns regarding CNS disease (Table 71).

Of these, 2 patients received etoposide due to CNS signs (re-occurrence of pleocytosis in CSF) and symptoms (onset of opisthotonus). Both patients were in response with regards to systemic HLH manifestations at the time of etoposide administration (in 1 patient only a single dose was given) and maintained the same level of response at EoT04/05. Three patients received etoposide due to unsatisfactory response and remained non-responders at EoT 04/05. Based on the above, the addition of therapies in the NI-0501-05 study cannot be considered to have biased the results.

## 3) Cyclosporine A

In addition to the above, the continuation of cyclosporine A (CsA) treatment was allowed per protocol if ongoing at the time of enrolment. CsA could not be started during the study. Five patients continued receiving CsA during NI-0501-04 study, in 2 of them CsA was continued until EoT 04, whereas in 3 patients CsA was discontinued either at week 1 or at week 3. Since CsA was discontinued long before EoT 04, no impact on the response status in the primary efficacy analysis can be expected for the 2 responders. All other patients had no response at EoT 04. During Study NI-0501-05 none of the patients received CsA prior to start of conditioning, therefore there was no impact on response at EoT 04/05, while CsA was thereafter administered for GvHD prophylaxis. No new CsA treatment was introduced during the conduct of the clinical trials, although doses could be tapered or discontinued. Therefore, the use of CsA cannot be considered to have biased the results of the clinical study.

## Impact of HLH treatments at a patient level

The results discussed above are supported by further examination of the data at an individual patient level. Figure 18 shows the levels of response in relation to administration of ATG, CsA, etoposide and alemtuzumab presented individually for representative patients in (a) the NI-0501-04 study (b) the extension study NI-0501-05 and (c) after discontinuation of emapalumab. When a co-medication is administered it appears as a dot on the black lines on the top of the graphs:

Orange dots represent time of administration of antithymocyte globulin (ATG).

<div style=\"page-break-after: always\"></div>

Blue lines represent administration period of cyclosporine (CYC) (cyclosporine treatment was ongoing at the time of emapalumab treatment initiation).

Green dots represent time of administration of etoposide (ETO).

Red dots represent time of administration of alemtuzumab (ALE).

The response level is presented as dots on a black line below the co-medications. Black dots represent no clinical response. Improvement, partial response and complete response are indicated from dark to light green dots. Time of HSCT, when applicable, is indicated by a vertical yellow bar. Emapalumab doses (mg/kg) are indicated at the bottom of the graph with vertical black lines when in study NI0501-04/05 and violet lines when in compassionate use treatment.

These patient level data demonstrate that the majority of patients who received additional HLH therapies, (n=9 of a total of 12) remained non-responders, and in the others a control of HLH had already been achieved.

In conclusion, the administration of etoposide/alemtuzumab/ATG or CsA did not substantially modify the course of the disease and the control of HLH activity provided by emapalumab and therefore the efficacy of emapalumab can be established even where additional therapies were added.

<div style=\"page-break-after: always\"></div>

## Figure 18 Individual time-profiles of etoposide/alemtuzumab/ATG administration during NI-0501-04 and NI-0501-05 studies with Overall Response until HSCT (if no HSCT, up to last available observation)

- a. Additional HLH treatments administered concomitantly to emapalumab in -04 study
- b. Additional HLH treatments administered concomitantly to emapalumab in -05 study

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

- c. Additional HLH treatments administered after completion/discontinuation of emapalumab treatment in -04 study

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 4) Other Supportive treatments

Other supportive treatments were allowed in the NI-0501-04 study including G-CSF, rituximab and IVIG. However, no impact on the response status of patients has occurred due to the administration of these supportive treatments.

With regards to G-CSF, the definitions applied for response assessment postulated that no administration of G-CSF should have occurred in the 4 preceding days in order to consider 'improvement or normalisation' for neutrophil counts and therefore this could not have biased the outcome of the study.

Administration of rituximab prior to conditioning occurred in 2 patients due to EBV positivity. One patient, diagnosed post-mortem with a NK/T cell EBV-positive lymphoma, did not achieve a response prior to death; the other patient only received one rituximab dose during study NI-0501-05.

IVIGs were not administered at doses known to exert immunomodulatory activity in any patient and therefore this could not be considered to have biased the outcome of the study.

## Conclusion on concomitant therapies

In conclusion, the use of concomitant therapies including GC, other potential HLH treatments and supportive therapies did not influence the results of the clinical trial as shown above and thus the efficacy of emapalumab can be ascertained. However, to fully reflect the design of the study, Section 4.2 Posology and method of administration of the proposed SmPC has been updated to include reference to the fact that additional concomitant HLH medication (including etoposide) is also allowed and this aspect of the study design and consequent data are clearly described in section 5.1.

## Emapalumab has a positive effect on bringing patients to HSCT and Survival supporting the results for the primary efficacy endpoint

The primary endpoint of ORR was further supported by a positive effect of emapalumab on HSCT and survival and the benefit were not impacted by the use of concomitant therapies.

One of the key goals of treatment of patients with primary HLH is to bring patients successfully to transplantation, and in the second-line patients 19 of the 27 (70.4%) proceeded to transplant. In the second line population, the 12-month probability estimates were 73% (95% CI: 52%, 86%) for Overall Survival and 89% (95% CI: 64%, 97%) for post-HSCT Survival, further supporting a clinically meaningful effect of emapalumab in this population.

Importantly, the analysis of the post HSCT event free survival (event being death, graft failure and HLH relapse), showed that 84.2% of second-line patients were event free pointing to the favourable condition ('fit for transplant') in which patients underwent HSCT.

These data are supported by a series of pre-planned and post-hoc analyses which all demonstrate a favourable effect on survival (Figure 19). Notably, in a post-hoc sensitivity analysis, the applicant also investigated the effect on survival of additional HLH therapies, by excluding any patient that received additional etoposide/alemtuzumab/ATG from the analysis. This post-hoc analysis showed a similar magnitude of the 12 months probability of survival as in the second line population of 0.69 (95% CI: 0.412, 0.860; N=17) and post HSCT of 0.83 (95% CI: 0.482, 0.956) (N=12) (Figure 19).

<div style=\"page-break-after: always\"></div>

Figure 19 Forest plot of overall and post HSCT survival

Overallsurvivalmonth12

<!-- image -->

## Comparison with historical control cohort confirms reduced risk of death in second line patients treated with emapalumab when compared to historical controls

To further complement the data from the single arm study, the applicant has also made extensive efforts to perform a retrospective collection of data from primary HLH patients to serve as a historical control cohort for the NI-0501-04 study. The use of an external control (including historical control) is included as part of ICH E10 (Choice of control group in clinical trials) and is relevant in this context where a controlled study would be neither ethically appropriate nor feasible. The collection of these data was performed in accordance with the emapalumab PIP.

There are limitations to such an analysis as the data are not collected prospectively and hence not all data could be retrieved. Nevertheless, through the collaboration of the Principal Investigators of Study NI-0501-04 in Europe and the United States, it was possible to gather sufficiently robust information on main relevant baseline characteristics and survival, so that the key endpoints of overall and postHSCT survival could be validly analysed. The historical control analyses demonstrated a reduction in risk of death by 44% (HR 0.56; 0.08 to 3.74) in second line patients treated with emapalumab when compared to historical controls. The outcome of the comparison of NI-0501-04 data with historical controls therefore supports the survival advantage provided by emapalumab treatment over other conventional treatments.

The totality of the evidence supports the positive benefit risk of emapalumab in the treatment of pHLH in patients with refractory or recurrent disease or intolerance to conventional HLH therapy; The remaining uncertainties will be addressed through confirmatory study NI-0501-09.

It is acknowledged that there are limitations inherent to a single arm study, however the applicant has clearly demonstrated that a randomised controlled study is neither ethically appropriate or feasible in second line pHLH with a potential study taking approximately 15-20 years to complete. Emapalumab did demonstrate clinically relevant and positive results in terms of ORR as well as across the secondary endpoints measured including overall survival. Seventy percent of second line patients proceeded to transplantation, which is the only curative treatment for these patients. Furthermore, there was a reduced risk of death by 44% (HR 0.56; 0.08 to 3.74) in second line patients treated with emapalumab when compared to historical controls. For ethical reasons and reflective of clinical practice, concomitant therapies were allowed during the study however, after careful review of the data and having performed sensitivity analyses, the applicant concludes that the efficacy observed can be causally

<div style=\"page-break-after: always\"></div>

attributed to emapalumab. 'Cumulative time in response' data supports the fact that emapalumab is effective despite the variability of the disease course.

Based on these efficacy results in combination with the clinically manageable safety profile (ground 4: Safety) and in light of the clear unmet medical need in second line patients the risk benefit profile of emapalumab in the proposed indication is positive and therefore supports approval of emapalumab in the context of a conditional marketing authorisation.

To address any remaining uncertainties the applicant is committed to completing study NI-0501-09. Study NI-0501-09 is an on-going open-label, single arm, multicentre study to assess efficacy (ORR), safety, impact on quality of life, and long-term outcome, in paediatric patients with primary pHLH treated with emapalumab, that will provide further understanding of the efficacy and safety of the medicinal product. While it is acknowledged that this study is also a single arm study the data will support the reproducibility and external validity of the data from NI-0501-04. Given that a randomised clinical study is simply not possible, Study NI-0501-09 offers the best option for additional data in a timely manner.

The study plans to enrol 34 patients, of which 22 patients have already been included (EU:20 and US:2), and preliminary data suggest 15/22 patients are in second line (all EU).

The NI-0501-09 study is part of the PIP, enrolment is progressing well (22/34), and last patient last visit is projected to be October 2022 with a final report six months later. Given the status of the study, the applicant does not have concerns around completion of this study, also with a conditional approval in EU.

## Overall conclusions Ground 2

In conclusion, the applicant has demonstrated that a randomised, controlled study would be ethically and practically infeasible in the context of this severe and rare paediatric disease and that the efficacy of emapalumab has been sufficiently demonstrated in the context of a conditional marketing authorisation. The primary endpoint of ORR was comprised of objective clinical and laboratory parameters and based on accepted diagnostic criteria and was clinically relevant. Emapalumab demonstrated a consistent effect on ORR in the primary analysis and in multiple pre-planned and posthoc sensitivity analyses. The efficacy is supported by the PK/PD profile and was demonstrated in spite of the inherent variability of pHLH and independently of concomitant therapies. The clear ORR data was also supported by a positive effect on HSCT and survival and by historical control survival data. The applicant therefore concludes that the efficacy of emapalumab has been sufficiently demonstrated in this rare disease with high unmet need to support a positive benefit risk in the context of a conditional marketing authorisation with study NI-0501-09 as a specific obligation to provide additional efficacy data post-marketing.

## CHMP assessment of ground 2

## Sample Size and RCT

The applicant claims that a randomised controlled study is not feasible, based on the rarity of the disease as well as the absence of a comparator. The argument on unethicality of randomisation to an unapproved therapy as raised by the applicant is not agreed to as standard of care could be used in the control group and thus these patients would not be deprived of an active treatment.  Based on these aspects, defining a control group consisting of standard of care and comparing this to gamifant administered on top of standard of care is considered feasible.

It can be agreed with the applicant that some authorisations for marketing Authorisation for rare disease have been approved based on SATs, but this needs to be assessed  on a case by case basis

<div style=\"page-break-after: always\"></div>

taking into account the indication, results, and each indication has its own setting as well as each product has its own profile and each trial its own results.

The rarity of the disease is acknowledged. However, considering that the ongoing study (NI-05-09), representing a replication of the pivotal study, the CHMP is not convinced that the patient numbers should not suffice for a RCT. The timelines for completing a RCT of 15-20 years is derived from a calculation for a non-inferiority setting, with different assumptions than were used for the single arm trial. A response rate of 70% for the comparator was assumed and used together with a non-inferiority margin of -15% (translating into a response rate of 55% for the test treatment, if the control group was indeed 70%). This scenario would make stricter requirements than the targeted demonstration of at least 40% response (in ORR) in the SAT. According to Meeths et al, 2015, 'the minimal annual incidence rate of primary HLH remained 0.12 per 100,000 children, equating to 1.8 per 100,000 live births'. Considering this and assuming a similar rate in the entire EU and that approximately 5 million births/per year were reported in the last years in the EU (Eurostat), a RCT with 85-110 patients would be indeed considered feasible.

## Statistical significance

The applicant claims that a statistically significant demonstration of a clinically relevant improvement in ORR was observed, but this is not agreed to. Relevant sensitivity analyses, including an analysis imputing patients initiating rescue therapy as non-responders, did however cross the predefined null hypothesis of 40% (minimum target) with the lower limit of the confidence interval (0.39%), and thus the results were not robustly above the target.

## Single Arm Trial

In order to draw a conclusion on a demonstrated treatment effect, it is required that observations on the primary endpoint can be attributed to be an effect of the investigational treatment. In a single arm trial this is particularly difficult. Several sources of bias are mentioned and agreed by the applicant, for instance the disease being characterised by 'high variability both between patients and importantly, within an individual patient over time'. This is fully agreed to as does also variability in background medication. Indeed, pHLH is characterised by a reported variety of mutations and a vicious inflammatory cycle. Taking this and the co-administration with different drugs and dose regimens and their potential effects or the absence thereof into consideration, this all adds up to a considerably high intra- and inter-patient variability that affects isolation of the treatment effect attributable to emapalumab from the observed ORR and other endpoints.

In the present trial, variability in the course of the disease refers to the variability on the primary endpoint ORR. The applicant argues with the lethal course of the disease if untreated which is agreed upon however this does not resolve the variability of the ORR. Time-dependent endpoints like mortality or endpoints that also depend on external factors like HSCT represent another problem in interpretation of SATs. Besides this, the reduction in risk of death by 44% as claimed by the applicant refers to the point estimate only. While the comparison to an external control is problematic, the upper limit of the confidence interval of 3.74 for the HR shows that this estimate is prone to extremely large variability and the results overall questioned.

## Treatment effect

Initially, the applicant chose exploratory endpoints with no specified hierarchy with criteria focusing on number of patients with non-active disease (nad) or time to achievement of non-active disease/complete response/partial response etc. but introduced a new primary endpoint later on (amendment 6 of the protocol): Overall Response, i.e. achievement of either Complete or Partial Response or HLH Improvement, at End of Treatment of Study NI-0501-04 (at week 8 or earlier if HSCT

<div style=\"page-break-after: always\"></div>

was available). The new criteria were less strict compared to the initially chosen ones. For instance, the initial protocols differentiated between complete response (CR) and non-active disease (nad) for ferritin as follows; CR: ferritin level &lt; 1000µg/L, nad: &lt;500µg/L. In contrast, the ferritin criterion for CR of the new PEP was defined as 'no hyperferritina emia at a serum level &lt; 2000µg/L'. This change to a less strict definition increases the response rate and thereby introduces a bias.

Moreover, the definition of nad in the initial protocols was in line with the HLH-04 study and thus would have allowed a more profound interpretation. Introducing a new primary endpoint, without a reliable link to previous data or descriptions of natural courses additionally impairs the interpretation of efficacy results and a subsequent conclusion on a benefit-risk balance.

Furthermore, the CHMP did not agree with the applicant that the chosen ORR is a 'clinically relevant endpoint that provides evidence of the medicinal product's efficacy in controlling the disease manifestations of HLH independently of type of HSCT, the selection of donor, conditioning and supportive treatments' and low HLH activity at the time of HSCT has been reported to be a favourable prognostic factor for transplant outcome and therefore for survival (Horne et al 2005; Trottestam et al 2011; Messina et al 2018; Bergsten et al 2020)'. Considering the high variability of HLH disease both between patients and within an individual patient over time, a measurement at a specific time point is not considered to reflect HLH activity sufficiently as patients may experience disease deterioration shortly after measurement.

In this context, it is important to note that the primary goal of pHLH therapy is to enable HSCT. 23/34 subjects (=67.7%, all treated set, see also page 89 [04 and follow-up 05 study] proceeded to transplantation. 19/27 (=70.4%) second-line patients and 4/7 (=57.1%) treatment-naïve subjects proceeded to HSCT. According to published efficacy data (Table 61), 80% and 76% of treatment-naïve patients in the HLH-04 and HLH-94 trial, respectively, proceeded to HSCT. In the Marsch study 17/22 (77%) paediatric and adult refractory HLH patients treated with alemtuzumab proceeded to HSCT (Marsch et al, 2013). Although a comparison of these literature findings to the provided study data is not optimal, it is noted that no meaningful improvement beyond current standard of care treatments is indicated. The significance of the sensitivity analysis conducted to evaluate the potential effect of concomitant HLH therapies on the efficacy of emapalumab appears unclear.

## Transition to pivotal trial

Trial adaptions are seen critical, especially in an open label trial, and there is concern that the transition to a pivotal trial was informed by the trial and has introduced bias. The concern on transition comes as an additional concern undermining the interpretability of the single arm trial. The comparison of the stage before/after the transition would be of interest, and while numerically the second stage has a somewhat smaller ORR, this is only based on 10 patients and is associated with a wide confidence interval, not allowing for a reliable comparison of the two stages. The small number of patients following the transition on the contrary means that the larger number of the population had already been included before, thus aggravating the concern on bias. For further considerations on trial conduct and integrity please see the discussion on the GCP inspection under Ground#5.

## NI-0501-09 as condition for CMA

Study NI-0501-09 is essentially a replication of the pivotal trial NI-0501-04. As a consequence, given that the trial population was the same, one may expect that the same information, and associated with the same concerns is provided, apart of the issue of trial adaption above described.

<div style=\"page-break-after: always\"></div>

## 6.1.3. Ground #3 - Pharmacokinetics/Pharmacodynamics

no substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since the role of IFN-gamma in the pathogenesis of pHLH is not completely understood

The applicant believes the CHMP have incorrectly concluded that no substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since the role of IFN-gamma (IFN γ ) in the pathogenesis of pHLH is not completely understood. The applicant asserts that the role of IFN γ in pHLH has been demonstrated by data from different animal models of pHLH, supported by the presence of elevated levels of IFN γ in pHLH patients and that the PK/PD profile clearly shows the relationship between the drug and its effect on disease parameters thereby allowing the definition of the posology.

## Overview of Ground

In this section, the pharmacometric findings in study NI-0501-04 are summarised, with a focus on the interpretation in second line patients, in order to support that:

- -CXCL9 is a specific biomarker for IFNγ activity.
- -pHLH  patients  in  study  NI-0501-04  exhibit  a  high  pre-emapalumab  baseline  IFN γ biological activity as shown by the high levels of CXCL9 (see section Role of IFNγ in HLH).
- -The treatment with emapalumab neutralises IFN γ biological activity as shown by the fast and marked decline in CXCL9 levels already from the first emapalumab administration (see section Pharmacodynamic effect of emapalumab).
- -During  emapalumab treatment, the neutralisation  of  IFN γ biological  activity  correlates  to  an improvement of clinical and laboratory HLH abnormalities as shown by the correlation between the individual decrease in CXCL9 levels and laboratory parameters such as ferritin, sIL-2RA, DDimer, platelets, neutrophils and fibrinogen at different time points, as well as overall clinical response at week 2 and EOT (see section Efficacy of emapalumab).
- -The required continuation of background therapy with glucocorticoids at the time of emapalumab initiation allows for the assessment of emapalumab drug effect on IFN γ neutralisation and on response  as  shown  by  the  differential  effect  of  glucocorticoids  and  emapalumab  on  CXCL9 derived by modelling (see section Effect of concomitant therapies).
- -Continuation of pre-existing cyclosporine (in 5 patients), as allowed by the protocol, also allowed for an assessment of emapalumab drug effect on IFN γ neutralisation as shown by the lack of apparent  significant  effect  of  cyclosporine  on  CXCL9  dynamics  (see  Effect  of  concomitant therapies).
- -The impact of additional HLH treatments (e.g. etoposide and alemtuzumab) administered in few patients  allowed  for  an  assessment  of  emapalumab  drug  effect  as  shown  by  the  lack  of appreciable  effect  on  response  by  these  additional  treatments  (see  Effect  of  concomitant therapies).

Therefore, considering:

- -The documented marked increase in IFNγ activity (evidenced by high CXCL9 concentrations).
- -The absence of a suf ficient control of IFNγ activity by means of the HLH therapies administered prior to emapalumab.

<div style=\"page-break-after: always\"></div>

- -The key role played by IFNγ in the pathogenesis of pHLH in animal models of this disease (Jordan et al 2004; Pachlopnik et al 2009; Das et al 2016; Rood et al 2016; Kögl et al 2013), the fact that IFNγ induces macrophages to produce and release high levels of proinflammatory cytokines and enhances macrophage phagocytic ability (Groom and Luster 2011) which damage organs and tissues (Jordan et al 2011).

The applicant considers that emapalumab, which specifically targets IFNγ and neutralises its activity with a mode of action different from the already available therapies, can be considered as an additional option for treating pHLH patients in particular in second line patients, given the high medical need.

In addition, the various PK, PK/PD, exposure efficacy/safety analyses shown will also be used to address the applicant's divergent opinion from the final CHMP clinical pharmacology assessment on posology and to support that:

- -The population PK, PK/PD and exposure efficacy models are adequate to support the posology of emapalumab since, as shown, they can predict the likelihood of overall clinical response for different dosage schemes of emapalumab considering various levels of IFNγ.
- -The proposed dosing scheme of emapalumab is appropriate as it allows efficient and safe dose titration that addresses the reported variable course of the disease, namely the possibility of disease reactivation that impacts the PK and PD of emapalumab (Jordan et al 2011).

Figure 20 PK, PK-PD, and Exposure-Response/Safety Analysis Strategy for emapalumab

<!-- image -->

## Overview of Ground 3

The applicant stated that the pharmacometric analyses have confirmed that in primary HLH the immune system is over-activated and that the background therapies received before study entry (e.g. corticosteroids, etoposide, cyclosporine A), and continued during the study (e.g. corticosteroids in all patients and cyclosporine A in few patients), were not able to sufficiently temper the immune system to de crease the IFNγ activity. The applicant stated that this is evidenced by high CXCL9 concentrations, a specific marker of IFNγ activity, at study entry. Emapalumab, due to its specific mode of action, markedly neutralises the uncontrolled IFNγ activity as s hown by a fast and profound decrease in CXCL9 concentrations. This decrease in CXCL9 concentrations is associated with a corresponding improvement in laboratory parameters such as ferritin, sIL-2RA, D-Dimer, platelets, neutrophils and fibrinogen, parameters that characterise the disease intensity. Overall, these findings support the pathogenic role of IFNγ in primary HLH patients and the favourable therapeutic effect of emapalumab . The proposed dosing regimen of emapalumab, tailored on the basis of the evolution of the clinical and laboratory parameters that characterise HLH activity, respond to the need to address

<div style=\"page-break-after: always\"></div>

the variable clinical course of the disease. The exposure-safety analyses, covering a wide range of emapalumab exposure, did not show any safety concerns in terms of increased occurrence of AEs and negative impact on parameters of liver and renal functions as a function of increased emapalumab exposure.

## CHMP assessment of Ground 3

One of the underlying mechanisms for HLH suggests a central role fo r IFNγ as the cause of symptoms. The applicant has not investigated in how far mechanisms unrelated to IFNγ -mediated inflammation contribute to pHLH in the targeted patient population. Moreover, although IFNγ levels are in general highly elevated in most patients, they strongly differ between patients and within individual patients between active disease and remission. The applicant has demonstrated a significant decrease in CXCL9 as a surrogate biomarker for IFNγ upon administration of emapalumab, along wi th decreases in ferritin and sIL2. However, the correlation between CXCL9 and clinical parameters, which ultimately drive the dose level has not been convincingly demonstrated: For example, in some patients, the CXCL9 level and ferritin remained low indica ting sufficient IFNγ neutralisation, but the dose was increased, suggesting a clinical worsening of symptoms. This may be explained by additional pathological mechanisms responsible for clinical symptoms.

As pointed out in the previous assessment, all relationships between PK/PD and clinical symptoms were only indirectly established thus introducing limitations. For example, the observed total IFNy and emapalumab concentration were used to describe the concentration of CXCL9, thus the correlation between PD and PK was not accounted for. The model cannot be used to describe the concentrations of CXCL9 over time using different dosing schemes and demonstrate a treatment effect in clinical symptoms over time and not only at the end of study.

Furthermore, the fact that around 60% of patients required a dose increase during the course of the study underlines the need for better understanding of posology and starting dose. Additionally, criteria laid out for dose adaptations included 'significant worsening of clinical conditions', thus potentially introducing variation in treatment based on the decision of each treating physician. It is also not clear how many patients had already undergone dose adaptations before the transition from a phase 2 to phase 3 trial and the concurrent protocol amendments.

It is noted that the applicant has made an effort to discriminate the effect of co-medications. However, due to the complex interplay between PK, PD and clinical response it is difficult to quantify the specific effect of co-medication.

## 6.1.4. Ground #4 - Safety

There are considerable uncertainties about the safety profile of emapalumab due to the study design and conduct

The applicant believes the CHMP have incorrectly concluded that there are considerable uncertainties about the safety profile of emapalumab due to the study design and conduct. The applicant asserts that the safety profile of emapalumab has been thoroughly documented through adverse event reporting and extensive safety laboratory testing and evaluation and is manageable, and clearly differentiated from off-label, undocumented alternatives that are associated with systemic toxicities.

## Overview of Ground

- Emapalumab is a fully human IgG1 monoclonal antibody.

<div style=\"page-break-after: always\"></div>

- The safety profile is manageable, being consistent with the characteristics of the targeted molecule and its mechanism of action with no-off target toxicities, hence allowing for an adequate safety characterisation in a single arm study.
- Higher emapalumab exposure does not seem to be related to the incidences of AEs or SAEs, or AEs related to infections supporting that adverse events have likely not been obscured by concomitant medication.
- The accumulating safety data including data from on-going studies in pHLH and sHLH, and the post-marketing experience in the US supports the initially submitted safety data with no new safety signals. The safety profile of emapalumab remains favourable.
- All clinical safety data were captured as planned- the clinical safety data are complete.
- o All laboratory abnormalities were captured at each visit (every 3 days during treatment) as part of laboratory data collection and are presented in the CSR.
- o Disease worsening/re-activation/flare (which describe worsening of specific HLH parameters, such as platelet count) were reported as an adverse event and are presented in the CSR.
- Drugs conventionally used for pHLH treatment are not approved for pHLH and include an aggressive immune- and chemotherapy-regimen, that has severe known side effects.
- The emapalumab safety profile, based on mechanism of action and data from prospective studies, is favourable when compared to conventional pHLH treatments.
- The safety of emapalumab treatment in pHLH will be further investigated in the NI-0501-09 study and as a post-marketing commitment in a proposed PASS.

## Detailed Ground

## Mechanism of action

Emapalumab is the first targeted agent developed for the treatment of pHLH and is a high affinity fully human antiinterferon gamma (IFNγ) IgG1 monoclonal antibody (mAb) that binds to and neutralises IFNγ. After binding to its receptor, IFNγ acts to produce a variety of physiological and cellular responses mainly involved in immunostimulatory and immunomodulatory effects. Numerous studies over the last 20 years have associated IFNγ with the pathogenesis and the maintenance of inflammatory diseases (Billiau 1996). As a targeted therapy, emapalumab was developed with the intention to provide efficacy without the systemic safety issues associated with other potential treatments for pHLH. The below safety data demonstrates that this is indeed the case and that emapalumab has a manageable safety profile that compares favourably with the current standard of care for the treatment of pHLH.

## Emapalumab has a manageable safety profile

The safety of emapalumab was initially established in 34 patients treated in the NI-0501-04 study and supported by data from 14 healthy volunteers in the NI-0501-03 study and 17 patients treated under compassionate use (CU). These data demonstrated that emapalumab was well tolerated at the doses investigated in the young, fragile, and highly co- medicated population that was enrolled in the clinical studies as well as in the patients who received emapalumab in CU. The safety profile of emapalumab was found to be consistent with the characteristics of the molecule and its mechanism of action.

No anaphylactic/anaphylactoid reactions have been reported. Only mild and one moderate IRRs have been reported in 27% of patients (approximately 3% of the total number of infusions). The majority of events occurred during or after the first infusions and none led to premature withdrawal, indicating no need for premedication.

<div style=\"page-break-after: always\"></div>

The presence of anti-drug antibodies (ADAs) was detected in 3 patients enrolled in Study NI-0501-04 and in 1 patient treated in CU. In none of these patients has the presence of ADAs affected the efficacy or safety of emapalumab or had an impact on the pharmacokinetic profile of the molecule.

Considering  the  mechanism  of  action  of  emapalumab,  IFNγ  neutralisation  might  potentially  lead  to selective  increased  susceptibility  to  intracellular  bacterial  infections,  predominantly  non-tuberculous mycobacterial  disease  (caused  by  weakly  virulent  atypical  mycobacteria),  and  to  lesser  extent Salmonella spp. and herpes zoster.

In the pivotal study, disseminated histoplasmosis has been reported in one patient. A Herpes zoster infection has been reported in a subject in the healthy volunteer study. Both events have been considered as possibly related to the administration of emapalumab. These infections had a normal course and resolved with standard antimicrobial therapy without sequelae. While testing positive for pathogens likely to be favoured by IFNγ neutralisation was an exclusion criterion of study NI -0501-04, infections by these pathogens did not emerge during the study, with the exception of the development of disseminated histoplasmosis in one patient. No TB was reported. The subject who developed Herpes Zoster during the healthy volunteer study did not receive prophylaxis prior to receiving emapalumab.

Infections occur frequently in HLH patients (Henter et al 2002; Trottestam et al 2011a; Bergsten et al 2017; Jordan et al 2011) and they are usually associated with flares of the disease. During treatment with emapalumab, 56% of patients developed infections in the pre-conditioning phase (35% bacterial, 41% viral  and  9%  fungal)  and  in  38%  of  the  patients  an  infection  was  already  present  at  start  of emapalumab treatment. None of these infections, with the exception of the disseminated histoplasmosis and  a  necrotizing  fasciitis,  were  related  to  emapalumab  treatment  by  the  Investigator.  In  general, infections  resolved  with  appropriate  antimicrobial  therapy  within  the  expected  timeframe  except  in patients who died when an infection was still ongoing.

The infections reported during the pivotal study were consistent with the ones reported in HLH patients in the literature (Henter et al 2002; Trottestam et al 2011a; Bergsten et al 2017; Jordan et al 2011) and known to be common triggers of HLH flares, such as EBV, CMV, adenovirus infections. Of note, none of these pathogens are amongst the ones reported to be favoured by IFNγ neutralisation.

While AEs were reported in all treated patients, the majority of them were mild, attributable to the underlying HLH and co-morbidities, and/or to documented toxicities of co-administered drugs. The most common AEs were disease related and included HLH reactivation and HLH worsening. Common HSCT complications were reported in the post-conditioning period.

During emapalumab treatment, no reduction in emapalumab dose and no discontinuation of emapalumab (with the exception of one patient due to disseminated histoplasmosis) were related to adverse reactions, while intolerance and  toxicity of conventional  treatment have  resulted in dose  reduction or discontinuation of conventional therapies, as also reported in the publication by Bergsten and colleagues (Bergsten et al 2017).

Although the neutralisation of IFNγ carries a potential risk of Therapeutic Protein -Drug Interactions (TPDI)  through  the  restoration  of  the  cytochrome  P450  iso-enzymes  (CYP)  activity  in  the  liver  while controlling inflammation, during the clinical trial programme with emapalumab, no events of TP-DI were reported in pHLH patients.

No  off-target  toxicity  has  been  observed  either  in  pre-clinical  studies  or  during  treatment  with emapalumab.

To summarise, emapalumab has shown good tolerability across the dose range administered and despite the frequent infusions in a fragile patient population with significant comorbidities and concomitant illness and medications. All patients in this study were able to receive the scheduled emapalumab infusions,

<div style=\"page-break-after: always\"></div>

and no infusions were discontinued due to acute infusion-related reactions. The relatively high incidence of AEs, SAEs, and deaths during this study was not unexpected given the underlying disease. No major safety concern has emerged.

## No important identified risks

As a result of the safety profile just described, there are no important identified risks with emapalumab and only one potential risk, which is 'Infect ions linked to lack of IFNγ biological activity' (RMP).

To mitigate this  potential  risk  the  SmPC,  section  4.4.  states:  'Patients  should  be  monitored  for  the development of infections and treated appropriately. Emapalumab should not be administered in patients with infections until appropriate treatment has been initiated if the infection is caused by pathogens potentially favoured by IFNγ neutralisations. These infections include mycobacteria (typical and atypical), salmonella, herpes zoster, histoplasma capsulatum, shigella and campylobacter (SmPC sections 4.8 and 5.3)'.

Prophylaxis for herpes zoster, Pneumocystis jirovecii, and fungal infections should be administered (Mo SmPC, section 4.2). Patients at risk of tuberculosis or known to have a positive purified protein derivative (PPD) test result should receive tuberculosis prophylaxis treatment.

The adverse reactions reported in the clinical trial involving 45 patients treated with emapalumab as presented in the SmPC (SmPC, section 4.8, table 2) is presented in Table 73 for reference.

Table 73 Adverse reactions as presented in the proposed SmPC

| MedDRA System Organ Class                            | Adverse reaction                                            | Frequency                               |
|------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------|
| Infections and infestations                          | Herpes zoster* Histoplasmosis disseminated                  | Common Common                           |
| Skin and subcutaneous tissue disorders               | Drug eruption Erythema Hyperhidrosis Rash Rash erythematous | Common Common Common Very common Common |
| General disorders and administration site conditions | Pyrexia                                                     | Very common                             |
| Investigations                                       | Mycobacteria test positive**                                | Common                                  |

* A single case of herpes zoster occurred in a healthy volunteer study (NI-0501-03)

** One case of non-tuberculous mycobacteria (NTM) without clinical and laboratory signs of an infection was reported after Hematopoietic Stem Cell Transplantation (HSCT).

## The patient numbers in the Safety database are increasing

The original safety database relative to the pivotal/confirmatory phase III study (NI-0501-04) consisted of 34 treated pHLH patients and was supported by data from 14 healthy volunteers in the NI-0501-03 study and 17 patients treated under compassionate use (CU).

The safety profile of emapalumab remained unchanged and favourable when the additional 11 patients enrolled after the cut-off date of July 2017 in the NI-0501-04 study were taken into consideration (NI0501-04).

<div style=\"page-break-after: always\"></div>

The safety profile of emapalumab described in the NI-0501-04 study and summarised in the section Emapalumab has a manageable safety profile is also consistent with the data emerging from two ongoing studies in HLH, the NI-0501-09 study in pHLH and the NI-0501-06 study in sHLH.

To date (data-cut off 19 May 2020), 102 patients have been treated in the US following FDA approval, and  post-marketing  surveillance  has  not  revealed  any  additional  safety  concerns  with  the  use  of emapalumab.

An overview of the number of patients included in the emapalumab safety database is provided in Table 74.

Table 74 Overview of the emapalumab safety database (data-cut-off 31 July 2020)

| Source                                               | Number exposed   |
|------------------------------------------------------|------------------|
| Healthy volunteer study NI-0501-03                   | 14 a             |
| Original Study data base Pivotal study NI-0501-04/05 | 34               |
| Complementary data from study NI-0501-04/05          | 11               |
| Compassionate use                                    | 17               |
| Study NI-0501-06                                     | 14               |
| Study NI-0501-09                                     | 25               |
| Post-marketing treatment in the US                   | 102              |
| Total number of patients                             | 217              |

a  healthy volunteers,  b  emapalumab is approved in the US for treatment of pHLH, and indications of individual patients is not possible to ascertain.

The safety profile of emapalumab will be further investigated as a specific obligation of the conditional marketing  authorisation  (study  NI-0501-09)  (see  Study  NI-0501-09  -  specific  obligation  of  the Conditional  marketing  authorisation)  and  as  a  post  marketing  commitment  in  a  PASS  (see  Postauthorisation safety study).

To  summarise,  although  the  small  size  of  the  safety  database  is  acknowledged,  it  is  considered appropriate  in  the  context  of  an  ultra-rare  disease  and  the  targeted  mechanism  of  action  of  the emapalumab antibody.

## Impact of the study design on the safety profile

The applicant acknowledges the limitations associated with a single arm design including the potential difficulties  to  distinguish  emapalumab  related  AEs,  disease  related  events  or  the  side  effects  of concomitant or prior medication. However, as expected based on its mechanism of action emapalumab did not cause aggravation of cytopenia and does therefore not cause an increased risk of generalised infections, as its neutralisation impact only certain identified pathways of immune defence.

In addition, higher concentrations of emapalumab do not seem to be related to the incidences of severe AEs or SAEs, or AEs related to infections (see ground 3: Exposure safety). These analyses support the favourable safety profile and that adverse events have likely not been obscured.

The existing safety data as reported from a single arm study include all adverse events whether or not they may have been attributable to emapalumab. Had a control arm been available to ascertain these differences then potentially fewer events would have been attributable to emapalumab, and hence a single arm study would if anything bias against emapalumab.

<div style=\"page-break-after: always\"></div>

When taken together and given that the emapalumab safety profile is consistent with the mechanism of action,  the applicant considers the impact of the single arm study design on the possibility to draw conclusions on the safety profile to be limited and that the safety data are adequate for a conditional marketing authorisation.

## The safety data are complete

The  applicant  confirms  that  all  safety  data  relevant  for  the  assessment  of  emapalumab  have  been collected, through a thorough process. The process for collection of clinical safety data in the NI-050104/05 studies is summarised below.

During the conduct of the NI-0501-04/05 studies, the clinical safety data i.e. adverse events (AEs), serious AEs (SAEs), vital signs, ECGs and laboratory data were collected in the clinical database to ensure accurate  assessment  and  adequate  characterisation  of  the  emapalumab  safety  profile  in  line  with appropriate regulatory guidance (ICH E2A, CT-3).

In addition, all SAEs were collected in the safety database (to allow for expedited reporting and periodic aggregated data reports such as DSURs).

The collection of safety data, including laboratory safety data, started from the signature of the ICF, up to and including the end-of-study visit. For patients who were rolled over to the long-term study (NI0501-05), the collection of safety data continued up to 1 year. The collection and handling of the safety collected are described below.

## Adverse events

All AEs, defined as \"any undesirable experience occurring to a subject during the study, whether or not considered related to the investigational product\" were collected in the case report form (eCRF) on the specific AE page. As a general principle, a medical diagnosis e.g. 'diabetes mellitus' were to be reported as an AE as opposed to individual signs or symptoms e.g. 'high blood glucose levels' which included also laboratory data if they are attributable to a diagnosis or syndrome (CIOMS VI: Management of Safety Information from Clinical Trials). As an example, if lab abnormality was due to \"worsening\" of pHLH, the worsening of the underlying HLH was to be reported.

Disease worsening/re-activation/flare were also reported as AEs; 'if a pre-existing medical condition recorded in the medical history worsens (clinically significant change in intensity or frequency), it must be recorded as an AE in the eCRF and, depending on the time of its occurrence, will be considered as a pre-treatment AE or a TEAE. If a medical condition recorded as a pre-treatment AE worsens post IMP administration, it will be recorded in the eCRF as a separate TEAE' (NI-0501-04 protocol, section 9.3.1).

Investigator verbatim terms were coded to MedDRA preferred terms using the most recent MedDRA dictionary available at the time (MedDRA v. 20.0). To ensure the completeness of safety information for analyses provided in the clinical study report, safety data were pooled to include data in NI-0501-04 patients who continued to be either treated and/or observed in the long-term follow study NI-0501-05. Reporting of adverse events also included laboratory abnormalities if they required treatment or led to a diagnosis of a new clinical event(s).

## Serious adverse events

All SAEs, defined as any AE that fulfilled criteria as described in the \"Note for Guidance on Clinical Safety Data Management: Definitions and Standards for Expedited reporting\" (ICH Topic E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting\") were collected on SAE forms as well as on the eCRF AE page. All SAEs were required to be reported by the investigator to the Sponsor

<div style=\"page-break-after: always\"></div>

Safety department within 24 hours of the investigator' s knowledge of the event. All SAEs were brought to the attention of the sponsor's Safety officer and were triaged for potential expedited reporting and for medical evaluation as part of ongoing benefit/risk assessment. Prior to final analyses were performed, the SAE information collected in the eCRF and safety database was reconciled to ensure consistency of the information.

## Potential risks related to emapalumab

To address potential risks associated with emapalumab as a therapeutic mAb targeting INFγ, infections and infusion related reactions were closely monitored, and intensified data collection was implemented:

## Infections

An infection surveillance process was implemented consisting of regular systematic search/monitoring of infections and collection of specific infection-related information such as the pathogen involved, and type of specimen used to detect a pathogen (NI-0501-04 protocol, section 8).

## Infusion related reactions (IRRs)

All patients who received emapalumab were closely monitored during the infusion and up to 24 hours post-infusion. To capture potential IRRs, the close monitoring included vital signs (blood pressure, heart and respiratory rate and oxygen saturation), skin aspect (rash, coloration, sweating), continuous cardiac/pulse oximetry monitoring and ECG at predefined timepoints during the infusion and up 24 hours post-infusion (NI-0501-04 protocol, section 9.5.2.3).

## Anti-drug-antibodies

A blood sample was taken pre-infusion and at Week 8 for anti-drug antibody (ADA) detection. In patients with still detectable emapalumab levels at Week 8, additional samples were taken at monthly follow-up visits. In case of presence of ADA, the potential effect on the PK of emapalumab was assessed (NI-0501-04 protocol, section 8.1 and section 8.7).

## Laboratory safety parameters

Laboratory parameters including complete blood count (white blood cells and subsets, red blood cells including reticulocytes and platelets, haemoglobin and haematocrit), coagulation tests (APTT, PT), Ddimer, fibrinogen, blood chemistry (glucose and electrolytes, ferritin, C-reactive protein, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, γ -glutamyltransferase, lactate dehydrogenase, triglycerides, bilirubin, albumin, creatinine and urea) and urinalysis (blood, glucose, protein, ketones, leucocytes, pH, specific gravity) were collected at baseline, throughout the treatment with emapalumab and up to the end-of study at predefined timepoints regardless whether they were considered as AEs or linked to the underlying pHLH by the Investigator.

The protocol specified which laboratory abnormalities that were to be reported as AEs (NI-0501-04 study protocol, section 9.3.4). In order to focus on clinically relevant laboratory abnormalities, any laboratory abnormality was to be reported as AEs if the abnormality:

## required specific treatment or,

led to further investigation and a diagnosis of a new clinical event.

All laboratory data collected in the NI-0501-04/05 were entered in the clinical database and analysed regardless whether the:

laboratory abnormality was reported as an AE as per definition provided in the protocol or,

<div style=\"page-break-after: always\"></div>

laboratory abnormality was assessed as sign/symptom of a distinct medical condition (e.g. HLH) reported as an AE or, laboratory abnormality was a sign/symptom of a distinct medical condition (e.g. HLH) present prior to enrolment into the study that has not worsened, therefore not fulfilling the definition of an adverse event or,

laboratory abnormality was an isolated finding present prior to enrolment into the study that has not worsened during the study.

The sponsor acknowledges that instructions regarding reporting of laboratory abnormalities provided in the eCRF completion guidelines were not fully consistent to those described in the study protocol (NI0501-04, section 9.3.4). However, the concurrent collection of all laboratory data ensured that any abnormal laboratory parameter was appropriately captured and analysed. For this reason, if a safety signal would have been present, it would have been identified independently of adverse event reporting. In addition, if the laboratory abnormality represented disease worsening/re-activation/flare, this was to be reported as an adverse event 'condition aggravated' is one of the most commonly reported adverse events in the study (see below). Moreover, this would also have an impact on the response criteria (lack of response), and the need to intensify treatment. Hence this domain is captured not only through adverse event reporting, but also through the response analysis. Finally, all laboratory data were captured throughout the study and included in the study report.

The collection of laboratory data during the study (at baseline, at pre-defined timepoints during the treatment up to 1-year long term follow-up) ensured that any laboratory abnormality including haematological abnormalities was captured and was subject to ongoing medical evaluation and final analyses as presented in the clinical study report (NI-0501-04, Supplementary CSR section 12.4).

The comments raised in the CHMP AR 23 July on the validation of the database and the admin rights and audit trail, are addressed under Ground 5.

To summarise, the sponsor acknowledges the inconsistencies in instructions on reporting laboratory abnormalities between the protocol and the eCRF, however, all safety data including laboratory abnormalities were captured during the study and thus the study safety data are complete.

## Severe adverse drug effects from standard of care first line treatments and other drugs used as first line treatment by adverse drug reaction

Primary haemophagocytic lymphohistiocytosis (pHLH) is a disease with high morbidity and mortality, despite the increasingly intensified treatment regimens tested during the last 30 years (Ehl et al 2018; Bergsten et al 2020). The standard of care first line treatment is recommended despite not being approved for treatment of pHLH and includes an aggressive immune- and chemotherapy-regimen. The side effect profile of first line treatments overlaps significantly with worsening of the underlying disease therefore limiting its ability to be applied successfully and further supporting the need for second line treatment options. Thus, the unmet need remains high in this young and fragile population underlining the need for an alternative targeted mechanism of action such as emapalumab for patients failing first line treatment (ground 1: When first line treatment fails).

To further evidence the concerns and limitation in the use of the currently available therapies for pHLH, is the fact that, the definition of response in the HLH-94 study foresees the assessment of cytopenias, except if drug-induced (Horne et al 2005).

The hyperinflammation characteristically present in pHLH patients combined with the toxicities of conventional pHLH treatment, can lead to potentially lethal complications, such as impairment of organ functions (e.g. bone marrow, liver, lungs, and kidneys) and, due to generalised immunosuppression, infections.

<div style=\"page-break-after: always\"></div>

When the safety profile of emapalumab is compared to existing pHLH treatment, in particular etoposide, ATG, cyclosporine A, the adverse effects of these drugs should be considered as these have not been established in a registration trial in pHLH.

Furthermore, when the search for a suitable donor takes a long time, HLH treatment might have to be prolonged. In this case, due to the toxicities described below, the use of first line pHLH treatments might not be feasible.

An overview of the adverse drug reactions of standard care first line pHLH treatment and other drugs used as first line treatment is provided in Table 75 and are described by reaction directly below. Toxicities by drug are described under the section Severe effects from standard of care first line treatments and other drugs used as first line treatment, by drug. Alemtuzumab was proposed as a salvage therapy in the CHMP AR 23 July (Section 4.1.2, page 135) despite not being approved as such or being part of the current standard of care HLH-94 treatment regimen. The adverse effects of alemtuzumab are therefore presented for reference in Table 75.

## Myelotoxicity

Patients with primary HLH very often present with cytopenia, which is one of the hallmarks of the disease (Jordan et al 2011). The use of drugs that cause cytopenia aggravates this important disease feature increasing the risk for severe systemic infections and clinically relevant haemorrhages which may lead to treatment discontinuation. It also prevents to assess the drug effect within a short period of time.

Myelotoxicity significantly increases the risk for infections, independently of the pathogen. Notably, if infections occur during treatment, treatment must be discontinued. Myelotoxicity is of particular concern in patients treated with etoposide (also if applied in second line patients which is the context of this application) which causes dose limiting bone marrow suppression. As a consequence of significant myelosuppression, infections or haemorrhages can occur and could be fatal. Administration of etoposide must be closely monitored for signs of myelosuppression using several haematological parameters such as platelet count, haemoglobin, white blood cell count and differential count.

Treatment with ATG is associated with generally reversible thrombocytopenia and/or leukopenia (including lymphopenia and neutropenia).

The  long-lasting  effect  of  alemtuzumab,  demonstrated  with  profound  CD57  lymphocyte  depletion, represents a significant concern, particularly in patients in whom performance of HSCT is delayed while the search of a suitable donor is employed, and is hence only a real treatment option for patients were a donor is available.

Thanks to its mechanism of action, emapalumab does not cause myelotoxicity. The neutralisation of IFNγ is reported to cause an increased suscepti bility only to certain specific pathogens and no evidence of a generalised risk for infection is reported. These can be handled by appropriate prophylaxis and monitoring of a limited number of pathogens.

<div style=\"page-break-after: always\"></div>

## Table 75 Adverse drug reactions in therapies used as standard of care first line treatment, other pHLH therapies and emapalumab

| SmPC/Product monograph (special warnings and precautions)     | Etoposide (Standard of care first line therapy)                            | Dexamethasone (Standard of care first line therapy)                                                           | Cyclosporine A                                                                | Anti-thymocyte globulin                                                    | Alemtuzumab                                                                                                                                                                                               | Emapalumab                                                                                          |
|---------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Myelotoxicity                                                 | Dose limiting bone marrow suppression resulting in severe myelosuppression |                                                                                                               |                                                                               | Thrombocytopenia and/or leukopenia (including lymphopenia and neutropenia) | Profound and prolonged lymphocyte depletion                                                                                                                                                               |                                                                                                     |
| Infections                                                    | Increased risk of infection                                                | Increased risk of serious infection, in particular due to bacteria, yeasts and/or parasites                   | Increased risk of bacterial, fungal, parasitic and viral infection            | Increased risk of bacterial, fungal, viral, and protozoal infection        | Increased risk of infection, predominantly viral infections                                                                                                                                               | Increased risk of infections caused by pathogens favoured by interferon gamma (IFNγ) neutralisation |
| Malignancies                                                  | Secondary leukaemia                                                        |                                                                                                               | Lymphoma and skin malignancies                                                | Lymphoma or post- transplant lympho- proliferative diseases                |                                                                                                                                                                                                           |                                                                                                     |
| Hypersensitivity reactions /Infusion Related Reactions (IRRs) | Anaphylaxis                                                                |                                                                                                               | Anaphylactoid reactions                                                       | Anaphylaxis or severe cytokine release syndrome                            | IRRs more often during initial administrations. Glucocorticoid pre-medication recommended                                                                                                                 | Mild to moderate IRRs                                                                               |
| Nephrotoxicity                                                |                                                                            |                                                                                                               | Creatinine and urea increase (if chronic use, interstitial fibrosis)          |                                                                            | Glomerular nephropathies                                                                                                                                                                                  |                                                                                                     |
| Others                                                        | Increased risk of haemorrhages associated with myelosuppression            | Hypercortisolism, including hypertension, hyperglycaemia, GI ulcerations/bleeding chorioretinopathy, cataract | Dose- dependent, reversible increases in serum bilirubin and in liver enzymes | Aggravation of pre-existing clotting disorders                             | Increased risk of autoimmune mediated conditions, potentially serious and life- threatening: thyroid disorders, immune thrombocytop. purpura, nephropathies, autoimmune hepatitis, acquired haemophilia A | Others                                                                                              |

## Infections

The increased risk of infections with etoposide is assumed based on the evidence of myelosuppression, a key etoposide toxicity. As a consequence of myelotoxicity, risk of infections caused by pathogens, both gram positive and gram negative, commonly seen in patients with neutropenia should be considered. Therefore, the risk of infections associated with neutropenia secondary to myelosuppression is an important adverse factor in patients treated with etoposide, especially in patients with HLH who are in dysregulated immune status due to the underlying disease.

<div style=\"page-break-after: always\"></div>

Treatment with cyclosporine A predisposes patients to the development of a variety of bacterial, fungal, parasitic and viral infections (including serious and fatal), often with opportunistic pathogens as described in the labelling information.

Similarly, ATG is associated with the occurrence of variety of bacterial, fungal, viral and protozoal infections including reactivation of CMV and sepsis.

Data pertaining to infections were reported in clinical studies with alemtuzumab as monotherapy in CLL (Fraser et al 2007). Incidence of all infections ranged from 30 to 93 % and included disseminated viral infections (varicella-zoster virus and herpes simplex virus VZV), fungal infections. (e.g. candida, aspergillosis, cryptococcal and PCP). Of other relevant infections, CMV reactivations were commonly reported in about 9% patients); CMV pneumonitis was reported in 4 patients (0.8% across studies).

## Malignancies

The occurrence of acute leukaemia, which can occur with or without myelodysplastic syndrome (MDS), has been described in patients that were treated with etoposide containing chemotherapeutic regimens. Etoposide may induce secondary AML, as documented by occurrence of 2 cases among patients included in the HLH-94/HLH-2004 (Bergsten et al 2017). The roles of both administration schedules and cumulative doses of etoposide have been suggested but have not been clearly defined (Vepesid SmPC).

Cyclosporine increases the risk of developing lymphomas and other malignancies, particularly those of the skin. The increased risk appears to be related to the degree and duration of immunosuppression rather than to the use of specific agents (Cyclosporine SmPC).

ATG, may increase the incidence of malignancies, lymphoma or lymphoproliferative disorders (which may be virally mediated). These events have sometimes been associated with fatal outcomes (ATG SmPC).

## Hypersensitivity reactions/Infusion related reactions

Hypersensitivity reactions are frequently seen with first line treatments in patients with pHLH. Anaphylactic-like reactions (including fatal reactions) were observed during or immediately after etoposide administration including paediatric patients.

In the NI-0501-04 emapalumab study, 2 patients had documented anaphylactic reactions;1 patient, who received etoposide as additional HLH therapy during the NI-0501-04 study, experienced an SAE of severe anaphylactic reaction to etoposide with severe respiratory distress requiring mechanical ventilation and 1 patient had anaphylactic reactions registered as medical history.

Cyclosporine A concentrate has been reported to cause anaphylactoid reactions following intravenous administration and requires that patients receiving Cyclosporine A infusion should be under close observation during the infusion.

Serious immune-mediated reactions have been reported with the use of ATG including anaphylaxis, in rare cases also fatal or severe cytokine release syndrome.

In patients treated with alemtuzumab, IRRs due to cytokine release were reported during the first course of treatment, of which a small proportion were reported as serious (3%). As per labelling information, premedication (glucocorticoids) is recommended, however, IRRs also occurred despite premedication.

<div style=\"page-break-after: always\"></div>

## Nephrotoxicity

Treatment with cyclosporine A has been associated with the increased risk of acute or chronic nephrotoxicity. There have been reports from clinical trials and from the post-marketing setting including cases of acute nephrotoxicity associated with ion homeostasis derangements, such as hyperkalaemia, hypomagnesaemia, and hyperuricaemia. In chronic use, cyclosporine A was linked to the occurrence of interstitial fibrosis. Similarly, glomerular nephropathies have been observed in patients treated with alemtuzumab.

## Severe effects from standard of care first line treatments and other drugs used as first line treatment, by drug Etoposide

## Haemorrhagic adverse effects

The increased risk of haemorrhagic events with etoposide is assumed based on the evidence of myelosuppression with subsequent thrombocytopenia. This is of particular concern in patients with pHLH who often present concurrently with cytopenias and impaired liver function.

## Hepatotoxicity

Etoposide undergoes liver metabolism and is also partially excreted by liver. Administration of etoposide was associated with the occurrence of liver toxicity; severe hepatocellular toxicity has been observed including when administered at standard dose.

## Dexamethasone

As direct effect on regulation of the hypothalamic-pituitary-adrenal axis, treatment with dexamethasone leads to adverse effects caused by hypercortisolism, including hypertension, hyperglycaemia, GI ulcerations/bleeding and eye disorders.

## Cyclosporine A

## Posterior Reversible Encephalopathy Syndrome (PRES)

Patients with pHLH can experience high rates of PRES when started on cyclosporine-A at the beginning of induction therapy HLH (Thompson et al 2009).

## Hepatotoxicity

Cyclosporine has been associated with hepatic adverse effects including increases in bilirubin and liver enzymes, liver injury, hepatitis and liver failure. Most reports included patients with significant comorbidities, concurrent conditions including infectious complications and co-medications with hepatotoxic potential.

## Renal toxicity

An increase in serum creatinine and urea may occur during cyclosporine-A treatment. These functional changes are dose-dependent and are initially reversible, usually responding to dose reduction. During long-term treatment, some patients may develop structural changes in the kidney.

## Alemtuzumab

Increased risk of autoimmune mediated conditions, potentially serious and life-threatening: thyroid disorders, immune thrombocytopenic purpura, nephropathies, autoimmune hepatitis and acquired haemophilia A.

<div style=\"page-break-after: always\"></div>

To conclude, first line therapies for pHLH treatment -not being approved for the treatment of pHLH have severe adverse drug reactions. Emapalumab, thanks to its targeted action represents, with the appropriate prophylaxis and monitoring in place, a valid alternative for second line treatment of pHLH.

## Additional safety data will be generated post-approval with emapalumab

## Study NI-0501-09 - specific obligation of the Conditional marketing authorisation

The applicant proposes to use the currently ongoing study in pHLH patients (NI-0501-09) as a specific obligation to confirm the safety profile of emapalumab in the proposed indication.

Study NI-0501-09 is an on-going open-label, single arm, multicentre study to assess efficacy, safety, impact on quality of life, and long-term outcome, in paediatric patients with primary pHLH treated with emapalumab, that will provide further understanding of the efficacy and safety of the medicinal product. Safety will be evaluated by means of adverse events, laboratory parameters and number of patients who discontinue emapalumab treatment for safety reasons.

The study plans to enrol 34 patients, of which 22 patients have already been included (EU:20 and US:2), and preliminary data suggest 15/22 patients are in second line (all EU). The protocol and Statistical Analysis Plan for Study NI-0501-09 are included within Module 5.3.5.2.

Study NI-0501-09 will not only provide meaningful complementary data to the NI-0501-04 study in patients with pHLH, but will also increase the size of the safety database.

The NI-0501-09 study is part of the PIP, enrolment is progressing well (22/34), and last patient last visit is projected to be October 2022 with a final report six months later. Given the status of the study, the applicant does not have concerns around completion of this study, also with a conditional approval in EU.

## Post-authorisation safety study

In addition, the applicant commits to performing a non-interventional long-term post-authorisation safety study of emapalumab for the treatment of pHLH to estimate patients` survival and the incidence of infections and possible long-term treatment in patients not eligible for HSCT.

The proposed PASS will aim to include a prospective cohort of patients treated with emapalumab and other conventional therapy, which will be further stratified by number of prior treatments received for better comparability.

The primary objective of the study is to describe the incidence of infections before receiving HSCT, in patients initiating emapalumab and in patients initiating other major HLH drugs for the treatment of pHLH.

The secondary objectives of the study are to describe:

Incidence of infections up to 1 year after treatment initiation

Mortality up to 3 years after treatment initiation.

in patients initiating emapalumab and in patients initiating other major drugs for the treatment of pHLH.

This study will be conducted in collaboration with the HLH registry, which offers the largest available coverage of data and includes several European countries (Austria, Czech Republic, Denmark, Germany, Netherlands, Poland, Spain, Sweden, Switzerland), as well as Australia, Canada, Egypt, Israel, Russia and the United States. Information is collected by attending physicians, trained study

<div style=\"page-break-after: always\"></div>

nurses and trained documentation assistants and thus misclassification and missingness is expected to be very small, if any.

An overview of the study design of the proposed PASS is provided in Figure 21.

Figure 21 Overview of the proposed emapalumab non-interventional post-authorisation safety study

<!-- image -->

## Summary of the applicant's ground for re-examination # 4

The applicant considers that the safety profile of emapalumab is manageable and consistent with the characteristics of the targeted molecule and its mechanism of action with no-off target toxicities. The potential risks based on emapalumab's mechanism of action i.e. infections, infusion related reactions, and antidrug antibodies are manageable and preventable. Since the emapalumab safety profile is consistent with the mechanism of action, the applicant considers the impact of the single arm study design on the possibility to draw conclusions on the safety profile to be limited, and fully adequate for a conditional marketing authorisation.

All clinical safety data were captured as planned- the clinical safety data are complete. The accumulating safety data, including data from on-going studies in pHLH and sHLH and the postmarketing experience in the US supports the initially submitted safety data with no new safety signals.

Drugs used for pHLH treatment are not approved for pHLH and includes an aggressive immune and chemotherapy-regimen, that has severe drug effects. The emapalumab safety profile, based on mechanism of action and data from prospective studies, is favourable when compared to conventional pHLH treatment and other salvage treatments applied in second line patients.

The safety of emapalumab treatment in pHLH will be further investigated in the NI-0501-09 study as a specific obligation providing comprehensive data and as a post-marketing commitment in a proposed PASS adding data to the increasing data base.

## CHMP assessment of ground 4

The CHMP overall agreed with the applicant and concluded that the safety profile of emapalumab appears to be manageable. However, the small sample size, the limited experience in the higher dose range, the lack of comparative data and absence of long-term safety data (i.e. 2 years after

<div style=\"page-break-after: always\"></div>

administration), together with the presence of a severe debilitating disease and the administration of many concomitant HLH-targeted products hamper a full characterisation of the safety profile. Additionally, concerns have been raised in the triggered GCP inspection if adverse events were correctly collected while underreporting may occur. Therefore, the future safety profile should be carefully monitored, both in ongoing studies and within potential post authorisation measures. In this context it is noted that the applicant has committed to conducting a PASS post-approval in order to generate long-term safety data.

## 6.1.5. Ground #5 - GCP inspection

The triggered GCP inspection revealed substantial concerns on the integrity of study data and recommended that the results of this study should not be used to support the marketing authorisation application, thus adding to the above uncertainties

The applicant disagrees with the GCP inspection recommendations and believes, as thoroughly documented, that the submitted data are reliable and can form the basis of a conditional marketing authorisation.

## Overview of Ground

In response to the inspection findings, corrective actions such as a retrospective validation of one of the systems used for the NI-0501-04 clinical study and a reconstruction of data management procedures have been performed, which is described further down in this document. Preventative actions to improve the quality of the internal processes going forward according to highest GCP standards were implemented within the 6 months following the last inspection, i.e. completed by 30 June 2020. Furthermore, a GAP assessment was performed for all ongoing emapalumab studies; importantly this assessment included the NI-051-09 study which is proposed as a specific obligation of the conditional marketing authorisation, and actions were implemented where indicated. This GAP assessment was not described in the initial response to the individual Inspection Reports (IRs) but was included in the Responses to the Integrated Inspection Reports (IIR).

The detailed grounds discussed in this document are primarily based on the emapalumab CHMP AR 23 July 2020 (Section GCP Inspection) and restricted to those with relevance for the full study. The following demonstrates that throughout the flow of the clinical trial from patient inclusion to the data processing and reporting, the data are valid and reliable. For ease of review, the discussion has been divided into the following categories:

- Background
- Patient inclusion
- Overall study conduct
- Source data
- Data collection
- Data processing and reporting

References are made to prior responses to the individual Inspection Reports (IR) and Integrated Inspection reports (IIR) respectively where required.

<div style=\"page-break-after: always\"></div>

## Detailed Ground

## Background

Emapalumab (NI-0501) was initially developed by Novimmune S.A, a biotech company in Switzerland developing therapeutic mAbs to treat patients suffering from immune-related disorders and Novimmune B.V. (SME reference EMA/SME/067/09/R9) was the initial MAA applicant. Swedish Orphan Biovitrum AB (publ) (Sobi) acquired the rights for the product on 20 July 2018.

In 2010, emapalumab (NI-0501) received orphan drug designation from both the FDA and the EMA and Novimmune was awarded by the European Commission a Seventh Framework Program (FP7) grant to confirm the relevance of IFNγ as a pathogenic factor in HLH and to investigate the neutralisation of IFNγ as a potential additional treatment for this disease. Bot h PRIME and Break through designation were received from the EMA and FDA respectively.

Novimmune, in collaboration with major academic centres, such as Hôpital Necker-Enfants Malades in Paris (Pachlopnik-Schmid et al 2009), conducted the required translational work that supported the relevance of targeting IFNγ in primary HLH and enabled the initiation of the clinical development activities.

During the start of the NI-0501-04 clinical study, trial activities were contracted to CROs with wellestablished Quality Management System (QMS) systems. The QMS at Novimmune underwent continuous improvement and expansion as Novimmune S.A. grew and the clinical research moved from the first pilot into the pivotal study, and more study activities were transferred to inhouse staff. Study specific manuals were developed over time to become controlled documents as part of the QMS.

SOPs and Quality System documentation relevant to clinical research was developed and implemented progressively. The first SOPs on safety management and protocol development were developed before 2013, other SOPs followed as per the company and activity needs. Figure 22 illustrates the development of SOPs and Quality System documentation in relation to the first site initiation visit and the development of the CSR.

As a result of the acquisition former Novimmune has now been integrated into Sobi QMS, and a thorough review and revision of standard operating procedures (SOPs) has therefore taken place. Implementation of the corrective and preventative actions (CAPAs) following the inspections has been a prioritised part of this integration and by June 30, 2020 the Sobi QMS integration was completed.

The below further outlines the applicant's basis for standing by the integrity of the data and in support of a marketing authorisation approval, this will be done by following the process from data collection to the final CSR in separate sections.

<div style=\"page-break-after: always\"></div>

Figure 22 Development of SOPs and Quality system documentation

<!-- image -->

Abbreviations: AE, adverse event; CRO, contract research organisation; DMC, data monitoring committee; DSMB, data safety monitoring board; DSUR, drug safety update report; QA, quality assurance; SAE, serious adverse event; SIV, site initiation visit; SOP, standard operating procedure.

## Patient inclusion

Patient information and consenting was conducted in accordance with GCP and local Ethics Committee requirements and ensured that the patients and their parents/guardians were fully informed of the potential benefits and risks associated with participation in the study and consented to participation. Assent was obtained when relevant to patient's age and condition. As outlined in the response to the IIR, issues raised during the GCP inspection with regards to the detailed content of the ICF did not impact the rights of the clinical trial subjects nor the validity of the data ultimately collected during the clinical trial.

Patients were enrolled based upon study inclusion and exclusion criteria and the eligibility was monitored using a screening/enrolment grid to ensure adherence with the protocol, which, although not referenced specifically in the protocol and ICF, reflected the data required by the protocol for patient eligibility. It is important to take into account the severe and complex nature of the disease and the vulnerable, very young population; the process followed for enrolment was aimed at ensuring that the right patients entered the study in accordance with the inclusion/exclusion criteria. For future studies, the enrolment process will be described in more detail in the protocols.

The inspection report and subsequent CHMP assessment report suggested that multiple waivers to the inclusion and exclusion criteria were allowed. However, upon assessment of these cases, all patients except one met the inclusion and none of the exclusion criteria. This one patient was enrolled despite meeting the exclusion criterion \"Acute isolated or multiple organ failure\" based on the request by the treating physician due to the presence of refractory disease with progressively worsening of clinical condition during conventional dexamethasone and etoposide treatment (the protocol was subsequently amended to allow for inclusion of such patients in protocol version US5.1 and EU6.0). The applicant acknowledges that deviating from eligibility criteria is not acceptable and is addressing this through tightening of updated procedures. However, the enrolment of one severely compromised patient cannot have biased the results in favour of emapalumab. The criterion was already under internal discussion and was subsequently amended (removed) in protocol version US5.1 and EU6.0. The inclusion of this single patient ahead of the approved amendment has not impacted the overall integrity of the study data.

<div style=\"page-break-after: always\"></div>

In conclusion, the patient population included met the eligibility criteria and is representative for the study and patients were adequately informed of the study procedures and the potential risks of participation.

## Study Conduct

Several aspects of the GCP inspection findings were related to the general conduct of the study. These aspects are specifically addressed below to support the applicant's position that data is reliable and can be considered for review.

## Transition from pilot to pivotal and design of the confirmatory trial

As noted in the assessment report, the NI-0501-04 study was converted from an exploratory phase II to a confirmatory phase III trial driven by the high unmet need and the nature of the disease following interactions with the FDA. Preliminary, patient level data from the pilot part of the trial were available and shared with the EMA and FDA in the context of PRIME and Break Through Designation, respectively and the trial steering committee prior to the decision to amend the trial. No aggregate analysis was performed. This data presentation, as it was not considered as an interim analysis, was not described in the protocol. The applicant asserts that there is no reason to believe that this change from pilot to pivotal resulted in bias or ultimately impacted the integrity or reliability of the data in this open label study.

The transition from an exploratory to a confirmatory study, including the definition of the primary endpoint, occurred as a result of discussions and agreement with the FDA and reflected the rare and serious nature of the disease and the high unmet need. The amendments implemented at the time of the change from pilot to pivotal included:

- Definition of the primary patient population as second line (the proposed indication in the EU)
- Primary  endpoint  determined  as  ORR  based  on  robust  objective  laboratory  and  clinical parameters;

The definition of the primary patient population as second line reflected the majority of the patients enrolled and those with the highest unmet medical need who are the hardest to treat.

The justification for the primary endpoint is provided in detailed GROUND2: Selection of the primary endpoint of ORR. However, the applicant would like to clarify that these were based on the existing HLH diagnostic criteria, and hence based on what the leading experts in the field have obtained consensus in defining as important for the disease. Modifications in the response definition were:

- -setting the threshold of normalisation for ferritin at 2,000 µ g/L based on available literature supporting the clinical value of this threshold value
- -inclusion of D-Dimer in the assessment of coagulopathy in addition to fibrinogen

These changes were made on the basis of the best available scientific evidence, in collaboration with the scientific steering committee and were made in order to provide a robust, valid and clinically meaningful assessment of clinical response in these patients.

The thresholds introduced in the response definitions in the pivotal protocol for all other clinical and laboratory HLH parameters were consistent with the HLH-2004 diagnostic criteria (see Table 76).

<div style=\"page-break-after: always\"></div>

Table 76 Diagnostic criteria in the HLH-2004 study compared with the NI-0501-04 study

| HLH-2004 diagnostic criteria                                                                                                                                                                                                                                                                                                                                             | NI-0501-04 protocol                                                                                                                                                                                                                                                                                                                                                      | Comments                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fever                                                                                                                                                                                                                                                                                                                                                                    | No fever = body temperature <37.5°C                                                                                                                                                                                                                                                                                                                                      | Same                                                                                                                                                                                                                                                                                                                                                                     |
| Splenomegaly                                                                                                                                                                                                                                                                                                                                                             | Normal spleen size                                                                                                                                                                                                                                                                                                                                                       | Same                                                                                                                                                                                                                                                                                                                                                                     |
| Cytopenia affecting 2 of 3 lineages in the peripheral blood (haemoglobin < 90 g/L; platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L)                                                                                                                                                                                                                                   | No cytopenia = ANC ≥ 1.0x10^9/L and platelet count ≥ 100x10^9/L [absence of G-CSF and transfusion support must be documented for at least 4 days to report no cytopenia]                                                                                                                                                                                                 | Same thresholds for ANC and platelets; haemoglobin not considered due to the profound impact of frequent transfusions on this parameter                                                                                                                                                                                                                                  |
| Hypertriglyceridaemia (fasting triglycerides ≥ 3 mmol/L or ≥ 265 mg/dL) and/or hypofibrinogenaemia (≤ 1.5 g/L)                                                                                                                                                                                                                                                           | No evidence of coagulopathy, i.e. normal D-Dimer and/or normal (> 150 mg/dL) fibrinogen levels                                                                                                                                                                                                                                                                           | Same threshold for fibrinogen; D-Dimers added. Fasting triglycerides are difficult to obtain in clinical practice and when triglycerides are assessed it is extremely difficult to ascertain whether they in fasting condition or not. For these reasons triglycerides have been excluded.                                                                               |
| Ferritin < 500 mg/L                                                                                                                                                                                                                                                                                                                                                      | No hyperferritinaemia = serum level is < 2000 mg/L                                                                                                                                                                                                                                                                                                                       | Threshold for hyper- ferritinaemia changed to reflect literature                                                                                                                                                                                                                                                                                                         |
| Soluble CD25 (sCD25; i.e. soluble IL-2 receptor) ≥ 2400 U/mL                                                                                                                                                                                                                                                                                                             | No sustained worsening of sCD25                                                                                                                                                                                                                                                                                                                                          | Threshold for sCD25 cannot be set due to the different assays used                                                                                                                                                                                                                                                                                                       |
| 'Haemophagocytosis in bone marrow, spleen or lymph nodes, with no evidence of malignancy' and 'Low or absent natural killer (NK)-cell activity' are inconstantly present and cannot be used for response Abbreviations: ANC, absolute neutrophil count; CNS, central nervous system; G-CSF, granulocyte-colony stimulating factor; sCD25, soluble cleavage product CD25. | 'Haemophagocytosis in bone marrow, spleen or lymph nodes, with no evidence of malignancy' and 'Low or absent natural killer (NK)-cell activity' are inconstantly present and cannot be used for response Abbreviations: ANC, absolute neutrophil count; CNS, central nervous system; G-CSF, granulocyte-colony stimulating factor; sCD25, soluble cleavage product CD25. | 'Haemophagocytosis in bone marrow, spleen or lymph nodes, with no evidence of malignancy' and 'Low or absent natural killer (NK)-cell activity' are inconstantly present and cannot be used for response Abbreviations: ANC, absolute neutrophil count; CNS, central nervous system; G-CSF, granulocyte-colony stimulating factor; sCD25, soluble cleavage product CD25. |

As additional support to the absence of any bias in the response definition with respect to the implementation of the amendment and the transition to the phase III protocol, the applicant undertook a post-hoc sensitivity analysis of ORR in second line patients enrolled after the finalisation of protocol amendment in February 2016:a similar magnitude of response was shown in this second line population as in the full second line population of 0.60 (95% CI: 0.31, 0.83 (N=10).

In summary therefore, the change in the study from pilot to pivotal was driven by the high unmet need and the nature of the disease following interactions with the FDA. The primary endpoint was based on objective criteria used for the assessment of response, and the sensitivity analysis showed a similar

<div style=\"page-break-after: always\"></div>

response on the primary endpoint before and after the amendment. Hence there is no support for any bias being introduced.

## Sponsor involvement in the conduct of the trial

Concerns were raised during the GCP inspection that sponsor involvement in Data Monitoring Committee (DMC) meetings may have resulted in bias in the study particularly with regards to protocol waivers.  As noted above, only one patient was ultimately enrolled not meeting study inclusion or exclusion criteria.

Furthermore, the applicant wishes to reiterate/clarify that the involvement of the sponsor in some aspects of the conduct of the study was described in the study protocol. Given the fact that the NI0501-04 study was the first study in which emapalumab was administered to patients and that the patient population was characterised by a high morbidity and mortality, a benefit risk assessment by the treating physician was requested prior to the administration of each dose of the drug (every 3 days) and the determination of the dose to be administered had to be made by the sponsor (every 3 days) in accordance with the decision tree in the clinical study protocol. These procedures, well described in the protocol, have required close and frequent exchanges between the sponsor and the treating physician.

The applicant would also like to further clarify the DMC set up. The DMC was set up according to the 'EMA-CHMP Guideline on Data Monitoring Committee (2005)' and the 'US-FDA Guidance on Establishment and Operation of Clinical Data Monitoring Committees (2006)'.

The DMC consisted of an independent multidisciplinary group of 6 voting members, one of whom served as Chairperson that oversaw the study conduct and evaluated both safety and efficacy parameters, an experienced biostatistician, 4 qualified clinicians, and one expert qualified in Ethics (see section 6.1, DMC charter).

DMC members were not permitted to be employed by Novimmune and should have no financial interests in NovImmune or any of the partners involved in the development of emapalumab. With the support of the SSC of the study, NovImmune selected the members of the DMC and its chairperson specifically as they have scientific expertise in immunodeficiency, onco-haematology, and clinical biostatistics as well as practical experience conducting and monitoring the safety and efficacy of clinical studies. It was also instrumental for setting up the composition and the charter of the NI-0501-04 study DMC.

The regular pre-scheduled DMC meetings were set up as open meetings with only DMC members having voting rights (see section 5.1, DMC charter). The DMC members could call for a closed ad hoc meeting/session, if they considered it necessary to discuss the ethical conduct of the Study without the presence of any investigators and/or Novimmune representatives (see section 7.2.3, DMC charter). On no occasion did any of the DMC member request a 'closed' meeting.

In summary the DMC composition was appropriate and only members had voting rights (sponsor representatives attended but could not vote). Moreover, the DMC charter approved by all DMC members specified that closed meetings could be requested at any time by any voting member. The participation of the sponsor did not therefore ultimately influence the recommendations by the DMC nor the conduct of the trial.

## Trial Master File and Sponsor oversight

<div style=\"page-break-after: always\"></div>

The TMF was not yet closed at the time of the inspection, as the clinical study was ongoing, but it included in excess of 52,000 documents organised using the DIA model as a reference. The TMF is a hybrid model composed of both electronic files and paper documents.

It is acknowledged that during the course of the study a portion of the TMF documents were progressively migrated from a secured drive at the sponsor to the current TMF (M-Files) in a manner that is not contemporaneous to the creation of each document. The TMF underwent routine QC checks which are documented as part of the TMF, independently of the date of filing of the MAA.

The TMF, in combination with study management activities as described above and monitoring, enabled the sponsor to have robust oversight over the study.

## GCP training

Employees at Novimmune were experienced and qualified in the conduct of clinical trials from working with other pharmaceutical companies. It is acknowledged that the GCP training process within Novimmune was not adequately formalised at the beginning of the study. However, since study initiation, the training process and practices have evolved within the company:

SOPs and working instructions have been implemented on training processes (i.e. a global SOP Personnel Training Management is effective since 2015, further enhanced in 2018 by instructions on Initial Training and Personnel Qualification).

Since September 2018, for all new employees, individual training needs are assessed and documented in \"Initial Training Plans\", based on their job description and individual background and experience. The training matrices of Clinical Development include a dedicated module to cover GCP regulatory requirements (i.e. module CDD/008). This module is either performed via e-learning and/or classroom training.

In addition, since 2017, annual GCP training is given to the relevant employees, as part of Annual Quality Training Plan (including classroom training of Clinical Development employees, as appropriate considering their scope of activity).

As part of the transition to Sobi's organisation, current training processes will be progressively integrated into the Sobi QMS, and the standard operating procedures for managing clinical studies (GCP) have now been adopted.

## Conclusions

In conclusion, the applicant considers that the study conduct reflected the challenges inherent to conducting clinical trials in this setting of a serious and rare disease as well as the growing nature of the company conducting the trials. The applicant has demonstrated that the potential issues identified with regards to study conduct do not impact the data validity and thus that the study results should be assessed in the context of a conditional marketing authorisation.

## Source data

In order to reassure the CHMP that the data are valid, the applicant wants to present the quality control steps that were in place during the study to ensure the validity of the source data from the clinical trial, and that the collected data represents the source. The study included 12 investigator sites, each including at least one patient, and these were closely monitored on-site by sponsor's appointed monitors. A Monitoring plan was in place at the start of the study, stipulating 4 monitoring visits at each site within the first 8 weeks of the first patient being treated. Monitoring frequency was

<div style=\"page-break-after: always\"></div>

then to be adjusted based on rate of site enrolment and any study conduct issues. In total for the complete study, the number of monitoring visits per site varied between 20-60 visits.

The monitoring included 100% Source data verification to ensure the accuracy and completeness of the data in the CRF. It comprised a comparison between e.g. medical records and study specific worksheets and all data points collected in the eCRF. Such study specific work sheets were used by some sites to facilitate collection and ensure completeness of data very specific for the study, e.g. infusion data of IMP.

Besides the query process by the on-site monitors, the sponsor also performed continuous in-house medical monitoring to assess data from a medical perspective, which resulted in queries to the sites as needed.

Reports of laboratory data, which represent the major part of response assessment, were provided by the sites to the sponsor that performed, on an ongoing basis and prior to database lock, a cross-check between the lab reports received and the information entered in the eCRF regarding lab samplings, so that missing reports could be retrieved.

Other source data such as PK/PD data was obtained at central bioanalytical laboratories in Switzerland (Novimmune) and US and underwent quality checks at those laboratories as part of their internal procedures.

The applicant acknowledges that, at one of the clinical trial sites, some of the data was entered late in the eCRF. However, through comprehensive monitoring across all study sites, including this site, all source data is accurately included in the MAA. Nevertheless, while the applicant stands by the data then the applicant performed a post-hoc sensitivity analysis excluding the data from the site mentioned above. There were four patients enrolled at this site and three of these were second line patients. The sensitivity analysis on ORR in second line patients showed a similar magnitude of response as in the primary analysis with 62.5% responding (95% CI: 0.41 0.81); N=24).

Based on the quality checks and data reviews performed throughout the study, by various functions, the applicant confirms that collected data are valid, complete and represents the source data. The sensitivity analysis performed excluding patients from site 17 was entirely consistent with the primary analysis.

## Data collection

Potential issues with regards to the eCRF were noted in the assessment report and these are therefore specifically addressed below to demonstrate that the eCRF is fit for purpose and the data collection in the study is such that the data can be considered valid for review in the context of this marketing authorisation.

## Set-up and validation of the eCRF

The applicant confirms that the system used for the eCRF was appropriately validated such that the data collection can be considered valid. This validation is explained in more detail below. The eCRF computer system is a multi-tenant cloud solution provided, developed and operated by the Application Service Provider (ASP). It is not sold as a software, nor is it installed on customer servers. Customers purchase licenses to use, i.e. the opportunity to use the software, for the collection of data for their trials, and that data is collected on cloud installations hosted and maintained in compliance with relevant regulatory requirements and guidelines, such as GAMP 5 and ICH GCP. The software development and release procedures include creating/maintaining a URS for each software release and ensuring adequate verification and testing prior to release to the production environment (including key functionalities such as audit trail and time stamps). Customers are provided with validation

<div style=\"page-break-after: always\"></div>

documentation for each release, such as the URS and a Release Certificate, which are issued as part of the release documentation. The Release Certificate ensures that the software version has passed the acceptance testing conducted is approved for release.

The system versions applicable for study Nl-0501-04 up until the Database Lock cut-off date have been maintained and updated meaning that 8 software versions were used during the study until the Database Lock cut-off date. None of the software releases originated from requests from Novimmune, i.e. they were regular releases to all customers in the multitenant environment addressing e.g. minor issues or bugs. The assessment of new software releases to determine the need for User Acceptance Test (UAT) activities was not performed in a timely manner during the course of the study. Therefore, a retrospective assessment of the impact of software updates released was done showing that only minor software changes had been implemented and none of the releases could have affected the integrity of the data collected or key functionalities in the implemented eCRF.

With respect to the study-specific set up of the eCRF, the configuration was based on the clinical study protocol provided by Novimmune. It is acknowledged that the sponsor had not defined company or trial specific requirements in a separate URS.

Before introducing the study specific eCRF in live production, the eCRF study configuration was set up and agreed in a Prototype (test) environment. The Novimmune Clinical Operations team conducted oversight of the setup, verified and provided feedback based on the tests performed in the Prototype environment through email exchange as documented in the TMF. Any required changes were implemented and an updated version of the Study configuration report was generated after each substantial update.

After ensuring (via e.g. email correspondence) that all the protocol required functionalities were set up correctly in the test environment, a final Study configuration - Customer Approval Form was signed off. The eCRF was then implemented in the Production environment, and a final Study Configuration Report was generated on 26-FEB-2013.

Thus, the applicant acknowledges that the eCRF was not implemented at the time the first patient was screened (31 January 2013) but most importantly, the eCRF was available when the first patient was enrolled into the study on 28 July 2013 and thus was in place in a timely manner and would not have impacted the quality of the data.

The system includes FDA 21 CRF Part 11 compliant audit trial functionality, that is automatically activated for all customers (and cannot be disabled). The audit trail functionality is included when configuring the eCRF data collection forms and the audit trail captures all changes in the system. All automated time stamps in are stored in UTC system-wide but are translated into the time zone of the end-user when presented on the screen and in reports and are therefore consistent within each site.

In conclusion, based on the evidence provided, the applicant regards having a robust and validated system and in compliance with regulatory requirements, including functionality for audit trail and time stamps. Novimmune conducted oversight of the setup, verified and provided feedback on the eCRF during the setup phase, i.e. ensuring that the study specific CRF was fit for purpose. No system changes have been implemented during the course of the trial that could have jeopardised the validity of the collected data. Data collected should be considered as valid, reliable and without effect on the integrity of the data.

## eCRF alignment with protocol

The applicant wishes to clarify that the exclusion criteria of the eCRF were fully aligned with protocol version US 5.1/EU 6.0, whereas it is acknowledged that the eCRF inclusion criteria were incompletely

<div style=\"page-break-after: always\"></div>

aligned to the protocol in two instances, i.e. a) the new text (pivotal protocol) referring to patients having received prior conventional therapy was added to the text of previous protocol versions (pilot protocol) rather than replacing it, and b) the question \"has conventional treatment been received\" was not deleted, thus implying that a \"no\" for this inclusion criteria could be ticked in treatment-naive patients.

Neither of these eCRF design issues had an impact on the inclusion of patients which was thoroughly assessed during the screening/enrolment grid process above described. No impact on data quality can also be expected.

## eCRF collection of adverse events

Adverse events were collected in accordance with regulatory requirements (ICH E2A, CT3). The applicant acknowledges that there was a discrepancy between the protocol and the eCRF instructions with regards to the verbatim term (clinical diagnosis vs laboratory abnormality) to be used for some clinically significant laboratory abnormalities related to the HLH disease (namely haematological abnormalities, such as thrombocytopenia and anaemia) as indicated in the GCP inspection report. However, the applicant can confirm that clinically significant laboratory abnormalities were captured and assessed as follows:

isolated laboratory abnormalities (not related to HLH disease) such as hypokalaemia or hyperglycaemia were reported as individual AEs haematological abnormalities related to HLH disease were reported as an adverse event of worsening of HLH/disease aggravation. Not only is 'condition aggravated' one of the most commonly reported adverse events in the study (see below), but this would also have an impact on the response criteria (lack of response), and the need to intensify treatment. Hence this domain is captured not only through adverse event reporting, but also through the response analysis. Moreover, all laboratory data were captured throughout the study and fully analysed by presenting the shift tables included and discussed in the study report. Hence, no safety signal arising by laboratory abnormalities has been missed or not reported.

For further details please see to ground 4: The safety data are complete.

## Conclusions

In conclusion the data collection within the study is consider by the applicant as robust and the potential issues identified during the GCP inspection with regards to the eCRF did not impair the validity of the data and the completeness of reporting.

## Data processing and reporting

Data processing and reporting in the NI-0501-04 trial were robust such that the data can be considered valid. Key aspects of this including the systems used for data processing and reporting and the statistical analysis plan in the context of the GCP inspection findings are outlined below. A retrospective analysis performed on the system is also discussed.

The system includes FDA 21 CRF Part 11 compliant audit trial functionality, that is automatically activated for all customers (cannot be disabled). The audit trail functionality is included when configuring the eCRF data collection forms and the audit trail captures all changes in the system.

the main Clinical Data Management System (CDMS) used for data entry of safety laboratory data as well as the data handling of all data from eCRF and laboratories. As a corrective action, a full retrospective system validation of the CDMS and related modules has now been completed with all key functionality successfully tested. Please see the final validation report.

<div style=\"page-break-after: always\"></div>

In addition, as part of the validation, the applicant reconstructed the data management and handling process involving both the eCRF as source and the double data entry process. In summary, following the successful outcome of the retrospective system validation and the reconstruction of eCRF and lab data, the eCRF data-imported and laboratory data entered, then handled through the CDMS are considered as valid and reliable and the integrity of the data is intact. Therefore, in conclusion, the data are valid and should be used in the assessment of this marketing authorisation.

## BaseCon

BaseCon is a cloud-based system provided by the vendor BaseCon and was used as safety database for all studies conducted by Novimmune as a sponsor. During the period from 2008 up to August 2009. Since 2009, the database was managed internally by Novimmune. From November 2017, BaseCon is no longer used for emapalumab and has been replaced with Argus safety database.

Four different roles were configured in the database: Administrator (12), Data Manager (1), Medical Expert (5) and Reader (not used). The roles are applicable for the Novimmune setup, and inherent for all studies.

Due to the configuration of the database, the \"Administrator\" role was the only role that allowed the user to have access to the Audit trail, the Partner Database (link between BaseCon and Competent Authority to enable expedited reporting) and the applicant database (included all products of the company). The access to the Partner Database and the Register was essential to carry out PV tasks regarding ICSR processing and/or expedited reporting.

Based on the BaseCon user access audit trail during the time period of the study Nl-0501-04, i.e. since 28-Jul-2013 (first patient enrolment), 9 Novimmune users, 8 of whom had administrator role, had logged in and accessed the database. No other non-Novimmune users accessed Basecon during this period.

Based on the above, considering the configuration of the database and users' respective roles, their administrator roles were justified for PV compliance reasons and this without affecting human subject protection.

After the cut-off of 20-Jul-2017, the sponsor upgraded its safety database and transitioned to the Argus system in November 2017. All SAEs reported in clinical trials using emapalumab are entered in Argus safety database. As per UBC SOPs, Argus user access is granted/modified/disabled in a controlled manner. Individual user roles and associated rights are periodically reviewed and evaluated to ensure compliance with regards to active user accounts for the project.

During the conduct of the study, the BaseCon safety database was regularly updated to ensure continuous E2B compliance. At each software release during the period of Nl-0501-04 study, the vendor performed system-related tests, and the sponsor performed user acceptance testing (UAT) in the testing environment. When UAT was satisfactorily completed and Test Case Report was released; the new version was subsequently deployed in the production environment. Therefore, the sponsor considers validation activities to verify consistency of the data as sufficient.

## The statistical analysis plan

The applicant acknowledges that the SAP should preferably have been finalised earlier (and have addressed this in a CAPA), but would like to emphasise that a draft version of the SAP was available in April 2013 when only a single patient (a screen failure) had signed the informed consent and prior to any patients being treated. This SAP was provided to the Inspector team during the Inspection and is

<div style=\"page-break-after: always\"></div>

now archived in the TMF. This version of the SAP was the basis for the preparation of a document submitted to FDA as part of the briefing package for the type B meeting on 16 November 2015.

Importantly, the key study features were discussed and revised in collaboration with FDA who agreed that the study had a potential to serve as a pivotal (confirmatory) study, although recommending a change in statistical methodology, which was subsequently implemented.

Version 2.0 of the SAP, dated 2 November 2016, was prepared to reflect the amended pivotal protocol and submitted to both EMA (Scientific Advice briefing package in November 2016) and FDA (End-ofPhase 2A Meeting submission on 22 December 2016) for review. Based on this review, the SAP version 3.0 was finalised and signed. Thereafter, the SAP remained the same with respect to the statistical methodology used for the primary efficacy analysis. Additional details were added to handle specificities that arose during the output programming of the study, with all changes outlined in version 4.0 of the SAP.

Following feedback from the GCP inspections, in order to explore the potential impact of the revisions made following the agreement with FDA and the amended pivotal protocol, an additional subgroup analysis was performed with the subset of second line patients enrolled after the protocol amendment. These patients had a similar magnitude of response as in the full second line population of 0.60 (95% CI: 0.31, 0.83 (N=10). These results show that the primary analysis is unbiased with respect to the implementation of the amendment and the corresponding revisions of the SAP.

## Overall conclusions Ground 5

NI-0501-04 trial was a complex clinical trial conducted in a rare and serious paediatric disease and is the first company sponsored study in this vulnerable group of patients with no currently approved therapies in Europe. The conduct of the clinical trial reflected the challenges inherent to conducting clinical trials in this setting of a serious and rare disease as well as the growing nature of the sponsor company. The applicant acknowledges and takes seriously the GCP inspection findings as evidenced by the CAPAs implemented to address these. However, as demonstrated here following the flow of the clinical trial from patient inclusion through the entire conduct of the study (i.e. source data, data collection and finally data processing, analysis and reporting), the data can be considered to be reliable and therefore deserve to be reviewed in the context of this marketing authorisation application.

## Applicant's Overall Conclusions

Primary Haemophagocytic Lymphohistiocytosis (pHLH) occurs mainly in infancy and early childhood with the disease manifesting in most patients between 1 and 6 months of age (Henter et al 1991a; Aricò et al 1996; Janka and Lehmberg 2014). It is a serious and life-threatening disease, which is invariably lethal if untreated, with a median survival of less than 2 months after diagnosis (Janka 1983; Aricò et al 1996). Once primary HLH has been diagnosed, therapy should be started as soon as possible with the objective to reduce the hyperinflammation and, if known, targeting the underlying disease in order to bring patients successfully to transplantation, which is the only curative therapy in primary HLH.

The applicant believes the inaccuracies and misinterpretation in the CHMP AR 23 July 2020 as described in ground 1: Underestimated unmet medical need and misinterpretations in the assessment report has negatively impacted the review of the emapalumab marketing application. As described in ground 1: Underestimated unmet medical need and misinterpretations in the assessment report there are no medicinal products currently approved in the EU for the treatment of primary HLH, either for first or for second line treatment. Current conventional treatment modalities are glucocorticoids in combination with chemo-immuno-suppressive therapies (etoposide), as recommended by the

<div style=\"page-break-after: always\"></div>

Histiocyte Society. Importantly, there is no second line treatment recommendation (Ehl et at 2018) and no evidence on which physicians may base treatment decisions in patients failing on first line therapy or experiencing a reactivation of disease. Despite the more and more aggressive regimens applied, no improvement in survival has been documented in the past 20 years and the high medical need for patients suffering from HLH remains undisputable as shown by the poor survival with the current treatment protocols of only 54% to 59% 5-years probability of survival (Trottestam et al 2011a; Bergsten et al 2017).

As discussed in ground 2: Efficacy and study design, contrary to the initial CHMP opinion, the applicant has demonstrated that the efficacy and safety of emapalumab in second line pHLH patients can be determined from the NI-0501-04 study and that a randomised, controlled clinical trial would be neither ethically appropriate nor feasible in this disease setting.  The efficacy is demonstrated by an objectively measured and clinically relevant endpoint, ORR, and is supported by multiple pre-planned and post-hoc analyses and by HSCT and survival data as well as in comparison to historical control data. The applicant has shown that the efficacy can indeed be demonstrated taking into account the natural variability in the disease course and the allowance of concomitant therapies and that it is supported by the PK/PD profile (ground 3: Pharmacokinetics/Pharmacodynamics). Moreover, the safety profile has been clearly demonstrated and is favourably differentiated from other commonly used, non-approved, HLH therapies (ground 4: Safety). The applicant therefore concludes that in the context of this high unmet medical need the benefit risk ratio of emapalumab is positive.

The NI-0501-04 trial was a complex clinical trial conducted in a rare and serious paediatric disease. The conduct of the clinical trial reflected the life-threatening clinical setting and the vulnerable patient population. The applicant acknowledges and takes seriously the GCP inspection findings as evidenced by the 64 CAPAs in place to address these. However, as demonstrated in GROUND 5 following the flow of the clinical trial from patient inclusion through the entire conduct of the study (i.e. source data, data collection and finally data processing, analysis and reporting), the data can be considered to be reliable and therefore deserve to be reviewed in the context of this marketing authorisation application.

As noted throughout this document, the applicant has proposed a conditional marketing authorisation and has demonstrated that the requirements for this are met, as outlined in Table 1. The applicant has clearly demonstrated that there is a high unmet need for treatments for patients with pHLH who have failed first line treatment and that, in this context, the positive benefit risk of emapalumab has been demonstrated. Additional data from the on-going NI-0501-09 study and proposed PASS will provide additional data to confirm the benefit risk of emapalumab. As such, the public health benefits of approving emapalumab based on the available data, far outweighs the risks inherent in the fact that additional data are still required.

In summary, considering the totality of the data, the strengths and limitations of the NI-0501-04/05 study and the high unmet medical need and the demonstrated positive benefit/risk in the target patient population, the applicant proposes a conditional marketing authorisation with the ongoing study NI-0501-09 as a specific obligation to confirm the safety and efficacy profile of emapalumab.

## CHMP assessment of applicant's ground #5

There are concerns that the change from the phase 2 to a phase 3 trial appeared not to be pre-planned by well-defined criteria. At that time data from several patients were available and could have informed the criteria for the pivotal phase 3 trial, such as the definition of the primary endpoint. Furthermore, it is seen critical that the inclusion criteria were adapted during the recruitment process. Apart from deficiencies in GCP, this also relates to methodological concerns regarding the composition of the patient population for the primary evaluation (as referred to in the assessment of ground #2).

<div style=\"page-break-after: always\"></div>

Furthermore, late amendments and the modifications of the SAP after database lock raise important concerns whether the analyses were driven by the available data. The problems arising from the amendment of the protocol and statistical analyses plan cannot be resolved by source verification of the source data alone.

The applicant acknowledges that the GCP training process within Novimmune was not adequately formalised at the beginning of the study. Training processes were only implemented in 2015 and annual GCP trainings were only introduced in 2017. Thus, no adequate GCP training process was in place during most parts of the study (1 st  patient enrolled on 28-JUL-2013, last patient completed on 20-JUL-2017) and the initial concern is not alleviated.

The applicant now performed a post-hoc sensitivity analysis excluding the data from the site with critical/major findings regarding the source data. The sensitivity analysis on ORR in second line patients showed a similar magnitude of response as in the primary analysis with 62.5% responding (95% CI: 0.41, 0.81; N=24). Despite the remaining uncertainties about data integrity as pointed out in the final inspection report, it is acknowledged that the results of that analysis are comparable to the primary analysis.

Regarding data collection, processing and reporting, no data trail could be established and that a lack of GCP/trial specific training may have contributed to impaired data collection, particularly when the protocol does not align with the eCRF.

Taking all these issues into consideration, the CHMP considered that the earlier conclusion that the triggered GCP inspection revealed substantial concerns on the integrity of study data, thus adding to the above uncertainties, remained unsolved.

## 6.1.6. Ad-hoc Expert Group meeting on emapalumab

The applicant requested that an ad-hoc Expert group is held in the context of the re-examination. The outcome of the expert group meeting held on 30 October 2020 is detailed below:

## Question 1

The Experts are invited to provide their views  on the data submitted by the applicant as part of the grounds for re-examination, in support of the efficacy of emapalumab  in the currently claimed indication: Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH) with refractory or recurrent disease or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide)

All Experts acknowledged that the single arm pivotal study was poorly designed and presented methodological problems; this was considered by the Experts as a major concern. The Experts also commented that strict and robust criteria are of major importance especially in the context of a single arm trial.

In particular, concerns were raised on the following aspects:

- Inclusion criteria for second line patients:

The definition of unsatisfactory response or incomplete response to conventional treatment was based on the physician's understanding of the clinical condition. Intolerance to previous therapies was not clearly defined. A strict definition would have been needed. The Experts also commented that the HLH re-activated patients (n=15 patients) often respond well to retreatment with the initial drugs.

<div style=\"page-break-after: always\"></div>

The Experts considered that the disease severity reported by the studied patients was not the most severe among the pHLH population. They commented whether this might have contributed to the efficacy observed in the second line patients' population.

All Experts agreed that the inclusion criteria were considered too vague and not strict enough. The patient population was therefore not found appropriately defined, which is even more a concern in the heterogeneous setting of pHLH, thus contributing to the overall heterogeneity of the studied population.

An issue for criticism was also that for 5/27 patients primary HLH could not be confirmed, adding substantially to the already great heterogeneity. One Expert mentioned that in the treatment-naïve patients two were classified as FHL-1; however, the genetic defect that causes FHLl-1 has not yet been characterised.

## - Response criteria:

The Overall Response Rate was defined by an achievement of either complete or partial response or HLH improvement at end of treatment (week 8). The current response criteria as defined were based on clinical symptoms (fever, splenomegaly, CNS symptoms) and laboratory outcomes (cytopenia, hyperferritinaemia, coagulation, sCD25). The Experts noted that cerebrospinal fluid is a not a common defined criterion for response. All patients with CNS disease received intrathecal methotrexate that is known to normalize the CSF reliably. Corticosteroids may decrease fever. Thus, change in only one additional parameter (or no sustained worsening of sCD25) would already lead to partial response.

The primary efficacy results on ORR were closer to the predefined threshold of 40% to achieve efficacy when considering sensitivity analysis (for the primary analysis ORR was 63% with a 95% CI of 0.420.81 in the second line treated set and 59.3% with a 95% CI of 0.39-0.78 when excluding patients receiving additional HLH treatments). Concerns were raised by the majority of the Experts, since the efficacy database was small (n=27 patients) therefore addition of 1 or 2 patients may have sufficed to change the observed trend. One expert considered the database sufficient in view of the very rare disease. The robustness of the observed results were questioned. It was also commented that efficacy results in the study were largely driven by the rate of partial responders and patients with improvement.

The Experts raised also concerns with the fact that none of the 11 pHLH patients who were treatment naïve achieved complete response. Out of the 11 patients, 4 had no response, 4 achieved partial response and 3 had improvement.

## - Additional therapies used before and during the study:

The Experts considered that the observed efficacy may be driven by the effect of concomitant or previous therapy. They expressed concerns on observed results with the sensitivity analysis excluding patients receiving additional therapies.

Overall, all these issues hampered Experts to provide final conclusions on the efficacy of emapalumab in the claimed indication based on the currently available data. The Experts contextualised also that efficacious therapies are available for salvage therapies, even though therapies with less toxicity would be desirable. The Experts acknowledged the need for new drugs, with proven efficacy and a more acceptable safety profile than the currently available treatments. However, in this severely affected patient population, the Experts expressed concerns for the use of emapalumab while proven efficacious other therapies are available as standard of care but no therapies are authorised.

The Experts acknowledged also that emapalumab may be considered for use as a combination therapy.

<div style=\"page-break-after: always\"></div>

The majority of Experts acknowledged that emapalumab was probably efficacious in some patients' subgroups. However, the subgroups could not be defined in the study. Suggestion was given by one Expert to characterise patients with involveme nt of IFNγ pathway that would be identified with the use of several surrogate markers (eg. STAT phosphorylation and/or elevated CXCL9). This Expert considered that emapalumab may be used in these patients.

This Expert was convinced about the observed 60% ORR considering the heterogeneity of the disease.

The Experts considered that a new study should be conducted on a well-defined target population in order to characterise efficacy and define an appropriate subgroup of patient responders to emapalumab.

One Expert also commented that the dose escalation strategy was not clear and recommended to look at CLCX9 as a biomarker of response instead of using clinical criteria. The dosing regimen does not seem justified and questions remain on when to start the treatment and the dose to use.

The 2 patient representatives commented that there is a need for new drugs to be administered at time of diagnosis before undergoing transplantation. They both experienced successful HSCT outcome with their children.

## Question 2

The Experts are invited to provide their views whether a RCT in the second-line indication is considered clinically feasible, e.g. comparison against other treatments as applied in the pivotal trial. The Experts are also asked to comment on the potential size of the patient population to be included in such a trial, both in Europe, but also considering a possible global spread.

All Experts agreed that conducting an RCT in HLH is very challenging due to the limited number of patients.

The Experts indicated that there are already issues on feasibility to conduct an RCT as 1 st  line treatments and that this would be even more challenging in the 2 nd  line treatment setting. Additionally, a large number of patients now undergo HSCT earlier, which limits the number of patients available for second line therapy.

The Experts agreed that a well conducted single arm study would be the only option. A single arm study would need to be well designed under very strict conditions (clear inclusion criteria, response criteria) in order to provide robust data.

## Question 3

The Experts are invited to provide their views on the anticipated success rate of current treatments in a second-line population after re-intensification of therapy. How many second-line patients are expected to achieve complete remission before HSCT and how many are expected to proceed to HSCT (approximate percentages)?

The Experts acknowledged that the success rates of current treatments (alemtuzumab, ATG) in second-line population are available in the published literature (Marsh RA et all 2018 3 ) as provided by

3 Alemtuzumab: Marsh RA et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013; 60:101-109 ATG: Mahlaoui N et al: Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins; a single-centre retrospective report of 38 patients. Pediatrics 200; 120: e622-e628

<div style=\"page-break-after: always\"></div>

the applicant. One Expert emphasised that in the latter study with ATG, a high response rate of 5 CR and 4 PR was achieved in 10 patients. The Experts noted that there have been improvements in treating refractory pHLH patients in the last years that are currently not well reflected in the published literature.

Of note :  One Expert mentioned that a larger study with ruxolitinib (not currently approved in EU in this indication) for refractory patients has been performed in China in addition to many case reports documenting efficacy of this drug (Wang et all 2020 4 ) These were, however, nearly all secondary HLH patients.

The Experts think that the available salvage therapies have shown to get the same percentage of patients to HSCT as emapalumab. A new drug such as emapalumab, with a better safety profile than the available salvage treatment protocols, however, would be a good alternative option to current therapies for relapsed and refractory HLH.

The Experts agreed that the main goal of therapy is to undergo HSCT as soon as possible. This applies to front-line and second-line therapy alike. Genetic HLH patients can nowadays be identified rapidly, enabling early search for a donor. Present standard-of-care therapy for pHLH results in an ORR over 80%. In the two international HLH studies time to transplant was very long, resulting in many reactivations. It is expected that fewer patients will need salvage therapies with earlier HSCT. Additionally, mortality after HSCT has been very high in the past, which can be markedly improved, as several recent studies have shown.

The Experts agreed that the main goal is early transplantation and not necessarily to achieve complete remission before HSCT.

The Experts acknowledged that the timelines for access to HSCT vary across the countries and difficulties are encountered in Eastern parts of Europe (eg. Bulgaria or Romania) leading to longer delays for transplantation. It is not always possible for patients to get access to best available treatment. In case access to transplantation is not feasible or affordable, another 'salvage' drug may be of need.

## Question 4

The Experts are invited to provide their views on the role/involvement of IFNγ regarding the MoA of Gamifant. In particular, what proportion of HLH patients (not limited to pHLH) may be expected to benefit from a drug with this specific MoA considering that the clinical manifestation differs between the patients and also between the non-clinical model and the clinical situation?

The Experts agreed that IFNγ is involved in the pathogenesis of pHLH, but that this is not the only pathway. Treatment of HLH patients cannot be based alone on the efficacy of the antibody in mouse models. For example, if mice are infected with a different infectious agent than LCMV (e.g. MCMV), the situation is different. Additionally, given the heterogeneity of pHLH patients, it would not be expected that emapalumab will be efficacious for all pHLH patients. The Experts considered that some subgroup of patients could benefit from emapalumab, however, such a subgroup has not been identified.

4 Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, Wang Z. Ruxolitinib for refractory/relapsed hemophagocytic lyphohistiocytosis Haematologica 2020;105:e210-212

<div style=\"page-break-after: always\"></div>

The following comments were made on the secondary forms of HLH:

- Macrophage Activation Syndrome in autoinflammatory (sJIA) / autoimmune diseases:

The Experts agreed that there are effective medicinal products available (e.g. anakinra, tocilizumab) and agreed that emapalumab would only be necessary for a small number of patients who are refractory to the therapies used as standard of care but not authorised (e.g.anakinra).

## - Infection-associated HLH without genetic defect:

The Experts noted that no data are available. It is difficult to answer whether emapalumab may play a role in the treatment of this subgroup of HLH patients; however, unless studies are performed to ascertain a benefit from emapalumab, the Experts could not presently recommend its use. They agreed that emapalumab would not be indicated for HLH patients with bacterial, protozoan or fungal infections that can be treated otherwise.

- Malignancies associated HLH:

The Experts noted that no data are available based on their knowledge.

## Question 5

The Experts are invited to provide their views on the extent of the variability that may be expected in a trial population as observed. The Experts are asked to comment on the impact that patient heterogeneity, the course over time and background and rescue therapies applied may have had on the primary endpoint.

The Experts agreed that there is variability observed in pHLH patients regarding different genetic background and disease presentation. The Experts agreed that the heterogeneity of the included population in the study may have had an impact on the primary endpoint. This heterogeneity further reinforces the need for strict inclusion criteria to define appropriately the target subgroup of patients (see recommendations provided in response to Question 1).

On the other hand, one Expert considered that the population could be seen as homogenous when considering the elevated biomarker CLXC9, in term of mechanism leading to pHLH in included patients.

This Expert noted that emapalumab targets only the IFNγ pathway. However, other pathways are involved such as the lymphoproliferative and hyper-inflammatory features of HLH. This may explain why some patients did not respond to emapalumab.

The Experts also considered that some of the efficacy observed with emapalumab could be derived from the background therapy (e.g. glucocorticosteroids) used in the study. The Experts acknowledged that the effect of the rescue therapy on the results remained difficult to interpret.

Overall the majority of the Experts agreed that the factors that contributed to the response observed were not possible to distinguish. The responses seen in the pivotal single-arm study cannot, with sufficient certainty, be attributed to treatment with emapalumab, given that emapalumab was used in combination with other therapies. According to one expert the study did show efficacy in spite of the methodological issues, and emapalumab could represent a valuable alternative for treatment of patients with primary HLH with refractory disease or intolerance to conventional therapy.

The Experts considered that only patients who did not receive additional therapy during the study should be considered.

## Question 6

<div style=\"page-break-after: always\"></div>

The Experts are invited to provide their views whether the safety profile of emapalumab has been sufficiently characterised, would be acceptable and clinically manageable in the proposed target population?

The Experts agreed that the safety profile of emapalumab is not a concern. Overall, the Experts would consider the safety profile manageable. The Experts noted that it is difficult to distinguish the side effects from the disease itself due to the design of the trial but it did not raise particular concern among the Experts.

## 6.1.7. Oral Explanation

Following the Ad-hoc Expert group meeting the applicant was invited to an oral explanation to discuss the outstanding issues in particular:

The applicant was requested to justify a positive benefit-risk balance for emapalumab in view of the following critical issues:

- a) Substantial deficiencies were encountered pertaining to the demonstration of efficacy of Gamifant, which is not considered established.
- Multiple issues obviating causal attribution of efficacy to Gamifant are identified, particularly due to severe limitations in the design of the SAT with insufficiently defined inclusion criteria leading to a greatly variable and possibly pre-selected patient population, as well as the influence of co-medication and variability thereof, both in terms of dose and specific drugs used.
- The late trial transition from exploratory to pivotal in an ongoing trial with potential data-driven decisions, and the introduction of a new PEP based on liberal response criteria that do not allow a relation to previous data or natural disease courses severely undermine the interpretability of the trial.
- The primary analysis does not robustly meet its primary target and per se prevents ascertaining a treatment effect.
- b) Based on the mode of action of emapalumab limited to one of several pathways in the pathogenesis of pHLH, it cannot be concluded from the current trial that dosing requirements are sufficiently established and that the patient population as defined will derive significant benefit from treatment.
- c) The applicant's retrospective analysis based on the critical findings observed in the triggered GCP inspection is not considered to solve the problem of missing data. The applicant is asked to convincingly dispel these additional uncertainties with regard to efficacy and safety of emapalumab.

## 6.1.8. Overall conclusion on grounds for re-examination

The CHMP assessed all the detailed grounds for re-examination and written argumentations presented by the applicant, considered the views of the Ad Hoc Expert Group and the arguments presented by the applicant in the Oral explanation.

Its conclusion is presented below:

Multiple issues obviating causal attribution of efficacy to Gamifant have been identified, particularly relating to the single arm trial design and - as also recognised by the experts in the Ad-Hoc Expert

<div style=\"page-break-after: always\"></div>

Group (AHEG) meeting - the influence of variable co-medications (both in drugs used and applied doses) and the high intra- and inter-patient disease variability.

Moreover, as noted by the Ad-hoc Expert Group, the inclusion criteria for the second-line patients were too vague and not stringent enough resulting in a patient population that was not appropriately defined, which contributed to additional variability.

In addition, the late trial transition from exploratory to pivotal while the trial was ongoing and with potential data-driven decisions, and the introduction of a new primary endpoint that was less strict compared to previous haemophagocytic lymphohistiocytosis (HLH) trials and thus did not allow a possible relation to previous data or natural disease courses severely undermine the interpretability of the trial. Beyond these deficiencies, the primary analysis did not robustly meet its primary target, as e.g. observed when patients receiving additional medications before measurement of the primary endpoint are rated as non-responders, and this per se prevents ascertaining a treatment effect, thus precluding a positive benefit-risk balance.

Concluding from the AHEG meeting, the e xperts agreed that IFNγ is involved in the pathogenesis of primary haemophagocytic lymphohistiocytosis (pHLH), but that this is not the only pathway. Given the heterogeneity of pHLH patients, it would not be expected that emapalumab will be efficacious in all pHLH patients. On the basis of the current data it is not possible to define a target pHLH population that would benefit from emapalumab and this would need further investigation.  Furthermore, dosing requirements (when to start the treatment and the criteria for defining a starting dose) are not properly established.

In addition, the triggered GCP inspection revealed substantial concerns on the integrity of study data and recommended that the results of this study should not be used to support the marketing authorisation application based on impaired conduct of the study, impaired data quality and lack of data trail, amongst others. These findings add to the uncertainties of the single arm trial with regard to efficacy and safety. Retrospective analyses conducted by the applicant are not considered to solve the findings, since missing data cannot be corrected retrospectively, and therefore the reliability of the data remains questionable.

The grounds related to safety are considered sufficiently addressed.

Based on the uncertainties pertaining efficacy, as outlined above, the CHMP concluded that the benefitrisk balance of Gamifant is negative.

The CHMP also took note that when adopting the PIP, the PDCO discussed the ongoing clinical study NI-0501-04, that had already been agreed with other regulatory Authorities, and concluded that it would have been preferable to conduct a randomised controlled trial and that for the MAA to be successful the results would need to be extremely convincing. The PDCO also commented that strong justification for the applied dosage regimen, the dose adjustment algorithms and the treatment duration would be important. An amendment to the study would have significantly delayed the planned submission for authorisation and was not possible at time of PDCO opinion.

<div style=\"page-break-after: always\"></div>

## 7. Benefit-risk balance following re-examination

## 7.1. Therapeutic Context

## 7.1.1. Disease or condition

Haemophagocytic lymphohistiocytosis (HLH) is a very rare group of disorders of uncontrolled immune activation associated with severe hypercytokinaemia. The symptoms of disease wax and wane over time and are sensitive to external factors like infections. HLH can be categorised as primary (familial) or secondary (acquired). Primary HLH corresponds to genetically inherited forms and secondary (acquired) HLH occurs in the setting of infectious, malignant, rheumatologic, or metabolic conditions. The incidence of HLH in paediatrics is estimated as 1 to 225 per 300 000 live births and HLH occurs mostly in infancy and early childhood. The incidence in the adult population is unknown. The current application targets paediatric patients with primary HLH.

Primary HLH (pHLH; or familial HLH) is caused by genetic mutations, of which most affect the cytotoxic function of T lymphocytes and natural killer (NK) cells. This ultimately results in a vicious cycle of amplified cytokine secretion (e.g. IFNγ, TNFα, IL -6, etc) and leads to pancytopenia, disseminated intravascular coagulation followed by multiple organ failure. Several underlying mechanisms for HLH have been proposed. Based on the observations in perforin knock-out mice one of them suggests a central role for IFNγ in the disease. Based on this model, neutralisation of IFNγ has been proposed as a treatment strategy for pHLH, with the aims to provide a bridge to haematopoietic stem cell transplantation.

The applied indication has been amended during the procedure to: ' Treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide).

An Orphan drug designation has been granted for emapalumab in the treatment of HLH in the European Union (EU) (EU/3/10/749).

The applicant requested a conditional marketing authorisation (CMA) during the procedure (D180).

## 7.1.2. Available therapies and unmet medical need

There is an unmet medical need in the treatment of pHLH. If left untreated pHLH has a dismal prognosis with a median survival of less than 2 months after diagnosis. There is no approved pharmacotherapy for the treatment of pHLH, however the current standard of care is the HLH-94 or HLH-04 treatment protocol which improved the survival of patients with HLH. These protocols consist of an 8-week treatment with etoposide plus backbone treatment of dexamethasone with/or without cyclosporine-A (CSA). Continuation therapy should last until haematopoietic stem cell transplantation (HSCT), which is the only curative treatment for pHLH. While ideally performed when patients are in remission, around 30% to 60% of patients have been transplanted with active disease. For treatment naive patients treated according to HLH 94/04 protocols the estimated 5-year survival in patients with familial or pHLH is 56-59%. Around 76%-80% of the patients survive to HSCT, with overall survival reported to be up to 70% at 5 years post HSCT.

Although the treatment of HLH therapy has improved the survival of patients with HLH, there is still a need for additional treatments. Patients with a relapse/reactivation who initially responded to therapy may respond to intensification of standard -of-care therapy, which is advised per HLH-04 protocol. For

<div style=\"page-break-after: always\"></div>

patients refractory to steroids and etoposide, there is limited evidence available, but most physicians recommend alemtuzumab. The prognosis of pHLH patients who need treatment beyond first line is poorly described in the literature. Disease reactivation is common, particularly when etoposide and dexamethasone are reduced. These reactivations usually respond to a re-intensification of therapy (Ehl, 2018). 5 Treatments that can be used as salvage therapy are alemtuzumab, anakinra or ATG. Specific recommendations for salvage therapy are difficult because of limited data. Consultation with an HLH expert is strongly encouraged before choosing and starting salvage therapy (Ehl, 2018.)

## 7.1.3. Main clinical studies

The main studies to support this application are the single arm, open label pivotal study NI-0501-04 and the follow-up study NI-0501-05. The pivotal study NI-0501-04 is a single arm study and was initially designed as pilot study in primary HLH patients with reactivating disease. Upon the final amendment, the study was changed to a single arm phase 2/3 study intended to support authorisation. After completion of study NI-0501-04, patients were invited to participate in the follow up study NI-0501-05.

In study NI-0501-04, the starting dose of emapalumab was 1 mg/kg biweekly added to a continuous background treatment with dexamethasone. During the study the posology of emapalumab was modified. In the final posology, the dose could be increased based on clinical and laboratory criteria. HSCT was allowed after a minimum of 4 weeks of emapalumab. Upon protocol amendments, patients could use concomitant HLH medication in both the 04 (if meeting certain criteria) and 05 study (no limitations). The initial dataset comprised of in total 34 patients were treated with emapalumab in study NI-05-1-04/05, of which 7 were treatment naïve and 27 'second line'. The primary analysis set consists of the second line all treated set, which is regarded as the primary efficacy population from here on. The initially provided results were based on an interim analysis, as at Day180, additional data of N=11 treated patients from study NI-0501-04 were presented. These patients were treated after 20 Jul 2017 with a data cut off 31 Jan 2019. The data set included 7 second line and 4 treatment naive patients.

The primary endpoint is the overall response rate (ORR) measured at the end of treatment (week 8 or earlier) in study NI-0501-04 as defined by complete (CR) or partial response (PR) or HLH improvement. The definition of this endpoint differs from the outcome measure investigated in previous studies in several of the individual response criteria used.

The applicant has presented data from compassionate use (CU) (8 subjects with pHLH and 9 with sHLH) as supportive of study NI-0501-04/05. A historical cohort of 72 mainly treatment naïve patients with pHLH treated from 2010 onwards has been presented, seeking to indirectly demonstrate benefit over SOC. Also, additional safety data from n=22 pHLH patients of study NI-0501-09 and n=14 patients in secondary HLH were provided.

## 7.2. Favourable effects

At the time of the interim analysis (IA), the overall response rate (ORR) at end of treatment (EoT) in study NI-0501-04 (4-8 weeks) was 63% (0.42-0.81, n=17) in the second line treated set.

The overall response rate was 59.3% (n=16, 0.39-0.78) when treating subjects identified by the applicant as patients receiving additional HLH treatments (in addition to the dexamethasone

5 Ehl et al. Recommendations for the use of etoposid based therapy and bone marrow transplantation for the treatment of HLH: consensus statement by the HLH steering committee of the Histiocyte Society. J ALLERGY CLIN IMMUNOL PRACT: 1508-1517. https://doi.org/10.1016/j.jaip.2018.05.031

Gamifant

<div style=\"page-break-after: always\"></div>

background treatment) as non-responders (n=5).

A complete response was seen in 7 (26%), PR in 8 (30%) and HLH improvement in 2 (7%) patients.

The median time to first response was 8.0 days in the second line treated set.

Twelve (44.4%) patients could reduce the dose of glucocorticoids by at least 50% at EoT Study NI0501-04 in the second-line set.

A total of n=19 (70%) proceeded to transplantation in the second line set. The median time to HSCT was 100 days (95% CI: 73, 155) in the All Treated and 83 days (95% CI: 64, 139) in the Second-Line analysis sets, respectively. Responses at conditioning were: 5 in CR, 5 in PR and 3 had HLH improvement. Six second line patients (and 2 first line patients) underwent a HSCT with no response.

Twelve-month survival probability is 0.73 (0.522, 0.864).

The post HSCT survival 12-month probability estimate was 0.89 (0.641, 0.973).

A Cox regression model of Overall Survival with HSCT as a time-dependent covariate indicated HSCT reduced risk of death by 44%, HR 0.56 (0.08 to 3.74) in 2 nd  line patients when they were compared to historical controls.

The final data from study NI-0501-04 included n=11 additional patients including n=7 treatment experienced. From the data presented, n=23 patients of the primary analyses are considered representing the latest applied indication i.e receiving dexamethasone and etoposide as first line treatment. The ORR was 20 /34 (59%), 95% CI 40.7, 75.4; p=0.02. Additional analyses excluding those patients who receive additional HLH therapy showed an ORR of 19/23 (55.9%) (95% CI 37.9, 72.8, p=0.04).

## 7.3. Uncertainties and limitations about favourable effects

Trial NI-0501-04 used an own, new definition for the ORR at week 8, which is less strict compared to previous trials and thus does not allow for sufficient comparison to data from previous trials. This hampers elucidation of a potential treatment effect of Gamifant as it increases the response rate in the Gamifant group thereby introducing a bias. Moreover, pHLH is characterised by high intra- and interpatient variability; the measurement at a single time point may thus not adequately reflect the patients' disease activity. Furthermore, the primary endpoint was not validated and the clinical relevance remains unclear. In addition, in relevant sensitivity analyses, including a non-responder imputation analysis the predefined target was not met.

The transition from an ongoing explorative phase II trial to a pivotal phase III trial was not preplanned. There is a concern that these changes were data driven since the corresponding amendments were made after a descriptive analysis conducted in the first n=11 patients which was shared with trial decision makers. These amendments changed the goal of the study, dosing scheme, concomitant HLH treatment and definitions of primary and secondary endpoints. Moreover, the statistical analyses plan has been amended twice after the data base lock.

On the patient population provided in the primary analyses set (20 July 2017) for some of the patients the pHLH diagnosis could not be confirmed. Inclusion criteria were not precisely defined, both in terms of unsatisfactory response or incomplete response as well as intolerance to previous therapies. This, together with the fact that patients received various concomitant or previous therapies precludes a clear identification of the patient population treated in second line and the isolation of a potential treatment effect of emapalumab.

<div style=\"page-break-after: always\"></div>

The proposed posology is symptom based. The relationship between emapalumab and clinical symptoms was only indirectly demonstrated (via CXCL9) on a population level, without considering dose alterations. The influence of concomitant HLH medication and dynamic nature of the disease further hamper the assessment of the effect. The applicant's arguments provided in the grounds for reexamination could not convincingly alleviate these concerns. Therefore, it remains unclear if emapalumab provides a complete neutralisation of the free and receptor bound IFNγ and if this confers to symptom and disease improvement. From a pharmacokinetic and clinical perspective, the proposed posology (i.e. starting dose, dosing frequency, dosing on clinical symptoms, termination of emapalumab treatment before HSCT) has not been adequately justified and the central role of IFNγ neutralisation in the overall pathophysiology of pHLH is not completely understood. Given that emapalumab was used in combination with other therapies, as well as due to the known variability in the course of pHLH, the responses seen in the study cannot be causally attributed to treatment with emapalumab. Similarly, the contribution of emapalumab to patient eligibility for HSCT, and its impact on OS, cannot be ascertained.

The indication is not supported by the primary analyses (n=27 patients, date 20 July 2017). A total of n=4 patients did not receive conventional first-line HLH therapy. When subjects identified by the applicant as receiving some of these additional HLH treatments (added to a continuous background treatment with dexamethasone) are classified as non-responders, the 95% CI of the primary endpoint fails to meet the pre-specified target of ORR &gt;40% (ORR 59.3%, 95% CI: 0.39-0.78). With the exclusion of those second-line patients that did not receive front-line etoposide (although they were eligible), the ORR was 60.9% (95% CI: 0.385, 0.803), with the lower limit of the 95% CI being less than the pre-set limit of 40%. From the updated data of Study-0501-04 (31 Jan 2019) a total of n=7 patients were identified as treatment experienced, but only 4/7 received upfront the combination of dexamethasone and etoposide. None of these n=4 patients showed a response on emapalumab. The long-term efficacy of emapalumab is unknown as the median FU time for the pivotal study is short (13.4 months) updated to (14.6 [4.6-20] months. The selection methods for the historical controls (HCs) were not considered appropriate as they are prone for selection bias. Comparison of these controls to the pivotal study is considered inappropriate due to the differences in patient populations for which the analyses were not adjusted. For the pHLH patients treated in CU it is not clear what dosing regimen and concomitant treatments these patients received and therefore they are not considered as supportive for the pivotal study outcomes. Improvement of overall survival (OS) is the ultimate goal in the treatment of HLH. However, the comparison with historical data failed to show a convincing improvement in OS. Although the point estimate showed an improvement of 44%, the 95% CI was very wide. Of concern is that the upper limit of the confidence interval of 3.74 for the HR shows that this estimate is prone to extremely large variability and may even show a detrimental effect on overall survival. The additional patient data for the NI-0501-04 study with a data cut off 31 Jan 2019 were collected under the same circumstances as the pivotal data. Thus, these were also subject to the GCP findings. The application has been subject to a triggered GCP inspection. The conclusion of the inspection was that the clinical data of study NI-0501-04 should not be used for evaluation of the MAA of Gamifant. The deficiencies refer mainly to a lack of trial oversight by the Sponsor, which affects the data collection, data management and analyses of trial results resulting in that the quality of the data could not be confirmed. This also relates to the data of the additional patients enrolled as the GCP inspection

<div style=\"page-break-after: always\"></div>

was performed after the data cut-off for these patients. The applicant put forward a ground for reexamination concerning the applicant's disagreement with the GCP inspection recommendations. However, most of these explanations had already been provided in the answers to the Integrated Inspection Report. After assessment of this ground for re-examination, it was concluded that the Rapporteurs' initial conclusion remains unchanged; i.e. that the triggered GCP inspection revealed substantial concerns on the integrity of study data, thus adding to the above uncertainties.

In summary, due to the study design as SAT, the fluctuations in disease activity, patient variability and background therapy, the issues regarding efficacy measurement, and the changes during the ongoing trial, the estimation and isolation of a treatment effect that is causally attributed to Gamifant is significantly impaired.

## 7.4. Unfavourable effects

The primary safety database consists of 34 treated HLH patients in study NI-0501-04/05 with a median FU of 14.6 months. Additional HLH patients (8 pHLH and 9 sHLH) were treated in CU. In total, n=81 primary and secondary HLH patients were treated with emapalumab in clinical studies. Additional supportive data is obtained of n=102 patients treated in the post marketing setting.

Up to 31 January 2018, 95% of patients reported at least one AE in the pre-conditioning period. The most common treatment emerging and on-study AEs in the pre-conditioning period were infections (56%), condition aggravated (50%), hypertension (41%), infusion-related reactions (IRRs) (27%) and pyrexia (24%). During the post-conditioning period (n=23), the most commonly reported AEs were pyrexia (52.2%), hypertension (43.5%) and graft versus host disease (GVHD) (30%). During the preconditioning period, 52.9% of patients had a severe AE, 29.4% had a moderate AE and 11.8% had a mild AE. A similar pattern was seen in the post-conditioning period.

Reported treatment related TEAEs consisted of IRRs and infections potentially favoured by IFN γ neutralisation (mycobacteria (typical and atypical), salmonella, shigella, campylobacter, herpes zoster and histoplasma capsulatum). Most related TEAEs were non-severe and resolved. Two severe related infections were reported: a patient with disseminated histoplasmosis and a healthy volunteer with a herpes zoster infection. All these events resolved after appropriate treatment.

The number of patients that discontinued due to side effects was low (n=2, 6%). Only one patient withdrew treatment due to direct toxicity (disseminated histoplasmosis).

During the study, 10 patients died (29%) and two additional study patients died after the data cut-off (updated safety data till 31 Jan 2018). None of the deaths were considered related to treatment with emapalumab.

No anaphylactic/anaphylactoid reactions have been reported. Only mild and one moderate IRRs occurred in 27% of patients (approximately 3% of the total number of infusions). The majority of events occurred during or after the first infusions and none led to premature withdrawal.

The applicant provided additional safety data up to the cut-off date of 24-Nov-2019 from n=11 additional patients in the NI-0501-04 study and 15 patients from the NI-0501-09 study in a comparable population. Additional data was also provided by N=22 patients from study NI-0501-06, a single arm study in secondary HLH. These data are supportive for the here reported safety profile.

The applicant stated that the safety profile of the post-marketing surveillance data provided from 102 US primary HLH patients has not revealed any additional safety concerns (data not provided - data cut off 19 May 2020).

<div style=\"page-break-after: always\"></div>

Overall, the safety profile of emapalumab appears to be manageable.

## 7.5. Uncertainties and limitations about unfavourable effects

The single arm design hinders conclusions on treatment related AEs. In this particular case, the distinction between treatment related AEs, disease related events, or the side effects of concomitant/prior medication is difficult to make and underreporting is likely to occur.

Moreover, the small sample size of the pivotal trial (n=34) and supportive trials preclude the characterisation of rare AEs, leaving the safety profile not comprehensively characterised. This also pertains to the infections potentially favoured by INFγ neutralisation which cannot be verified clinically. However, infections in the clinical trials resolved with appropriate antimicrobial therapy.

The low number of discontinuations might indicate that the drug is well tolerated, but it remains uncertain if the tolerability is due to the safety profile of the drug.

Haematological abnormalities might be underreported in the current study because they were only reported if they were considered not being related to the studied disease (HLH).

No long-term safety data are available. The short duration of exposure might not be problematic since emapalumab is not intended for chronic treatment in pHLH patients, but it may be considered that relatively long-term treatment might be envisaged for subjects not (yet) eligible for HSCT.

The only safety data available from the historical control cohort is limited to the causes of death reported.

There may be accumulation of emapalumab with the currently proposed posology bearing an unknown safety risk. However, currently available data from ongoing studies and US patients do not indicate such a safety concern.

All additional safety data including the post marketing data have similar limitations as those initially submitted as they were collected in a non-comparative setting, pertain to a heterogenous patient population and concomitant (HLH) treatment was allowed.

## 7.6. Effects Table

<div style=\"page-break-after: always\"></div>

Table 77 Effects Table for emapalumab in paediatric patients aged under 18 years with primary HLH (data cut-off: 20 July 2017)

| Effect                           | Short Description                                             | Unit               | Treatment                                                                              | Control            | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Refere nces        |
|----------------------------------|---------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects               | Favourable Effects                                            | Favourable Effects | Favourable Effects                                                                     | Favourable Effects | Favourable Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Favourable Effects |
| ORR at EOT4                      | Overall Response Rate at End of Treatment of study NI-0501-04 | n,%                | Primary analyses (data cut off 20 July 2017) n=17/27; 63% (0.42- 0.81) (1L: n=5, 71%)* | -                  | - no control arm, results cannot be contextualised -allowance of HLH co-medication upon transition to phase 2/3 study hinders the evaluation of the treatment effect - very heterogeneous study population which questions validity of outcomes: -unclear clinical relevance of a response - no contextualisation of ORR possible due to use of novel response criteria, and changes of treatments over time. So adequate external controls are missing. - dosing regimen not justified - central role of IFNγ in the disease can be questioned as other pathways might also be involved. Updated data for the treatment experienced (data cut off 31 Jan 2019) ORR 20/34 (58.8%) 95% CI 40.7, 75.4) Sensitivity analyses of the patients supporting applied indication Data cut off 20 July 2017: N=23 ORR 14/23 (60.9% (95% CI 0.385-80.3) (n=23). |                    |
| Patients able to proceed to HSCT | -                                                             | n,%                | n=19, 70% (1L: 4, 57.1%)*                                                              | -                  | - no control arm, influence of prognostic/predictive factors on outcome cannot be excluded -allowance of HLH co-medication upon transition to phase 2/3 study hinders the evaluation of the treatment effect - very heterogeneous study population which questions validity of outcomes - dosing regimen not justified Updated data 31 Jan 2019 Treatment experienced 27/34 (79%) Patients supporting the applied application: data not reported.                                                                                                                                                                                                                                                                                                                                                                                                    |                    |

<div style=\"page-break-after: always\"></div>

| Effect               | Short Description                                | Unit                 | Treatment                      | Control              | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Refere nces          |
|----------------------|--------------------------------------------------|----------------------|--------------------------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| OS                   | Overall survival - 12-month survival probability |                      | 0.73 (0.522, 0.864) (1L: 46%)* | -                    | - no control arm, influence of prognostic/predictive factors on outcome cannot be excluded -allowance of HLH co-medication upon transition to phase 2/3 study hinders the evaluation of the treatment effect - very heterogeneous study population which questions validity of outcomes - dosing regimen not justified Updated data 31 Jan 2019 treatment experienced 0.73 (4.6-20.6)* Subgroup patients supporting the applied indication Data cut off 20 Jul 2017: 0.70 (95% CI 0.46, 0.83) Data cut off 31 Jan 2019: not provided |                      |
| Unfavourable Effects | Unfavourable Effects                             | Unfavourable Effects | Unfavourable Effects           | Unfavourable Effects | Unfavourable Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Unfavourable Effects |
| TE-AE                | Patients with at least 1 treatment emerging AE   | %                    | 100.0% (pre: 94% post: 100%)   |                      | Database on primary safety analyses, data cut off 20 July 2017. - uncontrolled study for which the results cannot be contextualised - small sample size, short exposure and no long term follow up leave the safety profile not properly characterised - many AEs might be obscured due to the seriousness of the disease, concomitant medication, or concomitant diseases and underreporting is likely to occur. Updated safety data (24 Nov 2019) aligns with this safety database. Only 32.4% patients with TE-AE                 |                      |
| TE-SAE               | At least 1 treatment emerging Serious AE         | %                    | 88.2% (pre: 61.8) post: 65.2)  |                      | see above Only 5.9% patients with TE-SAE related to study drug                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                      |
| deaths               |                                                  | %                    | 29% (pre: 24% post: 9%)        |                      | see above none related to study drug                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                      |
| Discontinu ations    | Patients who discontinued due to AEs             | n,%                  | (n=2, 6%)                      |                      | see above -uncertain if the tolerability is due to the safety profile of the drug or that in very sick patients more AEs may be accepted or are not recognised.                                                                                                                                                                                                                                                                                                                                                                      |                      |

Abbreviations: ORR= overall response rate, EOT4= end of study NI-0501-04, HSCT= haematopoietic stem cell transplantation, OS= overall survival TE= treatment emerging, AE= adverse event, SAE= serious adverse event.

Notes: Favourable effects are reported for the second line treated analysis set.

* The outcomes for the all treated analysis set and first line analysis set are shown in brackets.

Unfavourable effects are reported for patients initially enrolled in the NI-0501-04 study and includes safety data from studies NI-0501-04 and NI-0501-05.

**In total 34 patients entered the preconditioning period and 23 the post conditioning period.

<div style=\"page-break-after: always\"></div>

## 7.7. Benefit-risk assessment and discussion

## 7.7.1. Importance of favourable and unfavourable effects

Primary HLH is a heterogeneous disease with a fluctuating course. HSCT is considered to be the ultimate treatment goal for pHLH patients and hence HSCT and OS outcomes are generally considered to determine patient benefit in this population. The improvement/resolution of disease may provide a better clinical condition before commencing to HSCT, however there is no general agreement regarding the need for achieving CR before HSCT in order to improve outcome.

The indication was limited to second line patients who received upfront etoposide and dexamethasone (n=23) (data cut-off 20-07-2017). A majority of second-line pHLH patients had a response when receiving emapalumab and a continuous background treatment with dexamethasone, as well as a majority of patients proceeded to transplantation and survived during the first year after treatment. No major safety concerns have been reported in the pivotal study.

There are a number of key issues to the efficacy data obviating isolating and estimating a treatment effect to Gamifant. These concern the allowance of concomitant therapies in a single arm trial with patients known to have a variable disease course and in a variable patient population, lack of strictly defined inclusion criteria partly left to physician's decision, as well as the transition from an ongoing explorative phase II trial to a pivotal phase III trial with a new primary endpoint and thus potentially data driven changes, less strict primary endpoint definition compared to previous trials that introduces bias and increases response rate compared to data from studies with standard-of-care medication and the unclear relevance of the primary endpoint. All of these methodological issues did preclude the attribution of responses to efficacy of Gamifant. This was also a major concern for the majority of the experts in the Ad-Hoc Expert Group meeting held during the re-examination. Besides all biases from the trial design, results of the primary endpoint analysis were not supported by relevant sensitivity analyses which did not meet the predefined target, taking into account confidence intervals. Moreover, no substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since even though IFN-gamma is involved in the pathogenesis of pHLH, other pathways contribute to the disease. Additionally, the sparse data collected on CXCL9 do not allow for a full PK/PD assessment. As highlighted in the Ad-Hoc Expert Group meeting, the pHLH target population that could benefit from emapalumab remains unclear and dosing has not yet been established.

Also, the symptom-based posology is not sufficiently justified. Finally, the indication is not robustly supported by the primary efficacy analyses. As a consequence, the CHMP concluded that efficacy is not considered established.

Despite the methodological uncertainties pertaining to the lack of a control arm and difficulty in distinguishing the true safety profile, the safety appears to be manageable. No new safety risks have been identified from the ongoing studies or US patients treated for primary HLH.

Further to the uncertainties described above, the GCP inspection on study NI-0501-04 concluded that clinical data from this study should not be used for evaluation of the MAA of emapalumab as data quality of this study could not be confirmed. The GCP findings also apply to the updated data provided by the applicant with a data cut of 31 Jan 2019.

<div style=\"page-break-after: always\"></div>

## 7.7.2. Balance of benefits and risks

Given that emapalumab was used in combination with other therapies, as well as due to the known variability in the course of pHLH, the lack of strict inclusion criteria, the transition from an exploratory trial to a pivotal trial with potentially data-driven decisions including the introduction of a new less strict primary endpoint without a possible relation to previous data or natural disease courses, the responses seen in the study cannot be causally attributed to treatment with emapalumab. Similarly, the contribution of emapalumab to patient eligibility for HSCT, and its impact on OS, cannot be ascertained. Whether and which subgroup of pHLH patients could benefit from emapalumab remains unclear and dosing has not yet been established.

No substantial pharmacometric support for the emapalumab effect can be derived from available data on PK/PD parameters, in part since the role of IFN-gamma in the pathogenesis of pHLH is incompletely understood and also considering that other pathways are involved in the pathogenesis of pHLH.

Due to the study design and conduct, there are uncertainties about the safety profile of emapalumab. Although the safety profile is not fully characterised at this time, it appears to be overall manageable.

The triggered GCP inspection revealed substantial concerns on the integrity and reliability of study data and recommended that the results of this study should not be used to support the marketing authorisation application based on impaired conduct of the study, impaired data quality and lack of data trail, amongst others. These findings add to the uncertainties of the single arm trial with regard to efficacy and safety.

Based on the uncertainties pertaining efficacy, as outlined above, the CHMP concluded that the benefitrisk balance of Gamifant is negative.

## 7.7.3. Additional considerations on the benefit-risk balance

## The applicant requested a conditional marketing authorisation (CMA) at Day180 of the application and considered that all four criteria for a CMA are fulfilled.

The CHMP is of the views that all four required criteria for CMA are not considered to be fulfilled and are addressed hereafter:

## The benefit-risk balance of the product is not positive.

The efficacy of Gamifant could not be established.

In particular, the SAT design, the multiple issues regarding the primary endpoint, the co-medication and variability thereof (dose and drug), the transition from exploratory trial to pivotal trial with potentially data-driven decisions, on top of a high intra- and inter-patient disease variability in a primary analysis that does not robustly meet its primary target prevents ascertaining of a treatment effect that can be causally attributed to Gamifant. This precludes the conclusion of a positive benefitrisk balance. Moreover, the findings of the GCP inspections question the reliability of the study data.

## It is unlikely that the applicant will be able to provide comprehensive data.

Study NI-0501-09 is essentially a replication of the pivotal trial NI-0501-04. As such this ongoing study will address the same questions already contained in the pivotal trial NI-0501-04. As a consequence, given that the trial population is the same, one may expect that essentially the same information is provided, which might increase the precision of the estimated outcome, but will not add further information to overcome many of the above described methodological shortcomings and uncertainties in the data.

<div style=\"page-break-after: always\"></div>

## The unmet medical needs will be not fulfilled.

As the efficacy of Gamifant could not be established in the conducted trials, CHMP concluded that the unmet medical need in pHLH has not been demonstrated to be addressed by Gamifant.

## The benefit to public health of the medicinal product's immediate availability on the market does not outweigh the risks due to need for further data.

The efficacy of Gamifant has not been established due to the uncertainties derived from the single arm trial and from study conduct, which do not allow for the assessment of its effect over the concomitantly applied standard of care and additional (rescue) medication.

## In conclusion:

A positive B/R for Gamifant cannot be concluded by CHMP. On the basis of the currently ongoing study NI-0501-09, it is unlikely that the applicant will be able to provide comprehensive, additional data to resolve the outstanding uncertainties regarding efficacy post-authorisation. In addition, based on the available data, it is currently not possible to conclude that Gamifant is able to address an unmet medical need in patients (in)eligible for SoC HLH therapy or who fail that treatment. Therefore, the current application for a CMA for Gamifant is not supported.

## 7.8. Conclusions

The overall B/R of Gamifant is negative.

## 8. Recommendations following re-examination

Based on the CHMP review of data on efficacy and safety for Gamifant in the treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) refractory, recurrent or intolerant to conventional HLH therapy (combination of dexamethasone and etoposide) the CHMP considers by majority decision that the efficacy of the above-mentioned medicinal product is not sufficiently demonstrated and therefore recommends the refusal of the granting of the conditional marketing authorisation for the above-mentioned medicinal product  based on the following grounds for refusal:

- In the single arm trial, the responses seen cannot be causally attributed to treatment with emapalumb given that (i) emapalumab was used in combination with other therapies that differed in drugs and doses used, (ii) stringent inclusion criteria were lacking and rather left at the discretion of the treating physician, (iii) the transition from an exploratory trial to a pivotal trial was based on potentially data-driven decisions including the introduction of a new primary endpoint that was less strict compared to previous HLH trials and thus did not allow a possible relation to previous data or natural disease courses, as well as (iv) the course of pHLH  is characterised by both intra- and inter-patient variability. In addition, the primary analysis did not robustly meet its primary target. Similarly, the contribution of emapalumab to patient eligibility for haematopoietic stem cell transplant (HSCT), and its impact on overall survival, cannot be ascertained;
- No substantial pharmacometric support for the effect of emapalumab can be derived from available data on PK/PD parameters, as the sparse data collected on CLCX9 do not allow full assessment of PK/PD. The role of IFN-gamma is not completely understood and represents only one of several pathways involved in the pathogenesis of pHLH.  In conclusion, the pHLH target population that could benefit from emapalumab treatment remains unclear and dosing has not yet been established;

<div style=\"page-break-after: always\"></div>

- The triggered GCP inspection revealed substantial concerns on the integrity and reliability of study data and recommended that the results of this study should not be used to support the marketing authorisation application, thus adding to the above uncertainties;

For these reasons, a positive B/R cannot be ascertained thus the benefit risk is considered negative.

Divergent positions to the majority recommendation are appended to this report.

## Appendix

1. Divergent positions to the majority recommendation
2. Detailed grounds for the re-examination

<div style=\"page-break-after: always\"></div>

## APPENDIX

DIVERGENT POSITION DATED 23 July 2020

<div style=\"page-break-after: always\"></div>

## DIVERGENT POSITION DATED 23 July 2020 Gamifant EMEA/H/C/004386/0000

The undersigned members of the CHMP did not agree with the CHMP's negative opinion recommending the  refusal  of  the  granting  of  the  marketing  authorisation  of  Gamifant  indicated  for  ' treatment  of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide)'.

The reason for divergent opinion was the following:

Haemophagocytic lymphohistiocytosis (HLH) is a very rare group of disorders. There is an unmet medical need in the treatment of primary HLH (pHLH). If left untreated pHLH has a dismal prognosis with a median survival of less than 2 months after diagnosis.

The pivotal study NI-0501-04 showed clinically encouraging results in terms of ORR, CR and PR. Almost half of the patients could reduce the dose of glucocorticoids by at least 50%. A total of n=23 (67.7%%) proceeded to transplantation, which is the only curative treatment for these patients. The safety profile is clinically manageable and there are currently no major safety concerns. Furthermore, data from the post marketing setting from US are supportive of the pivotal study in terms of safety.

The applicant has applied for a conditional marketing authorisation, and all the criteria are considered fulfilled: 1) The results are clinically meaningful and the benefit-risk balance is considered positive, 2) there is a high unmet need and Gamifant fulfills this need, 3) The applicant has committed to provide confirmatory data from study 09, 4) the benefit to public health of Gamifant's immediate availability on the market outweighs the risks due to need for further data.

In conclusion, Gamifant provides a valuable treatment option in a very rare disease, with a dismal prognosis, and should be allowed on the market.

Sinan B. Sarac

Jan Mueller-Berghaus

John Joseph Borg

<div style=\"page-break-after: always\"></div>

Gamifant

## APPENDIX

DIVERGENT POSITION DATED 12 NOVEMBER 2020

<div style=\"page-break-after: always\"></div>

## DIVERGENT POSITION DATED 12 NOVEMBER 2020 Gamifant EMEA/H/C/004386/0000

The undersigned member of the CHMP did not agree with the CHMP's negative opinion recommending the  refusal  of  the  granting  of  the  marketing  authorisation  of  Gamifant  indicated  for  ' treatment  of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or intolerance to conventional HLH therapy (combination of dexamethasone and etoposide)'.

The reason for divergent opinion was the following:

Haemophagocytic lymphohistiocytosis (HLH) is a very rare group of disorders. There is an unmet medical need in the treatment of primary HLH (pHLH). If left untreated pHLH has a dismal prognosis with a median survival of less than 2 months after diagnosis.

The pivotal study NI-0501-04 showed clinically encouraging results in terms of ORR, CR and PR. Almost half of the patients could reduce the dose of glucocorticoids by at least 50%. A total of n=23 (67.7%%) proceeded to transplantation, which is the only curative treatment for these patients. The safety profile is clinically manageable and there are currently no major safety concerns. Furthermore, data from the post marketing setting from US are supportive of the pivotal study in terms of safety.

The applicant has applied for a conditional marketing authorisation, and all the criteria are considered fulfilled: 1) The results are clinically meaningful and the benefit-risk balance is considered positive, 2) there is a high unmet need and Gamifant fulfills this need, 3) The applicant has committed to provide confirmatory data from study 09, 4) the benefit to public health of Gamifant's immediate availability on the market outweighs the risks due to need for further data.

In conclusion, Gamifant provides a valuable treatment option in a very rare disease, with a dismal prognosis, and should be allowed on the market.

Sinan B. Sarac

John Joseph Borg